Optimising targeted antibodies for the treatment of metastatic solid tumours by Herbertson, Rebecca A.
Herbertson, Rebecca A. (2009) Optimising targeted 
antibodies for the treatment of metastatic solid tumours. 
DM thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/10844/1/20090702_R_Herbertson_MD_thesis.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
 1 
 
 
 
 
 
 
 
 
 
  
 
Thesis submitted to the University of Nottingham for the 
Degree of Doctorate of Medicine 
 
 
 
 
 
 
 
Dr Rebecca A Herbertson, BMedSci, BMBS, MSc. 
Optimising targeted 
antibodies for the 
treatment of metastatic 
solid tumours 
February 2009  
 2 
Abstract 
This thesis describes three different strategies employed with the aim of 
optimising targeted antibodies for the treatment of metastatic solid tumours.  
Whilst the search for improved predictors of response to anti-EGFR antibodies 
continues, paired primary and metastatic archived tissue from 32 patients 
with metastatic colorectal cancer was explored for the immunohistochemical 
expression of EGFR, pEGFR and pMAPK and activating mutations in K-ras, B-
raf and PI3KCA.  The resulting discordance between expression of pEGFR and 
pMAPK between primary and metastatic tissue CRC suggests they are unlikely 
to be useful biomarkers for response unless metastatic tissue is also analysed.  
Confirmation that mutations in KRAS, BRAF and PI3KCA are concordant in 
primary and metastatic tissue supports the analysis of archived primary tissue 
alone for mutation screening.  PI3KCA mutations were shown to be present in 
patients with both wild-type and mutant KRAS, which provides both an 
additional method for resistance in wild type tumours and a mechanism for 
high resistance in those with mutant primary tumours, suggesting screening 
patients for all 3 mutations should be encouraged for future trials of anti-
EGFR antibodies. 
 
The Phase I biodistribution study of Ley targeting immunoconjugate in 
advanced epithelial cancers, primarily explored the biodistribution and 
pharmacokinetics of the immunoconjugate CMD-193 (a humanised anti-Ley 
antibody conjugated with calicheamicin) in 9 patients with advanced Ley 
expressing solid tumours.  Cycle one was trace labelled with 111In for 
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biodistribution assessment, and subsequent cycles were administered every 3 
weeks, to a maximum of 6 cycles, depending on toxicity and response. 
Tumour targeting was assessed using gamma camera imaging and single 
photon emission computerised tomography (SPECT), and PK analysis was 
based on gamma counting of 111In-CMD-193. There were 2 dose cohorts 
(1.0mg/m2 and 2.6mg/m2), and patients with Ley positive, measurable, 
advanced and treatment refractory malignancies, were eligible.  Nine patients 
(6 in dose cohort 1, 3 in cohort 2) were enrolled (and received 1-6 cycles of 
treatment) before the study was terminated.   Biodistribution imaging 
demonstrated initial blood pooling, followed by markedly increased hepatic 
uptake by day 2 (persisting to day 8), and fast blood clearance. This pattern 
was seen for all patients and dose levels. There was no significant uptake in 
ƚƵŵŽƵƌ ǀŝƐƵĂůŝƐĞĚ ŝŶ ĂŶǇ ƉĂƚŝĞŶƚ ? dŚĞ ŽǀĞƌĂůů d  ? ? ? ɴ ŽĨ 111In-CMD-193 was 
102.88 ± 35.67 hours, with no statistically significant difference between the 2 
dose levels.  One patient had a partial metabolic response on 18F-FDG PET 
after 4 cycles, but no radiologic responses were observed. Myelosuppression 
and effects on liver function were the most significant toxicities, but no severe 
or unexpected toxicities were observed.  The result of this trial highlight the 
importance of biodistribution and pharmacodynamic assessment in early 
phase studies of new biologics to assist in clinical development. 
 
The Phase I trial of oral capecitabine combined with 131I-huA33 in patients 
with metastatic colorectal cancer built on the previous development of the 
humanised antibody huA33 which targets the A33 antigen, known to be 
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expressed in >95% of human colon cancers.  This study used radiolabelled 
huA33 in combination with capecitabine chemotherapy to target 
chemoradiation to metastatic colorectal cancer, with safety and tolerability 
being the primary objective.  Pharmacokinetics, biodistribution, 
immunogenicity, and tumour response were also assessed.  Eligibility included 
measurable metastatic colorectal cancer, adequate hematological and 
biochemical function, and informed consent.  An outpatient scout 131I-huA33 
dose was followed by a single therapy infusion one week later, when 
capecitabine was commenced.  Dose escalation occurred over 5 dose levels. 
Patients were evaluated weekly, with tumor response assessment at the end 
of the 12-week trial.  Tumour targeting was assessed using gamma camera 
and single photon emission computerised tomography (SPECT) imaging.  
Nineteen patients were enrolled, and although the dose escalation protocol 
required an amendment following 2 dose-limiting toxicities in the second 
cohort, subsequent cohorts demonstrated good tolerability.  Biodistribution 
analysis demonstrated excellent tumour targeting of the known tumour sites, 
expected transient bowel uptake, but no other normal tissue uptake. 131I-
huA33 therefore achieves specific targeting of radiotherapy to sites of 
metastasis and can be safely combined with chemotherapy, providing a 
promising opportunity to deliver chemoradiation specifically to metastatic 
disease in colorectal cancer patients. 
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CHAPTER 1: Introduction to therapeutic antibodies 
 
 
1.1 Introduction 
It has long been recognised that harnessing the power of the human immune 
system, and successfully directing it towards malignant cells is likely to have a 
significant impact on the treatment of cancer.  The success of the human 
immune system lies in the ability of B-lymphocytes, dendritic cells and 
macrophages to recognise foreign molecules, bind, process and present them 
with major histocompatibility complex (MHC I and II) for recognition by T-cells 
and B-cells.  Antigen recognition then leads to immune activation with B-cell 
proliferation (stimulated by cytokines), which in turn stimulates the 
production and secretion of antibodies by these plasma cells.  Although the 
immunoglobulin family are not typically able to kill cells themselves, they 
instigate the recruitment of effector cells such as cytotoxic T cells and 
macrophages to cause cell death.  Unfortunately tumour cells are able to 
escape this usual immune surveillance mechanism, as their antigens are often 
not significantly different from those on normal tissue, nor do they induce the 
same effector cell recruitment and function as foreign particles.   
 
The discovery of tumour associated antigens was a significant step forward in 
determining ways in which antibodies could be used therapeutically to target 
cancer cells.  The subsequent evolution of therapeutic antibodies finally took 
this concept from the laboratory into clinic for the first time in 1997, when 
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rituximab first received FDA approval for the treatment of relapsed or 
refractory low-grade or follicular, CD20- positive, B-cell Non-Hodgkin 
lymphoma (NHL).  The journey from antigen discovery to the characterization 
and approval of a monoclonal antibody for clinical use is often long and 
tortuous.  Following the discovery and characterisation of a potential new 
antigen, and creation of a targeting antibody, extensive preclinical 
characterization is required prior to it reaching patients.  Phase I trials are the 
next vital step which enable clinical characterization of the antibody in vivo.  
Many newly developed antibodies then require further engineering and 
further characterisation of the modified antibody before it is clear whether 
they are suitable for ongoing clinical development and Phase II trials. 
 
It is now clear that antibodies can be used in a variety of different ways to 
impact on the survival of patients with many different types of cancer.  
Although patients with haematological malignancies were the first to benefit 
from this evolving technology, metastatic solid tumours are now also being 
successfully targeted.  This thesis aims to describe ways in which monoclonal 
antibodies can be optimised for the treatment of metastatic solid tumours 
with the aim of expanding treatment options, finding better predictors of 
response to such antibodies, and ultimately improving patient outcome.  
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1.2 Monoclonal antibodies: Structure and function 
1.2.1 Structure 
Antibodies (immunoglobulins, Igs) are soluble glycoproteins belonging to the 
immunoglobulin super family, with 5 distinct types that are classified 
according to differences in their heavy chain constant regions.  IgA is found in 
mucous membranes or secretions (e.g. gut and respiratory tract), IgD mainly 
functions as a B cell antigen receptor, whilst IgE binds allergens and stimulates 
the release of histamine from mast cells.  IgM is involved in early B cell 
mediated immunity response as it is expressed on the surface of B cells. IgG is 
the antibody that has the greatest contribution in the antibody-mediated 
immune response, and it is this subclass that is typically used in the 
development of therapeutic antibodies.  
 
Serum half life differs significantly between the four IgG subclasses, which is 
why the choice of for therapeutic antibodies usually belong to the IgG1 
subclass owing to its long half life and its ability to trigger complement-
dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity 
(ADCC).  IgG1, IgG2, IgG4 have a typical serum half life of 21 days compared to 
that of IgG3, which is 7 -14 days.  
 
The structure of an IgG is a pair of light chains and a pair of heavy chains.  
Light chains have two separate regions (one variable region VL, and one 
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constant region CL), and the heavy chains have four regions (VH, CH1, CH2 and 
CH3).  Figure 1.2.1 illustrates this. 
 
Figure 1.2.1 IgG Structure 
 
 
 
1.2.2 Mechanism of action 
The distinct binding sites of antibodies enable these proteins to have a pivotal 
role in immune effector function.  The specificity of antigen binding is 
provided by the variable (Fv) region of the antigen-binding fragment (Fab), 
which is encoded by three complementarity-determining regions (CDRs).  The 
Fc (constant) region of the antibody is the area that binds serum proteins 
directly and hence also initiates effector cells recruitment.  Subsequent cell kill 
is then mediated through CDC and/or ADCC.  CDC occurs following the 
activation of a number of complement proteins.  C1q complement factor 
interacts with the CH2 constant region of the mAb, activates the classical 
Antigen binding 
site  
Heavy chain 
Light chain 
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complement cascade, which leads to the formation of a membrane-attack 
complex (MAC), which is able to lyse the target cell.  In contrast, ADCC 
involves the recognition of a surface antigen by an antibody and subsequent 
binding allows the bound antibody to be recognised by natural killer cells and 
macrophages by interaction with the CH3 region. This ability to induce ADCC is 
dependent on factors such as the antibody subclass, the type of effector cell 
activated (via Fc gamma receptors), and the level of antigenic expression on 
the tumour cell.  An additional mechanism of cell killing can be via 
engagement of the Fv with target receptors on the tumour cell surface, 
inhibition of receptor dimerisation / activation, and subsequent abrogation of 
cell signalling. 
 
1.2.3 The role of Fc receptors (Fc R and FcRn) 
During ADCC antibodies bound to a foreign antigen are able to recruit 
immune effector cells that express receptors specific for the antibody 
constant region (Fc).  These Fc gamma receptors (Fc Rs) can trigger the 
subsequent release of cytokines and inflammatory mediators, and induce 
phagocytosis of the IgG coated cells. They are also able to send signals to 
leucocytes to secrete pro-inflammatory cytokines1. These Fc Rs therefore 
allow elements of the adaptive and innate immune system to combine to 
induce cellular cytotoxicity2.  There are three classes of Fc  receptor, Fc RI, 
Fc RII, and Fc RIII, which have highly conserved extracellular Ig domains, but 
different cytoplasmic regions3.  Effector cells are known to express multiple 
Fc R isoforms, which are known to differ in their molecular structure, 
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antibody affinity and hence ability to induce phagocytosis3 ?  Ŷ ĂŶƚŝďŽĚǇ ?Ɛ
ability to lyse tumour cells is predominantly determined by the class of the 
constant regions.  As IgG1 and IgG3 can both activate the classical 
complement cascade and interact more potently with Fc R than other 
members of the IgG family, these immunoglobulins are most frequently 
utilised for therapeutics.   
 
As well as recruiting cytotoxic effector cells by interacting with their Fc R, the 
Fc domain can also help to prolong the serum half-life of IgG by interaction 
with the MHC class I Wrelated (neonatal) receptor, FcRn.  FcRn has an 
important recycling role, by transporting IgG within and across cells4.  FcRn 
bound IgGs are protected from lysosomal degradation, salvaged and recycled 
at the cell surface, hence this receptor has the ability to rescue IgGs from 
intracellular degradation4 5.  It has become increasingly clear that the 
induction of ADCC via Fc Rs is likely to greatly influence the effectiveness of 
therapeutic antibodies, and is the focus of intense investigation.  It has also 
been suggested that genetic polymorphisms in the Fc R family which impact 
on the interaction between effector cells and IgGs, may be one source of 
variability of efficacy of monoclonal antibodies6.  The role FcRn plays in the 
regulation of serum IgG levels is also a potential target for manipulating 
serum half-life (and potentially efficacy).  Pre-clinical work suggests that by 
engineering IgGs for improved FcRn binding, it may be possible to modulate 
their half-lives in humans.  Therapeutic antibodies with longer half-lives may 
demonstrate improved efficacy secondary to sustained serum concentrations, 
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and reduced dosing frequency7.  Alternatively, there maybe circumstances 
where a shorter serum half-life might be clinically beneficial, for example if 
exposure to toxic immunoconjugate or radionuclide needs to be minimised.  
In this situation engineering reduced FcRn binding might be a suitable strategy 
to investigate. 
 
1.2.4 Antibody diversity 
The human immune system has the ability to create thousands of millions of 
different antibodies from which appropriately specific antigen-binding 
antibody can be selected in response to each antigenic stimulus8.  The gene 
encoding  and  light chains are located on chromosome 22 and 2 
respectively, whilst the gene encoding the heavy chain is on chromosome 14.  
The  and  light-chain contain V, J and C gene segments, and the rearranged 
VJ segment codes the variable region of the light chains.  Gene segments for 
the heavy chains contain V, D, J and C segments, with the rearranged VDJ 
gene segments encode the variable region of the heavy chain.  In both light 
and heavy chains, the C gene encodes the constant region.  During B cell 
maturation, these multigene families require rearrangement, and when the 
genes are brought together the functional immunoglobulin genes are formed.  
This combinatorial diversity obtained by random combination of germ line 
gene segments is one of a number of sources of antibody diversity9.  As 
ƐƵŵŵĂƌŝƐĞĚŝŶ>ŽŶŐĞƌ ?ƐĚŝĂŐƌĂŵ ?&ŝŐƵƌĞ ? ? ? ? ? ? ?ĂĚĚŝƚŝŽŶ ůŵĞchanisms which 
ĐŽŶƚƌŝďƵƚĞ ƚŽ ĂŶ ŝŶĚŝǀŝĚƵĂů ?Ɛ ĂŶƚŝďŽĚǇ ƌĞƉĞƌƚŽŝƌĞ ŝŶĐůƵĚĞ junctional diversity 
obtained by random addition and deletion of nucleotides (at the joints 
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between these gene segments), and somatic mutation of the entire variable 
region during T-cell-dependent secondary immune responses9. 
 
 
Figure 1.2.4 Sources of antibody diversity 
Adapted from Lonberg N. Nat Biotechnol 2005;23(9):1117-25. 
 
 
 
 
Somatic hyper mutations can occur throughout the VJ or VDJ segment, but 
are focused within the CDRs in mature B cells.  This is because a mutation 
here has the greatest opportunity for influencing affinity of antigen binding.  
 
1.2.5 Specificity and affinity of binding 
The strength of antigen-antibody interaction is determined by both the 
specificity and affinity of binding.  A strong antigen-antibody interaction is 
dependent on a high degree of complementarity between antigen and 
antibody.  This specificity of an antibody provides the ability to discriminate 
between different epitopes.  Although antigen-antibody reactions are usually 
highly specific, in some instances an antibody elicited by one antigen can 
cross-react with an unrelated antigen, which may share a similar or identical 
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epitope  (for example as can occur with ABO blood group antigens).  Binding 
affinity of an antibody for an epitope is the strength of binding between a 
single antigen-binding site on an antibody, and a single epitope.  Whilst 
antibodies with low affinity bind weakly and easily dissociate, high affinity 
antibodies remain bound longer, as the interaction is stronger.  
 
As described, the human immune system is able to create a large antibody 
repertoire by multi-gene rearrangement, junctional rearrangement and 
somatic mutations, but increased antigen affinity of a population also occurs 
within the germinal centers of lymph nodes by affinity maturation.  This 
process takes place following antigenic exposure, when B cells with higher 
affinity receptors are preferentially selected for survival, hence increasing the 
affinity of the population.   
 
The determination of antibody specificity and affinity are vital early steps in 
the characterisation of potential therapeutic antibodies.  Currently the most 
sensitive (and rapid) method for measuring antibody affinity is surface 
plasmon resonance (SPR).  This technique uses buffer solution containing 
antibody under investigation passed through a flow chamber also containing a 
layer of immobilised antigen.  Antigen-antibody complexes which form on this 
layer cause a change in resonant angle of a beam of polarised light, which is 
detected as the complexes form10.  As well as determining affinity constants, 
it can measure rate of reactions and concentrations of antibody (e.g. human 
anti-human antibodies, HAHA). 
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1.2.6 Antibody internalisation and intracellular trafficking 
The fate of an antibody once it has bound target antigen is variable (and is 
dependent on properties of the antibody and the antigen).  Some antibodies 
remain bound to the cell surface, whilst others are internalised via 
phagocytosis, macropinocytosis, or clathrin mediated endocytosis (such as 
receptor targeted antibodies).  Clathrin mediated endocytosis involves the 
formation of endocytic clathrin-coated vesicles, which occurs when 
components of the inner plasma membrane interact with cytosolic proteins11.  
After clathrin forms a lattice inside the cell membrane, coated pits and 
subsequent invagination occurs, prior to the newly formed vesicles being 
 “ƉŝŶĐŚĞĚ ŽĨĨ ? ĂŶĚ ŝŶƚĞƌŶĂůŝƐĞĚ11.  The intracellular passage of internalised 
antibodies also differs.  Whilst some are recycled back to the cell surface, 
others are taken to lysosomes for degradation, so the type of vesicle is it 
taken to, will determine how long it remains in the cell.  As described in 
section 1.2.3, FcRn are involved in saving IgGs from lysosomal degradation by 
recycling them back to the cell surface.  As will be described later, and 
understanding of the internalisation properties and intracellular trafficking of 
potential therapeutic antibodies is essential if their development and clinical 
use are to be optimised. 
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1.3 Tumour associated antigens 
Whilst tumour associated antigens (TAA) are often no different in structure 
from antigens found on normal cells, they are often over-expressed. Tumour 
associated antigens include differentiation antigens, cancer/testes antigens, 
and over expressed/amplified antigens.  Differentiation antigens are proteins 
expressed by normal cells in a tissue specific way, but can be co-expressed by 
tumour cells.  Examples include MART-1, which is expressed by normal 
melanocytes and melanoma cells, and cluster differentiation antigens such as 
CD20 expressed in many B cell malignancies.  An over expressed/amplified 
antigen is a glycoprotein, carbohydrate or ganglioside which is over expressed 
in a cancer cell compared to a normal cell, such as the epidermal growth 
factor receptor (EGFR) family.  EGFR-1 (EGFR/Erb-1) is over expressed in a 
number of epithelial cancers including colorectal and lung cancer, whilst HER2 
(Erb-2) is over expressed in a proportion of breast cancers.  Cancer/testes 
antigens are encoded by genes that are only expressed in the human germ 
line (germ cells within the testis, the trophoblast and immature germ cells in 
the foetal ovary), but during oncogenesis, these foetal antigens can be re-
expressed and become tumour antigens12.  Because germ line cells do not 
express major histocompatibility complex (MHC) molecules, they are unable 
to present antigens on their surface, thus a cancer therapy would not target 
these normal cells.  Tumour types known to express such antigens include 
lung, liver and bladder carcinomas and melanomas.  The first cancer/testes 
antigen to be discovered was MAGE-1, which is now known to be expressed 
only on melanoma cells and healthy testis13.  Since then more than 40 other 
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antigens have been discovered and are in development including NY-ESO-1, 
which is expressed in testis, and in a variety of tumors such as melanoma, 
breast, ovary, prostate, bladder, sarcoma, and lung cancer.  These antigens 
are usually only expressed on the cell surface in the context of presentation 
by MHC, and as such are not usually considered targets for antibody-based 
therapies.  Mutation antigens result from DNA mutations which lead to the 
expression of altered proteins or cell surface receptors, and are tumour 
specific such as the mutated EGFR receptor, de2-7 EGFR, which has an 
extracellular truncation and is often found in glioblastoma and possibly breast 
and prostate cancer14. 
 
1.3.1 Cancer antigen discovery 
 
^ĞƌŽůŽŐŝĐĂů ĂŶĂůǇƐŝƐ ŚĂƐ ďĞĞŶ ƵƐĞĚ ƐŝŶĐĞ ƚŚĞ  ? ? ? ? ?Ɛ ƚŽ ŝĚĞŶƚŝĨǇ ĐĞůů ƐƵƌĨĂĐĞ
antigens expressed on cancer cells. This has resulted in a broad range of 
tumour associated antigens being identified that can be used as cancer 
targets15.  More recent approaches have included computational library 
selection and database mining from genome and transcriptional databases12. 
 
Ludwig Institute for Cancer Research (LICR) scientists discovered the first 
human cancer antigen, MAGE, in 1991 by T cell epitope cloning.  They found a 
patient with metastatic melanoma whose CD8+ T cells were found to 
specifically and rapidly destroy her own cancer cells in vitro13.  After 
determining that many human melanoma tumours express antigens 
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recognised in vitro by cytolytic T lymphocytes (CTLs) derived from tumour-
bearing patients, a gene was identified that directed the expression of a 
specific antigen on a human melanoma cell line.  
 
Establishing cancer cell lines and the T-cell lines required for T-cell epitope 
cloning was a significant obstacle for the further identification of other cancer 
antigens.  The subsequent development of another technique, not reliant on 
established tumour cell lines, allowed many more cancer antigens to be 
identified.  Serological analysis of recombinant cDNA expression libraries 
(SEREX) enables the humoral immune response of cancer patients to be 
analysed.  Using this technique, expression of cDNA libraries from human 
tumours such as melanoma, renal cancer, astrocytoma, and Hodgkin 
lymphoma in Escherichia coli, and screening for clones reactive with high titre 
IgG antibodies in autologous patient serum, lead to the discovery of antigens 
with restricted expression patterns. It also became clear from sequence 
analysis that many of these molecules could have an influence on tumour 
growth16.  These antigens are ideal for vaccine based therapeutic strategies in 
view of the presentation of peptides encoded by these genes by MHC on the 
tumour cell surface, and the suitability of this peptide presentation for 
antigen presenting cell / T cell recognition.  
 
1.3.2 Cancer antigen characterisation 
It is vital that a new cancer antigen is extensively characterised, and 
expression in cancers and normal human tissues is analysed using 
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immunohistochemistry (IHC).  Fresh and archived tissue is examined to map 
degree of expression.  When looking to develop a therapeutic antibody 
against a cancer antigen, restricted tissue expression is ideal in order to avoid 
potential toxicity to normal tissues.  Other factors that can impact on the 
suitability of a target for antibody based therapeutics include: the 
overexpression or mutation of the gene encoding the target in cancer cells; 
abundant expression in tumour; lack of soluble form of the target; and 
phenotypic stability of expression with tumour progression. 
 
Antigenic systems studied by LICR over the last decade include A33 (a 
glycoprotein which demonstrates selective expression in normal and 
malignant gastrointestinal epithelium)17, the G250/CAIX antigen (a heat 
sensitive transmembrane cell-surface antigen homologous to carbonic 
anhydride present in >85% of renal cell cancers18), Ley (a carbohydrate 
expressed  on glycolipids and glycoproteins of many epithelial malignancies19-
22), GD3 (a ganglioside with high expression in melanoma and other 
neuroectodermal tumors)23, FAP  (a glycoprotein strongly expressed in the 
stromal fibroblasts of epithelial cancers)24 and the mutated epidermal growth 
factor receptor, de2-7 EGFR (expressed in gliomas and other solid tumours)14.  
Characterisation of Ley and A33 antigens will be described further in sections 
1.8.1 and 1.9.1 respectively. 
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1.4 Targeted antibody therapies: From antigen discovery 
to Phase I trials 
 
/ƚƚĂŬĞƐŵĂŶǇǇĞĂƌƐĨŽƌĂŶŽǀĞůƚŚĞƌĂƉĞƵƚŝĐĂŶƚŝďŽĚǇƚŽďĞƚĂŬĞŶ “ĨƌŽŵďĞŶĐŚ
ƚŽ ďĞĚƐŝĚĞ ? ?  &ŽůůŽǁŝŶŐ ĂŶƚŝŐĞŶ ĚŝƐĐŽǀĞƌǇ and characterisation, monoclonal 
antibodies are created, expressed and produced.  Extensive preclinical 
characterisation of the antibody to determine specificity, affinity, 
internalisation properties, immune effector function and biodistribution, as 
well as mechanism of action and toxicology studies, prior to clinical 
characterisation in Phase I trials.  The following section will describe this 
translational journey. 
 
1.4.1 Antibody production and engineering 
In the 1970s it was discovered that malignant plasma cells could be hybridised 
in culture with immune lymphoid cells25 26.  This finding led to the production 
of monoclonal antibodies by taking splenic cells from a mouse immunised 
with a specific antigen, and culturing them in a mutant myeloma cell line.  
Neither the mutant myeloma cell line (with an enzyme deficiency), nor the 
spleen cells are able to grow in (HAT) cell culture medium.  The fused 
lymphoid-spleen cells grow, as the necessary enzyme (deficient in the 
myeloma cells) is provided by the splenic cells when fused. The resulting 
ŚǇďƌŝĚ ĐĞůůƐ ? Žƌ  “ŚǇďƌŝĚŽŵĂ ?ĐĂŶďĞ ƐĞůĞĐƚĞĚĂŶĚĐůŽŶĞĚ ƚŽƉƌŽĚƵĐĞ ƐƉĞĐŝĨŝĐ
antibodies.  Large amounts of murine antibody can then be made by growing 
the hybridoma as ascites in mice.  This method then requires the generating a 
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stable cell line capable of making the antibody.  Although this initial work 
produced murine antibodies with high affinity and specificity, therapeutic 
implications of these early murine antibodies was limited by immunogenicity.  
Human anti-mouse antibody (HAMA) response was a frequent occurrence in 
early phase trials (as will be described later), which often led to rapid 
clearance, transfusion reactions and anaphylaxis, when the murine antibody 
was recognised as a foreign pathogen27.   
 
The use of hybridoma technology for the production of human monoclonal 
antibodies remained problematic, until the development of antibody 
engineering using recombinant DNA technology.  These methods for 
producing less immunogenic monoclonal antibodies facilitate the production 
ŽĨƉĂƌƚůǇŽƌĨƵůůǇ “ŚƵŵĂŶŝƐĞĚ ?ĂŶƚŝďŽĚŝĞƐ ?ŚŝŵĞƌŝĐĂŶƚŝďŽĚŝĞƐĂƌĞĞŶŐŝŶĞĞƌĞĚ
by cloning recombinant DNA containing the promoter, leader and variable-
region sequences from a mouse antibody gene and the constant region exons 
from a human antibody gene.  As the resulting antibody combines the murine 
variable region with the human constant region (and hence is 75% human), it 
is far less immunogenic to humans.  Humanised antibodies are all human 
except for the antigen specific murine CDRs, and as a result retain human 
antibody effector functions (as human Fc regions are able to bind to Fc R with 
greater affinity, and have longer half lives in vivo) and the ability to trigger 
complement activation10.  
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More recently mice have been engineered to produce human 
immunoglobulin.  This can be achieved by first introducing a human artificial 
chromosome (with human heavy chain and  light chain loci) to embryonic 
stem cells from an Ig knockout mouse.  Transferring this stem cell to the 
mouse blastocysts to produce a chimeric mouse and subsequent inter-
breeding can produce mice making only human Ig.  Hybridomas generated 
following immunisation of these mice then secrete antigen-specific human 
monoclonal antibodies.  This ability which enables transgenic mice to express 
repertoires of human antibody gene sequences, is a technology which is being 
fiercely investigated by an number pharmaceutical companies9.  
 
Phage display technology is an alternative approach for monoclonal antibody 
production, which does not rely on immunisation and hybridoma technology.  
A phage (a virus that only infects bacteria) can be genetically engineered to 
ĞǆƉƌĞƐƐĞƐ ĨƵŶĐƚŝŽŶĂů ĂŶƚŝďŽĚǇ ĨƌĂŐŵĞŶƚƐ ƐƵĐŚ ĂƐ  “ƐŝŶŐůĞ-chain fragment 
ǀĂƌŝĂďůĞ ?  ?ƐĐ&ǀ ? ? ǁŚŝĐŚ ŝƐ Ă ĨƌĂŐŵĞŶƚ ĐŽŶƚĂŝŶŝŶŐ sH and VL genes with a 
peptide linker isolated from a population of B cells.  Using this technique, 
large rĞƉĞƌƚŽŝƌĞƐ ĐĂůůĞĚ  “ƉŚĂŐĞ ĚŝƐƉůĂǇ ůŝďƌĂƌŝĞƐ ? ĂƌĞ ĂďůĞ ƚŽ ĞǆƉƌĞƐƐ ŵĂŶǇ
different antibody-binding sites.  Following amplification of a phage 
population by introduction into E. coli, incubation with immobilised antigen 
allows screening for specificity.  Following identification of antigen specific 
phages, genetic engineering allows recovery of the VH and VL encoding regions 
from the phage genome and engraftment onto genes encoding the Ig heavy 
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and light chain constant regions, which can when expressed in cells produce a 
specific monoclonal antibody9. 
 
1.4.2 Pre-clinical antibody characterisation 
Extensive pre-clinical characterisation of a novel antibody is required in order 
to confirm suitability and safety for ongoing clinical development.  This 
includes detailed characterisation of its antigen binding capabilities and 
biological properties.  Specificity (distribution in tumour and normal tissue 
using immunohistochemistry), affinity, internalisation properties and 
intracellular trafficking are all vitally important if an antibody it to proceed to 
clinical testing. Determining effector function (ADCC and CDC), and anti-
tumour activity in pre-clinical models, and establishing biomarker profiles to 
guide patient selection and dosing strategies for clinical trials, are 
components of this process.  Toxicology studies are also an essential part of 
pre-clinical assessments of any new antibody construct, and are required for 
regulatory submissions.  Once full pre-clinical characterisation has been 
perfoƌŵĞĚ ?ĂŶĂŶƚŝďŽĚǇ ?ƐƉƌŽƉĞƌƚŝĞƐǁŝůůĚĞƚĞƌŵŝŶĞŝƚƐĐůŝŶŝĐĂůƵƐĂŐĞƐ ?^ƚƌŽŶŐ
ĞĨĨĞĐƚŽƌĨƵŶĐƚŝŽŶŝƐƉĂƌƚŝĐƵůĂƌůǇŝŵƉŽƌƚĂŶƚĨŽƌ “ŶĂŬĞĚ ?ƚŚĞƌĂƉĞƵƚŝĐĂŶƚŝďŽĚŝĞƐ ?
if cell kill is to be induced.  If an antibody is conjugated with a toxin or 
radioisotope however, strong effector function is not required, as cell kill is 
ŝŶĚƵĐĞĚ ďǇ ƚŚĞ ĂŶƚŝďŽĚǇ ?Ɛ ƚŚĞƌĂƉĞƵƚŝĐ ƉĂǇůŽĂĚ ?  Another important 
component of pre-clinical characterisation is to generate antibodies to the 
candidate antibody and develop laboratory assays capable of measuring the 
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candidate antibody serum pharmacokinetics, and quantifying 
immunogenicity28. 
 
1.4.3 Clinical characterisation 
Once pre-clinical characterisation has indicated that an antibody has 
therapeutic potential, the next step is accurate clinical characterisation in 
Phase I trials.  The pharmacokinetics, biodistribution and toxicity profile of an 
antibody must be accurately determined in patients.  Whilst pharmacokinetic 
assessment is a uniform component to Phase I antibody trials, biodistribution 
assessment using radiolabelled antibody is a novel aspect being undertaken at 
specialist institutions, which can provide important information to support 
pharmacokinetic data, and help to explain the behaviour of an antibody in 
patients.  Immunogenicity and potential efficacy are also key end points to 
early clinical characterisation.  Biomarker analysis (blood, tumour) may also 
be important in scenarios where tumour cell function is perturbed by the 
antibody.  OptimisĂƚŝŽŶŽĨĂŶĂŶƚŝďŽĚǇ ?ƐƉƌŽƉĞƌƚŝĞƐŵĂǇĂůƐŽďĞŶĞĐĞƐƐĂƌǇƚŽ
continue successful therapeutic development, prior to Phase II trials. 
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1.5 Therapeutic monoclonal antibodies in metastatic 
disease 
 
Monoclonal antibodies that have been approved for the treatment of 
haematological and solid malignancies cause tumour cell death by a variety of 
mechanisms.  Direct mechanisms of action include competitive antagonist of 
receptor activation, inhibition of the cell cycle or DNA repair and induction of 
apoptosis.  Indirectly antibodies may induce cytotoxicity via immune effector 
cell function if they are able to induce CDC and ADCC.  To date, nine 
monoclonal antibodies have been approved by the FDA for treatment of a 
number of different tumour types (summarised in Table 1.5) 
Table 1.5 FDA approved monoclonal antibodies in oncology 
Antibody 
Year FDA 
approved 
Target Isotype Species 
FDA Approved 
Indication 
Rituximab 
(Rituxan) 
1997 CD20 IgG1K Chimeric Non-Hodgkin lymphoma 
Trastuzumab 
(Herceptin) 
1998 HER-2 IgG1K Humanised HER-2+ breast cancer 
Gemtuzumab 
ozogamicin 
(Mylotarg) 
2000 CD33 IgG1 K Humanised 
Relapsed acute myeloid 
leukaemia 
Alemtuzumab 
(Campath) 
2001 CD52 IgG1 Humanised 
Chronic lymphocytic 
leukaemia 
Ibritumomab 
tiuxetan 
(Zevalin) 
2002 CD20 IgG1 K Murine 
Relapsed Non-Hodgkin 
lymphoma 
Tositumomab 
(Bexxar) 
2003 CD20 IgG2a Murine 
Relapsed chronic 
myeloid leukaemia 
Cetuximab 
(Erbitux) 
2004 EGFR IgG1 K Chimeric 
Colorectal cancer 
Head/neck squamous 
cell carcinoma(+XRT) 
Bevacizumab 
(Avastin) 
2004 VEGF IgG1 K Humanised 
Colorectal , non-small 
cell lung, breast  cancer 
Panitumumab 
(Vectibix) 
2006 EGFR IgG K Humanised Colorectal cancer 
Solid tumours highlighted in blue 
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Rituximab was the first of such therapeutic antibodies to be approved for the 
treatment of Non-Hodgkin lymphoma.  This chimeric anti-CD20 antibody 
binds avidly to the CD20 antigen (expressed on 95% of B-cell lymphoma cells 
and on normal B-lymphocytes) and cytotoxicity is thought to be a result of 
ADCC29, apoptosis30-32 and possibly CDC33 34.  Owing to significant 
improvements in survival when rituximab is added to chemotherapy regimen, 
it is now included in the standard therapy for a number of types of NHL, 
including diffuse large B-cell35 36 and follicular subtypes37.  
 
1.5.1 Monoclonal antibodies for treatment of solid tumours 
The four monoclonal antibodies which have subsequently been approved by 
the FDA for the treatment of metastatic solid tumours all target growth factor 
receptors or their ligands; Trastuzumab targeting ErbB2/ Her2, cetuximab and 
panitumumab targeting EGFR/ErbB1 (and described in greater detail in 
subsequent sections), and bevacizumab targeting vascular endothelial growth 
factor ligand (VEGF-A).  Trastuzumab is an obvious successful example of a 
monoclonal antibody making a significant effect on the management of 
patients with breast cancer.  After initially making an impact in metastatic 
disease38, it was then shown to improve survival in the adjuvant setting39 40, 
and is now an integral part of the management of HER-2 positive breast 
cancer.  Bevacizumab is a humanised anti-angiogenic IgG1, which prevents 
the pro-angiogenic growth factor VEGF-A from binding with its target receptor 
vascular endothelial growth factor receptor (VEGFR) on vascular endothelium.  
Amongst it anti-angiogenic effects, it has been shown to cause rapid 
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regression of tumour vasculature, prevent the formation of new blood vessels 
ĂŶĚ  “ŶŽƌŵĂůŝƐĞ ? ƚƵŵŽƵƌ ǀĂƐĐƵůĂƚƵƌĞ ďǇ ĚĞĐƌĞĂƐŝŶŐ ƚŚĞ ƌĂŝƐĞĚ ŝŶƚĞƌƐƚŝƚŝĂů
pressure in tumours, and allowing vessels to become smaller and less 
tortuous41-43.  Bevacizumab is FDA approved for the treatment of metastatic 
colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and breast cancer 
in combination with chemotherapy44-47.  
 
As will now be described, the EGFR pathway is an ideal target for therapeutic 
antibodies in metastatic solid tumours, and survival advantages have been 
demonstrated.  The following sections will describe the unconjugated 
monoclonal antibodies, which target the EGFR family currently in clinical use 
in metastatic solid tumours. 
 
1.5.2 Antigen discovery and characterisation: The ErbB family  
The ErbB family of receptors are transmembrane cell surface receptors with 
tyrosine kinase activity.  The family comprises of 4 related receptors. ErbB1 
(EGFR, EGFR-1 or HER1), ErbB2 (HER2/neu), ErbB3 (HER3) and ErbB4 (HER4).  
They all have an extracellular ligand binding domain, a transmembrane 
domain, and an intracellular protein tyrosine kinase, although ErbB3 has no 
tyrosine kinase activity.  ErbB-1/EGFR has 6 known ligands (with differing 
binding affinity), all with unique expression patterns during fetal development 
and adulthood48. Amongst these, the most extensively investigated are 
epidermal growth factor (EGF) and transforming growth factor-ɲ  ?d'&ɲ ? ?
These ligands (as well as ErbB-1/EGFR receptor) are involved in foetal 
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epithelial cell development (particularly in the lung, gastrointestinal tract and 
skin)49, and are all known to be over expressed in malignant tumours50-52.  The 
neuroregulins are the ligands for ErbB-3 and ErbB-4, which are expressed in 
the embryonic nervous system and adult neural and mesenchymal tissues53. 
 
1.5.2.1 EGFR related signal transduction 
EGFR binding ligand at the cell surface results in receptor 
homo/heterodimerisation (either with another EGFR, or with another 
member of the ErbB family such as ErbB2), which activates the intracellular 
tyrosine kinase domain of the receptor by auto-phosphorylation.  The two 
major signalling cascades that are initiated as a result of EGFR activation are 
the PI3K-Akt and Ras-Raf-MAPK pathways.  These multi-step cascades 
ultimately lead to tumour cells avoiding apoptosis, promoting angiogenesis 
and activating proteins involved in cell survival.  After signal transduction, 
receptors are either down regulated or regenerated on the cell surface54.  This 
receptor family therefore has a critical role to play in promoting cell 
differentiation and proliferation via this complex network of downstream 
signal transduction cascades55, and disruption of this tightly regulated 
network can lead to malignant transformation.  
 
1.5.2.2 ErbB expression in normal and malignant tissues   
Members of this receptor family and their ligands have a number of different 
roles in foetal development and a wide range of cellular processes56.  EGFR 
(Erb1) regulates foetal epithelial proliferation and differentiation57, and ErbB2 
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and ErbB4 are essential for normal foetal cardiac muscle development and 
differentiation58 59.  EGFR is expressed in a number of normal epithelial 
tissues, especially in the basal layers of stratified epithelium (and in squamous 
epithelium).  Although the EGFR is expressed by a number of different normal 
cell types, the reported incidence of receptor over expression or dysregulation 
in human malignancies in variable60.  Up-regulation and over-expression of 
the ErbB family contributes to the many molecular mechanisms involved in 
malignant tumour growth by a number of routes, including autocrine 
stimulation of tumours by the production of their own growth factors (EGF 
and TGF-alpha), uncontrolled cellular proliferation, and providing tumour cells 
with the ability to avoid apoptosis.  Mutant forms of EGFR can result in ligand 
independent constitutive receptor activation61.   
 
In clinical series of epithelial malignancies 30-50% of tumours have 
demonstrated dysregulated EGFR expression62.  EGFR over expression is 
associated with NSCLC and has been correlated with high metastatic rate and 
poor prognosis63 64.  Gliomas and glioblastomas65, head and neck66, bladder, 
colorectal67, ovarian, and prostate cancers68, have demonstrated over 
expression of this receptor, although this correlates with poor prognosis and 
inferior survival in only a selection of these tumour types67 69 66 70.  
ErbB2/HER2 amplification and over expression also has a significant role in the 
early pathogenesis and progression of a number of cancers, most notably in 
breast cancer where HER2 positive, node-positive breast cancer patients have 
been shown to have an inferior prognosis71 72. 
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1.5.3 Characterisation of ErbB antibodies 
Establishing the crucial role this receptor family plays in the pathogenesis a 
many solid tumours identified the ERbB family as attractive targets for 
therapeutic monoclonal antibodies, and a large number of such antibodies are 
in development.  
 
1.5.3.1 Pre-clinical characterisation 
Pre-clinical studies of EGFR antibodies indicated an ability to have anti-tumour 
effect via a number of different mechanisms including effects on cell cycle 
control, proliferation, apoptosis, angiogenesis, and tumour cell invasion73.  
Studies of EGFR signaling inhibition with cetuximab demonstrated 
proliferation inhibition in cultured epithelial tumour cells, which is thought to 
be primarily a result of a blockade of cell cycle progression at G1 
60 73 74.  
Apoptosis was promoted by EGFR inhibition in human NSCLC or DiFi (colon 
cancer) cells in culture74.  EGFR inhibition has also been shown to down 
regulate VEGF in squamous cell carcinomas75, and down regulate MMP-9 
mRNA in a dose-dependent manner with regression of lymph node metastases 
in a human transitional cell carcinoma of the bladder model 76. 
 
1.5.3.2 Clinical characterisation 
As described, trastuzumab, cetuximab and panitumumab have all been fully 
developed and reached Phase III clinical trials.  Although there are many new 
antibodies targeting the ErbB family under investigation at varying stages of 
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development, these three that are currently FDA approved will be described 
in further detail.  
 
Trastuzumab is a humanised anti-ErbB2 (HER-2) antibody.  The ErbB2 
receptor does not have any known ligands but activates signal transduction by 
the formation of heterodimers with other receptors in the same family (such 
as EGFR-1), and acts as co-receptor for a number of EGFR ligands.  EGFR 
heterodimers that contain ErbB2 have a greater signally potency owing to 
their higher affinity for ligand, lower endocytosis rate compared to 
homodimers, and the fact that internalised heterodimers are recycled back to 
the cell surface following internalisation rather than being degraded54 77.  The 
HER-2/neu proto-oncogene, which encodes the ErbB2 receptor, is amplified in 
around 25-30% of breast and ovarian cancers (which is associated with over 
expression) and is established as a poor prognostic factor and predicts relapse 
and survival in node positive breast cancer patients71 72.  Trastuzumab is a 
recombinant, humanised anti-ErbB2 IgG1 (Kd=5nM), which inhibits signal 
transduction by preventing the formation of EGFR heterodimers, inducing 
ADCC and improving the efficacy of chemotherapy in HER-2 positive cancers.  
It may also remove ErbB2 from the cell surface and promote receptor 
degradation, leading to a subsequent decreased formation of ErbB2 
heterodimers, and hence reduced EGFR induced signalling78.  In vitro 
phenotypic changes as a result of trastuzumab treatment include down 
modulation of the ErbB2 (HER-2) receptor, inhibition of tumour cell growth, 
and reduced vascular endothelial growth factor production77.  As described, 
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trastuzumab is now a well-established component of the treatment for HER-2 
positive breast cancer patients, and trial evidence suggests its use is 
associated with improvements in disease free survival (DFS) and overall 
survival (OS) in both early breast cancer79 80 and metastatic patients38 81-83.  
Humanisation ensured low immunogenicity, with <1% of patients developing 
HAHA in clinical trials84. 
 
Cetuximab is a chimeric IgG1 capable of binding EGFR (EGFR-1) with high 
affinity (Kd=87 pM)
85, preventing ligand-induced EGFR phosphorylation and 
activation86 87.  The EGFR-cetuximab complex is internalised88, and it is 
thought by some that intracellular trafficking leads to degradation and 
recycling to the cell membrane6 54.  It is a competitive antagonist, which has 
been shown to lead to cell cycle arrest89, and enhance tumour cell death 
when cells are damaged by concurrent chemotherapy or radiation74.  Early 
Phase I and I/II trials demonstrated the safety of cetuximab alone or in 
combination with chemotherapy for patients with metastatic squamous cell 
carcinoma of the head and neck, CRC, and NSCLC.  It has been shown to 
achieve response rates in chemotherapy refractory CRC patients of 8.8% 
when used alone, and 22.9% when combined with irinotecan90 91.  Recent 
phase III trials in CRC have reported that the addition of cetuximab to first and 
second line irinotecan based chemotherapy regimens improved progression 
free survival (PFS)92, and OS and quality of life were improved when 
cetuximab monotherapy was compared to best supportive care in the third 
line setting93, although in all these studies the improvement was modest.   It 
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has been shown to improve survival of patients with untreated head and neck 
carcinomas in combination with radiotherapy compared to radiotherapy 
alone94.  Anaphylactic reactions in 3-4% (with geographical variations) have 
been reported 95 96.  
 
Panitumumab is a fully humanised IgG2-isotype human antibody generated 
from XenoMouse strains (Abgenix Inc).  It has a high-affinity (Kd=50 pM)
, and is 
able to totally block binding of EGF and TGF binding to the EGFR, which 
induces profound and rapid internalisation of the receptor97 98.  As a result, 
receptor phosphorylation, EGFR-dependent signal transduction, angiogenesis 
and cellular proliferation are inhibited97 98.  It is not capable of inducing a 
biological effect through an immune mediated mechanism (as IgG2-isotopes 
are not able to induce CDC).  Instead cytotoxicity occurs only as a result of 
EGFR signal transduction inhibition.  In preclinical mouse xenograft models, it 
was found to be as potent as cetuximab97, and in early phase clinical trials, 
demonstrated similar single agent activity, with some achieving response 
rates of 9-10% in metastatic CRC99 100.  There is evidence panitumumab may 
inhibit angiogenesis in prostate cancer101 and Phase II trials in hormone-
resistant prostate cancer are ongoing.  /ŶZŽǁŝŶƐŬǇĞƚĂů ?ƐƌĞƉŽƌƚŽĨƚŚĞŝƌĚŽƐĞ
escalation study in 88 metastatic renal cell carcinoma (RCC) major responses 
occurred in three patients, and an additional 44 patients (50%) demonstrated 
stable disease at their first 8-week assessment. Although response rates were 
low, it was tolerable, with a dose-dependent skin rash being the most 
common toxicity encountered98.  Despite response rates comparable to 
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cetuximab in early monotherapy trials, full humanisation means it is non-
immunogenic, and hence seen by some as a significant improvement on 
cetuximab, in which immune responses including fatal anaphylactic reactions 
have been reported102 ?/ƚ ?s role in combination with chemotherapy and other 
biological agents however, is yet to be confirmed103-105. 
 
Other EGFR targeting antibodies in development include 2F8, which is also 
fully humanised, but is an IgG1 so unlike panitumumab may have effector 
function in addition to EGFR inhibition capabilities106.  Matuzumab (EMD-
7200) is a humanised EGFR antibody now in Phase II trials after establishing 
tolerability (and activity) in Phase I trials in patients with solid tumours 
including head and neck, ovarian, colon, lung107 and cervical cancers108.  h-R3 
also targets EGFR, and Phase II trials are ongoing109.  Pertuzumab is a 
humanised HER2 antibody in Phase II development in breast, ovarian, 
prostate and NSCLC110.  More recently, a chimeric antibody targeting a 
tumour specific epitope of EGFR has entered clinical development, and has 
shown exciting tumour targeting properties, and without side effects14. 
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1.6 Optimising the therapeutic potential of monoclonal 
antibodies for the treatment of metastatic solid tumours 
 
Despite monoclonal antibodies offering significant therapeutic promise for 
patients with metastatic solid tumours, response rates for monotherapy with 
cetuximab, panitumumab and bevacizumab remains disappointingly low and 
survival advantage for these agents are modest.  With costs remaining high, 
public funding for these treatments in metastatic disease is limited in many 
countries.  Potential barriers to therapeutic efficacy of this treatment strategy 
are numerous, and exploring ways to overcome these obstacles may hold the 
key to optimising their therapeutic potential in metastatic solid tumours. 
 
1.6.1 Barriers to therapeutic efficacy of monoclonal antibodies in solid 
tumours 
 
1.6.1.1 Biological barriers 
Heterogeneity of target antigen expression, reduced vascular permeability, 
abnormal vasculature and areas of hypoxia are all significant physical barriers 
to solid tumour penetration of systemically administered monoclonal 
antibodies.  Intra-tumoural or intravenous injection with vasoactive agents or 
cytokines prior to administration of therapeutic antibody to improve vascular 
permeability and tumour penetration has been suggested and explored in 
mouse tumour xenografts, with some pre-clinical success111 112. 
 
As well as the possibility of a potentially hypoxic, necrotic component to a 
bulky solid tumour, stromal and interstitial barriers (such as increased 
 45 
interstitial fluid pressure) are also likely to contribute further to inadequate 
and heterogeneous perfusion of such disease sites113.  Large proteins like 
antibodies can have difficulty penetrating solid, high density tumours 
adequately, which is why this treatment strategy maybe more successful in 
small volume disease.  Using tumour necrosis factor to lower interstitial 
pressure and increase monoclonal antibody perfusion in mouse tumour 
xenografts by promoting tumour cell apoptosis has been demonstrated114.  
This approach is, however, impractical in human subjects due to the marked 
side effects of systemic TNF treatment. 
 
1.6.1.2 Complex downstream signal transduction pathways 
The varied success of EGFR and VEGFR antibodies in the clinic clearly 
illustrates that although many different tumour types utilise signalling 
pathways in order to their promote their growth, this occurs via a multitude 
of mechanisms, some of which are yet to be fully described.  As will be 
discussed in greater detail in section 1.7, there is no clear correlation between 
EGFR over expression in primary tumour and response agents such as 
cetuximab, indicating the presence of the target does not automatically mean 
success for targeted antibodies.  As the molecular profile of tumours is slowly 
being characterised, explanations as to why response to antibodies targeting 
the EGFR family (and EGFR tyrosine kinase inhibitors) is so variable are coming 
to light.  Understanding how individual tumours use this pathway, is likely to 
greatly aid the optimisation of therapeutic antibodies that target it (as 
discussed in section 1.7 and explored in Chapter 2).  This is also illustrated by 
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the limited response seen by EGFR tyrosine kinase inhibitors (TKI) in 
unselected NSCLC patients.  After a disappointing lack of significant survival 
advantage in Phase III trials of TKI gefitinib115, it was discovered that 
mutations in the EGFR tyrosine kinase domain in a subset of NSCLC could 
predict response to gefitinib and erlotinib116 117, indicating that it is this subset 
of patients these mutations were likely dominant contribution of their 
ƚƵŵŽƵƌ ?ƐŵĞĐŚĂŶŝƐŵƐŽĨ'&ZŽǀĞƌĂĐƚŝǀĂƚŝŽŶ ? 
 
When it was determined that EGFR expression in primary CRC did not 
correlate with response to cetuximab118, it became clear that determination 
EGFR status by IHC on primary tumour alone, does not accurately reflect 
intracellular signal transduction pathway activation driving tumour growth.  In 
tumours shown to display ligand overproduction, a strategy to block ligand-
receptor binding is likely to be efficacious.  If a tumour has an activating 
mutation of the EGFR tyrosine kinase domain however, blocking ligand 
binding is unlikely to induce a response, but a tyrosine kinase inhibitor may 
slow tumour growth. If over expression of EGFR also leads to increased 
expression of vascular epithelial growth factor (VEGF), then blocking the EGFR 
alone is unlikely to prevent angiogenic changes induced by VEGF.  If more 
than one component of the downstream signal transduction cascade is 
activated, then selecting potential non-responders on the basis of detecting 
one such activating mutation is likely to be unsuccessful.  The complex 
network of intracellular pathways and cross talk in tumours therefore 
provides a diverse array of potential barriers to therapeutic efficacy of 
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monoclonal antibodies in solid tumours.  Mutations of receptors or 
intracellular components of the signal transduction cascade downstream of 
target receptors are being recognised as potential predictors of response in 
CRC patients, which may improve patient selection for treatment with EGFR 
antibodies and optimise their clinical use. 
 
1.6.2 Combining antibodies with other treatment modalities 
The modest survival advantage gained by the use of antibodies such as 
cetuximab, trastuzumab and bevacizumab as a single agent in metastatic solid 
tumours have led to their combination with other treatment modalities in 
clinical development. 
 
1.6.2.1 Targeted antibodies with concurrent chemotherapy 
There is a considerable body of evidence to demonstrate that inhibition of 
ErbB family members, particularly EGFR and ErbB2, can enhance the efficacy 
of cytotoxic chemotherapy.  Trastuzumab was first shown to significantly 
enhance the tumouricidal effects of paclitaxel in patients with ErbB2 over 
expressing breast cancers, and this additive interaction has also since been 
seen with anthracyclines and some antimetabolites119.  Pre-clinical evidence 
also revealed a synergistic interaction with alkylating agents, platinum analogs 
and topoisomerase II inhibitors in HER-2/neu-overexpressing breast cancer 
cells119.  Whilst trastuzumab in combination with paclitaxel for treatment of 
HER2-overexpressing metastatic breast cancer is standard practice worldwide, 
trials combining this antibody with many other chemotherapy regimen are 
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also ongoing38 81 120.   Cetuximab can potentiate the therapeutic effects of a 
variety of types of chemotherapy over a broad range of cell and tumour types 
expressing EGFR60.  ƵŶŶŝŶŐŚĂŵ Ğƚ Ăů ?Ɛ ůĂŶĚŵĂƌŬ ƚƌŝĂů ƌĞƉŽƌƚĞĚ Ă ƌĞƐƉŽŶƐĞ
rate of 22.9% when combined with irinotecan, in irinotecan refractory 
patients90, suggesting it can reverse chemoresistance when given in 
combination with chemotherapy.  Recent Phase III trials in CRC have reported 
that the addition of cetuximab to first and second line irinotecan based 
chemotherapy regimens improved PFS92 93.  Cetuximab can also be safely 
combined with chemotherapy for the treatment of squamous cell carcinoma 
(SCC) of the head and neck121. 
 
The addition of bevacizumab to 5-fluorouracil/leucovorin (5-FU/LV) provided 
a statistically significant improvements in response rate, progression-free 
survival, and overall survival in patients with previously untreated metastatic 
colorectal cancer44 122.  Bevacizumab and chemotherapy combinations have 
been explored in metastatic breast cancer, but the synergistic effect is less 
clear. In metastatic breast cancer patients, although the addition of 
bevacizumab to capecitabine produced a significant increase in response 
rates, this has not always translated into improved PFS or OS47 123.  The 
addition of bevacizumab to paclitaxel plus carboplatin in the treatment of 
selected patients with NSCLC patients demonstrated a 2 month improvement 
in median survival, suggesting potential synergy, but this was at the expense 
of increased treatment-related deaths46. 
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1.6.2.2 Targeted antibodies with concurrent external beam radiation 
It has recently been established that in certain solid tumours, the addition of 
an EGFR targeting antibody to radiotherapy can improve the therapeutic 
efficacy of ionising radiation.  It has been demonstrated that increased 
activation of the EGFR pathway in cancer cells can occur when exposed to 
ionizing radiation124 125.  In vitro exposure of EGFR-positive human breast 
cancer cells lead to increased mitogen-activated protein (MAP) kinase 
signaling124, whilst in vivo exposure of human breast cancer xenografts, 
increased the level of phosphorylated EGFR125.  This finding that exposure to 
radiation can induce EGFR receptor activation, suggests that EGFR signaling is 
likely to play a role in the survival of cancer cells after radiation. EGFR-
mediated radiosensitisation may also be a result of enhanced radiation-
induced apoptosis seen with EGFR blockade74.  Logically therefore, the 
addition of EGFR targeting antibodies to concurrent radiation is likely to cause 
radiosensitisation and potentially improve patient outcome. 
 
The addition of cetuximab to radiotherapy has an established role in the 
treatment of squamous cell carcinoma (SCC) of the head and neck.  This 
combination has been shown to improve loco regional control and survival of 
such patients compared to radiotherapy alone (without increasing common 
toxic effects) in a randomised study of 424 SCC patients94.  Improved 
therapeutic effect of cetuximab when combined with external beam 
radiotherapy is thought to be due to enhancement in radio sensitivity and 
amplification of radiation-induced apoptosis in squamous cell carcinoma cells, 
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which can be observed in both single-dose and fractionated radiation 
experiments74.  Combined treatment induces an accumulation of human SCC 
cells in the more radiosensitive cell cycle phases (G1, G2-M) with concurrent 
reduction in the proportion of cells in the more radioresistant S phase.  Strong 
inhibitory effect of cetuximab on post radiation damage repair has also been 
demonstrated75.  
 
Combining cetuximab with pre-operative chemoradiation has also recently 
been explored, with no dose-limiting toxicity (DLT) occurring with this 
combination in 40, high-risk rectal cancer patients126.  A non-randomised, 
open-label, multi-centre Phase II study of neoadjuvant therapy of T3-4 rectal 
cancer patients with cetuximab and irinotecan, given concurrently with 
radiation (50.4 Gy/28 fractions) and capecitabine is currently underway127.  
Prelimary findings of the first 21 patients enrolled reported promising 
pathologic responses with mild toxicity profiles.  
 
1.6.2.3 Targeted antibodies combined with other biological agents 
As the increasing complexity of molecular pathways involved in tumour 
growth is slowly uncovered, it is being suggested that improved efficacy may 
come from combinations with other biological agents.  Strategies under 
investigation include; targeting both EGFR and ErbB2 pathways 
simultaneously128, targeting the EGFR or ErbB2 with both a monoclonal 
antibody and a tyrosine kinase inhibitor(TKI) simultaneously129 (trials of 
herceptin with lapatinib, an ErbB2 TKI, are currently underway in breast 
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cancer patients), combining EGFR and VEGFR blockade104, and combining 
EGFR antibodies with agents that target other downstream molecules.  An 
recent pre-clinical example of this strategy would be the addition of the B-raf 
inhibitor sorafenib which may restore sensitivity to panitumumab or 
cetuximab in CRC carrying a B-raf mutation130.  
  
1.6.3 Predictors of response 
Whilst strategies to combine monoclonal antibodies with other treatment 
modalities have led to significant outcome improvements for patients with 
metastatic solid tumours, the key to optimising the use such may lie in the 
better characterisation of the molecular profile of the tumours they are 
designed to target.  By expanding our knowledge of the molecular basis of 
tumours, and how they may be resistant to such treatments, it is hoped that 
these targeted treatments can be better tailored to individual patient/tumour 
profiles.  Treatment could then be selected on these profiles so that response 
can be predicted, and only those likely to respond would then be exposed to 
the potentially toxic side effects and high cost involved.  
 
Trastuzumab has made its way into the routine management of patients with 
HER-2 positive breast cancer, largely due to the correlation of HER-2 over-
expression and response to trastuzumab, allowing easy identification of 
patients whom are likely to benefit from such a targeted therapy.  As will be 
described in more detail in Section 1.7 the story is not as clear cut for 
antibodies which target EGFR and VEGF.  Over expression of EGFR does not 
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consistently predict response to cetuximab131, and although bevacizumab 
inhibits VEGF-A, available assays of VEGF expression do not predict response 
to bevacizumab132.  Possible confounding factors may include; tumour 
heterogeneity, sub-optimal methods for detecting target expression, complex 
signalling pathways, and differences in primary and metastatic tumours. 
 
Using microarray technology to profile tumour specimens or gene expression 
profiles maybe a way to identify patients likely to response to certain targeted 
treatments.  Non-responding tumours may over express other receptors, or 
display activation of alternative signal transduction pathways.  Transcriptional 
profiling of breast cancer patients identified several possible predictors for 
poor response to trastuzumab and vinorelbine therapy which included genes 
associated with insulin-like growth factor-I receptor (IGF-IR) pathway 
members133.  
 
Where presence of target does not predict response to targeted therapy, 
more must be learnt of the molecular profile of tumours, and what stimulated 
tumour growth.  One of the important questions still to be answered is 
whether the molecular make-up is consistent across distant metastatic sites.  
Patient and tumour biomarkers for predicting response to targeted therapies 
is an area of intense investigation, which has a real chance of helping to 
improve the use of such antibodies in the near future. 
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1.6.4 Targeted antibodies with a therapeutic payload 
Optimisation of therapeutic monoclonal antibodies maybe achieved by a 
number of mechanisms.  As described, for unconjugated antibodies, this 
maybe facilitated by combining with concurrent chemotherapy, radiotherapy, 
or other targeted therapies such a small molecule inhibitors or identifying 
methods for predicting response to therapy and improving patient selection.  
Although these approaches have shown progress can be made in improving 
outcomes for patients with metastatic disease (largely in terms of slowing 
progression), the magnitude and duration of benefit still requires significant 
improvement.  Another strategy, which has reached the clinic in 
haematological malignancies, is to conjugate antibodies with a toxin or 
radionuclide.  This allows the antibody to target the tumour cells and deliver 
ŝƚƐ  “ƉĂǇůŽĂĚ ? ŝŶ Ă ƐƉĞcific manner.  Extensive preclinical characterisation is 
essential for the development of such immunoconjugates, as the properties of 
the antigen, antibody, conjugate must all be suitable for such an approach for 
clinical efficacy to be possible.  Whilst agents such as Mylotarg, Bexaar and 
Zevalin have been approved in the treatment of certain haematological 
malignancies, the race is on to develop similar agents for the treatment of 
solid tumours, with varying success. Antibody-directed enzyme prodrug 
therapy (ADEPT) is another targeted therapy strategy in which a prodrug is 
activated selectively at the tumour site by an enzyme, which has been 
targeted to the tumour by an antibody (antibody-enzyme conjugate)134,135. 
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1.6.5 Immunoconjugates: Antibody-targeted chemotherapy 
The concept of therapeutic agents being able to target diseased cells whilst 
leaving normal tissues unharmed has been the goal for those treating cancer 
for many years, with some recent success.  Whilst chemotherapy and 
radiotherapy have both demonstrated efficacy in killing most types of cancer 
ĂŶĚƌĞŵĂŝŶƚŚĞŵĂŝŶƐƚĂǇŽĨƚŚĞŽŶĐŽůŽŐŝƐƚ ?ƐƚƌĞĂƚŵĞŶƚĂĐƵŵĞŶ ?ƚŚŝƐĐĂŶďĞĂƚ
the expense of toxicity to the patient.  Sequelae of a toxic regimen include the 
delivery of sub-optimal treatment, significant impact quality of life 
(particularly important for treatment with palliative intent), morbidity and 
mortality.   
 
Tumour antigens offer a potential cellular marker by which a novel targeted 
therapy may begin to distinguish between malignant and normal cells, and 
deliver targeted therapy, sparing the surrounding normal tissues. 
Theoretically this should improve therapeutic index of conjugated cytotoxics, 
as administration of an adequate dose should not be limited by unacceptable 
toxicity, as targeted delivery should prevent indiscrimate killing of normal 
cells.  Although monoclonal antibodies are a promising method for delivering 
targeted therapy, many obstacles need to be overcome for this to happen 
effectively.  As described, overcoming the development of human anti-mouse 
antibodies (HAMA) by patients infused with the earlier murine therapeutic 
monoclonal antibodies was made possible by the development of chimeric 
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and humanised antibodies, although some humanised antibodies can still 
induce HAHA responses.   
 
Problems that persist in the successful development of immunoconjugates 
include tumour heterogeneity, meaning only a proportion of tumour cells that 
express the target antigen are reached, and localisation and penetration of 
the antibody into the tumour, to deliver its therapeutic payload.  The success 
of any antibody-targeted chemotherapy or immunotoxin can be influenced by 
a number of factors.  The potency of the cytotoxic agent (whether a drug or 
toxin), the sensitivity of the tumour cells being targeted, the level and location 
of antigen expression, the ability of the bound antibody to internalise (and 
hence deliver its cytotoxic intra-cellularly), and the chemical stability of the 
conjugate.  
 
Targeted cytotoxicity has been demonstrated in xenografted tumours by 
conjugating number of different tumour associated antigens with toxins (e.g. 
pseudomonas exotoxin136) or chemotherapeutics.  Chemotherapeutics used in 
this way include those also used systemically like doxorubicin137, and those 
too toxic to use systemically such as maytansinoid138 and calcheamicin139.  An 
example of how this therapeutic strategy has already been translated into 
patient benefit is the immunoconjugate gemtuzumab ozogamicin (Mylotarg), 
which was approved by the FDA in 2000 for the treatment of refractory acute 
myeloid leukaemia (AML)140.  Gemtuzumab ozogamicin combines anti-CD33 
antibody with NAc-gamma calicheamicin, a derivative of calicheamicin methyl 
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trisulfide.  This is done by an acid-hydrolysable AcBut bifunctional linker [4-(4'-
acetylphenoxy) butanoic acid], which is bound to a disulfide analog of the 
semi-synthetic N-acetyl calicheamicin, producing N-acetyl calicheamicin-
dimethyl hydrazide (CalichDMH). Calicheamicin belongs to the emetine class 
of cytotoxics  W natural substances produced by Micromonospora echinospora, 
ssp calichensis. They contain an enediyne "warhead" that when activated 
causes double-stranded DNA breaks and subsequent apoptosis and cell 
death141.  Myelosuppression was found to be the principle toxicity in Phase I 
trials of Mylotarg because of the expression of CD33 on myeloid progenitor 
cells.  Subsequent overall response rates were found to be in the region of 
30% in Phase II studies140, but duration of response was difficult to determine, 
and hepatotoxicity was significant with 31% showing abnormal liver function 
tests.  Post-marketing reports highlighted the need for careful monitoring for 
acute hypersensitivity, hypoxia, and delayed hepatotoxicity following 
treatment with gemtuzumab ozogamicin140. 
 
Clinical trials are ongoing to find equivalent agents that are efficacious in solid 
malignancies.  Examples that have reached early clinical trials include 
cantuzumab mertansine and huN901-DM1.  Cantuzumab mertansine is an 
immunoconjugate of the potent maytansine derivative (DM1) and the 
humanised monoclonal antibody (huC242), which is directed to the antigen 
CA242.  This demonstrated tumour localisation, and encouraging biologic 
activity in chemotherapy-refractory patients with CA242-expressing 
tumours142.  huN901-DM1 is composed of the humanised monoclonal CD56-
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targeted antibody huN901, and the same potent anti-microtubule agent, 
DM1.  It is thought to have potential as a novel treatment of CD56 expressing 
cancers such as small-cell lung cancer143 144.  CMB-401 is an immunoconjugate 
combining monoclonal antibody directed against polymorphic epithelial 
mucin (hCTM01) bound covalently to calicheamicin.  Despite a suggestion of 
efficacy in a Phase I trial145, a subsequent Phase II study of 21 patients, also 
with recurrent platinum-sensitive epithelial ovarian carcinoma, failed to 
demonstrate efficacy in this setting, possibly due to the choice of linker146. 
 
As will be described in section 1.8, many of the properties of anti-Ley 
antibodies suggest they have the potential to make an impact as therapeutic 
immunoconjugate.  Limited expression of Ley in normal tissues, specificity to 
Ley of antibodies such as 3S193, BR96, and ABL364, internalisation of bound 
antibody-antigen complexes, and effector cell function by induction of CDC 
and ADCC, are all properties that are key if therapeutic benefit is likely.   
 
1.6.6 Immunoconjugates: Antibody targeted radiotherapy  
Although the therapeutic concept of radioimmunotherapy has been in 
existence for years, it finally reached the oncology clinic in 2002 when the FDA 
approved the use of 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of 
relapsed or refractory low-grade non-Hodgkin's lymphoma (NHL).  A similar 
antibody targeting the same CD20 antigen expressed in B cell lymphomas 131I-
tositumomab (Bexaar), was approved soon after in 2003 for the same 
indication.  For solid tumours such as breast, lung an
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to be radiosensitive, radiotherapy in the metastatic setting has been limited 
to palliative local treatment to problematic areas (e.g. painful boney 
metastases or symptomatic local recurrences).  It is obviously difficult for 
example, to give external beam radiotherapy to liver metastases because of 
the toxicity to surrounding normal liver.  Being able to deliver radiotherapy 
systemically and targeting it to sites of metastatic disease (as it is now 
possible in the treatment of lymphoma), is an exciting and promising 
approach under investigation.  Unfortunately it has yet to make any 
significant therapeutic impact in solid malignancies.  The reasons for this 
current lack of efficacious radioimmunotherapeutics aimed at solid tumours 
include the larger size of metastatic lesions being targeted, the difficulties in 
delivering a therapeutic dose of radiation to this type of tumour, less 
radiosensitive tumours, and difficulties finding suitable antigenic systems to 
target147.  Using this strategy to target the A33 antigen with 
radioimmunotherapy in CRC will be described in detail in section 1.9. 
 
1.6.6.1 Choice of radioisotope 
For effective radioimmunotherapy, the selected radioisotope must be stably 
conjugated to the antibody.  This is typically performed by either direct 
labelling of the antibody by substitution of iodine into tyrosine residues148, or 
by using a bifunctional metal ion chelate to act as a covalent linker. An 
example of such a chelate is C-functionalised trans-cyclohexyl-
diethylenetriaminepentaacetic acid (CHA- ?-DPTA), which has shown rapid 
and reproducible labelling, and stable binding both in-vitro, and in preclinical 
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and clinical studies.  Antibody internalisation and dissociation of radioisotope 
is not necessarily required for efficacy, (as demonstrated by 90Y-ibritumomab 
tiuxetan and 131I-tositumomab, neither of which are internalised on binding 
CD20 positive cells), but this may be preferential to maximise exposure of 
tumour cells to radiation. 
 
The physical properties and half-life of component isotopes in 
radioimmunotherapy must be carefully considered.  Path length and energy of 
emission should be selected depending on the likely size of the lesions to 
target and the internalising properties of the antibody147.  Because patients 
with metastatic solid tumours often have a significant disease burden (as 
apposed to micrometastatic disease), beta emitters (such as 131I, 177Lu, 90Y) are 
more suited to radioimmunotherapy in this scenario147, and hence will be the 
focus of this section.  Alpha emitters are being investigated in animal models, 
and in a small number of clinical trials, but remain experimental.  Beta decay 
involves the break down of a neutron, changing to a proton and emitting a 
high-energy electron (beta particle).  Adjacent cells may also be hit, which 
enhances cell kill through a bystander effect to adjacent tumour cells, but may 
also lead to myelosuppression when the bone marrow is irradiated by 
circulating radioactive antibody.  Beta emitters typically cause cell death by 
inducing single stranded DNA breaks (when free radicals are produced by the 
ionisation of water), which lead to cell cycle arrest and apoptosis149.   
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131
I has had an established role in the treatment of thyroid cancer for >20 
years, and has been used most extensively in the development of 
radioimmunotherapy.  There are a number of factors which make 131I such a 
ƐƵŝƚĂďůĞ ŝƐŽƚŽƉĞ ? ŝŶĐůƵĚŝŶŐ ŝƚƐ ƐƚĂďůĞ ĐŚĞŵŝĐĂů ƐƚƌƵĐƚƵƌĞ ? ƌĂŶŐĞ ŽĨ ɴ ƉĂrticles 
(0.08-2.3mm), and relatively long half-life (8 days).  Simultaneous gamma 
photon emissions by beta emitters 131I and 177Lu, means gamma camera 
imaging can be used to assess biodistribution without the need of an another 
radiotracer.  
 
177
Lu is another medium energy beta-emitter, which has a path length of 0.04-
1.8mm.  It can be conjugated to monoclonal antibodies, and has 
demonstrated tumour targeting and therapeutic efficacy as a 
radioimmunoconjugate in a range of preclinical models, and in early phase 
clinical trials in patients with prostate, colon and renal cancer147 150 151.  Blood 
and urinary pharmacokinetics, terminal half life, and total-body retention of 
activity can be similar for both 177Lu and 90Y labelled antibodies, although 
studies have demonstrated that radiation dose to bone marrow is higher with 
90Y152.  As well as beta emissions, 177Lu emits 15% of its energy as gamma rays, 
which can be imaged using a gamma camera.  
 
90
Y has one main advantage over 131I in the potential treatment of solid 
ƚƵŵŽƵƌƐ ?ĂŶĚƚŚĂƚŝƐŝƚƐůŽŶŐĞƌɴƉĂƌƚŝĐůĞƉĂƚŚůĞŶŐƚŚ ?ǁŚŝĐŚƚŚĞŽƌĞƚŝĐĂůůǇŵĂǇ
penetrate into larger, bulky tumours.  It is a high-energy beta-emitter, capable 
of penetrating up to 11mm and increase cell kill via the bystander effect.  As it 
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is not a gamma photon emitter, it needs to be given with an additional 
radiotracer (e.g. Indium-111) for localisation to be assessed.  Radiometal 
labelled antibodies are not as susceptible to intracellular degradation, and 
therefore maybe the more logical choice for conjugation with internalising 
antibodies. It is important to note that normal tissue toxicity from bystander 
effects, particularly bone marrow and gastrointestinal tract, may occur with 
90Y-labelled antibodies. 
 
Alpha-emitters such as 213Bi and 211At have a high energy but short path 
length emission, and studies have shown these radioisotopes labelled to 
antibodies are highly effective at killing tumour cells in-vitro and in-vivo153 154.  
The lower myelotoxicity of auger-emitters such as 125I or 111In labelled to 
antibodies is due to the short path length of their low-energy electrons155.  In 
order to facilitate cytotoxicity, these radioisotopes need to be internalised (to 
be close to the nucleus).  If internalisation of the antibody by red marrow 
stem cells can be avoided, then the nuclear DNA can be spared damage and 
myelotoxicity reduced.  Cytotoxicity can be achieved with only a few nuclear 
hits, and in mouse models, the formation of metastases has been inhibited156.  
There is little current evidence to suggest alpha-emitters are effective in the 
treatment of solid tumours, but preclinical studies and Phase I clinical trials 
are ongoing.   
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1.6.6.2 Choice of antibody 
As well as choosing a suitable radioisotope, the choice of antigenic system and 
properties of the antibody are also critical in the development of a potentially 
efficacious radioimmunotherapeutic agent.  Serum half-life and clearance will 
influence the degree of myelosuppression (maximal 6 weeks after a 
therapeutic radioimmunotherapy infusion) as well as efficacy.  The 
internalising properties of the antibody will effect how much radiation 
reaches the nucleus, impacting on degree of likely cell kill.  
 
1.6.6.3 Radioimmunotherapy in the treatment of haematological 
malignancies 
The emerging role of 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab 
(Bexaar) for the treatment of relapsed or refractory NHL is largely due to the 
known radiosensitivity of NHL cells, and the accessibility of disease to 
systemically administered antibodies157.  When disease is largely located in 
lymph nodes and bone marrow, it is easily reached by circulating radiolabelled 
antibodies.  Phase II studies have demonstrated high response rates to these 
agents (particularly in the first line treatment setting of follicular NHL) alone158 
or following chemotherapy159).   The only randomised controlled trial of 
radioimmunotherapy compared 90Y-ibritumomab tiuxetan to Rituximab in 
refractory and progressive low grade NHL160.  This small study found that 
response rates were significantly improved with 90Y-ibritumomab tiuxetan, 
but no statistically significant improvement in time to progression was seen.  
Response rates to 131I-tositumomab in relapsed or refractory low-grade NHL 
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range from 47-95%, complete response rates of between 20-38%, and 5-year 
PFS of 17-69% (depending of degree of prior treatment)158-161.  Current data 
suggests front line 90Y- ibritumomab tiuxetan does not preclude patients from 
receiving additional cytotoxic therapies162, and in a proportion of patients can 
lead to durable responses, even with treatment refractory disease163.  Many 
clinical trials are currently underway to clarify the degree of survival benefit 
and optimal therapy combination for these agents.  
 
1.6.6.4 Radioimmunotherapy in solid malignancies 
Targeting solid tumours with radioimmunotherapeutics remains a challenge.  
This is partly because the doses shown to be effective in haematological 
malignancies are insufficient in many epithelial cancers, and hence only a 
small number of such approaches targeting solid malignancies have shown 
substantial clinical efficacy.  Many tumour types including colorectal, prostate, 
breast, gliomas, renal and lung cancer have been targeted with this approach. 
 
The use of radiolabelled antibodies in a loco-regional infusion setting in solid 
tumours has shown some promise. The selective targeting of tumour, 
particularly in ovarian cancer and gliomas, has been demonstrated following 
intraperitoneal infusion, or direct intralesional infusion, of 131I, 177Lu and 90Y-
labelled antibodies, with improvements in response and PFS164 165 166-168.  A 
recent large Phase III trial of 90Y-anti-MUC1 antibody in ovarian cancer did 
not, however, show an improvement in response rate or PFS168.  It is likely 
 64 
that larger Phase II trials in gliomas, which are ongoing, may show more 
promising results and a possible clinical indication for this approach. 
 
A recent important development is the treatment of NSCLC with 131I-chTNT, 
which showed an objective response rate of 33% in 97 NSCLC patients169.  131I-
chTNT has subsequently been approved for the treatment of NSCLC in China, 
and additional clinical indications are being explored.  
 
The murine anti-Ley antibody B3 was conjugated with 90Y in a Phase I trial of  
26 patients with advanced epithelial tumours expressing Ley170.  In this trial 
the maximum tolerated dose (MTD) of 90Y-mAb B3 was determined to be 20 
mCi, with myelosuppression as the dose limiting toxicity (DLT).  This dose of 
radioactivity was not sufficient to achieve any anti-tumour effect. 177Lu-CC49 
administered to advanced cancer patients was associated with acceptable 
hematological toxicity but Mulligan Ğƚ Ăů ?Ɛ ƐƚƵĚǇ ƌĞƉŽƌƚĞĚ Ă ůŽǁĞƌ Dd  ?ŽĨ
only 15mCi/m2) compared to other 177Lu labeled immunoconjugates, and 
prolonged 177Lu retention in the reticuloendothelial system has not been 
reproduced in other studies171.  Little therapeutic benefit was demonstrated 
after intra-peritoneal radioimmunotherapy (RIT) in 6 patients with residual 
ovarian carcinoma treated with an ovarian cancer 125 F(ab')2 monoclonal 
antibody labeled with 120 mCi of 131I, injected 5-10 days after the surgical 
debulking167. 
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Reported Phase I radioimmunotherapy trials in prostate cancer patients 
include 90Y-CYT-356172, 90Y-2IT-BAD-m170 (murine antibody that targets 
adenocarcinomas)173,90Y-J591174 and 131I-CC49175, all of which were well 
tolerated, with myelosuppression being the principal toxicity. 90Y-2IT-BAD-
m170 (which utilises a murine antibody that targets adenocarcinomas) has 
shown ability to target metastatic prostate cancer, deliver mean radiation 
dose to boney and nodal metastases of 10.5 Gy/GBq with manageable side 
effects with some patients experiencing temporary palliation of pain173.  
Twenty-nine patients with hormone refractory prostate cancer received 90Y-
: ? ? ?ŝŶDŝůŽǁƐŬǇĞƚĂů ?ƐWŚĂƐĞ/ƐƚƵĚǇ174.  MTD was established as 17.5mCi/m2 
with targeting of known sites of metastases in the majority of patients.  Some 
efficacy was demonstrated two patients experiencing significant declines in 
prostate-specific antigen (PSA) levels (lasting 8 and 8.6 months), and objective 
measurable disease responses.  A further six patients experienced 
stabilisation of PSA levels.  The anti-prostate-specific membrane antigen 
(PSMA) specific humanised antibody : ? ? ? ǁĂƐ ĂůƐŽ ƵƐĞĚ ŝŶ ĂŶĚĞƌ Ğƚ Ăů ?Ɛ
study, conjugated with 177Lu157.  Myelosuppression was again dose limiting, 
this time at 75 mCi/m2, and the 70 mCi/m2 dose level was determined to be 
the single-dose MTD.  Acceptable toxicity, good targeting of known sites of 
prostate cancer metastases, and biologic activity has led to an ongoing Phase 
II trial.  Preliminary results presented at ASCO 2007 reported anti-tumour 
activity with single dose 177Lu-J591 (65-70mCi/m2) in patients with 
progressive, metastatic androgen independent prostate cancer with 
reversible myelosuppression150.  131I-CC49 was administered in combination 
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with adjuvant interferon, alpha-IFN in hormone resistant metastatic prostate 
cancer, and reported acceptable toxicity (myelosuppression) and significant 
absorbed radiation doses (>25 Gy in 4/8 tumours visualised)175.  Modest anti-
tumour effects were also seen.  
 
Attempts have been made to use radioimmunotherapy in metastatic renal 
cancer.  131I-G250 has been assessed in a Phase I/II trial. Thirty-three patients 
with measurable metastatic RCC were treated with a single infusion (MTD 
determined as 90 mCi/m2)176.  Myelosuppression correlated with whole-body 
radiation absorbed dose, and antibody immunogenicity restricted therapy to a 
single infusion but no major responses were seen.  Strategies to improve 
potential efficacy have been explored including the addition of IFN, adjunctive 
chelating therapy and concurrent chemotherapy (described in the next 
section).  NSCLC patients were infused with 90Y-mCC49 (anti-TAG-72 antibody) 
interferon (IFN), and either an adjunct or chemotherapy. 90Y-mCC49/IFN was 
well tolerated at a dose of 14 mCi/m2 177, but the clinical effect of adjunctive 
chelating therapy with diethylenetriamine penta-acetic acid (DTPA) was 
modest.  
 
A small number of Phase I and II trials have focused on CRC.  Twelve CRC 
patients with small volume liver metastases were entered into a Phase I dose 
escalation study with 131I- hMN-14.  MTD was reached at 60 mCi/m2 of hMN-
14, with 2 partial remissions and 5 minor/mixed responses reported178.  
Another Phase I trial explored 131I-CC49 in patients with advanced CRC 
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expressing the TAG-72 antigen reported, and reported a similar MTD of 75 
mCi/m2 in a heavily pretreated patient population179.  Myelosuppression was 
again found to be dose limiting.  All patients developed HAMA, which may 
have limited further clinical development despite excellent targeting of 
antigen-positive tumours.  Liersch et al studied 23 in a Phase II trial, who 
underwent surgery for colorectal liver metastases followed by 40 to 60 
mCi/m2 of 131I-labetuzumab (a humanised monoclonal antibody against 
carcinoembryonic antigen)180.  This small study demonstrated a promising 
51.3% 5-year survival rate (better than historical or contemporaneous 
controls) with transient myelosuppression being the commonest adverse 
effect.  
 
 
1.6.6 Targeted chemo-radiation: Combining radioimmunotherapy with 
chemotherapy 
 
Strategies to try and improve effective radiation dose delivered by other 
radioimmunoconjugates include the administration of higher doses of 
radiation with stem cell support (investigated in haematological 
malignancies)181 182, pre-targeting strategies based on the use of bi-specific 
antibodies, multiple/fractionated dosing183 or concurrent administration with 
radiosensitisers, chemotherapy, or novel tyrosine kinase inhibitors184 185.   
 
Published pre-clinical data suggests combining radioimmunotherapy with 
chemotherapy can induce enhanced anti-tumour effects186 187.  The aim of this 
approach is to use chemotherapy as a radiosensitiser, so that cancer cell cycle 
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is arrested in the in the radiosensitive G(2)/M phase, and efficacy is improved.  
The potential of this approach was exemplified by a radioimmunotherapy 
strategy with the anti-Ley antibody hu3S193 in a xenografted BALB/c nude 
mouse breast cancer model, with radioimmunotherapy given alone or in 
combination with chemotherapy188.  Significant tumour growth inhibition was 
seen with 131I-hu3S193, and there was synergy when combined with taxol 
chemotherapy (when both were administered at sub-therapeutic doses). 
Further studies with 177Lu-hu3S193 in prostate cancer models in conjunction 
with paclitaxel or EGFR inhibitors have confirmed the efficacy of this 
combination therapy approach189.  A small number of Phase I studies in 
patients with advanced solid tumours report this is a feasible and tolerable 
approach, with reversible haematological toxicity being dose limiting, with a 
suggestion of anti-tumour activity in some177 190-192.   
 
This thesis will focus on combining radioimmunotherapy with chemotherapy, 
as this strategy was employed in the Phase I trial which will be described. 
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1.7 Predictors of response: Improving therapeutic 
targeting of EGFR antibodies in metastatic disease 
 
As described in section 1.6.3, predicting response to monoclonal antibody 
therapies in patients with metastatic solid tumours may become a method by 
which patient management maybe personalised, toxic side effects and 
expensive drug costs avoided, and outcome improved.  This section will focus 
specifically on strategies for improving the therapeutic targeting of EGFR 
antibodies in CRC.  Chapter 2 will describe the findings of one such project 
undertaken as part of this thesis. 
 
1.7.1 EGFR expression in CRC 
Colorectal cancers often show a locally heterogeneous expression of EGFR 
with conflicting and inconclusive evidence explaining its role in the 
development and progression of tumours.  A number of series report over 
expression in 30-95% of primary CRC51 67 131 193-195, although this greatly 
depends on the immunohistochemical technique and method for scoring 
positivity.  A small number of published immunohistochemical studies have 
shown a definite correlation between primary EGFR expression and 
established pathological markers of tumour aggressiveness or advanced 
tumour stage67 70 196 197, but there is a larger body of evidence suggesting it is 
not a proven prognostic marker in CRC.  Analysis by Porschen et al failed to 
reveal correlations between the EGFR status and T, N and M stages or tumour 
differentiation, and the mean Ki-67 index did not differ between EGFR-
positive and EGFR-negative colonic adenocarcinomas198.  Scambia et al found 
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no correlation between EGFR and tumour localisation, tumour size, tumour 
stage, and grading in 43 CRC specimens199.  This conflicting evidence indicates 
the use of EGFR expression as a prognostic marker in CRC remains 
controversial. 
 
It is possible that whilst level of EGFR expression may not influence CRC 
progression, activation status of this receptor or components of downstream 
signal transduction pathways may have a role to play.  Despite similar staining 
for EGFR, human CRC samples were found to have higher and more variable 
staining with pEGFR and downstream effector proteins (Akt, pAkt, MAPK, 
pMAPK) when compared ƚŽŶŽƌŵĂůĐŽůŽƌĞĐƚĂůƐĂŵƉůĞƐŝŶDĞƐƐĞƌƐŵŝƚŚĞƚĂů ?Ɛ
study
200. 
  
1.7.2 EGFR related signal transduction in CRC 
The two major signalling cascades that are initiated as a result of EGFR 
activation are the PI3K-Akt and RAS-RAF-MAPK pathways.  Abnormalities in 
many of the component proteins involved in these signal transduction 
pathways have been identified in colorectal tumours (Figure 1.7.2). 
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Figure 1.7.2  Signalling pathways of EGFR 
Adapted from Mendelsohn et al, 2003 68 
 
 
 
 
 
1.7.2.1 PI3K-Akt pathway 
Phosphatidylinositol 3-kinase (PI3K) belongs to a family of ubiquitous kinases 
involved in signal transduction, and which lead to suppression of apopotosis 
and hence cell growth and tumourigenesis via downstream mediators Akt and 
mTOR.  The class I PI3Ks enzymes are involved in propagation of signal 
transduction following the activation of the EGFR, and this pathway has been 
shown to be up-regulated in CRC201 202.  Akt (protein kinase B) is an anti-
apoptotic proto-oncogene which has significant anti-apoptotic effects, and is 
over expressed in a number of malignancies, including CRC, often in the early 
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stages of malignant transformation201 203 204.  Akt becomes active once 
phosphorylated (pAKT), and it is thought that this phosphorylation is required 
for CRC cells to avoid apoptosis and lead to tumour progression205.  It has 
been suggested that pAKT levels may be utilised to monitor tumour cell 
growth and resistance to apoptosis, and clearly has a crucial role in CRC 
progression.  pAkt expression is associated with Ki-67 proliferative activity and 
maybe correlated with parameters such as depth of tumour invasion, venous 
infiltration, lymph node metastasis, and stage205. 
 
PTEN is a phosphatase whose major substrate is the second messenger 
phosphatidylinositol 3,4,5-triphosphate (PIP-3), produced by the activity of 
PI3K.  Loss of PTEN function results in increased PIP-3 concentration and 
subsequent over activation of downstream Akt, promoting cell survival and 
growth206.  PTEN therefore functions as a tumour suppressor, by negative 
regulation of the PI3K/Akt pathway207.  
 
1.7.2.2 RAS-RAS-MAPK pathway 
The RAS-RAF-MAPK (or Ras-Raf-MEK-ERK1/2) signal transduction pathway is 
involved in the control of cell proliferation, survival, and invasion in many 
cancers including CRC.  This is one of the intra-cellular pathways which involve 
the mitogen-activated protein kinases (MAPKs), which are a family of 
serine/threonine protein kinases. The p44/42 MAPK (ERK1/2) signalling 
pathway can be activated in response to many extra cellular stimuli, including 
EGFR activation. Upon stimulation (following upstream activation by 
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phosphorylation of the Ras family of GTP-binding proteins), a sequential 
three-part protein kinase cascade is initiated, consisting of a MAP kinase 
kinase kinase (MAPKKK), a MAP kinase kinase (MAPKK), and ending with a 
p44/42 MAP kinase (MAPK), ERK1/2.  Multiple p44/42 MAPKKKs have been 
identified, with those thought to be most relevant in CRC, being the members 
of the Raf family.  MEK1 and MEK2 are the primary MAPKKs in this pathway, 
and they activate p44 and p42 MAPK through phosphorylation.  
There are 3 closely related members of the Ras proto-oncogene family, HRAS, 
KRAS and NRAS.  They code for GTP-binding proteins, which are widely 
expressed in most cells and as described, have a role in the control of cell 
growth via downstream Raf/MAPK pathway.  Studies in mice have shown that 
HRAS and NRAS are not required for normal development, but KRAS is vital208. 
The RAS pathway is an important downstream cascade stimulated by EGFR 
(via adapter proteins), and a subsequent autocrine loop can induce EGFR 
ligand production.  RAS activation leads to the next step in this signal 
transduction cascade, which is the activation of RAF by phosphorylation.  
Members of the RAF family of serine threonine kinases (MAPKKKs) are ARAF, 
and BRAF, and CRAF (RAF-1).  As described, activated RAF phosphorylates 
MEK1 and MEK2, which in turn phosphorylates ERK.  There is also thought to 
be cross talk at the Raf-1 level between the RAF-MEK-ERK pathway and the 
pathway of phosphoinositol 3 kinase (PI3K) and Akt, which suggests that RAF-
1 has roles other than MEK activation209 210.   
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The Erk kinases MEK1 and MEK2, are the next functional protein kinases to be 
activated in the MAPK cascade after phosphorylation of the RAF family of 
molecules, and lead to the subsequent Erk 1/2 (44/42pMAPK) activation.  On 
activation, ERK enzymes phosphorylate cytoplasmic targets or migrate to the 
nucleus, where they target and activate transcription factors that regulate 
genes increasing cell proliferation and protecting cells against apoptosis211.  
Activation of this pathway also is thought to have a role in induction of the 
expression of vascular endothelial growth factor in CRC212. 
 
1.7.3 EGFR related signal transduction: Implications for the treatment of CRC 
Constitutive activation of the downstream components of EGFR signalling at 
any level of PI3K-Akt or RAS-RAS-MAPK pathways may play a role in CRC by 
promoting proliferation and inhibiting of apoptosis.  These downstream 
alterations in cell growth control may also contribute to the currently 
unpredictable response to anti-EGFR antibody monotherapy in many patients.  
Whilst expression of EGFR in primary tumour has proven to be an unreliable 
predictor of response to cetuximab, over expression, activation, or mutation 
of any of the downstream components may be more suitable indicators of 
likely response.  Only targeting the cell surface EGFR may not be adequate in 
the face of multiple alternative signal transduction pathways that may be 
activated and also be implicated in tumour growth. 
 
In contrast to prognostic factors, which are used to predict patient outcome 
independent of the therapy they receive, predictive markers are factors that 
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help to select which patients are likely to respond to a particular treatment 
being considered213.  As it has become increasingly clear that in primary CRC, 
EGFR and VEGF expression are not effective predictive markers of response 
(as was assumed when these antibodies first reached clinical trials), the race is 
on to unravel the molecular profile of these tumours so better predictors of 
response to targeted therapies can be found. 
 
1.7.4 Predicting response to EGFR targeting antibodies in metastatic CRC 
The specific targeting ability of cetuximab led to the logical assumption that 
only IHC EGFR positive patients would benefit, but more recent evidence fails 
to support the use of EGFR staining as a predictor of response, illustrating that 
the presence of EGFR does not guarantee a response to EGFR targeted 
therapy.  A 25% response rate to cetuximab and irinotecan therapy in EGFR 
negative patients is similar to the 23% response rate in EGFR positive patients 
treated with the same combination90 91 131.  Unlike HER2/neu-expressing 
breast cancers in which most Her-2/neu over expression is secondary to a 
gene amplification (hence a good predictive marker for response to 
trastuzumab exists), EGFR gene amplification is not necessarily a predictive 
marker for potential inhibitor activity in CRC214 215.  The search for better 
response predictors for EGFR antibodies in CRC is ongoing. 
 
1.7.4.1 Expression of EGFR and downstream effector molecules 
Recent studies have shown that EGFR positivity by IHC in primary colorectal 
tumours does not correlate with response to cetuximab.  In a retrospective 
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series reported by Chung et al, 4/16 (25%) objective responses were observed 
in patients (with irinotecan-resistant CRC) treated with irinotecan and 
cetuximab, whose tumours were EGFR negative by IHC131.  This lack of 
correlation maybe related to a number of factors, which include: suboptimal 
IHC technique, potential differences in primary and metastatic EGFR 
expression, or the fact that EGFR expression alone does not accurately 
represent the activity of the downstream EGFR pathway or its constituent 
effector proteins.  Potential inadequacies in the immunohistochemical 
method for staining, scoring, and interpreting receptor positivity, which 
include lack of standardisation of tissue fixation technique and sample storage 
time.  The testing of archived tissue is likely to be associated with protein 
degradation and loss of sensitivity, which could affect accuracy of results216. 
 
Currently EGFR expression is assessed usually on archived primary tumour 
tissue, whereas cetuximab therapy is used in the metastatic setting.  Studies 
have suggested that metastatic lesions maybe EGFR positive whilst the 
corresponding primary colorectal tumour is negative, and vice versa.  
Scartozzi et al demonstrated that 36% of primary CRC expressing EGFR were 
negative in the corresponding metastatic site, however 15% of EGFR positive 
metastatic sites were negative in the corresponding primary tumour193.  It is 
possible that the predictive value of EGFR expression by IHC maybe improved 
if corresponding metastatic sites are tested for positivity. 
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Expression of EGFR alone does not necessarily reflect the signalling activity in 
cancer cells.  Targeting a single receptor is only likely to work if the cancer 
cells are dependent on that particular pathway for growth, and hence 
receptor activation status, or simultaneous assessment of downstream signal 
transduction components may be more effective predictors of response.  
There is some evidence to suggest that receptor activation status (or 
phosphorylation) is a better predictor of potential efficacy.  Activated 
(phosphorylated) EGFR (pEGFR) may reflect the activity of EGFR mediated 
growth pathways in tumours better than receptor expression alone, and 
pEGFR has been shown to be significantly higher in colorectal tumours 
compared to healthy adjacent bowel tissue217.  Small trials have 
demonstrated that a pEGFR immunohistochemical score may correlate with 
higher disease control when treated with cetuximab (with or with irinotecan) 
suggesting it maybe a better predictor of cetuximab efficacy than receptor 
expression218.  
 
In a study by Scartozzi et al exploring the EGFR-related molecular profile of 
CRC by analysing the expression of activated (phosphorylated) Akt (pAkt) and 
pMAPK, 47/98 patients (48%) had EGFR-negative primary tumours, and of 
these 74% were pAkt and pMAPK positive, suggesting the downstream 
pathway was activated despite lack of EGFR expression by IHC194.  Of the 
51/98 (52%) EGFR-positive primary colorectal cancers, 25% were negative for 
pAkt and 29% were negative for pMAPK, suggesting the possibility that even 
in the presence of EGFR over expression, the downstream signal transduction 
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pathway may not also be activated.  Neither pAkt nor pMAPK positivity was 
consistent between paired primary and metastatic samples, again suggesting 
ƚŚĂƚƚŚĞŵŽůĞĐƵůĂƌƉƌŽĨŝůĞŽĨĂƉĂƚŝĞŶƚ ?ƐƉƌŝŵĂƌǇĂŶĚŵĞƚĂƐƚĂƚŝĐZŵĂǇďĞ
quite different.  
 
1.7.4.2 Activating mutations of components of the Erb1 receptor pathway 
Lung cancer patients with activating mutations in the EGFR tyrosine kinase 
domain (encoded by exons 18 W21) are now known to show significantly 
greater response to EGFR tyrosine kinase inhibitors such as gefitinib and 
erlotinib117 219.  Such somatic mutations are rare in colon cancer220, however it 
is becoming increasingly clear that activating mutations of a number of 
components downstream of the EGFR/Erb1 receptor do influence 
responsiveness to EGFR targeted therapies. 
 
1.7.4.2.1 KRAS mutations 
RAS functions by means of a switch between an inactive (proteins bound to 
GDP) and an active state (GDP is converted to GTP), controlled by regulatory 
proteins221.  Mutant RAS proteins have impaired intrinsic GTPase activity, 
which prevents inactivation by regulatory GTPase-activating proteins, hence 
providing a continual signal promoting cellular proliferation222.  KRAS 
mutations are thought to be early events in the multi-hit models of colorectal 
tumourigenesis, predominantly during the transformation of small to 
intermediate sized adenoma223.  Activating mutations have been detected in 
30-50% of CRC221 224-230, and are generally restricted to codons 12 and 13 in 
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exon 2, and codons 59 and 61 in exon 3, with 12 possible single base 
mutations shown to occur at these locations222 224 231.   
 
KRAS mutations lead to constitutively active signal transduction and have 
been associated with increased risk of recurrence224, quicker disease 
progression225 and inferior survival in some studies224 227, although other 
groups have not arrived at these same conclusions232 233.  More recently, it has 
been suggested that these activating mutations have an important role as a 
predictors of non-response to anti-EGFR antibodies225-227, and this remains an 
important area of research at present. 
 
/Ŷ >ŝĞǀƌĞ Ğƚ Ăů ?Ɛ ĨŝƌƐƚ ƌĞƚƌŽƐƉĞĐƚŝǀĞ ƐƚƵĚǇ ŽĨ  ? ? ŵĞƚĂƐƚĂƚŝĐ Z ƉĂƚŝĞŶƚƐ ǁŚŽ
had received cetuximab containing therapy, no KRAS mutations were found 
amongst the 11 responders, compared to 68.4% of the non-responders being 
KRAS mutation positive227.  The more recent larger series by the same authors 
confirmed this high predictive value of KRAS mutations on response to 
cetuximab and survival in metastatic CRC patients treated with cetuximab.  
Amongst the 24 patients in which a KRAS mutation was detected, there were 
no responses compared to 40% response rate in the 65 non-mutated 
patients234.  Other similar retrospective studies support these findings.  In 
tumour specimens from 59 patients with metastatic CRC treated with 
cetuximab, no KRAS mutations were found in the 20.3% of patients who 
responded, but mutations were associated with disease progression (p = 
0.0005) and reduced time to progression (p=0.015)225.  Frattini et al also 
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found a significant association between KRAS mutation and non-response to 
cetuximab in a small series of 27 patients235.  Khambata-Ford ĞƚĂů ?ƐƐƚƵĚǇŽĨ
110 patients with previously treated metastatic CRC undergoing cetuximab 
monotherapy found a higher disease control rate (48%) in patients with wild-
type KRAS than patients with KRAS mutation (10%) (P = .0003)236.  This study 
also found that high levels of the EGFR ligands amphiregulin and epiregulin 
correlated with response to cetuximab236 ? Ğ ZŽŽĐŬ Ğƚ Ăů ?Ɛ ƐƚƵĚǇ ŽĨ  ? ? ?
irinotecan refractory, EGFR positive patients receiving cetuximab and 
irinotecan documented an objective response in 27 of 66 (41%) KRAS wild-
type patients versus 0 of 42 (0%) in KRAS mutants229.   
 
Karapetis et al analysed tumour samples obtained from 394 of 572 patients 
(68.9%) with colorectal cancer who were randomly assigned to receive 
cetuximab plus best supportive care or best supportive care alone, to look for 
activating mutations in exon 2 of the KRAS gene237.  Of the tumours evaluated 
for KRAS mutations, 42.3% had at least one mutation in exon 2 of the gene.  In 
those treated with cetuximab, median OS was 9.5 months for wild-type KRAS 
compared to 4.8 months with mutated KRAS tumours (Hazard ratio for death 
0.55, 95% CI 0.41 to 0.74; P<0.001).  Median PFS was 3.7 months (wild-type) 
compared to 1.9 months (mutated) (Hazard ration for progression or death 
0.40, 95% CI, 0.30 to 0.54; P<0.001).  Among patients with mutated KRAS 
tumours, there was no significant difference between those who were treated 
with cetuximab and those who received supportive care alone with respect to 
overall survival (hazard ratio, 0.98; P=0.89) or PFS (hazard ratio, 0.99; P=0.96).  
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The mutation status of the KRAS gene had no influence on survival among 
patients treated with best supportive care alone237. 
 
ƌŵĂĚŽ Ğƚ Ăů ?Ɛ ƉƌŽƐƉĞĐƚŝǀĞ WŚĂƐĞ /// ƐƚƵĚǇ ? ƌĂŶĚŽŵŝƐĞĚ  ? ? ? ƉĂƚŝents with 
extensively pretreated metastatic CRC to treatment with panitumumab or 
best supportive care226.  KRAS mutations were detected in 43%, and a 
significant improvement in PFS was documented in the wild-type K-ras 
patients treated with panitumumab in comparison with best supportive care.  
No benefit from panitumumab was seen in patients with KRAS mutations, 
indicating that KRAS expression has a similar impact on the prediction of 
response to panitumumab238. 
 
1.7.4.2.2 BRAF mutations 
Mutations in the downstream threonine kinase BRAF, activated following 
KRAS activation, also provides a mechanism by which cancer cells can 
constitutively activate the RAS-RAF-MAPK pathway.  BRAF mutations have 
been demonstrated in CRC, as well as melanomas and ovarian tumours239-241.  
Such mutations are thought to occur at a similar stage of the colorectal 
adenoma-carcinoma sequence as KRAS mutations241, and are most frequently 
located in the kinase domain of the conserved region 3 in exon 15 of the BRAF 
gene241-243.  BRAF mutations have been found in 5 W15% of colorectal 
adenocarcinoma228 238 239 241 244 245, the commonest being a V600E substitution 
resulting from a 1799T>A base change, although others have been 
documented242 241 244 245.  In some studies V600E mutations have been 
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associated with microsatellite instability in sporadic tumours and features 
including infiltrating lymphocytes, poor grade and mucinous subtype241 244.  
BRAF ŵƵƚĂƚŝŽŶƐŚĂǀĞďĞĞŶƐŚŽǁŶƚŽďĞŵŽƌĞĐŽŵŵŽŶŝŶĞĂƌůǇƵŬĞƐ ?ƐƚĂŐĞ
carcinoma suggesting a less invasive behaviour that that seen in tumours with 
KRAS mutations241.  Yuen et al found that V599E mutations were not 
associated with simultaneous KRAS mutations whereas a proportion of 
tumours with alternative BRAF mutations also harboured KRAS mutations.  Di 
Nicolantonio et al recently demonstrated that wild-type BRAF is also required 
for response to panitumumab or cetuximab130.  They retrospectively analysed 
survival and mutational status of KRAS and BRAF in 113 tumours from 
cetuximab- or panitumumab-treated metastatic CRC patients.  The BRAF 
V600E mutation was detected in 14% of patients who had wild-type KRAS, 
none of whom responded to treatment, whereas none of the responders 
carried BRAF mutations (P = .029).  BRAF mutated patients had significantly 
shorter PFS (P = .011) and OS (P < .0001) than wild-type patients130.  
 
1.7.4.2.3 PI3KCA mutations 
Aberrant activation of the PI3K/Akt pathway is also known to impact on 
tumourigenesis downstream of the Erb-1 receptor.  Mutations in the PI3KCA 
gene, which encodes the catalytic subunit of PI3K, have been reported in a 
number of human cancers, including in 15-30% of CRC246-249.  Mutations most 
commonly occur at exons 9 and 20, the commonest types of mutations being 
E542K, E545K (helical domains) and H1047R (kinase domain)247 248 250.  In 
sĞůŚŽ Ğƚ Ăů ?Ɛ ƐĞƌŝĞƐ ŽĨ ĐŽůŽƌĞĐƚĂů ĐĂƌĐŝŶŽŵĂƐ ? PI3KCA mutations were 
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significantly more frequent in cases harbouring mutations in KRAS or BRAF 
genes than in cases negative for KRAS and BRAF mutations (P = 0.037)248.  
Within 47 colorectal carcinomas with KRAS or BRAF mutations, 21.3% had 
concomitant PI3KCA mutations, which compared to only 7.1% of the wild-type 
KRAS and BRAF tumours.  In this study there was no difference in incidence of 
mutations in microsatellite instability (MSI) and microsatellite stable (MSS) 
tumours.  
 
It is now thought that PI3KCA mutations may also influence response to 
cetuximab.  Jhawer et al screened colon cancer cell lines for cetuximab 
response in vitro251.  Whilst EGFR protein expression, mRNA expression and 
gene copy number did not correlate with cetuximab response, cell lines with 
activating PI3KCA mutations or loss of PTEN expression were more resistant to 
cetuximab than PI3KCA wild type (WT)/PTEN-expressing cell lines (P = 0.008).  
Cell lines that were PI3KCA mutant/PTEN null and RAS/BRAF mutant were 
highly resistant to cetuximab compared with those without dual 
mutations/PTEN loss (P = 0.002), suggesting constitutive and simultaneous 
activation of the RAS and PI3KCA pathways may lead to maximal resistance to 
cetuximab in colorectal cancer251.  
 
In Perrone et al retrospective study of 32 metastatic CRC patients treated with 
cetuximab, 31% showed a partial response to cetuximab249.  EGFR 
immunophenotype and FISH-based gene status did not predict response, 
whereas KRAS mutations (24%) and PI3K pathway activation, by means of 
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PI3KCA mutations (13%) or PTEN mutation (10%)/loss (13%), were significantly 
restricted to non-responders (41% and 37% respectively)249.  Twelve of the 32 
patients evaluated had paired primary and metastatic tissue analysed, with no 
significant difference in the frequency of KRAS (18% primary, 23% metastatic 
tumour samples) or BRAF mutations, although the BRAF mutation in one case 
was only detected in the metastatic sample.  In another patient, the PI3KCA 
point mutation detected in the K-ras wild-type primary tumour was absent in 
the paired metastatic sample. There were no differences in occurrence of 
PTEN mutations between the primary and metastatic tumour samples 
(observed in 10% of all patients)249. 
 
1.7.4.3 Loss of PTEN expression 
Mutations resulting in loss of PTEN expression also lead to constitutive 
activation of the PI3K/AKT signalling pathway.  PTEN mutations have recently 
been documented in 19.5% of sporadic colorectal tumours252 as well as 17 - 
19% of those with MSI253-255.  Mutations found in both PTEN alleles, together 
with the presence of PTEN protein expression in normal colon suggests that 
loss of function of this gene is likely to play a role in CRC tumourigenesis254. 
 
Loss of PTEN protein expression may also be a useful marker in predicting 
resistance to cetuximab235 252.  Preliminary data reported by Loupakis et al 
suggests that PTEN expression in primary and metastatic tumours may not be 
the same.  They documented positive PTEN immunostaining in 49% of primary 
tumours and 54% of metastases. There was concordance between primary 
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and metastases in 60% whilst 16% positive primary tumours were negative in 
corresponding metastases, and 24% negative primaries were positive in 
corresponding metastases256.  Whilst in this study PTEN status tested on 
primary tumour was not significantly predictive of response to cetuximab and 
irinotecan, loss of PTEN immunoreactivity tested on metastases did show 
some promise as a response predictor256. 
 
1.7.4.3 Predictors of response: expression of other ligands 
Gene expression levels of Cox-2, EGFR, IL-8 and VEGFR in metastatic CRC 
patients may be useful markers of clinical outcome with cetuximab therapy as 
suggested by Valbohmer et al257.  They demonstrated that higher gene 
expression levels of VEGF were associated with a resistance to cetuximab, and 
the combination of low gene expression levels of Cox-2, EGFR, and IL-8 was 
significantly associated with overall survival (independent of skin toxicity)257.  
EGFR ligands epiregulin and amphiregulin have also been linked to improved 
survival and increased likelihood of response to cetuximab in CRC236.  Further 
studies are ongoing to define the true predictive ability of these biomarkers in 
treatment response to EGFR inhibitors. 
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1.8 Immunoconjugates: Therapeutic targeting of the Le
y
 
Antigen 
 
One strategy which has yet to make a clinical impact in the treatment of 
patients with solid tumours, is to conjugate a targeted antibody with a toxin 
or chemotherapeutic.  For this approach to have any chance of success in the 
clinic the target antigen must be chosen carefully and the specific antibody 
must undergo extensive preclinical and clinical characterisation.  This section 
will describe the strategy to target the Lewis Y (Ley) antigen in a Phase I trial, 
where a Ley targeting therapeutic immunoconjugate was administered to 
patients with advanced Ley positive epithelial cancers. 
 
1.8.1 Antigen discovery and characterisation: Lewis Y antigen 
The Ley carbohydrate antigen (CD174) is a difucosylated tetrasaccaharide 
(&ƵĐ ?ɲ ?AP ? ?'Ăů ?ɴ ?AP ? ? ?&ƵĐ ?ɲ ?AP ? ? ?'ůĐEĐ ?present on the glycolipid and 
glycoprotein backbones of predominantly epithelial cells.  Other members of 
the Lewis carbohydrate antigen family include Lewis a (Lea), Lewis b (Leb) and 
Lewis X (Lex).  These antigens are structurally related to the ABO blood group 
system, and members of both these families are found on erythrocytes, 
endothelium, epithelium, and in some secretions.  Production of these 
antigens proceeds from precursor disaccharides by stepwise addition of 
monosaccharides through the action of fucosyltransferases (encoded by the 
FUT 1-7 genes)258.  Mucous secreting cells of the gastric epithelium express 2 
types of mucin genes, which are associated with Lewis antigens.  Neutral 
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mucins are secreted by superficial epithelial glands in association with Lea and 
Leb, whilst deep gastric epithelial mucin glands secrete acid mucins in 
association with Lex and Ley 259.  Unlike ABO blood group antigens, synthesis of 
Lewis antigens does not occur in erythroid progenitors.  Instead the 
expression of Lewis epitopes on erythrocytes is dependent on absorption of 
circulating Lewis-bearing glycolipids from the plasma, which are synthesised 
in exocrine epithelial cells258.  
  
Changes in ABO and Lewis antigen expression occur during foetal 
development and into adulthood, and a reversion back to the fetal expression 
pattern of expression has been demonstrated in certain malignant tissues260.  
Expression of Leb occurs throughout the colon during foetal development, but 
is lost from the distal colon after birth.  Re-expression (independent of 
anatomical site) occurs in colonic adenomas, and level of expression increases 
with increased progression260.  Increased Lewis antigen expression has been 
shown to affect tumour cell characteristics and has been linked to poor 
prognosis in some malignancies including lung, colon and breast 
carcinomas261-263.  In breast cancers, expression of Lea and Leb has been 
associated with lymph node involvement264, and high expression of Lewisy/b 
has been correlated with high grade and poor prognosis263.  Lea is expressed in 
40% of normal gastric mucosa cells but in the majority of gastric 
adenocarcinomas265.  The presence of sialyl-Lea or sialyl-Lex (ligands for 
selectins), promotes the development of metastases by facilitating interaction 
with distant organ endothelium266.  Lex and sLex are involved in cell 
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recognition and are thought to function as ligands for adhesion molecules (in 
development and adult tissues)267. 
 
The physiological role of Ley is not well established, but it is believed to have a 
role in cellular motility and adhesion20.  Expression has been demonstrated on 
normal epithelium of the gastrointestinal tract, acinar cells of the pancreas, 
ciliated epithelium of trachea and type 11 pneumocytes 268, as well as weak 
expression on circulating granulocytes20 269.  It is over-expressed in the 
majority of epithelial carcinomas (40-90%) including breast, ovary270, 
pancreas, prostate271, colon, and lung cancers19-22 268(including majority of 
small cell lung cancers272).  As with Leb, colonic expression of Ley present in the 
foetal colon is lost after birth, but is regained in the adenoma stage of colonic 
tumour development.  Colonic adenomas with high malignant potential 
(tubulovillous and villous adenomas) show greater proportion of cells 
expressing Ley compared to tubular adenomas and therefore maybe a useful 
marker of degree of dysplasia and malignant potential273 274.  Expression is 
also associated with increased CRC staging, showing the strongest positivity in 
stage IV disease21 and inferior prognosis in oesophageal carcinoma275.   
 
Ley expression has been correlated with apoptosis in some studies276 (but no 
correlation could be demonstrated in others21), and may have pro-coagulant 
and angiogenic activities266.  The frequency of blood vessel invasion in NSCLC 
was significantly higher in tumours with expression of Ley, indicating it may 
also influence metastatic potential277.  Cancer cells that express Ley do so 
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either as a glycolipid at the plasma membrane or as part of a cell surface 
receptor such as EGFR278 279, HER-2, and other glycoproteins including CEA280.  
High density of altered antigenic expression in a number of epithelial 
malignancies with restricted expression in normal tissues, make it an ideal 
antigen for molecular targeted therapy268 281-284. 
   
1.8.2 Le
y
 directed antibody production and characterisation  
The Ley antigen was established as a promising tumour associated antigen in 
which to therapeutically target epithelial cancers in the 1980s, but many 
challenges have faced researchers on the journey from antigen 
characterisation to the development of a therapeutic antibody for clinical 
trials.  One of the first challenges was to develop an antibody specific to Ley 
that would not cause unwanted toxicity by also binding other blood group 
antigens.   
 
Cross-reactivity with other blood group antigens of the same family including 
Lex and H-type 2 led to erythrocyte agglutination in some pre-clinical 
studies285.  Two such murine anti-Ley antibodies identified were B1 (which 
also binds H type-2), and B3 (which also binds di-Lex and tri-Le x)286.  Of the 
antibodies that have undergone specificity analysis, it is thought that there 
are subtle differences in the way in which each antibody reacts with slightly 
different sequences on the same core carbohydrate chain of the antigen286.  
Explanation of the apparent preferential targeting of antibodies to Ley 
expressed on cancer cells compared with normal tissues expressing the 
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antigen, may partly be explained by Ley localisation, or accessibility of antigen 
to monoclonal antibody, although this remains controversial.  When tissue 
arrays were used for immunohistological expression analysis of normal and 
tumour cell tissue in one study, Ley localised predominantly in the cytoplasm 
of normal tissue, but also on the cell surface of tumour cells.  It was 
postulated by some that this cell surface localisation allows it to be an 
accessible target for therapeutic antibodies, which are unable to contact the 
intracellular antigen in normal tissue287.   
 
Tumour growth inhibition secondary to the induction of ADCC and CDC by Ley 
directed antibodies was initially demonstrated in animal models282 288 289, but 
effector cell recruitment is not the only mechanism by which these antibodies 
can inhibit tumour growth.  Antibody mediated inhibition of EGF-induced 
signalling in Ley positive breast cancer cell lines was shown to be as a result of 
altered EGF-receptor recycling and down regulation of receptor expression, 
mediated by antibody binding the Ley part of the growth factor receptor, 
where it is also expressed279 290.   
 
BR96 is a chimeric IgG3 which is specific for Ley that has been shown to induce 
effector cell function by CDC and ADCC, but can also inhibit DNA synthesis in 
the absence of effector cells291.  Specific binding of Ley located in the cell 
membrane leads to receptor mediated internalisation of the BR96/Ley 
complexes where cytotoxicity has been demonstrated292.  Only modest anti-
tumour activity in lung cancer xenografts293 and the internalising properties of 
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the antibody led to its subsequent development as an immunoconjugate, 
(linked with doxorubicin) rather than as monotherapy, and this approach is 
still being investigated.  BR64 was a similar antibody (IgG1) which did not 
reach clinical trials because of early evidence of possible cardiotoxicity294 295.   
 
ABL364 (previously called BR55-2) is known to induce CDC, ADCC and TNF-  
release296, and has been shown to block stimulation of MAPK by EGF and 
heregulin in cell lines279 297.  It has demonstrated tolerability in early Phase I 
trials, with some suggestion of an anti-tumour effect, but HAMA development 
with repeated dosing has limited the ability to give multiple treatment 
cycles298 299.  As with many other monoclonal antibodies to reach this stage in 
development, success of the murine form was limited by the development of 
HAMA.   
 
IGN311 is the humanised IgG1 form of the parental antibody ABL364.  It has 
the same ability to induce CDC, ADCC, and can down regulate EGFR/Erb1279 
290.  IGN311 treatment of xenografted tumours was associated with a down-
regulation of ErbB1 in the excised tumour tissue, indicating an effect on 
signalling via binding of Ley on tumour EGFR290.  In Phase I trials it has 
demonstrated a good safety profile, with a suggested effect on peripheral 
blood tumour cells300 and effusion tumour cell counts301.  A number of 
strategies have been employed to try and improve the potency of IGN311, 
including increased effector function by selectively altering the 
ŝŵŵƵŶŽŐůŽďƵůŝŶ ?ƐŐůǇĐŽƐǇůĂƚŝŽŶƉĂƚƚĞƌŶ ?^ĐŚƵƐƚĞƌĞƚĂů ŝŶĚƵĐĞĚƚŚŝƐĐŚĂŶŐĞďǇ
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over expressing the GnT-III transferase in the antibody-producing cell line, and 
the result was improved Fc-mediated effector functions without changing 
binding affinity or stability287. 
 
3S193, the murine IgG3 was generated in BALB/c mice by immunisation with 
Ley-expressing cells of the MCF-7 breast carcinoma cell line282.  Preclinical 
characterisation indicated high specificity for Ley in ELISA tests with synthetic 
Ley and Ley containing glycoproteins and glycolipids.  It also reacted strongly in 
rosetting assays and cytotoxic tests with Ley-expressing cells, and did not lyse 
O, A, AB, and B human erythrocytes in the presence of human complement269.  
Following the demonstration this high specificity for Ley, the humanised form, 
hu3S193 (IgG1) was engineered by CDR grafting282 302.  The genes for this 
humanised 3S193 antibody were transfected into mouse myeloma NS0 cells 
for production.  Characterisation of hu3S193 is the focus of the subsequent 
sections.  
 
1.8.3 Using hu3S193 to target Le
y
 positive solid tumours 
1.8.3.1 Pre-clinical characterisation of hu3S193 
The specificity and reactivity characteristics of 3S193 were maintained with 
hu3S193, demonstrating similar avidity to the murine form (KD=100-200nM) 
but increased ADCC (humanised antibody had 100-fold greater ADCC activity 
compared to the murine antibody) and potent CDC141 269 282.  In vivo, gamma 
camera imaging was used to visualise labelled antibody and demonstrate 
localisation to Ley expressing breast xenografts with minimal normal tissue 
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uptake288.  The immunotherapeutic potential was demonstrated in vivo in a 
human breast xenograft model using MCF-7, Ley-positive cells.  In an MCF-7 
xenograft preventive model, a 1-mg hu3S193 dosage schedule was able to 
significantly slow tumour growth compared with placebo and isotype-
matched control IgG1 antibody282.  
 
Laboratory assays were developed at LICR to allow accurate assessment of 
serum pharmacokinetics and quantification of immunogenicity28.  Mice 
immunised with hu3S193 were used to generate hybridomas producing anti-
idiotype antibodies, capable of binding specifically to hu3S193 and 
competitive for antigen binding (LMH-3).  These enabled both the 
development of reproducible, sensitive, and specific ELISA assays for 
determining serum concentrations of hu3S193, and the detection of HAHA in 
serum using BIAcore (with LMH-3 as positive controls for quantification of 
immune responses to hu3S193)28.  
 
1.8.3.2 Clinical Characterisation: Phase I studies of hu3S193 
Following favourable preclinical characterisation, a Phase I dose escalation 
study of 15 patients with advanced Ley positive cancers was performed by 
Scott et al281.  Four infusions of hu3S193 were administered at weekly 
intervals, the first trace labelled with Indium-111 for biodistribution and 
pharmacokinetic analysis.  No HAHA were observed, selective targeting of 
metastatic disease (in liver, lymph node, lung and bone) was confirmed, 
although there were no objective responses281.  There was 1 DLT (Grade 3 
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elevated ALP), but otherwise all 4 dose levels (5, 10, 20, and 40 mg/m2) were 
well tolerated.  The main side effect encountered in the highest dose cohort 
was self-limiting grade 1-2 nausea and vomiting, which in 2 patients was 
associated with transient gastrointestinal activity on biodistribution 
assessment (soon after infusion completion).  Such gastrointestinal toxicity 
was not unexpected considering the known expression of Ley in normal 
stomach, and the toxicity previously reported in other Ley targeting antibody 
trials (unconjugated antibodies300 and immunoconjugates303-306).  This study 
established that hu3S193 has a prolonged terminal half-life (>1 week), no 
saturable normal tissue compartment, and potentially cytotoxic serum 
concentrations (that induced tumour cell kill in pre clinical studies) could be 
achieved by infusing tolerable doses.  It was shown to induce CDC and ADCC 
in vivo, although no objective responses were seen.  Although not designed to 
evaluate efficacy, there was indication of clear biologic effect in these early 
phase studies.   
 
1.8.4. Optimising therapeutic efficacy; Lewis Y directed immunoconjugates 
After demonstrating anti-Ley antibodies can be specific and bind to Ley with 
high affinity before rapid internalisation into Ley expressing cancer cells, 
conjugation with a toxin/chemotherapy to improve therapeutic efficacy was 
the next logical step for investigators.  A small number of Ley directed 
immunoconjugates have reached Phase I/II clinical trials in solid tumours, but 
none have reached Phase III trials. 
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BR96-Dox links doxorubicin to the chimeric IgG3 BR96.  After anti-tumour 
efficacy in animal models was demonstrated137, this immunoconjugate 
proceeded to Phase I and II trials.  An initial Phase I of 34 patients with Ley 
expressing tumours administered weekly doses of between 100-500mg/m2 
(equivalent to doses of 3-15mg/m2/wk doxorubicin).  Two DLT were 
experienced, both grade 4 vomiting with severe, superficial haemorrhagic 
gastritis on endoscopy.  A number of other toxicities were encountered 
including vomiting, haematemesis, neutropenia, hypersensitivity reactions, 
and transient elevations in amylase and lipase.  No objective responses were 
seen307.  Gastrointestinal toxicity was also a finding in a similar, large Phase I 
study of 66 patients with predominantly Ley positive colon and breast 
cancer303.  BR96-Dox deposition in tumours was documented, immunogenicity 
was minimal, MTD of BR96-Dox was 875mg/m2 (given on a 3 weekly basis), 
and 700mg/m2 (3 weekly) was suggested to take forward to Phase II trials.  
Tolcher et al reported a small randomised Phase II study in 23 patients with 
Ley positive metastatic breast cancer in which patients received either BR96-
dox (700mg/m2) or doxorubicin (60mg/m2) 3 weekly304.  Objective responses 
included one PR in the BR96-dox arm compared to 1 CR and 3 PR in the 
doxorubicin arm.  Haematological toxicity in this study was limited, but 
predictably gastrointestinal toxicity was evident in the immunoconjugate arm. 
 
LMB-1 is an immunotoxin which links the B3 anti-Ley antibody with PE38, a 
genetically engineered form of Pseudomonas exotoxin.  After significant anti-
tumour activity was shown in animal models, this immunotoxin entered Phase 
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I trials.  Although objective anti-tumour activity was also seen in patients, 
vascular leak syndrome was a serious side-effect which has limited its further 
clinical development308.      
 
SGN-10 and SGN-15 are two similar immunoconjugates which use the Ley 
targeting antibody BR96.  SGN-10 (BR96sFv-PE40) uses the toxin PE40, and 
internalisation of the antibody-Ley complex and subsequent cell death via 
catalytic inhibition of protein synthesis has been shown, but Phase I trial 
findings were disappointing.   SGN-10 (alone or in combination with 
docetaxel) led to vascular leak syndrome and HATA (human anti-toxin 
antibody) responses in the majority of patients was observed (including 1 
grade 5 pulmonary toxicity with high HATA response)309 310, and further 
clinical development was later abandoned.  SGN-15 (chimeric BR96 
conjugated with doxorubicin) has progressed through the developmental 
process, reaching Phase II trials.  Ross et al conducted a randomised (open-
labelled) Phase II trial of SGN-15 plus docetaxel compared to docetaxel in 
previously treated NSCLC patients.  Both arms were well tolerated and active 
in the second line treatment setting306.  
 
1.8.4.1 Development and characterisation of CMD-193 
Wyeth pharmaceuticals developed the Ley targeting immunoconjugate CMD-
193 based on the LICR parenteral antibody hu3S193.  Minor changes in the 
CH2 domain of hu3S193 were introduced to reduce complement-mediated 
cytotoxicity to form G193141.  Ley binding specificity of G193 and hu3S193 
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were shown to be identical.  As with Mylotarg, G193 was covalently linked to 
NAc-gamma calicheamicin DMH via an acid-labile bifunctional AcBut linker.  
This linker contains an acid-labile hydrazone bond which when internalised 
into the acidic lysosomal environment, is hydrolysed releasing the Nac-gamma 
calicheamicin DMH from the antibody.  Once the this toxin is released, it can 
make its way to the cell nucleus where it binds DNA and the enediyne 
warhead causes DNA strand breaks and ultimately cell death.   
 
The binding affinity of CMD-193 and G193 for Ley was compared, and 
conjugation with calicheamicin caused a slight reduction in its affinity for Ley 
on Biacore and ELISA, but binding of both conjugated and unconjugated 
antibody to Ley expressed on the surface of tumour cells was similar141.   
CMD-193 has been shown to be slightly less potent in inhibiting the growth of 
Ley expressing carcinoma cells when compared to unconjugated 
calicheamicin, and this is likely related to a slower rate of internalisation of 
the surface bound CMD-193. 
 
Preclinical studies have shown that CMD-193 has cytotoxic effects in-vitro, 
and leads to dose-dependent regression of human carcinoma xenografts in 
vivo141.  Treatment of subcutaneous xenografts of human carcinomas (gastric, 
colon and prostate) expressing Ley in athymic mice demonstrated inhibition of 
tumour growth, whereas G193 and unconjugated NAc-gamma calicheamicin 
showed no effect.  The results of a Phase I biodistribution study of 111In-CMD-
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193 in patients with advanced tumours expressing the Ley antigen will be 
reported in this thesis. 
 
1.9 Radioimmunotherapy: Therapeutic targeting of the 
A33 antigen in colorectal cancer 
 
1.9.1 Antigen discovery and characterisation: A33 antigen 
The A33 antigen was discovered and characterised using the murine antibody 
mA33, elicited by injecting mice with a human pancreatic carcinoma-derived 
cell line.  Antigen sequencing, cloning and characterisation, found A33 to be 
an organ specific cell surface differentiation antigen with exquisite tissue 
specific expression.  
 
1.9.1.1 A33 Structure 
The A33 antigen is a 43kDa transmembrane protein with 3 structural domains: 
an extra-cellular region with 2 immunoglobulin like domains (a V-type and a C-
type domain), a hydrophobic transmembrane domain, and a polar intra-
cellular tail17.  It has a similar structure to some Ig superfamily members that 
have roles in cell adhesion such as CTX and JAM311.  The A33 antigen gene is 
located on chromosome 1, and DNA sequenĐŝŶŐ ŽĨ ƚŚŝƐ ŐĞŶĞ ?Ɛ ƉƌŽŵŽƚĞƌ
region found binding sites for GKLF and CDX1 transcription factors312.  
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1.9.1.2 A33 Expression patterns 
Expression of the murine A33 antigen was defined during development using 
whole-mount immunohistochemistry.  Expression of mA33 in the blastocyst 
was maintained into adulthood, and was found to be uniformly high 
throughout the rostrocaudal axis of the intestine (running from duodenum to 
distal colon) and also along the entire length of the crypt/villus axis.  All 
differentiated cell lineages of the adult intestinal epithelium (enterocytes, 
goblet cells, and Paneth cells) expressed mA33 antigen as well as 
undifferentiated cells located close to the base of the crypts of Lieberkühn. 
Although A33 antigen expression is initiated by CDX1 in basal crypt epithelial 
cells of the intestinal crypts, expression is maintained as cells differentiate and 
migrate312.  It can be concluded that the A33 antigen is a definitive marker of 
all intestinal epithelial cells.  
 
The first published exploration of human tissue expression of A33 was 
performed by Garin-Chesa et al on a large panel of fresh frozen tissue 
specimens313.  Normal and malignant colonic epithelial cells were shown to 
express comparable levels of A33 (with no difference in sub-cellular antigen 
localisation), and the majority of colonic specimens showing uniform antigen 
expression in >80% cells.  Colonic adenomas also demonstrated strong and 
uniform A33 staining, and in CRC, no correlation was apparent between level 
of A33 expression and stage of disease or degree of histological 
differentiation, but >95% of samples were A33 positive.  This wide spread 
expression in normal, adenomatous and carcinomatous tissue, confirmed that 
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the A33 antigen is not an example of an embryonic antigen selectively re-
expressed in colon cancers, nor that the tumourigeneis process is 
characterised by over expression of the antigen.  This widespread expression 
also suggests it may have an (currently undetermined) important functional 
role in normal and malignant colonic epithelial cells.  As well as the uniform 
expression in colonic epithelium, some heterogeneous staining in gastric 
cancers was demonstrated (10-20% cancer cells staining positive), as well as 
homogenous staining in adjacent intestinal metaplasia.  Half of the pancreatic 
cancer specimens studied showed expression in 20-40% of cells.  The authors 
concluded that the A33 antigen is a constitutively expressed organ specific cell 
surface differentiation antigen which is retained by the majority of primary 
and metastatic colorectal cancer cells that were examined, in a similar 
manner to which cell specific differentiation antigens such as CD20 are 
expressed on the surface of normal and malignant B cells313.  A further 
immunohistochemical study by Sakamoto et al detected A33 expression in 
63% of gastric cancers (with uniform expression in 45% of cases) and in 50% 
of the pancreatic cancers, but with marked heterogeneity. Other epithelial 
cancers, sarcomas, neuroectodermal tumors, and lymphoid neoplasms were 
generally A33 negative314. 
 
The mechanism by which A33 is expressed in such a tissue-specific manner is 
not fully understood, but is likely related to the intestinal specific transcription 
factor CDX1 and gut-enriched Kruppel-like factor (GKLF)312 315, which are 
thought to have roles in the genetic control of intestinal development and 
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differentiation316 317.  (GKLF binds to the promoter region of A33 antigen gene 
in colonic carcinoma cells and mutations in this GKLF binding sequence lead to 
diminished A33 expression315).  Tissue specific expression, high numbers of 
binding sites per cell, and an absence of circulating A33 all make this antigen 
an attractive target for antibody directed therapies of colorectal cancer17. 
 
1.9.1.3 A33 Function 
Although ŝƚ ?ƐƉŚǇƐŝŽůŽŐŝĐĂůĨƵŶĐƚŝŽŶŝƐŶŽƚǇĞƚĐůĞĂƌ ?ƚŚĞ ? ?ĂŶƚŝŐĞŶ is thought 
to play a role in modulating the gut immune system, cell-cell recognition and 
signalling17.  The function of the A33 antigen in vivo, was explored in 
homozygous mutant A33 null (A33-/-) mice.  These investigations 
demonstrated that the A33 antigen is not indispensable for embryonic 
development, despite its expression in the early blastocyst. A33-/- mice 
displayed no evidence of A33 antigen mRNA or protein expression and 
appeared healthy, attained normal weights and were fertile. Intestinal 
morphology, epithelial cell differentiation and epithelial cell proliferation 
were unaffected in A33-/- mice, but it was postulated that it may have a role 
in the regulation of the activity of adjacent gut lymphocytes (unpublished 
observations, Tebbutt N, et al).  Exploration of the function of the A33 antigen 
is ongoing. 
 
1.9.2 Production and characterisation of muA33 
As described, the A33 antigenic system is an ideal target for the development 
of therapeutic antibodies owing to the widespread and often high expression 
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level of the antigen313 314 318.  The murine IgG2a monoclonal antibody muA33 
detects the heat-stable, protease-resistant epitope of target antigen A33, and 
was elicited by injecting mice with a human pancreatic carcinoma-derived cell 
lines. Preclinical characterisation found muA33 to have high specificity and 
affinity for A33319, and fluorescence microscopy has demonstrated that 
muA33 internalises into target cells318.   
 
Phase I trials of muA33 demonstrated selective targeting of CRC liver 
metastases, and some normal gut uptake, by the gamma camera detection of 
muA33 labelled with I131 320.  Autoradiographs of cancers and surrounding 
tissue of these patients demonstrated isotope accumulation in cancers which 
corresponded to antibody binding specifically to the cancer cells, while the 
surrounding stromal cells and vasculature did not concentrate the isotope320.  
Clearance of 131I-mAbA33 from blood showed a T 1/2  of 6.3 hours and T 
1/2  of 38.5 hours320.  There was no observed clinical toxicity, but HAMA 
developed in all patients which made it impossible to assess possible efficacy 
of this unconjugated murine antibody320.   
 
The first Phase I radioimmunotherapy study of muA33 was performed to 
assess the safety and tolerability of the murine antibody with potentially 
therapeutic doses of radioisotope131 321.  Twenty-three patients with end 
stage metastatic CRC were treated with escalating doses of 131I at dose levels 
of 30-90mCi/m2.  Safety, biodistribution and immunological analysis were 
performed, and targeting of known sites of metastatic disease was again 
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demonstrated.  Using 131I the maximum tolerated dose was 75mCi/m2 with 
neutropenia and thrombocytopenia being the most significant haematological 
toxicity encountered (especially in those who had been heavily pre-treated).  
The development of HAMA was an issue for all patients. 
 
A subsequent trial with 125I-muA33 was performed to investigate whether a 
radioisotope known to be a lower energy electron emitter might allow less 
toxicity to normal surrounding tissues322.  In this Phase I study patients 
received doses of 50-350mg/m2 of 125I-muA33.  There was no major toxicity or 
DLT, and hence MTD was not reached (but cytotoxicity assays did 
demonstrate patients treated with the highest dose had sufficiently high 
serum levels of 125I-mAb A33 to lyse colon cancer cells in vitro).  Good tumour 
localisation was again demonstrated.  This series of preliminary Phase I trials 
with the murine antibody muA33 confirmed targeting of the colon cancer 
specific antigen A33, which enabled the delivery of targeted radiation to CRC 
metastases, whilst avoiding significant toxicity to other organs except 
myelosuppression and HAMA. 
 
1.9.3 huA33 production and characterisation 
To overcome limitations to clinical use caused by high immunogenicity of the 
murine antibody, a humanised version huA33 was constructed.  This was done 
by grafting of the murine CDR regions into a human IgG1 framework, and this 
humanised version was shown to have similar binding affinity as the murine 
antibody (Kd = 1.3 nM)323.  
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Twelve patients were entered into a Phase I trial of huA33, which focused on 
biodistribution as well as toxicity, pharmacokinetics, and immune responses 
to a single infusion of radiolabelled huA33 in CRC patients prior to surgery.  
This confirmed excellent uptake of radiolabelled 131I-huA33 in metastatic CRC 
at 4 dose levels; 0.25, 1.0, 5.0, and 10 mg/m2, and penetration into to the 
center of large necrotic liver metastases. There was no significant difference 
in terminal half-life between dose levels and quantitative tumour uptake 
ranged from 2.1 x 10-3 to 11.1 x 10-3 %ID/g, and tumour/normal tissue ratios 
reached as high as 16.3:1.  Despite humanisation low-level HAHA was again 
detected in 4 patients302.  An intra-tumoural microdistribution sub study on 
tumour tissue from 10/12 of these patients found homogenous A33 
expression in viable tumour, but an absence of staining in stroma, necrotic 
areas of tumour, and adjacent normal tissue except colonic epithelium324.  No 
correlation could be demonstrated between micro vessel density (MVD) and 
% injected dose/cell in tumours with necrosis.  
 
Sakamoto et al performed a similar dose escalation biopsy-based Phase I 
clinical trial in gastric carcinoma patients325.  Thirteen patients were entered 
onto one of four (single infusion) dose levels (1.0, 2.0, 5.0 or 10.0 mg/m2) of 
131I labelled huA33 1 week prior to surgery. No DLT was observed during the 
trial, and gastric tumours which showed >25% A33 expression in biopsied 
sections showed good uptake of 131I-huA33325.  
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A Phase I multi-dose study of huA33 was conducted by Welt et al to define 
toxicity, immunogenicity and the MTD of unlabelled huA33319.  Eleven 
patients with advanced chemotherapy-resistant CRC received 4-weekly cycles 
of huA33 at 10, 25, or 50 mg/m2/week.  Despite humanisation, the majority of 
patients still developed HAHA (73%) 4 of whom developed clinically significant 
toxicity including fevers and hypotension326.  As HAHA activity was not huA33 
dose dependent (responses occurred at all dose levels), MTD could not be 
established.  One of the three patients who remained HAHA negative 
achieved a radiographic PR with reduction in serum carcinoembryonic antigen 
(CEA) level.  Four patients had radiological SD at 2-12 months with reductions 
in CEA levels in two cases, suggesting activity as monotherapy.  Toxicity 
included one or more of the following symptoms: mild rhinorrhea, cough, 
periorbital fullness, or headache, in 8 patients during or soon after infusion 
completion, which were independent of HAHA titre, and hence were 
attributable to huA33.  One patient in dose cohort 3 developed infusion 
related symptoms (nausea, hypotension, fever and rigors) with the fifth 
treatment cycle.  No episodes of antibody-induced colonic haemorrhage were 
reported, and only 2 patients had mild diarrhoea thought to be related to 
huA33.  
 
In summary, clinical characterisation of huA33 has shown this antibody to 
localise to metastatic CRC and show prolonged intra-tumoural retention, 
whilst elimination from normal bowel is consistent with the physiological 
turnover of basal colonocytes302.  Although the specific targeting qualities of 
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huA33 suggested many potential therapeutic uses, the persistent 
development of HAHA in a proportion of patients despite humanisation, made 
ongoing clinical development of strategies involving repeat infusions unlikely 
ǁŝƚŚ ƚŚŝƐ ĐŽŶƐƚƌƵĐƚ   /ƚ ?Ɛ ĐůŝŶŝĐĂů ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ ŚŽǁĞǀĞƌ ŽĨĨĞƌĞd significant 
potential as a radioimmunotherapeutic, which is the direction subsequent 
clinical development took. 
 
1.9.4 Optimising therapeutic efficacy: Radioimmunotherapy using huA33 
The first radioimmunotherapy trial using radio-iodinated humanised antibody, 
131I-huA33, was performed by Chong et al.  Fifteen patients with metastatic 
CRC who had progressed on at least one prior chemotherapy regimen were 
enrolled to this protocol which involved a trace labelled scout dose of 131I-
huA33 (5mg huA33 labelled with 5mCi 131I) followed by a therapy dose 1 week 
later comprising of a constant 10mg/m2 dose of huA33 with escalating doses 
of 131I (20mCi/m2, 30mCi/m2, 40mCi/m2 and 50mCi/m2)327.  Whole body 
gamma camera imaging was again used to assess biodistribution following the 
scout dose, and excellent tumour targeting was documented following this 
and the therapy infusion.  With this regimen of scout and single therapy dose 
of 131I-huA33, no acute infusion related adverse reactions were seen, but 
HAHA was documented in 4 patients (33%).  Haematological toxicity was 131I 
dose-dependent, with one documented grade 4 neutropenia and two 
episodes of grade 3 thrombocytopenia in patients in the highest cohort (50 
mCi/m2).  MTD was determined to be 40 mCi/m2.  There was no documented 
objective tumour response, however stable disease was observed in 4 
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patients, and progressive disease in 11 patients. The mean specific absorbed 
tumour dose was 6.49 ± 2.47 Gy/GBq.  
 
The studies described suggest 131I-huA33 has a number of features which 
could be compatible with therapeutic efficacy in metastatic CRC.  As the A33 
antigen is not rapidly degraded in lysosomes, huA33 allows the conjugated 
radioisotope to be in close proximity to the cancer cells for a longer duration.  
Homogenous distribution of A33 in tumours, relatively even uptake of the A33 
antibody into tumour including significant penetration into large, necrotic 
liver metastases from autoradiography on resected tissue, and transient 
retention in normal colonic epithelium justified further development of this 
approach. 
 
1.9.5 Targeted chemoradiation: 
131
I-huA33 with capecitabine  
After demonstrating that 131I-huA33 could be delivered as a well-tolerated, 
single infusion to patients with metastatic CRC at doses of up to 40 mCi/m2 327, 
ways of improving efficacy were explored.  Published evidence that 
chemotherapy including 5-FU can radiosensitise target tumour cells led to the 
concept of combining 131I-huA33 with capecitabine.  5-FU is known to act as a 
radiosensitiser, and neoadjuvant chemoradiation with infusional 5-FU 
chemotherapy is considered standard care for potentially resectable rectal 
cancer patients with unfavourable features on initial staging (fixed tumours or 
nodal involvement) to downstage tumours, improve resectability, and 
significantly reduce the risk of local recurrence328-330.  More recently 
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capecitabine has shown similar efficacy to infusional 5-FU in this setting, with 
comparable pathological responses331.  Synergistic anti-tumour effects when 
131I-huA33 is combined with 5-FU has also been shown in CRC xenografts332, 
suggesting this potential synergy also exists when 5-FU is combined with 
radioimmunotherapy.    
 
Capecitabine, an orally administered fluoropyrimidine carbamate was the 
obvious choice of cytotoxic to combine with radioimmunotherapy for the 
subsequent Phase I trial.  It is rapidly absorbed and metabolised to 5-FU in 
three steps333, with  the final conversion by thymidine phosphorylase (TP) 
occurring preferentially in tumour (where TP is more abundant).  This 
preferential activation potentially reduces systemic toxicities and maximises 
exposure of tumour cells to the cytotoxic metabolite.  Capecitabine has been 
shown to be equivalent in efficacy to intravenous 5-FU and leucovorin in the 
adjuvant and metastatic setting.  It is FDA and TGA approved as a single agent 
ĂŶĚ ŝŶ ĐŽŵďŝŶĂƚŝŽŶ ǁŝƚŚ ŽǆĂůŝƉůĂƚŝŶ ? ĨŽƌ ƚŚĞ ĂĚũƵǀĂŶƚ ƚƌĞĂƚŵĞŶƚ ŽĨ ƵŬĞ ?Ɛ
stage C colorectal cancers as well as in the metastatic setting102.  Two large 
randomised Phase III studies found capecitabine treatment resulted in 
superior response rates, equivalent time to progression and overall survival, 
an improved safety profile and improved convenience compared to 
intravenous 5-FU and leucovorin in metastatic CRC patients334.  
 
Capecitabine therapy is associated with lower incidences of stomatitis, 
alopecia and neutropenia; yet higher incidences of hand-foot syndrome and 
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uncomplicated hyperbilirubinaemia.  Fluoropyrimidine cardiotoxicity 
manifesting as ischaemic chest pain with or without ECG changes, or as 
arrhythmia, is a well-recognised, idiosyncratic toxicity associated with 5-FU, 
particularly infusional 5-FU. There is little published data on cardiac toxicity 
associated with capecitabine use although it is thought to be similar to 
infusional 5-FU.  Capecitabine product information quotes a 6% incidence of 
associated cardiac disorders and there are case reports in the literature335.  
 
As myelosuppression is the major toxicity resulting from 
radioimmunotherapy, cytotoxic agents with minimal myelosuppressive effect 
are preferred for combination therapy.  Capecitabine causes significantly less 
neutropenia compared to bolus 5-FU, therefore making it a preferable agent 
for use with 131I-huA33.  The incidence of grade 3/4 neutropenia with 
capecitabine monotherapy is approximately 2%.  In addition, it is orally 
administered, which circumvents potential radiation safety issues for staff 
associated with the simultaneous administration of chemotherapy and 
radioimmunotherapy.  An additional mechanism of potential synergy is the up 
regulation of intra-tumoural expression of TP by radiation336, which is likely to 
increase the intra-tumoural conversion of capecitabine to 5-FU, and hence 
improve efficacy.  The recommended dose of single agent capecitabine is 
2500 mg/m2/day (day1-14, 3 weekly), but when in combination with other 
cytotoxics, doses range from 625 mg/m2/day to 2500 mg/m2/day (d1-14, 3 
weekly)337 338.  When given concurrently with radiotherapy, MTD has been 
shown to be 1600mg/m2/day (day1-14)339.     
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The next step in the optimisation of huA33 for the treatment of CRC was to 
combine 131I-huA33 with oral capecitabine in an attempt to deliver targeted 
chemoradiation to metastatic disease.  This Phase I trial will be described in 
this thesis. 
 
1.10 Thesis outline 
This thesis will describe 3 component projects, which were aimed at making 
progress in the optimisation of targeted antibodies for the treatment of 
metastatic solid tumours. Three different approaches were explored: 
Improving response prediction of unconjugated EGFR targeting antibodies and 
improving therapeutic efficacy of targeted antibodies by conjugation with a 
toxin, or a radioisotope.  Both Phase I clinical trial protocols described in this 
thesis build on the results of preceding Phase I studies performed at The 
Ludwig Institute for Cancer Research.   
 
Recent evidence has demonstrated that the presence of a specific target does 
not always correlate with a therapeutic effect of a targeted antibody, and 
hence new predictive markers of response to such agents are required.  One 
explanation for this apparent lack of correlation is that the molecular profile 
of primary tumours and their corresponding metastases maybe different.  
One component of this thesis will describe a pilot project, which uses 
metastatic CRC as a model for exploring the molecular profile of tumours and 
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their corresponding metastases.  The aim of this project was to gain 
knowledge that might improve response prediction and patient selection for 
treatment with EGFR and targeted antibodies, and direct ongoing research. 
 
The immunoconjugate CMD-193 was developed by Wyeth pharmaceuticals in 
conjunction with the Ludwig Institute for Cancer Research, and was based on 
the parental anti-Ley antibody hu3S193, which demonstrated excellent 
tumour targeting in humans with solid tumours in a recent first-in-man 
biodistribution study.  Whilst a parallel study in US focused on toxicity and 
dose escalation of this agent, the Phase I study to be described in this thesis 
ĞŶƚŝƚůĞĚ  “ WŚĂƐĞ / ƐƚƵĚǇ ŽĨ ďŝŽĚŝƐƚƌŝďƵƚŝŽŶ ĂŶĚ ƉŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐ ŽĨ 111In-
CMD-193 in patients with advanced tumours expressing the Ley ĂŶƚŝŐĞŶ ? ?ǁĂƐ
designed to determine the biodistribution, pharmacokinetics, changes in 
tumour metabolism and anti-tumour response of this immunoconjugate.  
 
After demonstrating the feasibility and safety of administering 
radioimmunotherapy to patients with metastatic colorectal cancer in the form 
of 131I-huA33 in a prior Phase I trial, it was hypothesised that this approach 
could be optimised with the addition of chemotherapy.  The final component 
ŽĨƚŚŝƐƚŚĞƐŝƐǁŝůůĚĞƐĐƌŝďĞƚŚĞƐƵďƐĞƋƵĞŶƚ>/ZƚƌŝĂůĞŶƚŝƚůĞĚ  “WŚĂƐĞ /ƚƌŝĂůŽĨ
oral capecitabine combined with 131I-huA33 in patients with metastatic 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ? ǁŝƚŚ ƚŚĞ aim of delivering targeted chemoradiation to 
patients with metastatic colorectal cancer by combining 131I-huA33 with 
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capecitabine.  Safety, tolerability, pharmacokinetics, biodistribution, 
immunogenicity and tumour response of this combination were assessed. 
 
My role in these projects was to be involved in all aspects of study design, 
study conduct (as a clinical research fellow), analysis of all clinical and 
laboratory data, and results write-up. The final results of these studies are 
presented herein. 
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CHAPTER 2: Optimising the use of EGFR-targeting 
antibodies 
 
 
 
2.1 METHODS 
2.1.1 Study rationale and objectives 
The modest survival advantage provided by the addition of EGFR directed 
antibodies to the management of metastatic CRC patients illustrates that 
although many tumours may utilise the EGFR pathway to promote growth, 
activation of signalling downstream of EGFR may occur via a multitude of 
mechanisms.  Since the discovery that EGFR expression in primary CRC does 
not reliably correlate with response to cetuximab 118, and more recently that 
K-ras and B-raf mutations in primary tumour correlates with resistance to 
cetuximab/panitumumab, it is clear that the presence of molecular target in 
primary tumour does not automatically mean success for targeted 
antibodies90 91 130 131.  
 
As described in section 1.7.4.1 assessment of signalling pathways downstream 
of EGFR may be better predictors of efficacy of EGFR targeted antibodies, as 
they are likely to reflect the activity of EGFR mediated growth pathways in 
tumours better than merely expression of EGFR 218.  In some cases activation 
of signalling molecules is indicated by phosphorylation such as pEGFR 
(activated EGFR), pAkt and pMAPK.  In other cases, well-described mutations 
result in constitutive activation of the signalling molecules such as KRAS, BRAF 
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and PI3K.  KRAS mutations in primary tumours are now known to have a role 
as predictors of non-response to EGFR antibodies225-227 229 235 236 238, and 
evidence is building to suggest BRAF mutations may have a similar role130.  
Published data implicating PI3KCA mutations in EGFR antibody resistance is 
currently limited249 251.  Although some studies have focused on a limited 
number of components of the EGFR pathway, no evidence could be found 
drawing together expression of activated downstream components and 
activating mutations, and there is limited information about whether KRAS, 
BRAF or PI3KCA mutations in primary tumours correlate with those in 
corresponding metastatic disease. Although KRAS and BRAF mutations are 
thought to be early events in the development of colorectal carcinoma, a lack 
of concordance in mutation status in primary and metastatic disease would 
mean examination of metastatic tissue prior to cetuximab therapy could help 
to identify a greater proportion of resistant patients.  Evidence is also 
emerging regarding the possible relationships between such activating 
mutations130 248.  
 
Although progress has been made in terms of predicting response to EGFR 
targeted antibodies, with costs remaining high and limited public funding 
available for patients with metastatic CRC in many countries, further 
improvement of patient selection is required if the use of such targeted 
antibodies is to be optimised further.  The ability to understand the extent of 
correlatioŶďĞƚǁĞĞŶƚŚĞŵŽůĞĐƵůĂƌƉƌŽĨŝůĞŽĨĂƉĂƚŝĞŶƚ ?ƐƉƌŝŵĂƌǇƚƵŵŽƵƌĂŶĚ
metastatic tissue is likely to make a significant impact on improved patient 
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selection for EGFR targeted antibodies.  This descriptive study aimed to aid 
the development of such a predictive molecular profile by exploring whether: 
 
 The pattern of activation of signalling molecules downstream of EGFR 
in metastatic tissue is concordant with the primary tissue 
 There is any correlation between mutations in KRAS, BRAF and PI3KCA 
in primary and metastatic tissue 
 There is any relationship between relevant signalling molecule 
activation and mutation status 
 
These questions are important in order to aid the design of future trials 
exploring EGFR targeting therapies and ultimately optimise their clinical use.  
When decisions are made regarding the further management of patients with 
metastatic disease, currently molecular predictors of response such as KRAS 
mutations are analysed in the primary tissue.  This is because often the 
primary tissue alone has been surgically removed or biopsied, and further 
invasive procedures such as biopsies of metastatic disease are not generally 
thought to be necessary for appropriate treatment decisions to be made.  It 
was therefore important that this study used archived, paraffin embedded 
paired tumour tissue, as practically this is the source of tissue, which is most 
readily available to the clinical team. 
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2.1.2 Patient selection 
After approval was granted from Austin Health Research Ethics Committee, 
Austin Hospital pathology records were used to identify patients who had 
undergone a biopsy or metastectomy confirming the diagnosis of metastatic 
colorectal carcinoma.  The Kestrel database developed by the pathology 
department enabled an electronic search to be performed of certain 
keywords within the summary of the histopathology reports created by the 
department.  The search criteria were limited to 30 characters, which meant 
searching for certain phrases was not possible (metastatic colon 
adenocarcinoma and metastatic colonic adenocarcinoma).  As there was great 
variation in the wording used by pathologists in their reports, a number of 
different keywords and phrases were used in order to maximise the capture 
of suitable patients. Searches were performed using the following keyword 
combinations: Metastatic colonic; metastatic adenocarcinoma; metastatic 
colon carcinoma; metastatic colon; metastatic colorectal; colorectal primary; 
colorectal adenocarcinoma.  The pathology database was searched for these 
described keywords that were in reports generated between 1/1/00 and 
31/5/06 (the commencement of the study).  Using this method, 481 
histopathology reports were initially identified as possibly fitting the search 
criteria (out of a total of 857581 reports that had been generated during this 
time period).  Many of those found in the metastatic adenocarcinoma search 
criteria predictably, did not have a colorectal primary and these were 
excluded.  Further additional information on possible primary tumours was 
obtained from the hospital electronic records, and the remaining 
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uncertainties were clarified by searching the medical records or full 
histopathology reports on the electronic database.   
 
These searches identified 89 patients as possible candidates for paired 
primary and metastatic CRC specimen evaluation.  All these patients had a 
CRC related metastectomy (or possibly biopsy) performed at the Austin 
Hospital, and in whom a primary resection had been previously documented.  
As many patients had been referred to Austin Hospital for metastectomy, 
there was often scanty documented information in the medical records 
regarding their primary surgery.  In these cases the surgeon who performed 
the surgery was contacted (although they often did not have any details 
regarding their primary surgery), and if possible, the local treating oncologist, 
to obtain a copy of the primary histopathology report and details of the 
pathology lab in possession of the tissue blocks.  These difficulties in acquiring 
patient information meant it was not possible to collect data regarding 
treatment received or progression free survival.  The sessional nature of 
consulting surgeons (and oncologists) in the Australian Healthcare system, 
meant that many surgeons had a number of private consultation rooms in 
different locations, performed surgery in a number of different hospitals, and 
hence used a number of different pathology labs.  This made it impossible to 
centrally request tissue blocks unless it was known which pathology lab the 
tissue was sent to, and these identifying details were often missing from 
ŵĞĚŝĐĂůƌĞĐŽƌĚƐ ?ĞǀĞŶƚŚŽƐĞŚĞůĚŝŶƚŚĞƐƵƌŐĞŽŶ ?ƐƉƌŝǀĂƚĞƌŽŽŵƐ ? ? 
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Of the initial 89 patients, the location of the primary tissue was identified in 
70 (21 of these in our institution, 49 in local and regional pathology 
laboratories).  For the remaining 19 patients review of the medical and 
electronic records, contact with the surgeon performing the most recent 
surgery, and even the treating oncologist failed to identify where the initial 
primary surgery was performed, and which pathology lab would have 
received the tissue.  Letters were sent to the pathology laboratories 
documented as having received the primary specimens requesting the tissue 
blocks for the construction of the tissue microarrays (TMAs).  From the 70 
requests, tissue blocks were received for 33 patients, in 15 cases the primary 
tissue section could not be located, 15 were excluded as specimens located 
were from biopsies only (inadequate for evaluation), in 4 cases the laboratory 
refused to release the tissue, and no reply was received from the remaining 3 
contacted. 
 
2.1.3 Tissue microarray construction 
Immunohistochemical analysis of cancer specimens using TMAs is now a well-
validated approach for the molecular profiling of tumours.  The TMAs for the 
33 patients in this study were constructed by first selecting a representative 
block from the archived formalin-fixed, paraffin embedded tumour specimen.    
Five-µm sections stained with H&E were obtained to confirm the diagnosis 
and select representative areas of the primary and corresponding metastases 
specimens for tissue cores to be taken from.  Triplicate 1.0mm core biopsies 
were taken from the pre-selected areas, and placed into a recipient paraffin 
 119 
block340 341, with primary cores being located adjacent to their corresponding 
metastases.  Adjacent normal cores were also sampled and included on the 
TMA slide construction, but it was not possible to obtain a representative 
sample in many cases, and hence these were not included in the analysis of 
this project.  Five-µm sections of these tissue array blocks were then cut, 
placed on charged SuperFrost Plus slides, and used for immunohistochemical 
analysis. Malignant tissue known to express the antigens investigated were 
used as positive controls.  Immunoglobulin matched control antibody, or 
omission of primary antibody were used as negative controls.  
 
2.1.4 Immunohistochemistry methodology 
Tissue array sections were deparaffinised by heating for 30 minutes, bathed in 
xylene (two 5 minute periods), bathed in 100% ethanol (two 5 minute 
periods), before rehydration with distilled water.  The antigen retrieval 
method varied according to the target marker.  For EGFR, sections underwent 
enzyme digestion using Proteinase K (S3004, Dako, Glostrup, Denmark) at 
room temperature for 5 minutes.  For pEGFR, 10 minutes of microwave oven 
treatment with EDTA buffer, pH8.0 (Lab Vision Corporation, Fremont, CA) was 
used, and for pMAPK, retrieval was performed in a citrate buffer, pH6.0 (Lab 
Vision Corporation, Fremont, CA) by microwave treatment for 10 minutes.  
Following washes in distilled water (dH2O) and tris buffered saline pH (TBS), 
endogenous peroxidases were quenched using 3% H2O2.  
 
 120 
Slides were incubated with primary antibody (for 30 to 45 minutes); EGFR 
(Zymed, Clone 31G7, South San Franciso, CA;0.3mg/ml), pEGFR (Santa Cruz; 4 
mg/ml), and p44/42 pMAPK (Cell Signaling Technology, USA;0.3mg/ml).  
Corresponding slides using a subclass control were prepared simultaneously. 
All slides were washed again with TBS prior to incubation with horseradish 
peroxidase-conjugated secondary antibody for 30 minutes.  For antigen 
detection, EGFR samples were incubated with HRP conjugated anti-mouse 
immunoglobulins (Dako Envision Kit, Dako, Glostrup, Denmark) for 30 minutes 
at room temperature.  pEGFR, samples were incubated with biotinylated anti-
goat immunoglobulin (2mg/ml) followed by vectastain ABC reagent (Vector 
Laboratories, Burlingame, CA).  The Powervision Plus Poly-HRP detection kit 
(ImmunoVision Technologies, Daly City, CA) was used for pMAPK.  All staining 
ǁĂƐ ĚĞƚĞĐƚĞĚ ƵƐŝŶŐ  ? ? ?-diaminobenzidine (DAB; Sigma Aldrich Co. St. Louis, 
MO) chromogen.   EGFR signal was visualized with DAB+ (K3468, Dako) for 10 
minutes at room temperature.  Slides were counterstained with 
haematoxylin.  Immunohistochemistry methodology is summarized in Table 
2.1.4. 
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Table 2.1.4 IHC Methodology 
Target 
antigen  
Source of 
primary 
Antibody 
Primary antibody 
Antigen 
retrieval 
method 
Detection 
method 
EGFR Zymed 
Murine monoclonal 
(31G7) 
Prot K at room 
temperature for 
5 mins 
Dako Envision 
mouse HRP 
detection kit 
pEGFR Santa Cruz 
Goat polyclonal 
(Raised against the 
human sequence 
pTyr1173)  
EDTA  with 
microwave for 
10 mins 
-goat IgG-
biotinylated 
followed by 
vectastatin ABC 
reagent 
pMAPK 
Cell 
signalling 
 
Rabbit p44/42 
monoclonal 
(Thr202/Tyr204, 
20G11)  
Citrate buffer 
with microwave 
for 10 mins 
Immunovision 
Powervision 
plus HRP 
detection kit 
 
 
2.1.5 Immunohistochemical analysis 
Classification of immunoreactivity for each of the 3 markers analysed is 
described below.   Two out of three investigators (RH, DJ, DP) reviewed and 
scored slides, and any disagreements were resolved by an independent 
consultant histopathologist (SF). Tissue damage during the construction of 
TMAs is a well-recognized phenomenon341, and was therefore recorded.  
Damaged tissues were excluded from analyses of the respective markers340. 
 
In the evaluation of EGFR expression, only membrane staining of EGFR was 
scored.  Cytoplasmic reactivity as a result of internalised receptors without 
membrane staining was reported as negative193 342.  EGFR positivity was 
defined as 1% positive membrane staining of any intensity (complete or 
incomplete), in any of the triplicate tissue cores on the TMA193 194 342.  pEGFR 
was scored in a similar manner, but positivity was defined as  5% of cells 
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displaying granular cytoplasmic staining of any intensity343.  Evaluation of 
pMAPK expression was performed by scoring cells with cytoplasmic with 
nuclear brown staining194 344 345.  Proportion of neoplastic cells showing 
positivity were scored on a scale of 0-1, where 0 = none; 0.1  one tenth; 0.5 
 one-half; 1.0  one-half.  Intensity of staining was obtained for each core, 
where 0 = no staining; 1 = weak; 2=moderate, 3=strong.  Average intensity 
was determined, and this mean intensity was multiplied by proportion scores 
to give an H-score.  An H score 1.0 was deemed positive for pMAPK. 
 
2.1.6 KRAS, BRAF and PI3KCA mutation analysis methodology 
12.1.6.1 Introduction 
High resolution melting (HRM) is emerging as a practical and sensitive346 
technique for detection of nucleic acid sequence variation347-350.  Importantly 
this method can use specially designed primers to yield reproducible 
amplification even from DNA in which the quality has been compromised.  
 
The melting profile of a DNA duplex depends on a number of factors including 
the buffer, length and sequence of the DNA.  Conventional DNA melting is 
measured by UV absorbance, but this requires a lot of DNA, and often takes 
hours to perform347.  Analysing DNA melting by fluorescence however is quick, 
and can be performed using small amounts of DNA by performing in the same 
tube immediately after PCR amplification347.  The detected change in 
fluorescence is caused by the release of an intercalating DNA dye from a DNA 
duplex as it is denatured by increasing temperature222. The melt curve 
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accuracy is maximized by acquiring this fluorescence data over small 
temperature increments, with the curve shape being a function of the DNA 
sequence being melted, allowing amplicons containing different sequence to 
be discriminated on the basis of melt curve shape222. 
 
The use of HRM to detect somatic and germline mutations has been reported 
using DNA obtained from fresh tumour tissue350 351 and peripheral blood351.  
Somatic mutations in HER2, EGFR, BRAF and KRAS genes have been identified 
using this method240 346 352.  For this project, and in the clinical setting, often 
archived formalin-fixed paraffin-embedded tissue is the only sample available 
without subjecting the patient to an additional invasive procedure.  
Importantly HRM assays have also been optimised and validated for the 
analysis of formalin-fixed paraffin-embedded tissues for the detection of 
somatic mutations240 348 351. 
 
2.1.6.2 Mutation analysis methodology 
Mutation analysis was performed at a centralised laboratory (Peter 
MacCallum Cancer Centre), on DNA extracted from matched patient samples 
of formalin-fixed paraffin-embedded tissue. Tumour rich areas were marked 
by a pathologist and micro-dissected using buffer ATL (Qiagen, Hilden, 
Germany). Tissue was incubated in 100µl of buffer ATL and Proteinase K 
(240µg added initially and every 24hr) at 56oC for 72hr. DNA was extracted 
using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to 
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ƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐƚŝƐƐƵĞƉƌŽƚŽĐŽůǁŝƚŚƐĐĂůĞĚĚŽǁŶǀŽůƵŵĞƐŽĨďƵĨĨĞƌƐĂŶĚĂ
final elution volume of 50µl.  
 
PCR and HRM analysis was performed on a LightCycler® 480 (Roche 
Diagnostics, Penzberg, Germany) in the presence of the fully saturating 
intercalating dye, SYTO® 9 green fluorescent nucleic acid stain (Invitrogen, 
Carlsbad, CA). All samples were tested in triplicate. The reaction mixture 
contained; 1x PCR buffer, DNA template of various concentrations, 200 uM 
dNTPs (Fisher Biotec Australia, Wembley, Western Australia), 5 µM SYTO® 9 
(Invitrogen, Carlsbad, CA), 0.5U HotStarTaq polymerase (Qiagen, GmbH, 
Hilden, Germany), various concentrations of MgCl2 and primers were used 
specific to each assay in a 10µl final reaction volume. The MgCl2 
concentration, primer sequences, cycling and melting conditions for each 
assay are summarised in Table 2.1.6.2. 
 
All samples that were positive by HRM were confirmed and characterised by 
cycle sequencing according to the standard protocol.  A small number of wild-
type samples for each amplicon were also confirmed by cycle sequencing.  
PCR, Exo-SAP IT® (USB, Ohio, USA) and sequencing reactions were performed 
on a PTC-225 Peltier Thermal Cycler (MJ Research, MA, USA). Samples 
sequenced for the mutation hotspot regions of KRAS exon 2 and BRAF exon 
15 were sequenced straight from the HRM product whilst new amplicons 
were amplified for analysis by sequencing of the mutation hotspot regions in 
KRAS exon 3, PI3KCA exons 9 and 20.  A mix of genome specific and M13 
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primers were used.  Reaction conditions and primer details for each assay are 
included in Table 2.1.6.2.  Sequencing reaction pellets were re-suspended in 
20µl HiDiTM Formamide (Applied Biosystems, Foster City, CA, USA), 
denatured for 3mins at 95oC and run on a 3730 DNA Analyser (Applied 
Biosystems, Foster City, CA, USA). 
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Table 2.1.6.2 Mutation analysis reaction conditions and primer details 
Amplicon WƌŝŵĞƌ^ĞƋƵĞŶĐĞ ? ? ?-  ? ? PCR Details Melt Details Sequencing AT 
KRAS exon 2 
(PCR for HRM) 
TGTAAAACGACGGCCAGTTTATAAGGCCTGCTGAAAATGACTGAA MgCl2 2.5mM; Primer 200nM;   
AT TD 70-60
o
C 
65-95
o
C; 
4.4
o
C/sec 
M13 
CAGGAAACAGCTATGACCTGAATTAGCTGTATCGTCAAGGCACT 
KRAS exon 3 
(PCR for HRM) 
GGAGAAACCTGTCTCTTGGATATTCTC MgCl2 2.5mM; Primer 400nM;   
AT TD 65-55
o
C 
70-95
o
C 
4.4
o
C/sec 
 
AATGAGGGACCAGTACATGAGGACT 
KRAS exon 3 
(PCR for 
sequencing) 
AATAATCCAGACTGTGTTTCTCCCTTC MgCl2 1.0mM; Primer 400nM;   
AT TD 65-55
o
C 
 AT 50
o
C 
AATGAGGGACCAGTACATGAGGACT 
BRAF exon 15 
(PCR for HRM) 
CCTCACAGTAAAAATAGGTGATTTTGG MgCl2 2.5mM; Primer 200nM;   
AT TD 65-55
o
C 
70-90
o
C 
1
o
C/sec 
 
GGATCCAGACAACTGTTCAAACTGA 
BRAF exon 15 
(Secondary PCR) 
TGTAAAACGACGGCCAGTCCTCACAGTAAAAATAGGTGATTTTGG MgCl2 2.5mM; Primer 200nM;   
AT 60
o
C 
 M13 
CAGGAAACAGCTATGACCGGATCCAGACAACTGTTCAAACTGA 
PI3KCA exon 9 
(PCR for HRM) 
AAAGAACAGCTCAAAGCAATTTCTACAC MgCl2 2.0mM; Primer 400nM;   
AT TD 65-55
o
C 
65-95
o
C 
4.4
o
C/sec 
 
AATCTCCATTTTAGCACTTACCTGTGAC 
PI3KCA exon 9 
(PCR for 
sequencing) 
TGTAAAACGACGGCCAGTCAGAGTAACAGACTAGCTAGAGACAATG MgCl2 3.5mM; Primer 200nM;   
AT 55
o
C 
 M13 
CAGGAAACAGCTATGACCAATCTCCATTTTAGCACTTACCTGTGAC 
PI3KCA exon 20 
(PCR for HRM) 
TGAGCAAGAGGCTTTGGAGTATTTC MgCl2 2.5mM; Primer 400nM;   
AT TD 65-55
o
C 
65-95
o
C 
4.4
o
C/sec 
 
TGCTGTTTAATTGTGTGGAAGATCC 
PI3KCA exon 20 
(PCR for 
sequencing) 
TCGACAGCATGCCAATCTCTTC MgCl2 2.5mM; Primer 400nM;   
AT 58
o
C 
 AT 58
o
C 
TGCTGTTTAATTGTGTGGAAGATCC 
M13 
(For sequencing) 
TGTAAAACGACGGCCAGT 
  AT 60
o
C 
CAGGAAACAGCTATGACC 
Key: AT  W Annealing Temperature; TD- Touch down 
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2.1.7 Statistical analysis 
Potential correlations and associations were calculated using either univariate 
logistic regression or the conditional binomial exact test (CBET)353 as 
appropriate. The CBET test was used when cell frequencies were small and is 
a more powerful test to the standard chi-ƐƋƵĂƌĞĚŽƌ&ŝƐŚĞƌ ?ƐǆĂĐƚƚĞƐƚ ? 
 
2.2 RESULTS 
2.2.1 Patient characteristics 
Thirty-two patients were available for our analysis, as one did not have 
adequate tissue for analysis of paired samples in the constructed TMA.  
Twenty-two (68.8%) male and 10 (31.3%) female, with a median age of 60 
years (range 36-86 years).  The primary site was colon in 19 (59.4%) and 
rectum in 13 (40.6%) patients.  Additional polyps were found in the 
pathological specimen in 22 (68.8%) of patients.  Nine patients (28.1%) had 
Dukes stage B, 18 (56.3%) Dukes C, and 4 (12.5%) had Dukes D disease at 
diagnosis.  Pathologic specimens from corresponding metastatic disease in 
each patient were from a variety of sites.  Sites were: liver in 21 (65.6%), lung 
in 5 (15.6%), lymph node in 1 (3.1%), peritoneum/omentum in 2 (6.3%), ovary 
in 2 patients (6.3%), and bone in 1 (3.1%).  Four patients (12.5%) presented 
with synchronous metastases.  Patient characteristics are detailed in Table 
2.2.1.  
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Table 2.2.1 Patient characteristics 
 
Characteristic 
No. of patients 
(N=32) 
% 
Sex 
Male 22 68.8 
Female 10 31.3 
Age (years) 
Median 60 
Range 36-86 
Primary site 
Colon 19 59.4 
Rectum 13 40.6 
Dukes Stage at diagnosis 
A 0 0 
B 9 28.1 
C 18 56.3 
D 4 12.5 
Difficult to interpret 1 3.1 
Site of metastasis 
Liver 21 65.6 
Lung 5 15.6 
Lymph node 1 3.1 
Peritoneum/omentum 2 6.3 
Ovary 2 6.3 
Bone 1 3.1 
Timing of metastatic spread 
Metachronous 28 87.5 
Synchronous 4 12.5 
 
 
 
2.2.2 Primary tumour characteristics 
Although all metastatic tissue samples were obtained at Austin Health, and 
therefore reported on by the same department, primary tissue blocks were 
obtained from a number of different pathology labs.  This meant the 
pathological detail included in each report varied.  The primary demonstrated 
adenocarcinoma in 29 patients (90.6%), mucinous in 2 patients (6.3%), and 
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mixed in 1 patient (3.1%).  Primary size was documented as 15-30mm in 11 
patients (34.2%), >30-45mm in 8 patients (25.0%), and  >45mm in 8 patients 
(25.1%).  Size was not documented in the pathology reports of 5 patients 
(15.6%).  Nineteen patients (59.4%) had well differentiated tumours, 11 
(34.4%) had moderately differentiated and 2 (6.3%) patients had poorly 
differentiated tumours excised.  Twenty patients (62.5%) had involved lymph 
nodes, and 15 patients (46.9%) had documented evidence of lymphovascular 
invasion.  Tumour characteristics are shown in Table 2.2.2.1 
 
Table 2.2.2.1 Primary tumour characteristics 
 
Primary tumour characteristic 
No. of patients 
(N=32) 
% 
Histology 
Adenocarcinoma 29 90.6 
Mucinous 2 6.3 
Mixed adenocarcinoma/mucinous 1 3.1 
Size  
15-30mm 11 34.2 
>30-45mm 8 25.0 
>45mm 8 25.1 
Size missing from pathology report 5 15.6 
Differentiation (worst) 
Well differentiated 19 59.4 
Moderately differentiated 11 34.4 
Poorly differentiated 2 6.3 
Number of positive lymph nodes 
0 11 34.4 
1-3 15 47.0 
>4 5 15.6 
Unknown 1 3.1 
Lymphovascular invasion  
No 12 37.5 
Yes 15 46.9 
Not documented 7 21.9 
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Primary tumours expressed EGFR in 17.2%, pEGFR in 87.1% and pMAPK in 
19.4%.  KRAS, BRAF and PI3KCA mutations were detected in 10 (31%), 2 
(6.9%), and 4 (10%) of primary tumours respectively. 
 
Mutation analysis data obtained from HRM analysis can be read in three 
different formats (Figure 2.2.2.1); the melt curves, melting peaks, and as a 
differential plot, which shows the difference in fluorescence from samples 
and the selected normal/baseline sequence.  As this is the easiest way to 
distinguish mutations, subsequent mutation analysis figures are shown in this 
format.  
 
Of the 10 patients found to have KRAS mutations, all were in exon 2.  A 35G>A 
base change leading to a G12D amino acid sequence was found in 3 patients, 
and a 35G>T base change with subsequent G12V amino acid was found in 4 
patients. One patient demonstrated a 38G>A base change with a 
corresponding G13D amino acid sequence, 1 patient had a 34G>T substitution 
leading to a G12C amino acid sequence change, and the final patient had a 
35G>C base change leading to a G12A amino acid sequence.  Examples of the 
differential plots of HRM curves for patients with KRAS mutations are shown 
in Figures 2.2.2.2 and 2.2.2.3.  In both patients with a BRAF mutation, this was 
a 1799T>A base change leading to a V600E amino acid sequence alteration.  
The differential plots of HRM curves for patients with BRAF mutations are 
shown in Figures 2.2.2.4 and 2.2.2.5.  Of the 4 patients with PI3KCA 
mutations, 2 were located at exon 9, and 2 at exon 20.  At exon 9, 1 patient 
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had a 1625A>C base change leading to an E542A amino acid sequence change, 
and 1 had a 1624G>A base change with an E542K amino acid sequence 
change.  At exon 20, both mutations involved a 3140A>G base change leading 
to a H1047R amino acid sequence alteration.  Figures 2.2.2.6 and 2.2.2.7 
demonstrate the differential plots of HRM curves for patients with PI3KCA 
mutations.  Mutation analysis is detailed in Tables 2.2.2.2, 2.2.2.3 and 2.2.2.4. 
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Figure 2.2.2.1 HRM curves for primary tumour of patient 25  
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Figure 2.2.2.2 KRAS exon 2 differential plots of HRM curves and sequencing for patient 25 
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Figure 2.2.2.3 KRAS exon 2 differential plots of HRM curves and sequencing for patient 28 
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Figure 2.2.2.4 BRAF exon 15 differential plots of HRM curves and sequencing for patient 11 
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Figure 2.2.2.5 BRAF exon 15 differential plots of HRM curves and sequencing for patient 10  
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Figure 2.2.2.6 PI3KCA exon 9 differential plots of HRM curves and sequencing for patient 27  
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Figure 2.2.2.7 PI3KCA exon 20 differential plots of HRM curves and sequencing for patient 12  
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Table 2.2.2.2 KRAS mutation analysis 
Patient 
KRAS exon 2 mutation analysis 
Primary tumour Metastases 
HRM 
result 
base 
change 
amino 
acid 
sequence 
HRM 
result 
base 
change 
amino 
acid 
sequence 
1 WT     WT     
2 POS 35G>A G12D FAIL 
3 WT     WT    
4 WT     WT    
5 WT     WT    
6 WT     WT    
7 WT     WT    
8 WT     WT    
9 POS 35G>T G12V POS 35G>T G12V 
10 WT     WT    
11 WT     WT    
12 POS 35G>T G12V POS 35G>T G12V 
13 WT     WT    
14 WT     WT    
15 POS 35G>T G12V POS 35G>T G12V 
16 WT     WT    
17 WT     WT    
18 WT     WT    
19 POS 35G>A G12D POS 35G>A G12D 
20 WT     WT    
21 POS 38G>A G13D POS 38G>A G13D 
22 WT     WT    
23 WT     WT    
24 WT     WT    
25 POS 35G>T G12V POS 35G>T G12V 
26 POS 35G>A G12D POS 35G>A G12D 
27 WT     WT    
28 POS 34G>T G12C POS 34G>T G12C 
29 POS 35G>C G12A POS 35G>C G12A 
30 WT     WT    
31 N/A POS 35G>A G12D 
32 N/A WT     
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Table 2.2.2.3 BRAF mutation analysis 
Patient 
BRAF exon 15 mutation analysis 
Primary tumour Metastases 
HRM 
result 
base 
change 
amino 
acid 
sequence 
HRM 
result 
base 
change 
amino 
acid 
sequence 
1 WT     WT     
2 WT     FAIL 
3 WT     WT     
4 WT     WT     
5 WT     WT     
6 WT     WT     
7 WT     WT     
8 WT     WT     
9 WT     WT     
10 POS 1799T>A V600E POS 1799T>A V600E 
11 POS 1799T>A V600E POS 1799T>A V600E 
12 WT     WT     
13 WT     WT     
14 WT     WT     
15 WT     WT     
16 WT     WT     
17 WT     WT     
18 WT     WT     
19 WT     WT     
20 WT     WT     
21 WT     WT     
22 WT     WT     
23 WT     WT     
24 WT     WT     
25 WT     WT     
26 WT     WT     
27 WT     WT     
28 WT     WT     
29 WT     WT     
30 WT     WT     
31 N/A WT     
32 N/A WT     
 
 141 
Table 2.2.2.4 PI3KCA mutation analysis 
Patient 
PI3KCA exon 9 and 20  mutation analysis 
Primary tumour Metastases 
HRM result 
base 
change 
amino 
acid 
sequence 
HRM result 
base 
change 
amino 
acid 
sequence 
1 WT    WT   
2 WT   FAIL 
3 WT   WT   
4 WT   WT   
5 WT   WT   
6 WT   WT   
7 WT   WT   
8 WT   WT   
9 WT   WT   
10 WT   WT   
11 WT   WT   
12 POS exon 20 3140A>G H1047R POS exon 20 3140A>G H1047R 
13 WT   WT   
14 WT   WT   
15 WT   WT   
16 WT   WT   
17 WT   WT   
18 WT   WT   
19 WT   WT   
20 WT   WT   
21 WT   WT   
22 WT   WT   
23 POS exon 9 1625A>C E542A POS exon 9 1625A>C E542A 
24 WT   WT   
25 WT   WT   
26 WT   WT   
27 POS exon 9 1624G>A E542K POS exon 9 1624G>A E542K 
28 WT   WT   
29 WT   WT   
30 WT   WT   
31 N/A POS exon 20 3140A>G H1047R 
32 N/A WT   
 
 142 
Where sample numbers were adequate, univariate analysis was used to 
explore possible correlations between EGFR, pEGFR, pMAPK expression, KRAS, 
BRAF and PI3KCA mutations and primary tumour characteristics know to be 
associated with inferior prognosis.  No correlation was found between 
primary size or grade, lymph node involvement, or lymphovascular invasion 
and expression of EGFR, pEGFR, pMAPK or mutations in KRAS, BRAF and 
PI3KCA in primary tissue (Table 2.2.2.5). 
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Table 2.2.2.5 Univariate analysis of marker expression and primary tumour characteristics.  
 
Primary Tumour 
characteristic 
EGFR pEGFR pMAPK KRAS mutation BRAF mutation PI3KCA mutation 
Odds p 
95% 
CI 
Odds p 
95% 
CI 
Odds p 
95% 
CI 
Odds p 
95% 
CI 
Odds p 
95% 
CI 
Odds p 
95% 
CI 
Tumour size 0.97 0.37 
0.91-
1.04 
0.96 0.33 
0.90-
1.04 
0.98 0.53 
0.91-
1.05 
1.06 0.08 
0.99-
1.12 
0.93 0.32 
0.82-
1.07 
1.02 0.70 
0.93-
1.11 
Grade 0.58 0.51 
0.11-
2.97 
2.28 0.46 
0.26-
20.00 
0.65 0.60 
0.13-
3.26 
1.00 1.00 
0.29-
3.41 
1.00 1.00 
0.10-
10.15 
0.58 0.63 
0.06-
5.33 
Lymph node 
involvement 
1.50 0.09 
0.94-
2.38 
1.12 0.73 
0.59-
2.11 
1.00 1.00 
0.60-
1.67 
1.11 0.63 
0.74-
1.65 
1.15 0.68 
0.59-
2.25 
0.64 0.46 
0.20-
2.07 
Lymphovascular 
invasion 
3.63 0.28 
0.35-
38.16 
Not estimable 3.63 0.28 
0.35-
38.16 
2.00 0.42 
0.38-
10.58 
Not estimable 1.69 0.69 
0.13-
21.14 
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2.2.4 Concordance between primary and metastatic disease 
As described in section 2.1.3, the TMAs were constructed with triplicate 
samples of paired primary and metastatic tissue in order to minimise loss of 
data due to degradation or damage during construction.  Despite this there 
were a few cases for each of the markers evaluated where a result for paired 
samples could not be obtained.  Results are shown in Table 2.2.4. 
 
EGFR immunohistochemical expression was positive in 5 primary tumours 
(17.2%), and 3 in metastatic tumours (10.3%).  Correlation of EGFR positivity 
in primary and metastases did reach statistical significance (p=0.031), despite 
3 patients showing positivity in primary and negativity in corresponding 
metastases, and 1 patient having an EGFR negative primary, but a positive 
metastasis. 
 
Phosphorylated EGFR expression was detected in a much higher proportion of 
tumours than membrane expression of the inactivated receptor.  Twenty-
seven patients (87.1%) demonstrated pEGFR positivity in their primary 
tumour, and 19 (61.3%) in their metastatic disease.  pEGFR status was 
discordant between primary and metastatic disease in 10 patients (34.5%). 
Nine patients (29.0%) had pEGFR positivity in primary tissue but lacked 
expression in corresponding metastatic disease.  One patient showed an 
absence of pEGFR expression in their primary tumour, but positivity was 
demonstrated in their metastases. 
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Primary tumours were pMAPK positive in 6 patients (19.4%), and metastases 
were positive in 5 patients (16.1%).  Discordance between primary and 
metastatic tumour expression of pMAPK was demonstrated in 9/31 patients 
(29.0%) with paired samples analysed.  Six patients (19.4%) had a primary 
tumour which expressed pMAPK, whilst 5 (16.1%) had positivity in 
metastases.  Five patients (16.1%) had positive primary tumours with 
negativity in corresponding metastases, and four patients (12.9%) 
demonstrated pMAPK negative primaries with positive metastases. 
 
Examples of immunohistochemical staining for EGFR, pEGFR and pMAPK are 
shown in Figures 2.2.4.1 - 2.2.4.9.  All were photographed using the x20 
objective. 
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Figure  2.2.4.1 Concordant EGFR expression 
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Figure 2.2.4.2 Concordant EGFR expression 
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Figure 2.2.4.3 Discordant EGFR expression 
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Figure 2.2.4.4 Concordant pEGFR expression 
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Figure 2.2.4.5 Concordant pEGFR expression 
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Figure 2.2.4.6 Discordant pEGFR expression 
 
 
 
 152 
 
Figure 2.2.4.7 Concordant pMAPK expression 
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Figure 2.2.4.8 Concordant pMAPK expression 
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Figure 2.2.4.9  Discordant pMAPK expression 
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There was complete concordance for the presence of KRAS, BRAF and PI3KCA 
mutations between primary tumours and paired metastatic tissue.  Nine 
patients (31%) had KRAS mutations, 2 patients (6.9%) had BRAF mutations 
and 3 patients (10%) had PI3KCA mutations in both primary and metastases. 
These were initially detected using HRM PCR analysis, but subsequent 
sequencing confirmed concordance of mutations in each case. 
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Table 2.2.4 Biomarker expression and mutations of signalling molecules in 
primary tumours and corresponding metastases 
 
Primary metastasis 
Number of 
patients 
% of paired 
samples  
analysed 
P value 
EGFR 
Negative Negative 23 79.3 
0.031 
 
Positive Positive 2 6.9 
Negative Positive 1 3.4 
Positive Negative 3 10.3 
Missing paired samples 3 
pEGFR 
Negative Negative 3 9.7 
0.121 
Positive Positive 18 58.1 
Negative Positive 1 3.2 
Positive Negative 9 29.0 
Missing paired samples 1 
pMAPK 
Negative Negative 21 67.7 
0.996 
Positive Positive 1 5.2 
Negative Positive 4 12.9 
Positive Negative 5 16.1 
Missing paired samples 1 
KRAS mutation 
Negative Negative 20 68.9 
<0.001 
Positive Positive 9 31.0 
Negative Positive 0 0 
Positive Negative 0 0 
Missing paired samples 3 
BRAF mutation 
Negative Negative 27 93.1 
0.001 
Positive Positive 2 6.9 
Negative Positive 0 0 
Positive Negative 0 0 
Missing paired samples 3 
PI3KCA mutation 
Negative Negative 27 90.0 
<0.001 
Positive Positive 3 10.0 
Negative Positive 0 0 
Positive Negative 0 0 
Missing paired samples 2 
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2.2.5 Relationships between components of the EGFR/RAS/RAF/MAPK 
pathway  
When exploring a possible role for molecular markers in predicting response 
to EGFR targeted antibodies, it was important to determine whether any 
relationship existed between components of this pathway.  This analysis was 
performed on metastatic tissue.  No correlation was found between EGFR 
expression and pEGFR expression, and no correlation was found between 
EGFR expression and the presence of activated downstream components 
KRAS and BRAF mutations or pMAPK expression (Table 2.2.5.1). 
 
A statistically significant correlation between pEGFR and KRAS mutations was 
found, with 20 patients (66.7%) showing concordance between pEGFR 
expression and presence of KRAS mutation (p=0.02). The tumours in 9 
patients (30%) were positive for both pEGFR expression and the presence of a 
KRAS mutation.  No correlation was found between pEGFR expression and 
BRAF mutation or pMAPK expression (Table 2.2.5.2). 
 
When the relationship between KRAS and BRAF mutations and downstream 
pMAPK was analysed, a statistically significant correlation between KRAS 
mutation and pMAPK expression was found (p=0.01).  Concordance between 
KRAS mutation status and pMAPK expression was seen in 24 patients (77.4%). 
Both pMAPK expression and KRAS mutation status were negative in 20 cases (64.5%).   
In the 10 patients in which a KRAS mutation was present, 4 patients also 
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demonstrated expression of pMAPK, whilst the tumours in 6 patients did not 
express pMAPK (and none of these 6 had a simultaneous BRAF mutation).  
Both pMAPK expression and BRAF mutation status were negative in 24 
patients (77.4%).  Of the 2 patients (6.5%) with BRAF mutations, both were 
negative for pMAPK, whilst pMAPK was positive in 5 cases (16.1%) where no 
BRAF mutation was detected, but 4/5 of these had a KRAS mutation, which 
would explain this activation.  No significant relationship therefore was found 
between the presence of BRAF mutations and expression of pMAPK, 
suggesting that even in the presence of an activating mutation, downstream 
MAPK may not be activated (Table 2.2.5.3). 
 
In one patient pMAPK expression was present despite an absence of KRAS and 
BRAF mutation, indicating that downstream components maybe activated 
despite a lack of both upstream activating mutation.  (Unfortunately there 
was not data on EGFR or pEGFR expression in this patient).  
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Table 2.2.5.1 Relationship between EGFR and downstream pathway 
components 
 
 
Number of 
patients 
% of paired 
samples analysed 
P value 
EGFR pEGFR  
Negative Negative 10 33.3 
0.40 
Positive Positive 1 3.3 
Negative Positive 17 56.7 
Positive Negative 2 6.7 
Missing paired samples 2 
EGFR  KRAS mutation  
Negative Negative 17 58.6 
0.32 
Positive Positive 0 0 
Negative Positive 10 34.5 
Positive Negative 2 6.9 
Missing paired samples 3 
EGFR BRAF mutation  
Negative Negative 25 86.2 
0.62 
Positive Positive 0 0 
Negative Positive 2 6.9 
Positive Negative 2 6.9 
Missing paired samples 3 
EGFR pMAPK  
Negative Negative 23 76.7 
0.63 
Positive Positive 0 0 
Negative Positive 4 13.3 
Positive Negative 3 10.0 
Missing paired samples 2 
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Table 2.2.5.2 Relationship between pEGFR and downstream pathway 
components 
 
 
Number of 
patients 
% of paired 
samples analysed 
P value 
pEGFR KRAS mutation  
Negative Negative 11 36.7 
0.02 
Positive Positive 9 30.0 
Negative Positive 1 3.3 
Positive Negative 9 30.0 
Missing paired samples 2 
pEGFR BRAF mutation  
Negative Negative 11 36.7 
0.86 
Positive Positive 1 3.3 
Negative Positive 1 3.3 
Positive Negative 17 56.7 
Missing paired samples 2 
pEGFR pMAPK  
Negative Negative 12 38.7 
0.10 
Positive Positive 4 12.9 
Negative Positive 0 0 
Positive Negative 15 48.4 
Missing paired samples 1 
 
 
 
 
Table 2.2.5.3 Relationship between pMAPK expression and KRAS and BRAF 
mutations 
 
 
Biomarker status 
Number of 
patients 
% of paired 
samples analysed 
P value 
pMAPK KRAS mutation  
Negative Negative 20 64.5 
0.01 
Positive Positive 4 12.9 
Negative Positive 6 19.4 
Positive Negative 1 3.2 
Missing paired samples 1 
pMAPK BRAF mutation  
Negative Negative 24 77.4 
0.63 
Positive Positive 0 0 
Negative Positive 2 6.5 
Positive Negative 5 16.1 
Missing paired samples 1 
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2.2.6 Relationship between EGFR, pEGFR and PI3KCA mutations  
The PI3K/Akt pathway is also an important downstream pathway from the 
Erb-1 receptor, and hence possible relationships between EGFR and activating 
PI3KCA mutations were explored.  No significant concordance was 
demonstrated between EGFR and pEGFR expression and the presence of a 
PI3KCA mutation.  Although 24 patients (80%) were negative for both EGFR 
and PI3KCA mutation, 3 patients (10%) were positive for EGFR and negative 
for PI3KCA mutation, whilst 3 patients (10%) were negative for EGFR but 
positive for a PI3KCA mutation.  Negativity for pEGFR and PI3KCA mutations 
was found in 11 patients (35.4%), positivity for both pEGFR and PI3KCA 
mutation was found in 3 patients (9.7%), 1 patient (3.2%) was negative for 
pEGFR but positive for PI3KCA, and 16 patients (51.6%) were pEGFR positive 
but PI3KCA negative (Table 2.2.6 below). 
 
Table 2.2.6 Relationship between EGFR and pEGFR expression and PI3KCA 
mutations 
 
  
Number of 
patients 
% of paired 
samples analysed 
P value 
EGFR PI3KCA mutation  
Negative Negative 24 80.0 
0.64 
Positive Positive 0 0 
Negative Positive 3 10.0 
Positive Negative 3 10.0 
Missing paired samples 2 
pEGFR PI3KCA mutation  
Negative Negative 11 35.4 
0.58 
Positive Positive 3 9.7 
Negative Positive 1 3.2 
Positive Negative 16 51.6 
Missing paired samples 1 
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2.2.7 Correlation between activating mutations 
When the relationship between KRAS and BRAF mutations was explored, they 
were found to be mutually exclusive.  Nineteen patients (61.3%) had no 
mutation in KRAS or BRAF, whilst no patient had mutation in both KRAS and 
BRAF simultaneously.  Two patients (6.5%) were negative for KRAS but 
positive for BRAF mutations, whilst 10 patients (32.2%) were positive for KRAS 
and negative for BRAF mutations.  When a relationship was explored between 
KRAS, BRAF and PI3KCA mutations, 17 patients (54.8%) had no mutations.  
PI3KCA mutations did not occur concurrently with BRAF mutations, but 2 
patients (6.5%) had both a PI3KCA mutation and a KRAS mutation present.  
Two patients who were wild type for KRAS and BRAF were found to have a 
PI3KCA mutation.  Relationships between mutations did not reach statistical 
significance (Tables 2.2.7.1, 2.2.7.2, 2.2.7.3). 
 
Table 2.2.7.1 KRAS and BRAF mutation analysis 
 
  BRAF mutation 
Total P value 
  Negative Positive 
KRAS 
mutation 
Negative 19 2 21 
0.41 Positive 10 0 10 
Total  29 2 31 
 
Table 2.2.7.2 KRAS and PI3KCA mutation analysis 
 
  PI3KCA mutation 
Total P value 
  Negative Positive 
KRAS 
mutation 
Negative 19 2 21 
0.42 Positive 8 2 10 
Total  27 4 31 
 
 
 163 
Table 2.2.7.3 BRAF and PI3KCA mutation analysis 
 
  PI3KCA mutation 
Total P value 
  Negative Positive 
BRAF 
mutation 
Negative 25 4 29 
0.64 Positive 2 0 2 
Total  27 4 31 
 
 
 
 
2.2.8 Summary of findings 
The main aim of this study was to determine whether EGFR pathway 
activation in metastatic disease could be predicted by the molecular profile of 
primary tissue.  This was explored by examining expression, activation and 
mutation status of signalling molecules downstream of EGFR between paired 
primary and metastatic tissue.  Concordance was found between EGFR 
expression (p=0.031), but not for pEGFR expression (p=0.121) or pMAPK 
expression (p=0.996).  There was 100% concordance for each of the activating 
mutations analysed KRAS (p<0.001), BRAF (p=0.001) and PI3KCA (<0.001). 
 
Possible relationships between components of the EGFR/RAS/RAF/MAPK 
pathway in metastatic tissue were investigated.  The rationale behind this 
element of the study was to determine whether the presence of one 
activated component of the signal transduction cascade correlates with 
activation of downstream components.  If activation status of each 
component of the cascade is independent of each other, therapeutic targeting 
of a single level of this pathway is likely to be ineffective if downstream 
components demonstrate constitutive activation.  A summary of all marker 
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analysis is shown in appendix 2.1.  EGFR expression did not correlate with any 
of the downstream components pEGFR (p=0.40), KRAS mutations (p=0.32), 
BRAF mutations (p=0.62) or pMAPK expression (p=0.63).  Expression of pEGFR 
correlated with KRAS mutations (p=0.02), but not BRAF mutations (p=0.86) or 
pMAPK expression (p=0.10).  pMAPK showed a positive correlation with KRAS 
mutations (p=0.01), but not BRAF mutations (p=0.63), although sample 
numbers were small.   
 
When PI3KCA mutations were explored, there was no correlation between 
EGFR or pEGFR expression and presence of a mutation (p=0.64, p=0.58 
respectively), suggesting the pathway can be constitutively activated 
downstream of the membrane receptor in the absence of both receptor and 
activated receptor. 
 
When relationships between mutations in KRAS, BRAF and PI3KCA were 
explored, 45.2% of the sample population had a mutation in one of these 
components.  No patient had simultaneous  KRAS and BRAF mutations or 
BRAF and PI3KCA mutations, but 2 patients with KRAS mutations also had 
PI3KCA mutations.  The presence of a PI3KCA mutation in 2 patients who were 
wild-type for both KRAS and BRAF might explain non-response to 
cetuximab/panitumumab in the absence of KRAS or BRAF mutations. 
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Appendix 2.1 Summary of analysis of activating components of EGFR pathway 
Pt 
EGFR pEGFR pMAPK KRAS mutation BRAF mutation PI3KCA mutation 
prim met prim met prim met prim met prim met prim met 
1 1 1 1 0 1 0 0 0 0 0 0 0 
2 1 1 1 1 0 0 1 failed 0 failed 0 failed 
3 0 0 1 1 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 0 
5 0 0 1 0 0 0 0 0 0 0 0 0 
6 0 0 1 1 0 0 0 0 0 0 0 0 
7 1 no tissue 1 no tissue 0 1 0 0 0 0 0 0 
8 0 0 1 1 0 0 0 0 0 0 0 0 
9 0 0 0 1 1 1 1 1 0 0 0 0 
10 0 0 1 1 0 0 0 0 1 1 0 0 
11 0 0 1 0 0 0 0 0 1 1 0 0 
12 0 0 1 1 0 1 1 1 0 0 1 1 
13 0 0 1 0 0 0 0 0 0 0 0 0 
14 no tissue 0 1 0 0 0 0 0 0 0 0 0 
15 0 0 1 1 0 1 1 1 0 0 0 0 
16 0 0 1 1 0 0 0 0 0 0 0 0 
17 0 0 1 0 0 0 0 0 0 0 0 0 
18 1 0 1 1 0 0 0 0 0 0 0 0 
19 0 0 1 1 0 0 1 1 0 0 0 0 
20 0 0 0 0 0 0 0 0 0 0 0 0 
21 0 0 1 1 0 1 1 1 0 0 0 0 
22 0 0 1 1 1 0 0 0 0 0 0 0 
23 0 No tissue 1 1 1 0 0 0 0 0 1 1 
24 0 1 1 0 No tissue 0 0 0 0 0 0 0 
25 0 0 1 1 0 0 1 1 0 0 0 0 
26 0 0 1 1 0 0 1 1 0 0 0 0 
27 0 0 0 0 0 0 0 0 0 0 1 1 
28 0 0 1 0 1 0 1 1 0 0 0 0 
29 0 0 1 1 0 0 1 1 0 0 0 0 
30 1 0 1 0 0 0 0 0 0 0 0 0 
31 0 0 1 1 0 0 No section 1 No section 0 No section 1 
32 1 0 1 1 1 0 No section 0 No section 0 No section 0 
  166 
CHAPTER 3: Antibody-targeted chemotherapy  
 
Phase 1 biodistribution study of    
111
In-CMD-193 in 
patients with advanced tumours expressing the Le
y
 
antigen 
 
 
3.1 METHODS 
 
3.1.1 Clinical trial rationale  
Published evidence supports the use of anti-Ley antibodies for the specific 
targeting of Ley positive epithelial cancers, but to date, none have reached 
Phase III trials.  The parental antibody hu3S193 is known to be highly specific 
and bind to Ley with high affinity before rapid internalisation into Ley 
expressing cancer cells, making it an ideal antibody for conjugation with a 
therapeutic payload.  Calicheamicin conjugation using a linker containing an 
acid-labile hydrazone bond should offer an advantage when attached to an 
antibody known to be internalised and trafficked to the acidic lysosomal 
compartment of cancer cells, as in this acidic environment the linker is 
hydrolyzed releasing the Nac-gamma calicheamicin DMH from the antibody 
causing cell death.  Whilst proof of concept is provided by Mylotarg in the 
treatment of relapsed CML, this therapeutic strategy has not yet been 
successfully validated in solid tumours.  The subsequent sections will describe 
a Phase I biodistribution study of the immunoconjugate CMD-193, illustrating 
a novel and important component to the early drug development of targeted 
antibodies in cancer patients.  
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3.1.2 Study objectives 
This Phase I trial was primarily aimed at assessing the biodistribution of 
111Indium labelled CMD-193 in patients with advanced tumours expressing the 
Ley antigen.  It commenced alongside a similar dose escalation trial in the US, 
but was specifically designed with the primary endpoints being 
biodistribution, tumour uptake and pharmacokinetics of 111In-CMD-193.  
Secondary endpoints were changes in tumour metabolism and tumour 
response following infusions of CMD-193.  Apart from pharmacokinetics and 
tumour response, the US trial did not address any of the primary and 
secondary study objectives of this Phase I trial. 
 
3.1.3 Trial design  
This was an Investigator originated study sponsored by the Ludwig Institute 
for Cancer Research, and performed under the LICR submitted 111In-CMD-193 
IND 73,831 cross filed to Wyeth Pharmaceuticals Inc. IND 69,462. Wyeth 
Pharmaceuticals Inc. provided financial support and pharmaceutical 
investigational compound CMD-193 for the study.   
 
In this Phase I biodistribution study, following the pre-treatment assessments, 
eligible patients received a single infusion of Indium-111 labelled-CMD-193 
[111In-CMD-193; 3-7 mCi (120 - 280MBq)] administered intravenously over 1 
hour, on day 1 of cycle 1 at a protein dose level of 1.0 mg/m2 or 2.6 mg/m2 
followed by up to 5 further 3 weekly cycles of unlabelled CMD-193 subject to 
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toxicity and response.  Biodistribution data was collected after patients 
received this first infusion of 111In-CMD-193, but subsequent cycles were 
unlabelled.  Gamma camera imaging with anterior and posterior whole body 
scans using conjugate view methodology were performed on Day 1, Day 2, 
Day 3 or 4, Day 5 or 6, and Day 7 or 8 following 111In-CMD-193 infusion.  
Pharmacokinetics of 111In-CMD-193 based on gamma counting of serum 
samples collected during cycle 1. Subsequent infusions of CMD-193 were 
administered on day 1 of each 21-day cycle. Each patient could receive up to 6 
cycles of CMD-193 until disease progression, unacceptable toxicity, or 
withdrawal of consent. 
 
3.1.4 Patient eligibility/patient selection 
Patients were deemed eligible for enrollment if they fulfilled all of the 
following criteria: 
 Signed and dated IRB-approved informed consent before any protocol-
specific screening procedures are performed 
 Histologically confirmed malignant solid tumour that has progressed 
following standard therapy, or for which no standard effective treatment is 
available 
 Tumour expression of Lewis Y antigen ( 20% tumour cells positive for 
Lewis Y by immunohistochemistry assay) 
 Measurable disease defined RECIST, including the presence of at least one 
measurable lesion at least 2 cm in size suitable for 18F-FDG PET imaging 
 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1  
 Life expectancy of at least 18 weeks 
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 Age 18 years 
 Recovery to NCI grade 1 toxicity from any significant effects of prior 
surgery, radiation therapy, and cancer therapy (except alopecia) 
 Renal test: serum creatinine 1.5  upper limit of normal (ULN) 
 Hepatic tests: alanine aminotransferase (ALT) levels 2.5  ULN and total 
bilirubin 1.5  ULN 
 Pancreatic tests: amylase 1.5  ULN and lipase 1.5  ULN 
 Bone marrow tests: absolute neutrophil count (ANC) of  1,500mm3 ( 1.5  
109/L) and platelet count of 150,000/mm3 ( 150  109/L) 
 For women of child bearing potential, a negative serum pregnancy test 
result no longer than 48 hours before the first dose of CMD-193.  A woman 
of child bearing potential is one who is biologically capable of becoming 
pregnant.  This includes women who are using contraceptives or whose 
sexual partners are either sterile or using contraceptives. 
 All subjects who are not surgically sterile or postmenopausal must agree 
and commit to the use of a reliable method of birth control for the 
duration of the study and for 28 days after the last dose of CMD-193 
 Willingness of female subjects to refrain from breast feeding infants during 
the study or within 28 days after the last dose of CMD-193 
 
A 20% Ley antigen positivity of archived tumour samples was selected for 
screening of eligible patients, as preclinical evidence showed that the Lewis Y-
specific anti-tumor effect of CMD-193 is more pronounced against carcinomas 
with high expression of the Ley antigen than against carcinomas that had low 
expression of the Ley antigen. 
 
Patients were excluded from the study for any of the following reasons: 
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 Chemotherapy, radiation therapy, other cancer therapy, or investigational 
agents within 21 days of the first dose of CMD-193 (42 days if the previous 
chemotherapy included nitrosoureas or mitomycin C) 
 Symptomatic or clinically active central nervous system (CNS) metastases. 
Subjects who have had prior treatment with radiotherapy or surgical 
resection for CNS metastases will be permitted if CNS metastases have 
remained stable and have not required any treatment for at least 3 months 
prior to the first dose of CMD-193. 
 Significant prior allergic reaction to recombinant human or murine proteins 
 History of cirrhosis, current or chronic hepatitis B or C infections, or other 
significant active liver disease 
 Unstable or serious concurrent medical conditions. Examples include, but 
are not limited to, bleeding gastric ulcers, gastrointestinal bleeding, 
hepatitis, significant disorders of the immune system, pancreatitis, 
congestive heart failure, serious active infections, unstable angina, recent 
myocardial infarction, ongoing maintenance therapy for life-threatening 
ventricular arrhythmia, or uncontrolled major seizure disorder. 
 Other malignancy within 3 years prior to entry into the study, except for 
treated non-melanoma skin cancer and cervical carcinoma in situ.  
 ŶǇŽƚŚĞƌĐŽŶĚŝƚŝŽŶƚŚĂƚ ? ŝŶƚŚĞ ŝŶǀĞƐƚŝŐĂƚŽƌ ?Ɛ ũƵĚŐŵĞŶƚ ?ǁŝůůƐƵďƐƚĂŶƚŝĂůůǇ
ŝŶĐƌĞĂƐĞƚŚĞƌŝƐŬĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞƐƵďũĞĐƚ ?ƐƉĂƌƚŝĐŝƉĂƚŝŽŶŝŶƚŚŝƐƐƚƵĚǇ ? 
 
Before entering patients into the trial, written approval of the protocol and 
informed consent form was obtained from Austin Health Ethics committee.  In 
accordance with the Declaration of Helsinki, ICH Good Clinical Practice 
Guidelines, and the US FDA Regulations, patients had the right to withdraw 
from the study at any time for any reason without prejudice to their future 
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medical care by the physician or at the institution. The Investigator and 
Sponsor also had the right to withdraw patients from the study.  
 
3.1.5 Treatment and evaluation schedule 
Following pre-treatment assessments, eligible patients received a single 
infusion of Indium-111In labelled-CMD-193 [111In-CMD-193; 3-7 mCi (120 - 
280MBq)] over 1 hour on Day 1 of Cycle 1 at a protein dose level of 1.0 mg/m2 
or 2.6 mg/m2.  Biodistribution data was collected after patients received this 
first infusion of 111In-CMD-193, but subsequent cycles were unlabelled.  
Gamma camera imaging with anterior and posterior whole body scans using 
conjugate view methodology were performed on Day 1, Day 2, Day 3 or 4, Day 
5 or 6, and Day 7 or 8 following 111In-CMD-193 infusion. Single Photon 
Emission Computed Tomography (SPECT) images of a region with known 
target lesions was also performed on Day 7 or 8.  Blood for pharmacokinetics 
was taken at specified time points during the following week.  Blood for HAHA 
was taken pre-infusion and then prior to each subsequent cycle.  Subsequent 
cycles (without the 111Indium radiotracer) were given 3 weekly, and safety, 
tolerability and blood parameters were performed weekly throughout the 
trial.  Tumour reassessment was performed 6 weekly (after 2nd, 4th and 6th 
cycles) with CT and FDG-PET, and patients only remained on study if there was 
evidence of stable disease or response according to RECIST criteria.  Patients 
received up to a maximum of 6 cycles of CMD193 until disease progression, 
unacceptable toxicity, or withdrawal of consent.  The protocol schema is 
outlined in Tables 3.1.5.1 and 3.1.5.2. 
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Table 3.1.5.1. Protocol Schema - Screening and Cycle 1 
Study Procedures Screening Cycle 1 
Cycle day -28 to -1 1 3 8 15 
Cycle visit windows (days)   1 1 2 
Informed consenta, medical/cancer history X     
Archived tumour specimen for Ley expression X     
Physical examination X X    
Vital signs and observations  X    
Weight/BSA calculation  X    
ECOG performance status X     
-HCG (serum) X X 
When 
indicated 
CBC with differentiala X  X X X 
Blood chemistriesb X   X X 
Coagulation panel, urinalysis, blood group X     
Antibodies to CMD-193 X     
ECG X X    
Radiographic evaluation X     
18F-FDG PET scan X     
Premed and 111In-CMD-193 administration  X    
111In-CMD-193 gamma camera imaging  X    
PK sampling  X X X X 
Adverse events assessment Monitored and recorded continuously 
Concomitant medications review Monitored and recorded continuously 
 
a. Complete blood count (CBC) with 5-part differential, platelet count, and absolute 
neutrophil count (ANC), to be performed within 7 days before cycle 1 day 1. 
b. Blood chemistry determinations (sodium, potassium, chloride, bicarbonate, albumin, urea, 
random blood glucose, total protein, serum creatinine, lactate dehydrogenase [LDH], ALT, 
alkaline phosphatase, total bilirubin, amylase, lipase), to be performed within 7 days 
before cycle 1 day 1. 
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Table 3.1.5.2. Screening and Cycles 2-6 through Final Visit 
 
Study Procedures Cycles 2-6 Final Visit
a
 
Cycle day 1* 8 15 
2-6 wks of 
last dose 
Cycle visit windows (days) 2 2 2 5 
Physical examinationb X   X 
Vital signs and observation period X   X 
Weight/BSA calculationc X   X 
ECOG performance status X   X 
-HCG (urine or serum) Whenever clinically indicated X 
CBC with differentiald X X X X 
Blood chemistriese X X X X 
Coagulation panelf X   X 
Antibodies to CMD-193 (before dose) X   X 
Urinalysis  X   X 
ECG    X 
Radiographic evaluation   X X 
18F-FDG PET scan   X  
Premed and CMD-193 administration X    
PK sampling  X X X  
Adverse events assessmentj  Monitored and recorded continuously  
Concomitant medications reviewj  Monitored and recorded continuously  
 
 
3.1.5.1 Trial drug administration 
For the Cycle 1 infusion, the CMD-193-CHX-A -DTPA was prepared according 
to standard protocols and under aseptic conditions.  The labelling of chelated 
CMD-193 with 111In was performed in a Class II biohazard cabinet in the LICR, 
Tumour Targeting Laboratory, Melbourne, and in the Nuclear Medicine 
ĞƉĂƌƚŵĞŶƚ ŽĨ ƚŚĞ ZŽǇĂů ƌŝƐďĂŶĞ ĂŶĚ tŽŵĞŶ ?Ɛ ,ŽƐƉŝƚĂů ? ƌŝƐďĂŶĞ ?  
solution of the radiometal 111In- was added to the chelated CMD-193 and 
purified. A preparation demonstrating the correct labelling efficiency with the 
addition of CMD-193 to increase the total antibody dose to the prescribed 
amount, was aseptically injected via a 0.22 m filter into 100mL N/Saline in 
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5% HSA (human serum albumin) (CSL Ltd, Australia) for patient intravenous 
infusion. 
 
Following pre-treatment assessments, eligible patients received a single 
infusion of 3-7 mCi (120 - 280MBq) 111In-CMD-193 in 100ml of normal saline 
containing 5% human serum albumin over 1 hour (± 5 mins) via an infusion 
pump on Day 1 of Cycle 1.  As CMD-193 is light sensitive it was protected from 
direct and indirect sunlight and unshielded fluorescent light during the 
preparation and administration of the infusion. Premedication with 
paracetamol and loratadine were administered 0.5-2 hours prior to each 
infusion to reduce the incidence and severity of any potential infusion 
syndrome.   Following completion of CMD-193 infusion, the line was flushed 
with 10 mL of normal saline (or per standard operating procedure at the study 
sites). To avoid accidental occupational exposure, institutional 
chemotherapeutic hazardous materials handling guidelines were followed at 
all times. 
 
3.1.5.2. Dose reductions 
Dose reductions or delays in administration of CMD-193 for study drug-
related toxicity were permitted as described below.  Once a dose had been 
reduced for a subject, all subsequent cycles were to be administered at that 
dose, unless further dose reduction was required.  Subjects were to be 
discontinued from the study if more than 2 dose reductions were required. 
For those subjects enrolled in the first dose level, only 1 dose reduction (to 0.5 
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mg/m2) was allowed.  In addition, subjects experiencing a test article-related 
adverse event that fails to recover to CTCAE grade 1 (or within 1 grade of 
starting values for pre-existing laboratory abnormalities) leading to a 
treatment delay of > 3 weeks (43 days after any dose of CMD-193) were 
discontinued. Dose delay and dose reduction were considered for persistent 
or intolerable grade 2 CMD-193-related non-haematological toxicity.  Tables 3 
and 4 summarises dose reduction protocol for CMD-193 related 
haematological toxicity, protocol and non-haematological toxicity 
respectively. 
 
Table 3.1.5.2.1 Dose reductions for CMD-193-related haematological 
toxicities 
 
Dose Reductions for Neutropenia and Thrombocytopenia  
Event Action 
On the day of scheduled administration of 
CMD-193: 
ANC is <1.5 x 10
9
/L or 
Platelet count is <100 x 10
9
/L 
Withhold CMD-193 (for up to 3 weeks) 
until ANC is 1.5 x 10
9
/L and platelet 
count is 100 x 10
9
/L 
Administer CMD-193 at the next lower 
dose level for subsequent cycles. 
Febrile neutropenia (ANC <1.0 10
9
/L, and 
temperature  38.5 C) or 
Grade 4 ANC  5-day duration 
Withhold CMD-193 (for up to 3 weeks) 
until ANC is 1.5 x 10
9
/L  
Administer CMD-193 at the next lower 
dose level for subsequent cycles. 
Grade 4 thrombocytopenia  3-day duration Withhold CMD-193 (for up to 3 weeks) 
until platelet count is 100 x 10
9
/L  
Administer CMD-193 at the next lower 
dose level for subsequent cycles. 
ANC does not recover to 1.5 x 10
9
/L and /or 
platelet count does not recover to 100 x 
10
9
/L by 43 days after any dose of CMD-193. 
Discontinue administration of CMD-193 
ANC=absolute neutrophil count 
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Table 3.1.5.2.2. Dose reductions for CMD-193-related non-haematological 
toxicities 
 
Dose Reductions for Non-haematological Toxicities 
Event Action 
Any CTCAE grade 3 non-haematological 
toxicity, except nausea, vomiting, or 
diarrhoea unless subject is on appropriate 
medical therapy. 
Withhold CMD-193 (for up to 3 weeks) until 
resolution to grade 1 or to baseline 
Administer CMD-193 at the next lower dose 
level for subsequent cycles. 
Non-haematological toxicity that does not 
recover to  CTCAE grade 1 or baseline 
(except alopecia) within 43 days of any 
CMD-193 dose. 
Discontinue administration of CMD-193 unless 
discussed with LICR, and patient continued 
participation is considered appropriate. 
Any CTCAE grade 4 non-haematological 
toxicity 
Investigator and sponsor review to determine 
if subject may continue on study with 
appropriate dose adjustment. 
 
 
3.1.5.3 Dose-Escalation Criteria 
Initially 3 dose cohorts were planned, with the enrolment of 6-8 patients in 
each 1.0mg/m2, 1.7mg/m2 and 2.6mg/m2 dose cohorts.  After 
commencement of the trial, a protocol amendment was subsequently 
accepted to reduce this to 2 dose cohorts of 1.0mg/m2 and 2.6mg/m2 
(detailed in section 3.1.13).  This amendment was made on the basis of the 
provisional data being collected from the parallel US study, which enrolled 
patients into escalating cohorts of up to 3.6mg/m2.  As the dose level 
2.6mg/m2 was determined to be MTD, it was decided that the 1.7mg/m2 
cohort in this study should be omitted.  The 2.6mg/m2 dose level had been 
characterised as reasonably safe and well tolerated by the preceding Wyeth 
Phase I study, and did not represent a dose level exceeding the MTD 
characterised for CMD-193.  Escalation to the next dose cohort was permitted 
after 6 patients in cohort 1 had completed 21 days of the study requirements 
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following 111In-CMD-193 infusion, without experiencing severe and/or 
unexpected toxicity.  
  
The dose levels of CMD-193 and patients planned and recruited were as 
follows: 
 
Cohort 
number 
CMD-193 dose 
(mg/m
2
) 
Planned 
enrolment 
Patients enrolled 
1 1.0 6-8 6 
2 2.6 6-8 3 
 
All patients were enrolled at treated at Austin Hospital, Melbourne except 
one patient in dose cohort 2, who received their treatment in Royal Brisbane 
ĂŶĚtŽŵĞŶ ?Ɛ,ŽƐƉŝƚĂů ?ƚŚĞŽŶůǇŽƚŚĞƌŝŶƐƚŝƚƵƚŝŽŶŝŶǀŽůǀĞĚŝŶƚŚŝƐƐƚƵĚǇ ? 
 
3.1.6 Biodistribution and dosimetry 
3.1.6.1 Image Analysis 
The biodistribution of the investigative drug was determined by qualitative 
analysis of whole body planar and SPECT gamma camera images by 
experienced nuclear medicine physicians. Medical Internal Radiation 
Dosimetry (MIRD) formalism allowed the accurate quantification of 111In-CMD 
biodistribution by using mathematical formulae, whole body and organs 
models, and established decay data354.  This allowed the assessment of 
internal dose of 111In-CMD to whole body, organ and tumour based on the 
conjugate view images obtained from the whole body gamma camera images, 
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using methods which have been widely used in other LICR biodistribution 
studies.   
 
3.1.6.2 Whole body clearance methodology 
Whole body clearance, or biological halftime, T1/2-biol, was calculated from the 
whole body anterior and posterior planar images by first calculating a region 
of interest (ROI) to encompass the whole body, then for each ROI at each time 
point, the mean counts per pixel per minute was normalised to imaging time 
point Day 1. From this time-activity curve (TAC), an exponential clearance 
expression was fitted to obtain effective halftime, Teff. This was then corrected 
for the physical half-life, Tp, of 
111In (67.45 hours) to account for physical 
decay to obtain the biological half time, Tb, by the equation: 
 
   
 
 
 
2.2.6.3 Organ Clearance methodology 
Dosimetry analysis of normal organs (kidney, liver, lung, spleen and lung) was 
performed using the same method. Three regions were defined for the 
organs, a whole organ ROI, a sample region ROI, and a background ROI.  
Organ radioactivity content was estimated from the geometric mean (GM) of 
anterior and posterior sample ROI counts.  Mean counts within sample ROIs 
(counts/pixel) were then multiplied by the area of the organ (pixels), 
determined from the whole organ ROI at the time point where the organ was 
Teff
Tb Tp
Tb Tp
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best visualised to obtain total organ counts. For paired organs, kidney and 
lung, a single organ area was measured and then multiplied by two to find 
total area. The left kidney and right lung were used as representative organs 
due to minimal adjacent organ and blood pool contribution to organ counts. 
The counts for each organ were corrected for background using ROIs drawn 
adjacent to each organ, where whole body thickness was comparable.  
Correction for attenuation of individual organs was estimated using an 
analytical technique as described by Liu et al355.  Resultant counts were 
converted to activity using a camera sensitivity factor calculated from a 
standard of known activity that was scanned at the same time.  A time-activity 
curve (TAC) was generated from the derived activity for each imaging time-
point.  The TAC was fitted with a single component exponential clearance 
expression.  Tumour dosimetry was not performed, as there was no 
detectable uptake of 111In-CMD-193 by sites of known metastatic disease in 
any of the patients. 
 
3.1.7 Pharmacokinetics 
Pharmacokinetics of 111In-CMD-193, based on gamma counting of serum 
samples was one of the primary endpoints of this biodistribution study. 
During cycle 1 (111In-CMD-193 infusion), serum samples for pharmacokinetics 
was collected on Day 1 (pre infusion, 1 hr and 4 hrs post infusion 
commencement), Day 3, Day 8 and Day 15.     Serum obtained from patients 
following infusion of 111In-CMD-193 was aliquoted and counted in a gamma 
scintillation counter (Packard Instruments, Canberra, Australia). Duplicate 
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standards prepared from the injected material were counted at each time 
point with serum samples to enable calculations to be corrected for the 
isotope physical decay.  The results were expressed as % injected dose per 
litre (%ID/L) and mg/mL.  
 
A 2 compartment IV bolus model with macro-parameters, no lag time and first 
order elimination (WNL Model 8) was fitted to individual labelled infusions for 
each subject using un-weighted non-linear, least squares with WinNonLin 
version 5.2 (Pharsight Corp., Mountain View, CA).  Estimates were determined 
for the pharmacokinetic parameters: T½  and T½  (half lives of the initial and 
terminal phases of disposition); V1, volume of central compartment; Cmax 
(maximum serum concentration); AUC (area under the serum concentration 
curve extrapolated to infinite time); and CL (total serum clearance). 
 
Measurement of patient serum CMD-193 protein levels was performed using 
a validated ELISA protocol, with a 50 ng/mL lower limit of quantitation (LLOQ). 
All samples were assayed in triplicate and were diluted by a factor of at least 
1:2. Measured serum levels of CMD-193 were expressed as ng/mL. Serum 
samples were also obtained for measurement of total and free calicheamicin 
by a validated ELISA protocols (LLOQ = 2.45 ng/mL). 
 
3.1.8 FDG-PET data collection and evaluation  
18F-FDG-PET was performed at screening and between days 15 and 21 of 
cycles 2 and 4, or at study completion, if possible, where only one cycle was 
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completed.  Patient preparation and scanning conditions were standardised356 
357.  For each FDG-PET performed, the maximum standardised uptake value 
(SUVmax) corrected for body weight for all target lesions >2cm identified on 
CT imaging was calculated using ROI.  The ROI was determined with the aid of 
the anatomical detail provided by the CT scan.  This analysis was performed 
by an experienced nuclear medicine physician and checked by a second 
colleague to ensure consistency across the trial.  SUV for normal lung tissue 
was taken as the reference region for each patient, at each time point. This 
ensured that any SUV changes in tumours could then be directly attributed to 
treatment response or to disease progression357. 
 
Visual grading of the intensity of radiotracer accumulation was scored on a 4-
point scale (0 = less than normal soft tissues, 1 = iso-intense with normal soft 
tissues, 2 = mildly increased relative to normal soft tissues, 3= markedly 
increased relative to normal soft tissues).  On follow-up PET scans, as well as 
repeating SUVmax analysis of the target lesion with the greatest baseline 
value, the extent of tumoural uptake (0 = no tumour seen, 1 = less extensive 
tumoural uptake, 2 = no change in tumour extent, 3 = more extensive 
tumoural uptake), and presence/absence of new sites of disease was also 
recorded.   
 
Metabolic response was calculated using the target lesion with the greatest 
baseline SUV, and was categorised according to the EORTC guidelines356.  
Progressive metabolic disease (PMD) was classified as an increase in 18F-FDG 
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tumour SUVmax of greater than 25% within the tumour region of interest 
defined on the baseline scan, visible increase in the extent of 18F-FDG tumour 
uptake (>20% in the longest dimension) or the appearance of new 18F-FDG 
uptake in metastatic lesions.  Stable metabolic disease (SMD) was classified as 
an increase in tumour 18F-FDG SUVmax of less than 25% or a decrease of less 
than 15% and no visible increase in extent of 18F-FDG tumour uptake (>20% in 
the longest dimension).  Partial metabolic response (PMR) was classified as a 
reduction of a minimum of 15 W25% in tumour 18F-FDG SUVmax after one cycle 
of chemotherapy, and greater than 25% after more than one treatment cycle.  
A reduction in the extent of the tumour 18F-FDG uptake was not a 
requirement for PMR.  Complete metabolic response (CMR) was defined as 
complete resolution of 18F-FDG uptake within the tumour volume so that it 
was indistinguishable from surrounding normal tissue356. 
 
3.1.9 Efficacy assessment 
CT scan was performed at screening, and between days 15 and 21 of cycles 2 
and 4, and at study completion.  Response was assessed using the standard 
RECIST criteria358, and all response assessment was performed by a single 
experienced radiologist. 
 
3.1.10 Safety evaluation 
All adverse events were documented and graded according to Common 
Terminology Criteria for Adverse Events v3.0 (CTCAE).  Causality was 
ĚĞƚĞƌŵŝŶĞĚ ĂƐ  “ƌĞůĂƚĞĚ ƚŽ ƐƚƵĚǇ ĚƌƵŐ ? ŝĨ ƚŚe event was deemed definitely, 
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probably, or possibly related to the administration of CMD-193, by the 
investigator.  Events deemed not related or unlikely related were classified as 
 “ŶŽƚ ƌĞůĂƚĞĚ ? ƚŽ ƚŚĞ ƐƚƵĚǇ ĚƌƵŐ ?  WĂƚŝĞŶƚƐ ǁĞƌĞ ĐŽŶƐŝĚĞƌĞĚ ĞǀĂůƵĂďůĞ ĨŽƌ
toxicity if they had completed the study requirements up to 21 days following 
111In-CMD-193 infusion. 
 
Immunogenicity of CMD-193 ELISA was performed by Wyeth Pharmaceuticals, 
using a validated in house assay.  This involved a monoclonal anti-idiotype 
anti-G193 antibody for capturing molecule and a polyclonal anti-calcheamycin 
antibody as detection reagent.  Blood for baseline HAHA was drawn on day 1 
prior to infusion, and repeated prior to each subsequent cycle, and at end of 
study assessment. 
 
3.1.11 Data quality assurance 
The study coordinator, and occasionally also investigators largely performed 
data entry to the electronic case report form.  An independent monitor 
performed regular visits for source document verification.   
 
3.1.12 Statistical considerations 
The biodistribution of the drug was assessed visually and qualitatively from 
gamma camera images. Whole body dose and doses to individual organs 
results were summarised across the patients in each dose level using means 
and ranges.  Pharmacokinetic and dosimetry comparisons were made across 
the two dose cohorts, and with the previous trial of parental antibody 
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hu3S193, using the independent T test. 
 
Tumour metabolism response to 111In-CMD-193 treatment was evaluated as 
the difference in SUVmax between the pre- and the post-treatment FDG-PET 
scans.  This was summarised as the percent change in the maximal SUV of the 
most FDG-avid target lesion in each patient, and overall FDG-PET response 
was classified according to the 1999 EORTC recommendations for PET 
response356.  Comparative analysis was performed of FDG-PET results to CT 
response (RECIST).  
 
3.1.13 Protocol amendments 
One protocol amendment was submitted and approved by Austin Health 
Research Ethics Committee in May 2006.  The main clinical trial Participation 
Information and Consent Form for the study was changed to reflect the 
amended protocol, but no changes to the Screening Participation Information 
and Consent Form were required.  This amendment achieved the following 
outcomes: 
 
1. A reduction in the minimum number of patients required to be treated in 
each dose cohort.  
 
The original protocol stated that 8 patients would be treated in each of the 
three dose cohorts.  The MTD was determined to be 2.6 mg/m2 in the US 
Phase I dose escalation study.  While pharmacokinetic and biodistribution 
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data at the 1.0 mg/m2 dose level were needed for a complete PK, 
biodistribution and tumour targeting profile for CMD-193, 8 patients were 
not needed at either dose level for this purpose.  This amendment 
provided the flexibility to enter less than 8 patients in the subsequent (and 
final) cohort.    
 
2. Removal of the initial second dose cohort (1.7mg/m2), so that enrolment 
moved straight from dose cohort 1 (1.0mg/m2) to the new dose cohort 2 of 
2.6mg/m2 (cohort 3 in the initial protocol).  
 
The US study recruited and assessed patients in higher dose cohorts up to 
3.6mg/m2 and was satisfied with the safety of the MTD level (determined 
to be 2.6 mg/m2).  At the time of this amendment the US study was 
recruiting to an expanded cohort of patients at this MTD level to further 
assess anti-tumour activity of the agent.  It was deemed unnecessary for 
pharmacokinetic, biodistribution and tumour targeting data at the 
1.7mg/m2 dose level since the therapeutic dose being pursued was 
2.6mg/m2.  The amended protocol aimed to evaluate cohorts of 8 patients 
or less only at the 1.0 and 2.6 mg/m2 dose levels. 
 
3.1.14 Premature closure of the study 
Following a protocol amendment in May 2006, this biodistribution study was 
aiming to enrol 12-16 patients.  Unlike the parallel US study (sponsored by 
Wyeth Pharmaceuticals), which focused on dose escalation and toxicity as its 
primary endpoint (and established the toxicity profile and MTD of CMD-193), 
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the primary endpoint of this protocol was biodistribution and 
pharmacokinetics of 111In-CMD-193.  Adequate information regarding the 
biodistribution and pharmacokinetics of the study agent was obtained from 
the first 9 patients enrolled over the 2 dose cohorts, and no difference could 
be seen between the cohorts.  Of these patients, although all completed at 
least one full cycle of treatment and were thus evaluable for the study 
endpoints, adverse events or disease progression meant only 1 completed the 
full six-cycles available in the study.  As adequate information on 
biodistribution was obtained and the primary and secondary study objectives 
were met, it was decided therefore, to halt accrual and no further patients 
were entered into the study. 
 
 
3.2 RESULTS 
 
3.2.1 Study patient characteristics  
Ley expression screening was performed on 80 tumour samples.  Thirty four of 
these had Ley expression 20%.  Nine patients with a mean age of 58 years 
(range 46-77 years) were eligible and enrolled onto this Phase I, 
immunoconjugate biodistribution study. The final amended protocol 
evaluated two dose cohorts of 8 patients or less, cohort 1: 1.0 mg/m2, and 
cohort 2: 2.6 mg/m2.  Six patients were enrolled in cohort 1, 3 patients in 
cohort 2. Patient characteristics are summarised in Table 3.2.1.  There were 4 
female and 5 male patients, all with ECOG performance status of 0-1.  
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Enrolled patients had a variety of different primary tumours with confirmed 
Ley antigen positivity: Colon carcinoma (3 patients), cholangiocarcinoma (1 
patient), gastric carcinoma (2 patients), gastro-oesophageal junction 
carcinoma (1 patient), bronchoalveolar carcinoma (1 patient), and pulmonary 
adenocarcinoma (1 patient). 
 
3.2.2 Patient history and disease status at study entry 
All 9 patients had metastatic disease at study entry.  Sites of metastatic 
disease at study entry included lymph nodes (5 patients), liver lesions (7 
patients), lung lesions (3 patients), and bone metastases (1 patient).  One 
patient had a retro-pancreatic mass, and 1 patient had a pre-sacral mass.  
Disease status at study entry is documented in Table 3.2.2.1.   
 
Many patients had been extensively pre-treated, having received 1-5 lines of 
prior chemotherapy, monoclonal antibody or biological agent, with 7 patients 
having been previously enrolled onto another clinical trial.  No patient had 
received prior radiotherapy, which is a likely reflection of the extent of their 
metastatic disease.  Oncological treatment history is documented in Table 
3.2.2.2.  The advanced nature of the malignancies in this study population 
meant there were a number of pre-existing symptoms, haematological and 
biochemical abnormalities documented at baseline.  It was important to 
distinguish these from symptoms and abnormalities that developed during 
the study period, so causality could be estimated.   
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Table 3.2.1. Patient Characteristics 
 
 
Pt ID 
Age at 
study 
entry 
ECOG PS Sex Race Diagnosis 
Dose 
Cohort 
No. Cycles 
Completed 
Study 
Outcome 
Reason for 
Premature 
Withdrawal 
101 53 1 Female White/Caucasian Colon Carcinoma 1 2 
Premature 
withdrawal 
Progressive disease 
102 49 0 Female White/Caucasian Cholangiocarcinoma 1 6 Completed N/A 
103 71 0 Male White/Caucasian Colon Carcinoma 1 4 
Premature 
withdrawal 
Unacceptable toxicity 
104 58 0 Male Asian Gastric Carcinoma 1 3 
Premature 
withdrawal 
Unacceptable toxicity 
105 53 0 Male White/Caucasian Colon Carcinoma 1 2 
Premature 
withdrawal 
Progressive disease 
106 46 0 Male White/Caucasian 
Gastro-Oesophageal 
Junction Carcinoma 
1 2 
Premature 
withdrawal 
Progressive disease 
107 77 1 Male Asian 
Bronchoalveolar 
Carcinoma 
2 1 
Premature 
withdrawal 
Unacceptable toxicity 
108 69 0 Female White/Caucasian Gastric Carcinoma 2 5 
Premature 
withdrawal 
Unacceptable toxicity 
161 46 1 Female Asian 
Pulmonary 
Adenocarcinoma 
2 1 
Premature 
withdrawal 
Progressive disease 
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Table 3.2.2.1. Disease Status at study entry 
 
 
Pt ID 
Dose 
Cohort 
Primary Tumour Le
y
 
antigen positivity 
Primary Diagnosis 
Sites of Metastatic Disease at Study 
Entry 
101 1 20-50%  Colon Carcinoma 
 
Lymph nodes, Liver  
 
102 1 >75% Cholangiocarcinoma Retro-pancreatic mass 
103 1 51-75% Colon Carcinoma Liver 
104 1 20-50% Gastric Carcinoma Liver  
105 1 20-50% Colon Carcinoma 
Lymph nodes, Liver, Lung, Pre-sacral 
mass 
106 1 51-75% Gastro-Oesophageal Junction Carcinoma Lymph nodes, Liver 
107 2 20-50% Bronchoalveolar Carcinoma Lung 
108 2 20-50% Gastric Carcinoma Lymph nodes, Liver, Lung 
161 2 20-50% Pulmonary Adenocarcinoma Lymph nodes, Liver, Bone  
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Table 3.2.2.2. Prior Oncological Treatment history 
 
Pt ID 
Dose 
Cohort 
Primary Diagnosis 
Oncological Treatment History 
Definitive Surgical Procedures Chemotherapy Radiation 
101 1 Colon Carcinoma 
Right hemicolectomy                           
Hysterectomy, salpingo-oophorectomy 
5-Fluorouracil/FA                                       
Cetuximab/Irinotecan/5-Fluorouracil/FA (CRYSTAL Trial)      
5-Fluorouracil/FA/Oxaliplatin 
None 
102 1 Cholangiocarcinoma Cholecystectomy Cisplatin/Gemcitabine None 
103 1 Colon Carcinoma Hemicolectomy 
5-Fluorouracil/FA/Oxaliplatin                 
hu3S193 (Phase I Trial) 
131
I-huA33/Capecitabine (Phase I Trial)     
Irinotecan 
None 
104 1 Gastric Carcinoma Distal gastrectomy 
Docetaxel/Capecitabine (ATTAX Trial)         
  Docetaxel/Cetuximab (ATTAX2 Trial) 
None 
105 1 Colon Carcinoma 
Left hemicolectomy  
ERCP/bile duct stent 
5-Fluorouracil/FA                      
   5-Fluorouracil/FA/Oxaliplatin    
Irinotecan 
Cetuximab (C017 Trial)  
Gemcitabine/Erlotinib (Trial) 
None 
106 1 
Gastro-Oesophageal 
Junction Carcinoma 
None 
Docetaxel/Cisplatin/5-Fluorouracil (ATTAX Trial)            
Docetaxel/Cetuximab (ATTAX2 Trial)  
None 
107 2 
Bronchoalveolar 
Carcinoma 
None 
Vinorelbine  
Tarceva 
Alimta 
None 
108 2 Gastric Carcinoma None 
Docetaxel/Capecitabine (ATTAX Trial) 
Docetaxel/Cetuximab (ATTAX2 Trial) 
Epirubicin/Cisplatin/5-Fluorouracil 
None 
161 2 
Pulmonary 
Adenocarcinoma 
None 
Tarceva 
Carboplatin/Gemcitabine 
 Alimta 
Cyt997 (Trial) 
None 
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3.2.3 Patient status/outcome 
As will be described in greater detail in subsequent sections, only 1 patient, 
patient 102, dose cohort 1, received all 6 cycles of CMD-193.  Four patients 
were withdrawn secondary to progressive disease after 2 cycles of treatment: 
3 patients in the 1.0 mg/m2 dose cohort, patients 101, 105 and 106, and 1 
patient in the 2.6 mg/m2 dose cohort, patient 161.  Patient 161 received 2 
infusions CMD-193 but withdrew prior to completing cycle 2 due to rapidly 
progressive disease.  Four patients were withdrawn because of unacceptable 
toxicity: patients 103 and 104 from the first dose cohort after 4 and 3 cycles 
respectively, and patients 107 and 108 from the 2.6 mg/m2 dose cohort after 
1 and 5 cycles, of treatment respectively.  
 
3.2.6 Biodistribution analysis 
Biodistribution images for each patient are shown in Appendix 3.1 Figures 1-9.  
Evaluation of gamma camera imaging following infusion of 111In-CMD-93 
showed initial blood pooling, followed by markedly increased hepatic uptake 
by day 2 (which persisted to day 8), and fast blood clearance.  This pattern 
was seen for all patients in both dose levels, and confirmed with both planar 
gamma camera images and SPECT.  No significant uptake of 111In-CMD-193 in 
tumour was visualised in any of the target lesions, for any of the 9 patients 
enrolled on the study.  Even those patients with extensive liver disease did 
not demonstrate any tumour uptake, with areas of liver disease appearing as 
a cold region on the image (e.g. Patient 103).   
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3.2.6.1 Whole body clearance analysis 
Whole body clearance (Effective T ½) was calculated for all patients across 
both dose levels, and results are shown in Table 3.2.6.1 and Figure 3.2.6.1.  
The overall mean ± SD was 47.82 ± 3.24 hours, with consistency between the 
two dose levels. There was no statistically significant difference between dose 
levels, with a mean effective half-life of 47.54 ± 3.16 hr in the 1.0 mg/m2 
cohort, and 48.37 ± 4.03 hr for the 2.6 mg/m2 cohort, (p=0.74).  
 
Table 3.2.6.1. Whole body clearance (Effective T ½) of 
111
In-CMD-193 
 
Patient 
Dose Level 
(mg/m
2
) 
Whole body clearance 
 (Effective T ½) (hrs) 
Mean Effective 
T ½ ± SD (hrs)  
T test 
comparing 2 
dose levels 
101 1.0 51.52 
47.54 ± 3.16 
0.74 
102 1.0 50.08 
103 1.0 45.00 
104 1.0 48.26 
105 1.0 47.38 
106 1.0 43.00 
107 2.6 50.16 
48.37 ± 4.03 108 2.6 51.19 
161 2.6 43.75 
All 47.82 ± 3.24 
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Figure 3.2.6.1. Whole body clearance (Effective T ½) of 
111
In-CMD-193 
 
 
0 25 50 75 100 125 150 175
0.00
0.25
0.50
0.75
1.00 101
102
103
104
105
106
107
108
161
Time (hrs)
N
o
rm
al
is
ed
 
ID
 
 
 
 
3.2.6.2 Normal organ clearance 
Organ uptake and clearance for liver, lung, spleen and kidney are presented in 
Figure 3.2.6.2.  Only hepatic clearance analyses were possible with patient 
161 data. Normal organ clearance analysis confirmed the disproportionate 
hepatic uptake of 111In-CMD-193 visualised on gamma camera imaging.  
Hepatic uptake was much greater compared to that observed for lung, spleen 
and kidney.  Uptake in lung, spleen and kidney was very low, and consistent 
with blood pool activity.   
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Figure 3.2.6.2. Organ uptake and clearance of 
111
In-CMD-193 
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3.2.7 Pharmacokinetic analysis 
Individual patient pharmacokinetic parameters T½  and T½ , V1, AUC, CL and Cmax 
for the single infusion of 111In-CMD-193 were calculated.  The final results (mean ± SD) 
were: T½a =4.76 ± 2.15 hrs, T½b = 102.88 ± 35.67 hrs; CL = 113.22 ± 56.58 mL/hr and 
V1 = 4071.22 ± 731.41 mL (Table 3.2.7.1).  The individual patient curve fits are 
presented in Appendix 3.2.  The Mean ± SD results for each dose level and across the 
two dose levels are shown in Table 9. No significant differences were found in the 
111In-CMD193 pharmacokinetic parameters between the 2 dose levels.  Individual 
patient pharmacokinetic parameters are shown in Table 3.2.7.2.  Serum CMD-193 
protein measurements were below limits of quantitation in many patients, particularly 
at later time points, and pharmacokinetic analysis could not be accurately performed.  
Free calicheamicin levels were at or below the limit of assay quantitation in all 
patients.  
 
In conclusion, pharmacokinetic analysis determined that CMD-193 displayed a fast 
clearance from blood, which is consistent with the biodistribution findings of fast 
blood pool clearance and rapid uptake in liver parenchyma.  
 
 
 
  196 
Table 3.2.7.1 Mean pharmacokinetic parameters in all patients, and comparison 
between dose levels 
 
 
Parameter Units 
CMD-193 All (N=9) 
1mg/m
2
 CMD-
193 (N=6) 
2.6mg/m
2
 CMD-193 
(N=3) 
T test * 
Mean SD Mean SD Mean SD P Value 
T ½ a Hr 4.76 2.15 5.47 1.99 3.32 2.00 0.17 
T ½ b Hr 102.88 35.67 104.42 37.94 99.79 38.32 0.87 
V1 mL 4071.22 731.41 4366.18 586.87 3481.31 704.13 0.08 
CL mL/hr 113.22 56.58 130.04 61.25 79.56 29.67 0.23 
AUC mg.hr/mL 29.93 22.31 16.37 6.13 56.45 17.05 Not done 
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Table 3.2 7.2 Individual patient 
111
In-CMD-193 pharmacokinetic data 
 
 
Patient 
Dose 
(mg/m
2
) 
T ½ 
alpha 
(hrs) 
Std 
Err 
T ½ beta 
(hrs) 
Std  
Err 
V1 (mL) Std Err 
AUC 
(hr.mg/mL) 
 
Std  
Err 
CL (mL/hr) 
Std  
Err 
Cmax 
(mg/mL) 
Std Err 
101 1.0 4.03 0.44 105.23 20.27 3765.47 70.23 19.48 2.34 89.83 10.82 0.46 0.009 
102 1.0 8.14 1.16 133.69 53.50 3587.01 75.45 23.35 4.67 76.22 15.27 0.50 0.010 
103 1.0 7.54 0.77 160.66 35.56 5119.16 73.82 21.19 2.69 85.88 10.93 0.36 0.005 
104 1.0 4.16 0.53 81.25 32.65 4692.18 112.89 8.22 1.73 194.63 41.11 0.34 0.008 
105 1.0 5.63 0.44 90.81 11.60 4383.20 52.64 15.85 1.04 114.85 7.58 0.42 0.005 
106 1.0 3.35 0.40 54.86 15.12 4650.03 107.37 10.10 1.45 218.86 31.41 0.48 0.010 
107 2.6 1.46 0.41 84.06 23.55 2668.60 116.46 68.04 13.15 55.85 10.81 1.42 0.062 
108 2.6 5.43 0.54 143.48 25.22 3867.04 59.98 64.43 6.93 70.00 7.54 1.17 0.018 
161 2.6 3.07 0.30 71.84 10.58 3908.29 68.84 36.87 3.14 112.83 9.63 1.06 0.019 
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3.2.8 Efficacy assessment 
While patients were scheduled for tumour response assessment at the end of every 
second cycle of treatment, the protocol stipulated that patients were deemed 
evaluable for tumour response only after completion of 6 cycles of CMD-193.  It 
became clear that with the combination of an extensively pre-treated study population 
with advanced tumours, and a therapy with potential myelosuppressive side effects, a 
minority of patients would reach completion of 6 cycles of CMD-193 (in keeping with 
the findings of a parallel Phase I study of this agent in US).  Therefore, despite not 
being formally evaluable according to the original protocol outline, comments 
regarding tumour response measured as per the protocol scheduled tumour 
evaluation have been included in this report for each patient who completed protocol 
evaluations to at least 21 days following their first cycle (111In-CMD-193) and who 
underwent disease reassessment.  Of the nine patients enrolled, 8 were evaluable for 
response by FDG-PET and CT. Response could not be formally measured in patient 161, 
as she died of rapid progressive disease on Day 11 cycle 2, and did not have a repeat 
CT or FDG-PET scan but is assumed therefore to have had PD at study completion.  
 
3.2.8.1 Assessment of tumour metabolism using FDG-PET 
Of the 8 patients assessed by FDG-PET, there was 1 patient with a partial metabolic 
response (PMR), 3 with stable metabolic disease (SMD), and 4 with progressive 
metabolic disease (PMD) at end of study assessment.  Patient 103 (1.0 mg/m2 dose 
cohort) had a PMR, showing a 41.7% reduction in SUV after 4 cycles of CMD-193 
(Figure 3.2.8.1).  This was despite no change in target lesion dimension on CT scanning.  
Of the 3 patients with SMD: 2 patients were at the 1.0 mg/m2 dose cohort, patient 
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102, after 6 cycles and patient 104 after 3 cycles; and 1 patient from the 2.6 mg/m2 
dose cohort, patient 108, after 5 cycles.  Of the 4 patients with PMD, 3 were in dose 
cohort 1 (patients 101, 105 and 106), and patient 107 was in dose cohort 2.  
 
 
Figure 3.2.8.1  Partial metabolic response in patient 103 
 
 
 
Partial Metabolic Response to CMD-193: Assessment by 18F-FDG-PET. According to 
RECIST criteria, pt 103 had stable disease following 4 cycles of CMD-193 at a dose 1.0 
mg/m2, with a large liver lesion (arrow) remaining similar in size. The pt did however 
demonstrate a partial metabolic response in this lesion, with a 41.7% reduction in 
SUVmax observed by 18F-FDG-PET. Pre-study and post CMD-193 cycle 4 imaging is 
shown: Panels A and D, CT image; Panels B and E, 18F-FDG-PET; Panels C and F, fused 
PET/CT images. 
 
 
 
3.2.8.2 Efficacy assessment using CT 
Only 1 patient completed 6 cycles of study treatment (patient 102, 1.0 mg/m2 dose 
cohort).  This patient had demonstrated stable disease after cycles 2 and 4, but then 
progressed after her 6th cycle and therefore had PD at study completion.  Taking into 
account the scheduled disease reassessments in the protocol, tumour response 
according to RECIST criteria was ascertained in 8 patients.  Of these 8 patients, there 
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were 4 with stable disease (SD, 2 patients in each dose cohort) and 4 with progressive 
disease (PD) on CT scanning.  Target lesion assessment according to RECIST criteria are 
documented in Appendix 3.3.  It should be noted that although patient 104 
demonstrated a reduction in size of one if his liver lesions, this was secondary to 
compression by a liver cyst which had enlarged, and was thought unlikely to represent 
active tumour.  Overall this patient was thought to have stable disease after 2 cycles, 
but was withdrawn after cycle 3 because of unacceptable toxicity.   
 
3.2.8.3 Efficacy assessment summary and patient outcome 
Patient outcome and tumour response at study completion according to CT and FDG-
PET is summarised in Table 3.2.8.3.  Although there was no formal long term follow-up, 
an observation was made that patient 108, who had SD on CT and in whom a 25% 
reduction in SUVmax was observed at the end of study assessment, was alive and well 
10 months following study completion. 
 
  201 
Table 3.2.8.3. Patient Status/Outcome and Disease Response 
 
Pt ID Sex 
Age at 
Study 
Entry 
Dose 
Cohort 
Primary Diagnosis 
Days 
on 
study 
No. of 
cycles 
Study 
Outcome 
Principal 
reason for 
premature 
withdrawal 
Overall 
response  
(RECIST)  
New 
lesions on 
FDG-PET? 
% 
Difference 
in SUV max 
FDG-PET 
Response 
101 F 53 1 Colon carcinoma  49 2 
Premature 
withdrawal  
Progressive 
disease 
PD Y +8.7 PMD 
102 F 49 1 Cholangiocarcinoma  120 6 
Completed 
as planned 
N/A PD N -6.7 SMD 
103 M 71 1 Colon carcinoma  106 4 
Premature 
withdrawal  
Unacceptable 
toxicity 
SD N -41.7 PMR 
104 M 58 1 Gastric carcinoma 78 3 
Premature 
withdrawal  
Unacceptable 
toxicity 
SD N 
No 
difference 
SMD 
105 M 53 1 Colon carcinoma  50 2 
Premature 
withdrawal  
Progressive 
disease 
PD Y -18.3 PMD 
106 M 46 1 
Gastro-Oesophageal 
junction carcinoma  
52 2 
Premature 
withdrawal  
Progressive 
disease 
PD Y +39.5 PMD 
107 M 77 2 
Bronchoalveolar 
carcinoma  
29 1 
Premature 
withdrawal  
Unacceptable 
toxicity 
SD Y +20.3 PMD 
108 F 69 2 Gastric carcinoma  106 5 
Premature 
withdrawal  
Unacceptable 
toxicity 
SD N -25.0 SMD 
161 F 46 2 
Pulmonary 
adenocarcinoma  
32 2* 
Premature 
withdrawal  
Progressive 
disease* 
PD* N/A N/A N/A 
PD=progressive disease, SD=stable disease, N/A=not applicable or not assessed, PMD=progressive metabolic response, SMD=stable metabolic disease, PMR=partial 
metaboolic response. * Completed second infusion, withdrew early on Cycle 2, Day 9. Progressive disease (clinically).  This patient deteriorated quickly, and therefore did 
not have any end of study tumour assessments and therefore was not evaluable for tumour response 
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3.2.10 Adverse Events  
No serious or severe and unexpected events causally related to study drug CMD-193 
were observed.  Three serious adverse events (SAE) were reported.  One was reported 
in patient 105, dose cohort 1, which was not related to study drug.  He developed 
biliary sepsis secondary to a blocked biliary stent, and required admission for 
intravenous antibiotics and a stent change.  Two separate hospitalisations were 
reported in patient 161, dose cohort 2.  These hospital admissions were related to 
malignant pleural effusions and not related to study drug.  Patient 161 was removed 
early from study on cycle 2 day 9 and died 2 days later of rapid disease progression 
during the second of these hospital stays.  All adverse events (AEs) related to CMD-193 
are presented in Table 3.2.10.1.  In dose cohort 1 there were 70 events (in 6 patients), 
and in dose cohort 2 there were 34 events (in 3 patients). These related AEs are 
described in more detail in Table 3.2.10.2.  The distribution of all AEs by severity and 
relatedness are shown in Appendix 3.4.  
 
 
Table 3.2.10.1 Distribution of study agent related adverse events according to dose 
level 
 
Dose 
Cohort 
Number of 
patients 
CTCAE Grade  Total Adverse Events 
Related to CMD-193 (By 
Dose Cohort) 1 2 3 4 5 
1 6 44 18 8 0 0 70 
2 3 24 10 0 1 0 35 
Total  68 28 8 1 0 105 
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Table 3.2.10.2 Study agent related Adverse Events (possibly, probably or definitely related to CMD-193): Description and number of events 
System Organ Class Adverse Event G1 G2 G3 G4 Total 
Blood and lymphatic system disorders 
Anaemia 4 2 0 0 6 
Leukopenia 3 1 0 0 4 
Lymphopenia 3 2 1 0 6 
Neutropenia 1 2 0 0 3 
Thrombocytopenia 11 1 2 1 15 
Gastrointestinal disorders 
Abdominal bloating 1 0 0 0 1 
Epigastric discomfort 1 0 0 0 1 
Gastroesophageal reflux 1 2 0 0 3 
Nausea 8 2 0 0 10 
Vomiting 6 1 0 0 7 
General disorders and administration site 
conditions 
Flu-like symptoms 1 0 0 0 1 
Flushing 1 0 0 0 1 
Fatigue 0 2 0 0 2 
Lethargy 6 2 0 0 8 
Hepatobiliary disorders Hyperbilirubinaemia 4 2 0 0 6 
Investigations 
ALP increased 1 1 2 0 4 
ALT increased 2 3 0 0 5 
Amylase increased 1 0 0 0 1 
AST increased 2 0 1 0 3 
GGT increased 0 1 2 0 3 
Lipase increased 1 1 0 0 2 
Weight loss 0 2 0 0 2 
Metabolism and nutrition disorders Anorexia 7 1 0 0 8 
Respiratory, thoracic and mediastinal disorders Epistaxis 1 0 0 0 1 
Skin and subcutaneous tissue disorders 
Bruising 1 0 0 0 1 
Rash erythematous 1 0 0 0 1 
Total 68 28 8 1 105 
 3.2.10.1 Myelosuppression 
Anaemia 
CMD-193 was possibly a contributing factor to anaemia (grade 1-2) in some patients.  
The advanced nature of metastatic disease meant it was difficult to determine 
relatedness of observed falls in haemoglobin level.  Where anaemia was obviously part 
of their underlying malignancy it was deemed unrelated.  Patient 105 required a blood 
transfusion at commencement of the trial for pre-existing anaemia relating to 
advanced colon carcinoma.  Patient 108 had a large ulcerated gastric primary that led 
to episodes of malaena and gradual fall of haemoglobin requiring blood transfusion.  
For patients 101, 102, 104 and 106, anaemia was deemed to be related to study drug.  
Haemoglobin levels for all patients whilst on study are shown below in Figure 3.2.10.1. 
 
 
Figure 3.2.10.1 Haemoglobin levels for all patients 
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Lymphopenia and leukopenia 
Lymphopenia (grade 1-3) relating to study drug was seen in 4 patients (6 events) but 
did not cause symptoms.  In 2 patients this had not resolved by the end of the study.  
Grade 1-2 neutropenia was observed in 3 patients, but again patients remained 
asymptomatic and there were no episodes of sepsis attributable to this.  Neutrophil 
counts for all patients are shown below in Figure 3.2.10.2.  The rapid increase in 
neutrophil count seen in Patient 161 can be attributable to rapid and significant 
disease progression.  
 
Figure 3.2.10.2 Neutrophil counts in all patients 
 
 
Thrombocytopenia was very common, with all but 1 patient (patient 108) experiencing 
a fall in platelets whilst on the trial.  There were 15 thrombocytopenia events in these 
8 patients.  Thrombocytopenia was grade 1-2 in patients 102, 103, 105, 106 and 161, 
and grade 3 in patients 101 and 104, and grade 4 in patient 107. Grade 1 epistaxis 
(patient 107) and bruising (patient 101) were likely related to concurrent 
thrombocytopenia.  Platelet counts are shown below in Figure 3.2.10.3. 
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Figure 3.2.10.3 Platelet counts in all patients 
 
 
 
Thrombocytopenia was the reason for early withdrawal for 2 patients.  They were 
patient 104 in dose cohort 1: 1.0 mg/m2 CMD-193, and patient 107, in dose cohort 2: 
2.6 mg/m2 CMD-193.  
 
3.2.10.2 Gastrointestinal disorders 
Mild gastrointestinal disorders such as gastroesophageal reflux, nausea and vomiting 
(all grade 1-2) were relatively common, but the majority were self-limiting. Anorexia 
(grade 1-2) was also common occurring in 7 patients.  Grade 1 rise in amylase was 
observed in patient 107, and grade 1-2 rise in lipase was seen in patients 104 and 106, 
all of which were not clinically significant, transient, and required no treatment.  
 
3.2.10.3 General disorders 
Seven patients reported grade 1-2 lethargy and/or fatigue, which was likely to be 
related to study drug.  One patient experienced an episode of flu-like symptoms, and 
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another had transient flushing (both grade 1), both of which may have been related to 
CMD-193.  One patient developed a grade 1 erythematous rash, which was possibly 
related to study drug.   
 
3.2.10.4 Hepatobiliary disorders 
Liver enzyme abnormalities occurred in a number of patients, and were a contributing 
factor for early withdrawal of 2 patients (patient 103 and 108).  CMD-193 could not be 
excluded as a contributing factor for these rises in alkaline phosphatase (ALP), alanine 
transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl 
transpeptidase (GGT), which were seen in 4 patients.  Serum ALP and ALT levels are 
shown in Figures 3.2.10.4.1 and 3.2.10.4.2 respectively.  Patients 106 and 107 had a 
grade 1-2 ALP rise.  Patients 103, 105, 106 and 107 had a grade 1-2 ALT rise.  Patients 
107 and 161 had a grade 1 AST rise, and patient 107 had a grade 2 GGT rise.  Grade 3 
liver enzyme rises occurred in patients 103 and 105, both of whom had extensive liver 
disease, but an exacerbation by CMD-193 could not be excluded. 
 
Figure 3.2.10.4.1 Serum ALP levels in all patients 
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Figure 3.2.10.4.2  Serum ALT levels in all patients 
 
 
 
Hyperbilirubinaemia 
Four patients developed what was thought to be CMD-193 related (or partly related) 
hyperbilirubinaemia.  This was grade 1 in 2 patients (patients 107 and 161, 2.6 mg/m2 
dose cohort), and grade 2 in 2 patients (Patient 103, 1.0 mg/m2; and Patient 108, 2.6 
mg/m2).  Patient 105 had an episode of grade 3 hyperbilirubinaemia, but this was in 
the context of biliary sepsis secondary to a blocked biliary stent, and therefore was not 
thought to be related to study drug.  Bilirubin levels in all patients are shown in Figure 
3.2.10.4.3. 
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Figure 3.2.10.4.3  Serum bilirubin levels in all patients 
 
 
 
Grade 2 hyperbilirubinaemia was observed in patient 103 on dose cohort 1: 1.0 mg/m2 
CMD-193, and patient 108, on dose cohort 2: 2.6 mg/m2 CMD-193.  
 
3.2.10.5 Immune responses 
There were no documented infusion Wrelated reactions, and lack of immunogenicity of 
CMD-193 was confirmed by the evaluation of anti-CMD-193 antibodies (HAHA), which 
was performed by Wyeth Research (unpublished report CMD-193: Bioanalytical report 
on the presence of anti-CMD-193 antibodies in patients enrolled in clinical study).  No 
HAHA response was detectable at baseline, prior to each subsequent infusion, or at 
end of study assessment in any patient.  
 
3.2.11 Summary of findings 
This trial demonstrated that infusion of the immunoconjugate CMD-193 led to rapid 
hepatic uptake and clearance from blood, consistent with the observed short T½  and 
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dosimetric analysis of normal organ uptake.  Poor targeting to known sites of 
metastatic disease was also evident.  
 
There were no documented objective responses seen in size of tumour, but 1 patient 
did display a partial metabolic response according to 18F-FDG-PET analysis, hinting at 
the possibility of anti-tumour activity.  It was also shown that CMD-193 can be 
administered in multiple infusions (up to a maximum of 6 cycles), with 
myelosuppression and liver toxicity being the principle significant toxicities 
encountered. 
 
These results of this study highlight the importance of biodistribution assessment in 
early phase studies of immunoconjugates.  These findings will be discussed and 
compared to both the parental antibody and other calicheamicin immunoconjugates in 
Chapter 5. 
 Appendix 3 
Appendix 3.1 Biodistribution images for each patient 
 
Figure 1. Biodistribution of 
111
In-CMD-193 in Patient 101 
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Figure 2. Biodistribution of 
111
In-CMD-193 in Patient 102 
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Figure 3. Biodistribution of 
111
In-CMD-193 in Patient 103 
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Figure 4. Biodistribution of 
111
In-CMD-193 in Patient 104 
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Figure 5. Biodistribution of 
111
In-CMD-193 in Patient 105 
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Figure 6. Biodistribution of 
111
In-CMD-193 in Patient 106 
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Figure 7. Biodistribution of 
111
In-CMD-193 in Patient 107 
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Figure 8. Biodistribution of 
111
In-CMD-193 in Patient 108 
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Figure 9. Biodistribution of 
111
In-CMD-193 in Patient 161  
  
Appendix 3.2 Individual patient curve fits of serum 
111
In-CMD-193 clearance 
 
Patient 101, 1.0 mg/m
2
 Dose Cohort 
 
 
 
Patient 102, 1.0 mg/m
2
 Dose Cohort 
 
 
Patient 103, 1.0 mg/m
2
 Dose Cohort 
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Patient 104, 1.0 mg/m
2
 Dose Cohort 
 
 
 
Patient 105, 1.0 mg/m
2
 Dose Cohort 
 
 
 
Patient 106, 1.0 mg/m
2
 Dose Cohort 
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Patient 107, 2.6 mg/m
2
 Dose Cohort 
 
 
 
Patient 108, 2.6 mg/m
2
 Dose Cohort 
 
 
Patient 161, 2.6 mg/m
2
 Dose Cohort 
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Appendix 3.3 Target Lesion assessment throughout the trial with overall response 
 
Pt ID 
  
Target Lesion Description 
Screening Following Cycle 2 Following Cycle 4 Following Cycle 6 
Overall 
Response   LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
101 
Right para-aortic lymph node 62 
154 
62 
175 N/A N/A   N/A  N/A   PD 
Liver lesion (segment 7)  18 27 
Left para-aortic lymph node 30 33 
Anterior mediastinum lymph node mass 31 29 
Left axillary lymph node 13 24 
102 Retropancreatic mass  41 41 41 41 41 41 52 52 PD 
103 
Liver lesion (right lobe)  184 
200 
210 
226 
208 
223  N/A    N/A  SD 
Liver lesion (segment 2) 16 16 15 
104 
Liver lesion (segment 7/8)  104 
123 
78 
101 N/A   N/A   N/A   N/A   SD 
Liver lesion (segment 5) 19 23 
105 
Left upper lobe lung lesion 12 
306 
13 
342 N/A  N/A  N/A   N/A PD 
Right lower lobe lung lesion 10 9 
Left lower lobe lung lesion 11 12 
Right hilar lymph node 17 16 
Posterior oesophageal lymph node 20 19 
Liver lesion (segment 2/3) 92 103 
Liver lesion (segment 1) 52 64 
Liver lesion (segment 4a)  30 38 
Paraortic node (aortic bifurcation) 24 25 
Pre sacral mass 38 43 
LD= longest lesion diameter; N/A= Not applicable; PD=progressive disease, SD=stable disease ;   = Lesion with maximal SUVmax on FDG-PET, used for determining metabolic response 
  224 
ƉƉĞŶĚŝǆ ? ? ?ŽŶƚŝŶƵĞĚ ?dĂƌŐĞƚ>ĞƐŝŽŶĂƐƐĞƐƐŵĞŶƚƚŚƌŽƵŐŚŽƵƚƚŚĞƚƌŝal with overall response 
 
Pt ID 
 
Target Lesion Description 
 
Screening Following  Cycle 2 Following Cycle 4 Following  Cycle 6 
Overall 
Response LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
LD Sum 
(mm) 
 LD (mm) 
106 
Left hilar lymph node 21 
316 
20 
343 N/A  N/A  N/A  N/A   PD 
Liver lesion (segment 4)  133 148 
Lesser curvature of stomach lymph node  29 31 
Coeliac axis lymph node 76 84 
Post pericardial lymph node 26 31 
Left paraortic lymph node 31 29 
107 
Left upper lobe lung lesion 38 
144 
40   
146  
  
 N/A   N/A  N/A  N/A SD Left upper lobe lung lesion  18 17 
Left lower lobe lung lesion 88 89 
108 
Liver lesion (segment 7)  34 
154 
32 
151 
35 
150 N/A  N/A  SD 
Liver lesion (segment 7 posteriorly) 26 24 23 
Liver lesion (segment 2/3) 20 20 21 
Lesser curvature of stomach lymph node  58 59 57 
Liver lesion  (adjacent to right hepatic vein) 16 16 14 
161 
Left supraclavicular lymph node 12 
129 N/A   N/A N/A  N/A  N/A N/A PD 
Left internal mammary lymph node 12 
Liver lesion (dome) 29 
Liver lesion (segment 8) 20 
Liver lesion (segment 2) 13 
Liver lesion (segment5/8) 20 
Liver lesion (segment 6) 23 
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Appendix 3.4 All adverse events observed with CTCAE Grade and Relatedness to study drug 
 
System Organ Class Adverse Events 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Blood and lymphatic system 
disorders 
Anaemia 4 0 2 0 0 2 0 0 0 0 8 
Leukopenia 3 0 1 0 0 0 0 0 0 0 4 
Lymphopenia 3 0 2 0 1 0 0 0 0 0 6 
Neutropenia 1 0 2 0 0 0 0 0 0 0 3 
Neutrophilia 0 0 0 1 0 0 0 0 0 0 1 
Thrombocytopenia 11 0 1 0 2 0 1 0 0 0 15 
Ear and labyrinth disorders Vertigo 0 1 0 0 0 0 0 0 0 0 1 
Gastrointestinal disorders 
Abdominal bloating 1 0 0 0 0 0 0 0 0 0 1 
Abdominal crampy pains 0 1 0 0 0 0 0 0 0 0 1 
Abdominal discomfort 0 1 0 0 0 0 0 0 0 0 1 
Abdominal noises 0 1 0 0 0 0 0 0 0 0 1 
Constipation 0 2 0 0 0 0 0 0 0 0 2 
Diarrhea 0 1 0 0 0 0 0 0 0 0 1 
Epigastric discomfort 1 1 0 0 0 0 0 0 0 0 2 
Epigastric pain 0 1 0 0 0 0 0 0 0 0 1 
Gastroesophageal reflux 1 0 2 0 0 0 0 0 0 0 3 
Gastrointestinal hemorrhage 0 0 0 1 0 0 0 0 0 0 1 
Nausea 8 0 2 0 0 0 0 0 0 0 10 
Right upper quadrant pain 0 1 0 1 0 0 0 0 0 0 2 
Tenderness epigastric 0 1 0 0 0 0 0 0 0 0 1 
Vomiting 6 1 1 0 0 0 0 0 0 0 8 
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System Organ Class Adverse Event 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
General disorders and 
administration site 
conditions 
Ankle oedema 0 3 0 0 0 0 0 0 0 0 3 
Flu-like symptoms 1 1 0 0 0 0 0 0 0 0 2 
Flushing 1 0 0 0 0 0 0 0 0 0 1 
Oedematous feet 0 1 0 0 0 0 0 0 0 0 1 
Pitting oedema 0 2 0 0 0 0 0 0 0 0 2 
Fatigue 0 0 2 0 0 0 0 0 0 0 2 
Lethargy 6 0 2 0 0 0 0 0 0 0 8 
Hepatobiliary disorders Hyperbilirubinaemia 4 0 2 0 0 1 0 0 0 0 7 
Infections and infestations 
Biliary sepsis 0 0 0 0 0 1 0 0 0 0 1 
Cold symptoms 0 1 0 0 0 0 0 0 0 0 1 
Head cold 0 1 0 0 0 0 0 0 0 0 1 
Injury, poisoning and 
procedural complications 
Fall 0 1 0 0 0 0 0 0 0 0 1 
Investigations 
ALP increased 1 2 1 0 2 0 0 0 0 0 6 
ALT increased 2 0 3 0 0 0 0 0 0 0 5 
Amylase increased 1 0 0 0 0 0 0 0 0 0 1 
AST increased 2 0 0 0 1 0 0 0 0 0 3 
Chloride low 0 1 0 0 0 0 0 0 0 0 1 
GGT increased 0 0 1 0 2 0 0 0 0 0 3 
LDH increased 0 0 0 0 0 0 0 1 0 0 1 
Lipase increased 1 1 1 0 0 0 0 0 0 0 3 
Proteins serum plasma low 0 4 0 0 0 0 0 0 0 0 4 
Weight loss 0 0 2 0 0 0 0 0 0 0 2 
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Appendix 3.4 Continued  ? ?ůůĂĚǀĞƌƐĞĞǀĞŶƚƐŽďƐĞƌǀĞĚǁŝƚŚd'ƌĂĚĞĂŶĚZĞůĂƚĞĚŶĞƐƐƚŽƐƚƵĚǇĚƌƵŐ 
 
 
System Organ Class Adverse Event 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Metabolism and nutrition 
disorders 
Anorexia 7 1 1 0 0 0 0 0 0 0 9 
Hyperkalaemia 0 1 0 0 0 0 0 0 0 0 1 
Hypoalbuminaemia 0 1 0 0 0 0 0 0 0 0 1 
Hyponatraemia 0 0 0 0 0 1 0 0 0 0 1 
Musculoskeletal and 
connective tissue disorders 
Back pain 0 0 0 1 0 0 0 0 0 0 1 
Groin pain 0 0 0 1 0 0 0 0 0 0 1 
Pain in hip 0 0 0 1 0 0 0 0 0 0 1 
Weakness in extremity 0 1 0 0 0 0 0 0 0 0 1 
Nervous system disorders 
Dizziness 0 1 0 1 0 0 0 0 0 0 2 
Headache 0 2 0 0 0 0 0 0 0 0 2 
Paresthesia of fingers 0 1 0 0 0 0 0 0 0 0 1 
Vasovagal symptoms 0 0 0 1 0 0 0 0 0 0 1 
Psychiatric disorders 
Confusion 0 1 0 0 0 0 0 0 0 0 1 
Hallucinations 0 1 0 0 0 0 0 0 0 0 1 
Insomnia 0 1 0 0 0 0 0 0 0 0 1 
Renal and urinary disorders Dysuria 0 1 0 0 0 0 0 0 0 0 1 
Respiratory, thoracic and 
mediastinal disorders 
Cough 0 2 0 0 0 0 0 0 0 0 2 
Crackles lung 0 3 0 0 0 0 0 0 0 0 3 
Dyspnoea 0 2 0 0 0 2 0 0 0 0 4 
Epistaxis 1 0 0 0 0 0 0 0 0 0 1 
Lung consolidation 0 0 0 0 0 1 0 0 0 0 1 
Malignant pleural effusion 0 0 0 0 0 1 0 0 0 0 1 
Pleural effusion 0 0 0 0 0 1 0 0 0 0 1 
Runny nose 0 1 0 0 0 0 0 0 0 0 1 
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ƉƉĞŶĚŝǆ ? ? ?ŽŶƚŝŶƵĞĚ ? ?ůůĂĚǀĞƌƐĞĞǀĞŶƚƐŽďƐĞƌǀĞĚǁŝƚŚd'ƌĂĚĞĂŶĚZĞůĂƚĞĚŶĞƐƐƚŽƐƚƵĚǇĚƌƵŐ 
 
 
System Organ Class Adverse Event 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Skin and subcutaneous tissue 
disorders 
Bruising 1 1 0 0 0 0 0 0 0 0 2 
Discolouration skin 0 1 0 0 0 0 0 0 0 0 1 
Rash erythematous 1 0 0 0 0 0 0 0 0 0 1 
Sebaceous cyst 0 1 0 0 0 0 0 0 0 0 1 
Skin Ulceration 0 0 0 1 0 0 0 0 0 0 1 
Vascular disorders Hypotension 0 1 0 0 0 0 0 0 0 0 1 
Total 68 54 28 9 8 10 1 1 0 0 179 
 
 CHAPTER 4: Targeted chemoradiation 
 
 
Phase I trial of oral capecitabine combined with 
131
I-
huA33 in patients with metastatic colorectal cancer 
 
 
4.1 METHODS 
4.1.1 Clinical trial rationale 
Whilst radioimmunotherapy can lead to significant response rates and 
prolonged responses and disease stabilisation in haematological malignancies, 
it has yet to make a significant impact on the treatment of patients with solid 
tumours.  Colorectal cancer is known to be radiosensitive, but the 
administration of external beam radiotherapy to metastatic disease is 
problematic.  Radioimmunotherapy using 131I-huA33 remains an exciting 
potential treatment modality for patients with colorectal cancer for a number 
of reasons. The A33 antigen is a highly specific to colon cancer and normal 
coloncytes, and the humanised antibody huA33 is able to successfully target 
metastatic disease.  It has been shown that 131I-huA33 is deliverable as a 
single infusion to patients with metastatic colorectal cancer and it is well 
tolerated at doses of up to 40 mCi/m2 327.  The synergistic anti-tumour effects 
of concurrent radiotherapy and chemotherapy is well established, and this 
synergism has been documented in xenografts when radioimmunotherapy 
using 131I-A33 is combined with 5-fluorouracil (5FU)332.  Combining 131I-huA33 
with concurrent oral capecitabine has significant promise as a method of 
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optimising radioimmunotherapy for colorectal cancer, and this strategy is 
explored in the subsequent sections of this chapter.   
 
4.1.2 Study objectives 
The primary objective of this Phase I trial was to determine the safety and 
tolerability of capecitabine administered in combination with 131I-huA33 in 
patients with metastatic colorectal cancer.  Secondary objectives included the 
determination of pharmacokinetics, biodistribution and immunogenicity of 
131I-huA33 when given in combination with capecitabine in patients with 
metastatic colorectal carcinoma, and to document tumour responses in 
patients receiving this combination.  
 
4.1.3 Trial design 
Following pre-treatment assessments, eligible patients received an outpatient 
scout tracer dose of 131I-huA33.  Pre- and post-scout infusion 
pharmacokinetics and HAHA analysis, and post infusion gamma camera scans 
and Single-photon emission computed tomography (SPECT) imaging was 
performed.  If normal biodistribution and uptake in tumour on 131I-huA33 
tracer dose imaging was confirmed, then 7  2 days later it was followed by 
inpatient administration of a single therapy infusion of 131I-huA33. 
Commencing on the same day with this 131I-huA33 therapy infusion was oral 
capecitabine given in 2 divided doses per day from day 1 to 14 of each 21 day 
period for a total of 4 cycles. 
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Weekly assessments of clinical adverse events, haematology, serum 
biochemistry, and HAHA were performed.  Whole body gamma camera 
imaging was performed 1, 2 or 3, and 4 weeks following 131I-huA33 therapy 
infusion.  Tumour restaging was performed 12 weeks following 131I-huA33 
therapy infusion.  The trial schema is shown below in Figure 4.1.3. 
 
 
 
 
Figure 4.1.3 Trial schema 
 
 
 
 
A: Pre-treatment evaluation (history, physical examination, histopathology review, baseline 
blood tests) 
B:  Tumour evaluation 
C:  Scout infusion of 
131
I-huA33 (Studies of pharmacokinetics and biodistribution) 
D:  Therapy infusion of 
131
I-huA33 (Studies of pharmacokinetics and biodistribution) 
E:  Administration of capecitabine (in daily divided doses for 14 days) 
F:  Weekly evaluation of toxicity 
G:  Evaluation of HAHA 
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4.1.4 Patient eligibility/patient selection 
Patients were eligible for enrollment if they fulfilled all of the following 
criteria: 
 Metastatic colorectal cancer 
 Histologically or cytologically proven colorectal cancer 
 Measurable disease on CT scan with at least one lesion  2 cm diameter 
(in order to allow adequate scout infusion imaging) 
 Expected survival of at least 4 months 
 ECOG performance status 0-2 
 Within the last 2 weeks prior to 131I-huA33 scout infusion at week 0, the 
following vital laboratory parameters should be within normal range: 
Neutrophil count  1.5 x 109/L, platelet count  150 x 109/L, serum 
bilirubin < 34 mol/L, and a calculated creatinine clearance should be >50 
ml/ min (Cockcroft and Gault formula) 
 ŐĞA? ? ?ǇĞĂƌƐ 
 Able and willing to give valid written informed consent 
 
Patients were excluded from the study for any of the following reasons: 
 Previous treatment with capecitabine 
 Untreated active metastatic disease to the central nervous system, or 
within 3 months of treatment for brain metastases 
 Other serious illnesses, e.g., serious infections requiring antibiotics, 
bleeding disorders. 
 Liver involvement with metastatic disease > 50% liver volume 
 Chemotherapy, radiation therapy, or immunotherapy within 4 weeks 
before study entry (6 weeks for nitrosoureas) 
 Previous external beam irradiation except if: 
- it was for standard adjuvant pelvic radiation for rectal cancer, 
 - it was for localised irradiation for skin cancer, or 
 - the sum total of all previous external beam irradiation port areas is not 
greater    than 25% of the total red marrow 
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 Previous treatment with a monoclonal antibody or antibody fragment 
AND a positive huA33 HAHA titre  W defined as greater than 3 standard 
deviations above the mean patient normal range by Biacore analysis 
 Concomitant treatment with systemic corticosteroids 
 Mental impairment that may compromise the ability to give informed 
consent and comply with the requirements of the study 
 Lack of availability of the patient for clinical and laboratory follow-up 
assessment 
 Participation in any other clinical trial involving another investigational 
agent within 4 weeks prior to enrollment 
 Pregnancy or breastfeeding 
 Women of childbearing potential: Refusal or inability to use effective 
means of contraception 
 
Before entering patients into the trial, written approval of the protocol and 
informed consent form was obtained from the Human Research Ethics 
Committee (HREC) at Austin Health.  All patients were assigned to the same 
treatment schedule, and dose cohorts were filled sequentially.  Enrolled 
patients withdrawn from the study within six weeks of receiving the therapy 
dose of 131I-huA33 for reasons other than toxicity were replaced. 
 
4.1.5 Treatment and evaluation schedule 
All patients received a scout dose of 5 mg huA33 conjugated to 5-8 mCi 131I 
(Appendix 1).  The therapy dose of 131I-huA33 comprised of a constant protein 
dose of 10 mg/m2 huA33 (regardless of dose level), with the 131I dose 
determined by the assigned dose level.  Following the approval of a protocol 
amendment discussed in section 4.1.14, the dose escalation is detailed below 
in Table 4.1.5.1. 
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Table 4.1.5.1 Dose escalation 
 
 Dose Level 
131
I-huA33 dose  
(mCi/m
2
) 
Capecitabine dose 
(mg/m
2
/day) 
1 20 1500 
2 30 1500 
3 30 1000 
4 40 1000 
5 40 1250 
 
 
All doses of 131I-huA33 were administered intravenously in 100 ml of normal 
saline containing 5% human serum albumin over approximately 60 minutes, 
and patients were observed closely during infusions, and for 2 hours after 
infusion completion.  This included regular measurement of vital signs and 
toxicity assessment.   
 
The scout dose of huA33 on Week 0 was trace labelled with 5-8 mCi of 131I.  
Patients only received a therapy infusion of 131I-huA33 one week later, if 
normal biodistribution, and uptake of 131I-huA33 in tumour, was identified by 
gamma camera imaging following the scout infusion.  Normal biodistribution 
was defined as blood pool distribution in all major organs except for bowel, 
where uptake of 131I-huA33 may be seen owing to expression of A33 in normal 
bowel. Abnormal biodistribution was defined as uptake of 131I-huA33 in 
normal organs (apart from bowel) greater than blood pool, or in post therapy 
131I-huA33 images a change in biodistribution compared to an initial scout 
dose characterised by increased uptake of 131I-huA33 in normal organs 
(particularly liver or spleen) and reduced or absent uptake of 131I-huA33 in 
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tumour.  Therapy infusions were administered as an inpatient, and patients 
remained in a single room under radiation safety precautions until the whole 
body dose fell below 600MBq (15mCi) equivalent, when they were 
discharged.  Capecitabine was self-administered orally at doses of 1000 -1500 
mg/m2/day (depending on assigned dose level) in two divided doses (rounded 
to the nearest 150mg) daily for 14 days per each 21 day cycle, commencing on 
the day of the therapy 131I-huA33 infusion.  Potassium Iodide oral drops (SSKI) 
were administered to all patients to reduce 131I toxicity to the thyroid, and 
were commenced immediately prior to scout 131I-huA33 infusion (10 drops, 3 
times daily) and continued for a total of 4 weeks. 
 
Serum was obtained for pharmacokinetic analysis at the following time 
points: 
 During week 0: Immediately pre-scout 131I-huA33 infusion, then 5 minutes, 
60 minutes and 2 hours post infusion.  Then on day 1, day 2 or 3, day 4 or 
5. 
 During week 1: Immediately pre-therapy 131I-huA33 infusion, 5 minutes 
after, and 24 ± 2 hours after completion of infusion. 
 Week 2 - 5: Seven days post therapy 131I-huA33 infusion, then weekly until 
4 weeks post therapy. 
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Gamma camera scan time points for biodistribution assessment were as 
follows:  
 During week 0: 1  W 4 hours post scout 131I-huA33 infusion, then day 1, day 2 
or 3, day 4 or 5. 
 During week 1: Post 131I-huA33 therapy infusion, at week 2, week 3 or 4, 
and week 5.   
 
SPECT imaging was performed post scout 131I-huA33 infusion at day 4 or 5 
(same day as Gamma scan imaging), then post therapy 131I-huA33 infusion at 
week 2. 
 
The evaluation schedule is summarised in Table 4.1.5.2. 
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Table 4.1.5.2  Pre-treatment and treatment evaluation schedule 
 
Study Week 
Procedure 
Pre
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 
Consent x            
Histopathology Review x            
History x               
Examination & Toxicity assessment x x x x x x x x x x x x x x x 
Tumour assessment x              x 
CXR/RFTs/Gated cardiac blood pool scan x               
Faecal occult blood test x        x       
Haematology x  x x x x x x x x x x x x x 
Biochemistry x  x x x x x x x x x x x x x 
Pregnancy test x               
TSH, T3, T4 x              x 
CEA x              x 
HAHA x x x x x x x x x  x  x  x 
PKa  x x x x x x         
SSKIb  x x x x           
Scout 131I-huA33  x              
Therapy 131I-huA33   x             
Capecitabine   x x  x x  x x  x x   
Gamma scanc  x x x x or x x         
SPECTd  x x x            
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4.1.5.1 Dose reductions 
The following dose modification of capecitabine refers to non-haematological 
toxicities: 
 
Table 4.1.5.3 Dose modification schedule for non-haematological toxicity 
 
Toxicity grading 
(NCI-CTCAE v3.0)
 During a course of therapy 
Dose adjustment 
for next cycle 
(% of starting dose) 
Grade 1 Maintain dose level Maintain dose level 
Grade 2 
First appearance Interrupt until resolved to grade 0-1 100% 
Second appearance Interrupt until resolved to grade 0-1 75% 
Third appearance Interrupt until resolved to grade 0-1 50% 
Fourth appearance Discontinue treatment permanently  
Grade 3 
First appearance Interrupt until resolved to grade 0-1 75% 
Second appearance Interrupt until resolved to grade 0-1 50% 
Third appearance Discontinue treatment permanently  
Grade 4 
First appearance 
Discontinue permanently 
or 
Interrupt until resolved to grade 0-1 
ŝĨŝŶƉĂƚŝĞŶƚ ?ƐďĞƐƚŝŶƚĞƌĞƐƚƚŽ
continue 
50% 
 
 
As the incidence of myelosuppression with capecitabine is low, dose 
reductions of capecitabine were not introduced for haematological toxicities 
unless grade  4 neutropenia or thrombocytopenia with a platelet count < 10 
x 109/L occurred, (when capecitabine was withheld until < grade 2).  Patients 
with capecitabine-related CTCAE grade > 3 cardiotoxicity were planned to be 
removed from the study, and replaced if this toxicity occurred within 6 weeks 
of therapy infusion, as this was not considered to be a dose limiting toxicity 
(DLT). 
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4.1.5.2 Dose-escalation criteria 
Cohorts of 3 patients each were to be entered into each dose level, and when 
no DLT was observed in these patients within 6 weeks of the first therapy 
infusion of 131I-huA33, the next group of 3 patients were entered into the next 
highest dose cohort. When one patient in any cohort of 3 patients 
experienced DLT, an additional 3 patients (maximum of 6) were to be entered 
at that dosage level.  If no more than one patient out of 6 in any dose level 
experienced DLT, subsequent patients were entered at the next dose level.  
Maximum tolerated dose (MTD) was defined as the dose cohort below the 
cohort in whom 2 patients experienced DLT. 
 
4.1.6 Safety and tolerability evaluation 
Throughout the 13-week trial, patients were assessed for toxicity on a weekly 
basis.  This included a symptom assessment, clinical examination, vital signs 
assessment, and venepuncture.  All adverse events were documented and 
graded according to CTCAEv3359 360 ?ĂƵƐĂůŝƚǇǁĂƐĚĞƚĞƌŵŝŶĞĚĂƐ “ƌĞůĂƚĞĚƚŽ
ƐƚƵĚǇĚƌƵŐ ?ŝĨƚŚĞĞǀĞŶƚǁĂƐĚĞĞŵĞĚĚĞĨŝŶŝƚĞůǇ ?ƉƌŽďĂďůǇ ?ŽƌƉŽƐƐŝďůǇƌĞůĂƚĞĚ
to the administration of the combination of 131I-huA33 with capecitabine by 
the investigator.  Events deemed not related or unlikely related were 
ĐůĂƐƐŝĨŝĞĚĂƐ “ŶŽƚƌĞůĂƚĞĚ ?ƚŽƚŚĞƐƚƵĚǇĚƌƵŐ ? 
 
4.1.6.1 Dose Limiting Toxicities 
Dose limiting toxicity was defined as any of the following events occurring 
within 6 weeks of the first 131I-huA33 therapy infusion: 
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 Any grade 2 or greater allergic reaction related to huA33 antibody protein 
 ŶǇ ŐƌĂĚĞ A?  ? ŶŽŶ-haematological toxicity related to 131I-huA33 or 
capecitabine 
 ŶǇŐƌĂĚĞA? ?ŶĞƵƚƌŽƉĞŶŝĂA? ?ĚĂǇƐ ŝŶĚƵƌĂƚŝŽŶŽƌĂŶǇƚŚƌŽŵďŽĐǇƚŽƉĞŶŝĂ
with a platelet count < 10 x 109/L 
  
Although Capecitabine cardiotoxicity grade > 3 (including vasospasm, acute 
coronary syndrome and arrhythmia) necessitated stopping study drug in the 
affected patient, this was not considered DLT as these toxicities are 
recognized as idiosyncratic in nature and not known to be related to 
capecitabine dose361. 
 
Maximum tolerated dose was pre-defined as the highest safely tolerated dose 
level where at most 1 of 6 patients experienced a DLT with the next higher 
dose level having at least 2 of 6 patients who experienced a DLT. 
 
4.1.7 Pharmacokinetics 
Pharmacokinetics (PK) of 131I-huA33, based on gamma counting of serum 
samples was one of the primary endpoints of this study.  As described 
previously, blood for pharmacokinetics were performed immediately pre-
scout 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post scout 
131I-huA33 infusion, day 1, day 2 or 3, day 4 or 5 (Week 0 of protocol schema).  
In Week 1 PK samples were taken immediately pre-therapy 131I-huA33 
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infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post therapy 131I-
huA33 infusion, then weekly until 4 weeks post therapy. 
 
Serum obtained from patients was aliquoted and counted in a gamma 
scintillation counter (Packard Instruments, Canberra, Aust.). Duplicate 
standards prepared from the injected material were counted at each time 
point with serum samples to enable calculations to be corrected for the 
isotope physical decay.  The results were expressed as % injected dose per 
litre (%ID/L) and mg/mL based on actual protein dose infused. 
 
Pharmacokinetic calculations were performed on serum 131I-huA33 data using 
a curve-fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain 
View, CA).  A 2 compartment IV bolus model with macro-parameters, no lag 
time and first order elimination (WNL Model 8) was fitted to individual 
labelled infusions for each patient using un-weighted non-linear least squares. 
The analysis was applied to the scout dose only at a nominal dose level of 
5mg.  Patient 101 was not included in the determination of individual PK 
parameters and mean and standard deviation values due to curve fitting 
solution instability.  Patient 118 data gave an unstable curve fit solution as a 
result of the 60-minute measurement and so this data-point was removed for 
the modelling. 
 
The following variables were calculated from the model: T½  and T½  (half 
lives of the initial and terminal phases of disposition); V1, volume of central 
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compartment; Cmax (maximum serum concentration); AUC (area under the 
serum concentration curve extrapolated to infinite time); and CL (total serum 
clearance). 
 
4.1.8 Biodistribution and dosimetry 
Normal biodistribution was confirmed from the imaging performed prior to 
the therapy infusion in all patients.  As described, these gamma camera scan 
time points were at 1  W 4 hours post scout 131I-huA33 infusion, then day 1, day 
2 or 3, and day 4 or 5.  Imaging was also performed following therapy 131I-
huA33 infusion, at week 2, week 3 or 4, and week 5.  Gamma camera imaging 
was performed with anterior and posterior whole body scans using conjugate 
view methodology.  Whole body radioactivity measurements with a hand held 
probe, were also obtained at each visit in week 0, and SPECT imaging of 
relevant areas of disease were performed on at least one occasion.  
 
4.1.8.1 Gamma Camera Imaging and Blood Sampling 
Using a dual-headed gamma camera (Picker, Cleveland, OH, USA) anterior and 
posterior images were obtained simultaneously.  Images were collected using 
a high-energy, high-resolution collimator.  A dual-window technique was used 
to correct for scatter.  A calibrated standard with an activity on the day of 
infusion of approximately 100 Ci 131I was imaged in the same field of view as 
the patient. Using the same camera configuration and detector positions, a 
background scan was collected before patient arrival or after the patient had 
left the room.  SPECT imaging of areas of known tumour was performed on at 
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least one occasion.  Following the 131I-huA33 therapy infusion, gamma camera 
scans were performed on week 2, week 3 or 4 and week 5.  Blood samples for 
pharmacokinetics were collected at 5 minutes, 24+2 hours and 7+2 days after 
completion of the therapy 131I-huA33 infusion, and then weekly until week 5 
of the study.  Following infusions of 131I-huA33, serum samples were counted 
(in duplicate) in a gamma counter (Packard Instruments, Canberra, Australia) 
with appropriate standards of 131I, with subsequent calculation of percent 
injected dose per litre and serum levels in mg/ml. 
 
Patient image datasets were sent from the gamma cameras to an imaging 
database stored on a RAID (Redundant Array of Independent Disks) system, 
via DICOM (Digital imaging and communications in medicine) transfer.  Data 
relating to image acquisition (date and time of acquisition, camera bed speed, 
duration of scan, standard activity) were recorded for each image dataset for 
each patient, and this information was also used in image analysis.  
Biodistribution was assessed by experienced nuclear medicine physicians.  
 
4.1.8.2 Whole body clearance  
Whole body clearance, or biological halftime, T1/2-biol, was calculated from the 
whole body anterior and posterior planar images.  A region of interest (ROI) 
was calculated to encompass the whole body, and for each ROI at each time 
point, the mean counts per pixel per minute was normalised to imaging time 
point Day 1. From this time-activity curve (TAC), an exponential clearance 
expression was fitted to obtain effective halftime, Teff. This was then corrected 
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for the physical half-life, Tp, of 
131I (8.03 days) to account for physical decay to 
obtain the biological half time, Tb , by the equation: 
 
 
 
 
 
 
 
4.1.8.3 Normal organ clearance and dosimetry methodology 
Dosimetric analysis was performed on the series of gamma camera whole-
body planar images acquired in all patients following scout infusion. Whole 
body, lungs, liver, spleen, kidney, and thyroid regions of interest were defined 
for each time point on both anterior and posterior images. Organ radioactivity 
content was estimated from the geometric mean of anterior and posterior 
regions of interest counts. The counts for each organ were corrected for 
background using regions of interest drawn adjacent to each organ where 
whole body thickness was comparable. Correction for attenuation of 
individual organs was estimated using an analytic technique as described by 
Liu et al355. Resultant counts were converted to activity using a camera 
sensitivity factor calculated from a gamma camera standard of known activity, 
which was scanned at the same time.  A TAC was generated from the derived 
activity for each imaging time-point and fitted with an exponential clearance 
expression. 
 
For normal organ dosimetry analysis, the number of disintegrations, or 
cumulated activity, was calculated as the Area Under Curve (AUC) of the 
Teff
Tb Tp
Tb Tp
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exponential clearance expression for each organ362.  A remainder of body 
accumulated activity was calculated by removing each organs contribution 
from the cumulated activity attributable to the whole body.  This was 
calculated from the effective half-life, Teff by the equation, Ã = Teff . 1.443. The 
organ radiation dosimetries were calculated from data obtained from a new 
software package OLINDA (Organ Level Internal Dose Assessment), developed 
at Vanderbilt University363.  This program performs internal dose calculations, 
principally for radiopharmaceuticals, using the RADAR (Radiation Dose 
Assessment Resource) method of dose calculations and RADAR dose factors. 
 
4.1.8.4 Red Marrow Dosimetry 
Calculation of red marrow dose for 131I-huA33 was performed using a patient-
specific marrow dosimetry methodology based on imaging and blood 
clearance data.  Based on photon radiation from body and electron radiation 
from blood, a patient-specific marrow dose was determined by counting 
blood and total body radioactivity and measuring body weight.  Serum 
clearance calculations of 131I-huA33 scout dose were used to calculate serum 
cumulated activity concentration, and marrow cumulated activity 
concentration (A) ( Ci-h/gm).  Whole body cumulated activity concentration 
(B) ( Ci-h/gm) was calculated as previously described.  Due to the low number 
of imaging time points following the therapy infusion, red marrow absorbed 
doses for therapy infusions were performed using the whole body clearance 
determined from scout dose images.  
 
  246 
Red marrow absorbed dose (rad/mCi) was calculated with the formula: 
 
Red Marrow Absorbed Dose (rad/mCi) = (0.313*A  + 0.456*B) / injected dose 
(mCi)   
 
 
4.1.8.5 Tumour dosimetry analysis 
Tumour Volume Measurements 
To calculate tumour volume, dimensions were assessed on screening CT 
images.  The x- and y-dimension were directly measured, with the z-dimension 
being calculated as the geometric mean of x and y: 
 
 z xy  
  
Therefore the volume of the tumour Vtumour can be expressed as: 
 
 Vtumour /6
3 / 2
(xy)  
 
The tumour mass was estimated by multiplying the volume of the tumour by 
its density, that of water, being 1.0 g/cm3.   
 
Scout Infusion tumour dosimetry analysis 
Tumour radioactivity content was estimated from the geometric mean of 
anterior and posterior ROI counts. The counts for each organ were corrected 
for background using ROIs drawn adjacent to each tumour.  Correction for 
attenuation of individual organs was estimated using an analytical technique 
as previously described355.  Resultant counts were converted to activity using 
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a camera sensitivity factor calculated from a gamma camera standard of 
known activity, which was scanned at the same time. 
A TAC was generated from the derived activity for each imaging time-point for 
each tumour.  The TACs were fitted with a single component exponential 
clearance expression. The AUC was analytically determined and expressed as 
the cumulated activity in the tumour 362. 
Tumour mean absorbed dose was calculated as follows:  
 
сÃ . S 
 
 where  = mean absorbed dose to target 
Ã = cumulated activity in target 
S = absorbed dose in target per unit cumulated activity 
 
For 131I, S values were obtained from predefined tables corresponding to the 
calculated tumour mass [OLINDA, Sphere Module]363. 
 
Therapy infusion tumour dosimetry analysis  
Previous clinical studies with 125I radiolabelled A33 monoclonal antibody322 
and 131I-huA33327 reported long tumour retention with visible uptake of  
radiolabelled antibody in tumour even after one half-life of radioisotope (125I 
of 60 days or 131I of 6 days).  Imaging in this study therefore was performed up 
to week 5 of the study (28 days following therapy infusion).  For therapy 
infusions, dose to tumour was calculated by utilising the specific absorbed 
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dose calculated from the scout infusion images.  By using the assumption that 
the uptake of activity was linearly related to the amount of administered 
dose, tumour dose for therapy infusions was extrapolated from the specific 
absorbed dose (mGy/MBq).  
 
4.1.9 Immunogenicity 
Patient serum samples for HAHA assessment were collected prior to each 131I-
huA33 infusion, at weekly intervals during weeks 0-7, then alternate weeks 
until the end-of-study visit (at week 7, 9 and 13 visits).  Antibody responses 
against humanised antibodies (HAHA) induced after treatment of patients 
with huA33 were analysed by surface plasmon resonance technology using a 
BIAcore 2000 instrument as previously described326.  Owing to the duration of 
the study, analysis was performed in 2 groups, using 2 CM5 
carboxymethyldextran-coated gold surface chips. All samples were stored 
frozen at  W20oC until analyzed.  Samples were defined as HAHA positive if the 
response unit (RU) value at serum dilution of 1:100 exceeded a cutoff value of 
the mean inter-patient baseline RU value + 3 × SD of pre-treatment sera at a 
serum dilution of 1:100.  For patients 101-109, this value was 330RU, and for 
patients 110-119, this value was 14RU.  Monoclonal antibody hu3S193 was 
used as the control/reference channel. 
 
4.1.10 Efficacy assessment 
Tumour response was assessed by CT scanning, according to the Response 
Evaluation Criteria in Solid Tumours (RECIST)358.  CT was performed prior to 
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study entry and at end of study assessment.  Serum carcinoembryonic antigen 
(CEA) was also assessed at baseline and at end of study assessment.  Some 
patients also had FDG-PET performed as part of standard care.  In these 
patients, FDG-PET response was also assessed, although this was not part of 
the formal trial assessment.  Metabolic response was calculated using the 
target lesion with the greatest baseline SUV, and was categorised according to 
the EORTC guidelines (as described in Chapter 3, section 3.1.8)356.   
 
4.1.11 Long term follow-up  
Serum thyroid stimulating hormone (TSH) measurements at 6, 12 months 
after completion of study (and then annually) were collected where possible.  
The advanced naturĞŽĨŵĂŶǇƉĂƚŝĞŶƚƐ ?ĚŝƐĞĂƐĞŵĞĂŶƚƚŚŝƐǁĂƐŽĨƚĞŶĚŝĨĨŝĐƵůƚ ?
Chest X-ray, pulmonary function tests, and gated cardiac blood pool scan and 
serum urea and creatinine were also collected at 3, 6 and 12 months where 
possible. 
 
Following a protocol amendment detailed in section 4.1.14, clinical data 
regarding patient status, disease status and details of first progression after 
study completion for those patients who do not progress on trial, were 
collected.  For many of the patients this was done retrospectively, but for 
those who were still having regular follow-up (off trial), information was 
obtained from the subsequent clinic follow-up visits arranged by their own 
treating oncologist or from investigations performed as part of their 
subsequent standard clinical care.  Where possible, verbal consent was 
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obtained (and documented).  This data was used to calculate PFS and OS, 
where PFS was defined as time in months from scout infusion to date first 
subsequent progression was confirmed, and OS was defined as number of 
months from scout infusion to date of death or last follow up (where 
censored).  This data was purely descriptive, as the patient population was 
very heterogeneous in terms of prior oncological treatments and extent of 
disease. 
 
4.1.12 Data quality assurance 
Data was collected in paper case report forms (CRF) completed by the study 
coordinator, and thoroughly inspected and signed by one of the investigators 
for certification of the contents of the form.  All data collected in the CRF was 
checked against the source documents and verified by an independent 
monitor for adherence to the protocol, completeness, accuracy and 
consistency of the data, adherence to ICH Good Clinical Practice guidelines, 
and general data quality assurance.  
 
Data was then transferred to the institute database for electronic data 
ĐĂƉƚƵƌĞ ?ĐŽŵƉůŝĂŶƚǁŝƚŚƚŚĞ& ?ƐƌĞŐƵůĂƚŝŽŶƐĂŶĚƚŚĞůŽĐĂůƌĞŐƵůĂƚŽƌǇĂŐĞŶĐǇ
guidelines) and analysis.  This transfer of data was also verified by 
investigators to ensure accuracy.  
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4.1.13 Statistical considerations 
In this Phase I, open-label, dose escalation study, cohorts of patients were 
entered sequentially in five escalating dosage tiers with the aim of evaluating 
the safety of the dose combinations of capecitabine and 131I-huA33 tested.  
Biodistribution (whole body clearance, and organ clearance), tumour and 
normal organ dosimetry, and pharmacokinetic parameters were examined 
quantitatively and descriptive statistics were used to analyse this data. Where 
possible, comparisons were made to previous 131I-huA33 trials, using 
descriptive summary statistics such as mean, standard deviation and 
independent sample t test for comparison between 2 trials.  The number and 
durability of complete and partial responses was also summarised by simple 
descriptive summary statistics. 
 
4.1.14 Protocol amendments 
Seven protocol amendments were submitted and approved by Austin Health 
Research Ethics Committee over the duration of the trial and are detailed 
below: 
 
Amendment No. 1: 26th April 2003 
This amendment changed the protocol to remove reference to a possible 
repeat cycle of 131I-huA33 in patients with no evidence of disease progression 
at study completion.  The FDA requested it as it was felt that toxicity of a 
single infusion of 131I-huA33 with capecitabine must be established prior to 
consideration of the addition of a second infusion cycle.   
  252 
Amendment No. 2: 29th February 2004 
This amendment clarified the intended eligibility criteria with regard to 
previous external beam irradiation.  This was felt necessary in order to allow 
patients who had received radiation other than as adjuvant treatment for 
rectal cancer to be eligible for the study provided the sum total of all previous 
external beam irradiation port areas does not include greater than 25% of the 
total red marrow (without requiring documented calculation of red marrow 
exposure for those patients who have had prior standard pelvic radiotherapy 
alone and/or radiotherapy to skin lesions).  It also approved the use of the 
updated version of National Cancer Institute Common Terminology Criteria 
for Adverse Events Version 3.0 (CTCAEv3) for grading adverse events and 
toxicity.  
 
Amendment No.3: 6th May 2004 
The main function of the third protocol amendment was to clarify the 
definition of dose limiting toxicity with regard to thrombocytopenia, after 
adopting the updated CTCAE v3.0 for toxicity grading. According to CTCAE 
v2.0, Grade 4 thrombocytopenia was defined as a platelet count < 10 x 109/L.  
As the grading criteria for Grade 4 thrombocytopenia in the updated CTCAE 
v3.0 was altered to the definition of a platelet count < 25 x 109/L, it was 
appropriate to re-ĚĞĨŝŶĞ>dĨŽƌƚŚƌŽŵďŽĐǇƚŽƉĞŶŝĂĂƐ “ĂŶǇƉůĂƚĞůĞƚĐŽƵŶƚŽĨAM
10 x 109 ?> ?ŝŶƌĞƉůĂĐĞŽĨƚŚĞƉƌŝŽƌĚĞĨŝŶŝƚŝŽŶ ? 
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Amendment No. 4: 8th June 2004 
The fourth protocol amendment was required to clarify the definition of DLT 
with regard to capecitabine-related cardiotoxicity.  Capecitabine-related 
cardiotoxicity > grade 3 was removed from the trial protocol as a DLT, as a 
literature review revealed that cardiac toxicity (chest pain associated with 
ECG changes and arrhythmia) is a well-recognised, infrequent idiosyncratic 
side effect of 5-FU, and therefore is not known to be dose related.  Although it 
was agreed that it would be unsuitable for patients who developed this 
toxicity to continue on study, it was felt that this toxicity should not be 
considered as dose-limiting in the analysis of the trial. 
 
Amendment No. 5: 28th October 2005 
The fifth amendment changed the protocol to redefine capecitabine dosing 
after an interim analysis of toxicity in the first 9 patients enrolled into dose 
cohorts 1 and 2. Following 2 DLTs in dose cohort 2 (described in section 
4.2.4.8), it was decided that in order to maximise radiation dosing, future 
capecitabine dosing should be adjusted to aim to allow safe delivery of 
therapeutic radioimmunotherapy.  At the time of the protocol amendment, 
the safety of the 20mCi/m2 131I-huA33 in combination with capecitabine 
1500mg/m2 had been identified, and MTD of 131I-huA33 alone had been 
established at 40mCi/m2 in the previous Phase I trial.  The dose levels of 
capecitabine were therefore modified to allow continued patient accrual at 
higher 131I-huA33 dose levels.  The original protocol (Table 4.1.14.1) and 
approved, revised dose escalation protocol (Table 4.1.14.2) that was approved 
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is detailed below. Changes to the Participant Information Sheet and Informed 
Consent Form as a result of this amendment were made and approved. 
 
Table 4.1.14.1 Original dose escalation protocol 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1.14.2 Revised dose escalation protocol 
 
 
Amendment No. 6: 17th April 2007 
This amendment was to allow formal collection of clinical data from follow-up 
visits of patients who did not progress on trial (after trial completion), so that 
an exploratory analysis of progression free and overall survival can be 
performed.  This was in light of the observation that some patients 
demonstrated an unexpectedly prolonged survival following trial completion.  
Clinical data regarding patient status, disease status and details of first 
progression after study completion for those patients who do not progress on 
trial, was therefore collected from the subsequent clinic follow-up visits 
Dose 
Level 
131
I-huA33 dose  
(mCi/m
2
) 
Capecitabine dose 
(mg/m
2
/day) 
Patients 
treated 
1 20 1500 3 
2 30 1500 6 
3 40 1500 N/A 
4 40 2000 N/A 
5 40 2500 N/A 
Dose 
Level 
131
I-huA33 dose  
(mCi/m
2
) 
Capecitabine dose 
(mg/m
2
/day) 
Patients 
treated 
1 20 1500 3 
2 30 1500 6 
3 30 1000 3 
4 40 1000 3 
5 40 1250 4 
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arranged by their own treating oncologist or from investigations performed as 
part of their subsequent standard clinical care.  
 
Amendment No 7: 25 September 2007 
This final amendment corrected administrative errors in the investigational 
product details section of the protocol. 
 
4.2 RESULTS 
4.2.1 Study patient characteristics 
Nineteen patients with a mean age of 59 years (range 41-69) were eligible and 
enrolled.  Patient characteristics are summarised in Table 4.2.1.1.  Six were 
female, 13 were male, and all had a Karnofsky performance status of 80-100% 
at study entry.  Seven patients had initially been diagnosed with rectal 
primaries, whilst 12 had colonic primary tumours.  All patients had 
progressive metastatic disease at study entry (as described in Table 4.2.1.2), 
most commonly lung, liver or lymph node metastases, but prior oncological 
treatment received varied considerably.   
 
4.2.2 Patient history and disease status at study entry 
Eighteen patients had undergone resection of their primary tumour (although 
for one of these, this was a palliative debulking procedure).  Three patients 
had not received prior systemic treatment for metastatic disease.  Two of 
these (patients 101 and 118) had just received neodjuvant chemoradiation, 
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and one patient had received adjuvant 5-FU.  One additional patient (patient 
107) had just received neoadjuvant chemoradiation (5-FU) following surgery, 
but this was with palliative intent.  The other 15 enrolled patient had all 
received 1-4 chemotherapy regimen for metastatic disease.  In addition to 
those receiving neoadjuvant chemoradiation already described, 1 patient also 
received palliative radiotherapy (patient 112), and one received adjuvant 
chemoradiation (patient 116).  Table 4.2.2.1 summarises the prior oncological 
treatment history of patients. 
 
As the patients all had metastatic disease at study entry, there were a number 
of pre-existing symptoms in some patients (particularly those who had been 
extensively pre-treated), and it was important to distinguish these from new 
symptoms, which arose whilst on trial.  Table 4.2.2.2 summarises past medical 
history.   
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Table 4.2.1.1 Patient Characteristics 
 
Patient 
No. 
Sex 
Age at 
study 
entry 
Race 
Site of 
Primary 
Dose 
Cohort 
Capecitabine dose 
(mg/m
2
/day) 
131
I-huA33 dose 
(mCi/m
2
) 
101 Female 54 Asian Rectum 1 1500 20 
102 Male 59 White Colon 1 1500 20 
103 Male 59 White Colon 1 1500 20 
104 Female 69 White Colon 2 1500 30 
105 Male 60 White Rectum 2 1500 30 
106 Male 66 White Colon 2 1500 30 
107 Female 66 White Rectum 2 1500 30 
108 Male 69 White Colon 2 1500 30 
109 Male 51 Asian Colon 2 1500 30 
110 Male 52 White Colon 3 1000 30 
111 Female 61 White Colon 3 1000 30 
112 Female 41 White Rectum 3 1000 30 
113 Male 58 White Colon 4 1000 40 
114 Male 64 White Colon 4 1000 40 
115 Male 59 White Colon 4 1000 40 
116 Male 66 White Rectum 5 1250 40 
117 Male 66 White Colon 5 1250 40 
118 Male 48 White Rectum 5 1250 40 
119 Female 55 White Rectum 5 1250 40 
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 Table 4.2.1.2 Disease status at study entry 
 
Patient Dose cohort Site of primary Sites of metastatic disease at study entry 
101 1 Rectum  Lung, liver, lymph nodes 
102 1 Colon  Lymph nodes 
103 1 Colon  Lymph nodes 
104 2 Colon  Lung, liver, omentum/peritoneum, ascites 
105 2 Rectum Lung, liver, lymph nodes 
106 2 Colon  Liver, pelvis 
107 2 Rectum Lung, omentum, mesentry 
108 2 Colon  Lung, liver, lymph nodes 
109 2 Colon  Lung, lymph nodes 
110 3 Colon  Liver 
111 3 Colon  Lung, adrenal 
112 3 Rectum Lung, liver, paravertebral mass, psoas mass 
113 4 Colon  Lung, liver 
114 4 Colon  Abdominal wall, suprapubic mass, right iliac fossa mass, bowel 
115 4 Colon  Lung, liver, lymph nodes 
116 5 Rectum Lung, liver, lymph nodes 
117 5 Colon Liver 
118 5 Rectum Lymph nodes 
119 5 Rectum Lung, liver, lymph nodes 
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Table 4.2.2.1 Prior oncological treatment 
 
Pt No. 
Site of 
primary 
Dose 
cohort 
Prior Oncological treatment  
Definitive surgical procedures Prior chemotherapy Prior XRT 
101 Rectum 1 
Primary resection (AP resection) 
Neoadjuvant chemoradiation (5FU) 50.4Gy (Pelvis) 
Metastectomy (hemi-hepatectomy) 
102 Colon 1 
Primary resection (hemicolectomy) 
FOLFOX None  
Metastectomy (hemi-hepatectomy) 
103 Colon 1 Primary resection Adjuvant 5FU+FA  None 
104 Colon 2 Debulking primary resection 
FOLFOX 
 None FOLFIRI 
5FU+Mitomycin C 
105 Rectum 2 None 
Palliative chemoradiation (5FU) 
50.4Gy (Pelvis) FOLFOX 
Irinotecan 
106 Colon 2 Primary resection (hemicolectomy) 
Adjuvant 5FU+FA  
 None 
FOLFOX 
107 Rectum 2 
Laparotomy (omental graft) 
 Palliative chemoradiation (5FU) 50Gy (Pelvis) 
Primary resection (hemicolectomy) 
108 Colon 2 Primary resection (AP resection) 
FOLFOX 
 None Phase I monoclonal antibody trial                
(Lewis Y) 
109 Colon 2 
Primary resection (AP resection)         Metastectomy (hemi-
hepatectomy) 
Palliative 5FU+FA 
 None 
FOLFOX 
FOLFIRI 
5FU+Mitomycin C 
Cetuximab 
110 Colon 3 Primary resection (AP resection) FOLFOX  None 
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Table 4.2.2.1 Continued.......Prior oncological treatment 
 
Pt No. 
Site of 
primary 
Dose 
cohort 
Prior Oncological treatment  
Definitive surgical procedures Prior chemotherapy Prior XRT 
111 Colon 3 
Primary resection (hemicolectomy) 
FOLFOX   
   Irinotecan 
 None 
Laparotomy (attempted liver resection) 
Metastectomy (VATS wedge resection, lung) 
Metastectomy (liver resection) 
112 Rectum 3 
Primary resection (low anterior resection)     
Metastectomy (resection of left ovary and fallopian tube, 
liver metastases, right lung metastasis) 
FOLFOX 
25Gy (Pelvis) FOLFIRI+Cetuximab 
FOLFIRI+Cetuximab+ Bevacizumab 
113 Colon 4 
Primary resection (hemicolectomy) Adjuvant FOLFOX 
 None 
Radiofrequency ablation of liver metastases Irinotecan 
114 Colon 4 
Primary resection (hemicolectomy) with partial 
cystectomy and insertion of ureteric stents 
FOLFOX  None 
115 Colon 4 Primary resection (hemicolectomy) 
FOLFOX 
 None Irinotecan + Hyaluronan                       
(HYCAMP clinical trial) 
116 Rectum 5 Primary resection (AP resection) 
Adjuvant FOLFOX 
50.4Gy (Pelvis) Adjuvant chemoradiation (5FU) 
Irinotecan 
117 Colon 5 Primary resection (hemicolectomy) FOLFIRI + Bevacizumab  None 
118 Rectum 5 Primary resection (low anterior resection) Neoadjuvant chemoradiation (5FU) 50.4Gy (Pelvis) 
119 Rectum 5 
Primary resection (hemicolectomy) FOLFOX 
 None 
Metastectomy (hemi-hepatectomy) FOLFIRI , Cetuximab + Bevacizumab 
 
AP=abdominoperitoneal;5FU= 5-fluorouracil; FA=folinic acid; FOLFOX=infusional 5FU and oxaliplatin; FOLFIRI=infusional 5FU and irinotecan
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Table 4.2.2.2 Past medical history 
 
Pt No. Past Medical History System Past Medical History 
101 
Immune system disorders Penicillin Allergy 
Neoplasms benign, malignant and 
unspecified 
Uterine fibroids 
Renal and urinary disorders Bladder prolapse 
Respiratory, thoracic and mediastinal 
disorders 
Asthma 
Therapeutic and non therapeutic effects 
(excl toxicity) 
Drug effect increased (Warfarin)  
103 
Cardiac disorders Acute myocardial infarction 
Gastrointestinal disorders Hiatus hernia 
Infections and infestations Lung abscess 
Metabolism and nutrition disorders Hypercholesterolaemia 
Neoplasms benign, malignant and 
unspecified  
Breast carcinoma 
Renal and urinary disorders 
Benign neoplasm of bladder 
Kidney atrophic 
Ureteric obstruction 
Surgical and medical procedures Coronary artery surgery 
Vascular disorders Hypertension 
104 
General disorders and administration site 
conditions 
Drug effect increased (Pethidine)  
Drug effect increased (Stemetil)  
Immune system disorders 
Drug allergy (Metoclopramide) 
Drug allergy (Oxaliplatin) 
Metabolism and nutrition disorders Hypercholesterolaemia 
Neoplasms benign, malignant and 
unspecified 
Bladder transitional cell carcinoma 
Reproductive system and breast disorders Endometriosis 
Respiratory, thoracic and mediastinal 
disorders 
Pulmonary embolism 
105 
Cardiac disorders Supraventricular tachycardia 
Musculoskeletal and connective tissue 
disorders 
Chronic back pain 
Rheumatoid arthritis 
106 
Respiratory, thoracic and mediastinal 
disorders 
Asthma 
107 
Metabolism and nutrition disorders 
Hypercholesterolaemia 
Impaired fasting glucose 
Musculoskeletal and connective tissue 
disorders 
Osteoarthritis 
Vascular disorders Hypertension 
108 
Eye disorders Retinal vein occlusion 
Gastrointestinal disorders 
Haemorrhoids 
Hiatus hernia 
Neoplasms benign, malignant and 
unspecified 
Melanoma 
Surgical and medical procedures Varicose vein operation NOS 
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dĂďůĞ ? ? ? ? ? ? ?ŽŶƚŝŶƵĞĚ ?WĂƐƚŵĞĚŝĐĂůŚŝƐƚŽƌǇ 
 
Pt No. Past Medical History System Past Medical History 
109 
Gastrointestinal disorders Duodenal ulcer 
Metabolism and nutrition disorders 
Non-insulin-dependent diabetes 
mellitus 
111 
Psychiatric disorders Depression 
Reproductive system and breast disorders Endometrial cystic hyperplasia 
Respiratory, thoracic and mediastinal 
disorders 
Dry cough 
112 
Skin and subcutaneous tissue disorders Skin rash 
Social circumstances Menopause 
Vascular disorders Hypertension 
113 
Psychiatric disorders Depression 
Reproductive system and breast disorders Erectile dysfunction 
Surgical and medical procedures Appendicectomy 
114 
Respiratory, thoracic and mediastinal 
disorders 
Pulmonary embolism 
Vascular disorders DVT 
116 Metabolism and nutrition disorders Hypercholesterolaemia 
117 
Gastrointestinal disorders Reflux oesophagitis 
Infections and infestations Cellulitis of arm 
Metabolism and nutrition disorders 
Glucose intolerance 
Hypercholesterolaemia 
Surgical and medical procedures 
Haemorrhoidectomy 
Hernia repair 
118 
Eye disorders Glaucoma 
Gastrointestinal disorders Oesophageal reflux 
Immune system disorders Penicillin Allergy 
Musculoskeletal and connective tissue 
disorders 
Juvenile arthritis 
Psychiatric disorders 
Alcohol abuse 
Depression 
Reproductive system and breast disorders Prostatitis 
Skin and subcutaneous tissue disorders Psoriasis 
Surgical and medical procedures Tendon repair 
119 
Immune system disorders Drug allergy (tetracycline) 
Social circumstances Menopausal 
Surgical and medical procedures 
Tonsillectomy 
Uterine dilation and curettage 
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4.2.3 Patient status/outcome 
Of the 19 patients enrolled, 1 withdrew consent to remain on study after 33 
days on trial as he encountered side effects which he deemed to be excessive.  
As he had not completed a full cycle of capecitabine, he was therefore not 
evaluable for response, and so was replaced by patient 119.  Of the remaining 
18 patients, 12 completed the study as planned.  Six patients were withdrawn 
from the study early; 2 because of progressive disease, 3 secondary to 
unacceptable toxicity, and 1 following a new diagnosis of a secondary 
(unrelated) malignancy.  Of those who experienced excessive toxicity; patient 
105 had febrile neutropenia and thrombocytopenia (dose limiting toxicity), 
patient 109 experienced severe diarrhoea (dose limiting toxicity), and patient 
107 experienced cardiac chest pain relating to capecitabine.  Patient status 
and outcome is summarised below in Table 4.2.3. 
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Table 4.2.3 Patient status and outcome 
 
Patient 
No. 
Dose 
Cohort 
Capecitabine dose 
(mg/m
2
/day) 
131
I-huA33 dose 
(mCi/m
2
) 
Days on study Study status at end of study Reason for withdrawal 
101 1 1500 20 82 Study discontinued prematurely Progressive disease 
102 1 1500 20 98 Study completed   
103 1 1500 20 96 Study completed   
104 2 1500 30 88 Study completed   
105 2 1500 30 65 Study discontinued prematurely DLT 
106 2 1500 30 99 Study completed   
107 2 1500 30 50 Study discontinued prematurely Unacceptable toxicity  
108 2 1500 30 95 Study completed   
109 2 1500 30 47 Study discontinued prematurely DLT 
110 3 1000 30 97 Study completed   
111 3 1000 30 100 Study completed   
112 3 1000 30 57 Study discontinued prematurely Progressive disease 
113 4 1000 40 96 Study completed   
114 4 1000 40 79 Study discontinued prematurely Unrelated medical illness  
115 4 1000 40 94 Study completed   
116 5 1250 40 95 Study completed   
117 5 1250 40 94 Study completed   
118 5 1250 40 33 Study discontinued prematurely Patient request 
119 5 1250 40 98 Study completed   
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4.2.4 Adverse Events  
Of the 19 eligible patients enrolled, 7 withdrew from study without 
completing treatment; 2 due to progressive disease, 3 secondary to 
unacceptable toxicity, and 1 following a new diagnosis of an unrelated second 
malignancy (Non-Hodgkin lymphoma).  Of the 3 patients who experienced 
excessive toxicity and were withdrawn; patient 105 had febrile neutropenia 
and thrombocytopenia (dose limiting toxicity), patient 109 experienced severe 
diarrhoea (dose limiting toxicity), and patient 107 experienced cardiac chest 
pain relating to capecitabine.  One patient, 118, withdrew consent to remain 
on study after 33 days on trial as he encountered side effects which, although 
ŶŽƚĐŽŶƐŝĚĞƌĞĚ “ĚŽƐĞůŝŵŝƚŝŶŐ ?ďǇƚŚĞŝŶǀĞƐƚŝŐĂƚŽƌƐ ?ƚŚĞƉĂƚŝĞŶƚĚĞĞŵĞĚƚŽďĞ
excessive.  This patient maintained consent for continued collection of 
survival follow-up.  As he had not completed a full cycle of capecitabine, he 
was not evaluable for response (but was evaluable for other study endpoints), 
and so was replaced by patient 119.  Adverse events are documented for the 
time he was on trial.   
 
The adverse events (AEs) that were deemed related to the combination of 
131I-huA33 and capecitabine are detailed in Tables 4.2.4.1 (Summary of AEs 
according to dose cohort) and Table 4.2.4.2 (All related AEs).  The most 
frequently observed included myelosuppression, gastrointestinal symptoms 
including nausea and diarrhoea, hyperbilirubinaemia, fatigue, and minor skin 
toxicity.  The total number of study related AEs were greatest in dose cohort 
2, following which the dose escalation was adjusted for future cohorts, and 
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tolerated better by patients.  All adverse events experiences with CTC grade 
and relatedness are shown in Appendix 4.2. 
 
 
Table 4.2.4.1 Summary of related adverse events according to dose cohort 
 
Dose 
Cohort 
131
I-huA33 
dose 
Capecitabine Number 
of 
patients 
CTC Grade  Total 
related 
AEs 
mCi/m
2
 mg/m
2
/day 1 2 3 4 5 
1 20 1500 3 13 5 4 1 0 23 
2 30 1500 6 35 14 10 2 0 61 
3 30 1000 3 20 3 3 0 0 26 
4 40 1000 3 8 4 2 0 0 14 
5 40 1250 4 28 9 5 0 0 42 
Total  104 35 24 3 0 166 
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Table 4.2.4.2 Study agent related adverse events: Description and number of events  
Toxicities Experienced     
(Possibly- / Probably- / Definitely Related to either: 131I-huA33 or Capecitabine)        CTC Grade 1 
(Mild) 
CTC Grade 2 
(Moderate) 
CTC Grade 3 
(Severe) 
CTC Grade 4 
(Life threatening) 
CTC Grade 5 
(Fatal) 
Totals 
System Organ Class (MedDRA 9) Adverse event 
Blood and lymphatic system 
disorders 
Anemia 3 0 0 0 0 3 
Febrile neutropenia 0 0 1 0 0 1 
Leukopenia 4 6 5 0 0 15 
Lymphopenia 1 2 3 1 0 7 
Neutropenia 5 4 5 1 0 15 
Thrombocytopenia 2 6 6 1 0 15 
Sub-Total 15 18 20 3 0 56 
Cardiac disorders 
Chest pain - cardiac 2 0 1 0 0 3 
Retrosternal chest pain 1 0 0 0 0 1 
Sub-Total 3 0 1 0 0 4 
Gastrointestinal disorders 
Bloating 1 0 0 0 0 1 
Constipation 1 0 0 0 0 1 
Diarrhea 6 5 2 0 0 13 
Flatulence 1 0 0 0 0 1 
Gastroesophageal reflux 2 0 0 0 0 2 
Indigestion 2 0 0 0 0 2 
Lip dry 2 0 0 0 0 2 
Lip ulcer 1 0 0 0 0 1 
Nausea 16 0 0 0 0 16 
Rectal bleeding 1 0 0 0 0 1 
Stomatitis 1 0 0 0 0 1 
Taste alteration 2 0 0 0 0 2 
Vomiting 3 4 0 0 0 7 
Sub-Total 39 9 2 0 0 52 
Hepatobiliary disorders 
Hyperbilirubinaemia 7 2 1 0 0 10 
Sub-Total 7 2 1 0 0 10 
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dĂďůĞ ? ? ? ? ? ? ?ŽŶƚŝŶƵĞĚ ?^ƚƵĚǇĂŐĞŶƚƌĞůĂƚĞĚĂĚǀĞƌƐĞĞǀĞŶƚƐ PĞƐcription and number of events 
Toxicities Experienced                                        
(Possibly- / Probably- / Definitely Related to either: 131I-huA33 or Capecitabine) CTC Grade 1 
(Mild) 
CTC Grade 2 
(Moderate) 
CTC Grade 3 
(Severe) 
CTC Grade 4 
(Life threatening) 
CTC Grade 5 
(Fatal) 
Totals 
System Organ Class (MedDRA 9) Adverse event 
General disorders and 
administration site conditions 
Fever 0 1 0 0 0 1 
Lethargy 12 1 0 0 0 13 
Sub-Total 12 2 0 0 0 14 
Infections and infestations 
Cold sore mouth 1 0 0 0 0 1 
Oral thrush 0 1 0 0 0 1 
Sub-Total 1 1 0 0 0 2 
Metabolism and nutrition 
disorders 
Anorexia 7 0 0 0 0 7 
Sub-Total 7 0 0 0 0 7 
Musculoskeletal and connective 
tissue disorders 
Hand pain 1 0 0 0 0 1 
Pain foot 1 0 0 0 0 1 
Sub-Total 2 0 0 0 0 2 
Nervous system disorders 
Dizziness 1 0 0 0 0 1 
Headache 2 0 0 0 0 2 
Paresthesia distal 1 0 0 0 0 1 
Smell loss 1 0 0 0 0 1 
Sub-Total 5 0 0 0 0 5 
Renal and urinary disorders 
Dysuria 1 0 0 0 0 1 
Sub-Total 1 0 0 0 0 1 
Respiratory, thoracic and 
mediastinal disorders 
Epistaxis 1 0 0 0 0 1 
Sub-Total 1 0 0 0 0 1 
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dĂďůĞ ? ? ? ? ? ? ?ŽŶƚŝŶƵĞĚ ?^ƚƵĚǇĂŐĞŶƚƌĞůĂƚĞĚĂĚǀĞƌƐĞĞǀĞŶƚƐ PĞƐĐƌŝƉƚŝŽŶĂŶĚŶƵŵďĞƌŽĨĞǀĞŶƚƐ 
Toxicities Experienced                                      
(Possibly- / Probably- / Definitely Related to either: 131I-huA33 or Capecitabine) 
CTC Grade 1 
(Mild) 
CTC Grade 2 
(Moderate) 
CTC Grade 3 
(Severe) 
CTC Grade 4 
(Life threatening) 
CTC Grade 5 
(Fatal) 
Totals 
System Organ Class (MedDRA 9) Adverse event 
Skin and subcutaneous tissue 
disorders 
Desquamation 0 1 0 0 0 1 
Dry skin 2 0 0 0 0 2 
Erythematous skin rash 2 0 0 0 0 2 
Facial rash 1 0 0 0 0 1 
Maculopapular rash 0 1 0 0 0 1 
Palmar-plantar erythema 3 0 0 0 0 3 
Pruritic rash 1 0 0 0 0 1 
Pruritis 0 1 0 0 0 1 
Rash NOS 1 0 0 0 0 1 
Skin tenderness 1 0 0 0 0 1 
Sub-Total 11 3 0 0 0 14 
Overall totals 104 35 24 3 0 166 
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4.2.4.1 Myelosuppression 
Asymptomatic grade 1-3 thrombocytopenia was observed in 13 out of 19 
patients; 2/3 patients in dose cohort 1 (patients 101, 102), 3/6 patients in 
dose cohort 2 (patients 104, 108 and 109), 2/3 patients in dose cohort 3 
(patients 110, 111), 2/3 patients in dose cohort 4 (patients 114, 115), and 4/4 
patients in dose cohort 5 (patients 116, 117, 118, 119).  Asymptomatic grade 4 
thrombocytopenia was observed in patient 105.  In 11/18 evaluable patients 
the platelet count reached its nadir at week 5-6 of the trial, and recovered to 
above 150x109/L without treatment, by the end of the study (patient 118 
withdrew from the study in week 3 and therefore nadir was not assessable).  
Platelet count for all patients throughout the trial is shown below in Figure 
4.2.4.1.  Platelet and neutrophil count with corresponding red marrow dose 
are shown in Table 4.2.6.2.5.  Platelet toxicity did not seem to correlate with 
the radiation-absorbed dose to the bone marrow. 
 
Asymptomatic grade 1-3 neutropenia was seen in 12 of the 19 patients 
treated on study; 2/3 in cohort 1 (patients 101, 102), 3/6 cohort 2 (patients 
104, 108, 109), 2/3 cohort 3 (patients 110, 111), 1/3 cohort 4 (patient 115), 
and 4/4 cohort 5 (patients 116, 117, 118, 119).  Grade 4 neutropenia observed 
in patient 105, who also developed febrile neutropenia which will be 
described further in the dose limiting toxicity section.  Neutrophil count for all 
patients throughout the trial is shown in Figure 4.2.4.2.  Although Grade 1-2 
anaemia was common, it was only thought to be study drug related in two 
patients (cohort 3 patients 110, 112).  Six patients developed asymptomatic 
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lymphopenia (grade 2-4); 3/3 in cohort 1 (patients 101, 102, 103), 2/6 in 
cohort 2 (patients 105, 109), and 1/4 in cohort 5 (patient 119). 
 
Figure 4.2.4.1 Platelet count for all patients 
 
Figure 4.2.4.2 Neutrophil count for all patients 
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4.2.4.2 Gastrointestinal toxicity 
Mild gastrointestinal symptoms were common, particularly nausea, vomiting 
and diarrhoea.  Fourteen patients reported grade 1 nausea; 2/3 in cohort 1 
(patients 102, 103), 5/6 in cohort 2 (patients 105, 106, 107,108, 109), 3/3 in 
cohort 3 (patients 110, 111, 112), and 4/4 in cohort 5 (patients 116, 117, 118, 
119).  Four patients had episodes of grade 1-2 vomiting; 2/6 in cohort 2 
(patients 104, 105), and 2/4 in cohort 5 (patients 116, 118).   
 
Three patients reported diarrhoea with their worst grade reported as grade 1; 
2/6 in cohort 2 (patients 106, 107), and 1/3 in cohort 4 (patient 114).  Two 
patients developed grade 2 diarrhoea; cohort 2 patient 108 (which resolved 
after a dose adjustment of capecitabine), and patient 118 (dose cohort 5). 
Patient 109 (cohort 2) developed dose-limiting, grade 3 diarrhoea, which 
required hospitalisation and thus was reported as a serious adverse event.   
 
Faecal occult blood tests (FOB) were performed pre-treatment and at 7 
weeks.  Two types of FOB test were used: a chemical test (based on a 
chemical reaction to haem); and an immunological test (using antibodies that 
recognise haemoglobin). No disparities in the results of the two 
methodologies were observed.  No patient in whom FOBs were negative prior 
to study treatment returned a positive result at 7 weeks.  Results are shown in 
Appendix 4.4. 
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Other mild  (grade 1) and self-limiting gastrointestinal disorders that were 
documented amongst patients included bloating (patient 112), constipation 
(patient 112), flatulence (patient 114), gastro-oesophageal reflux (patients 
109, 114), indigestion (patient 107), dry/ulcerated lips or stomatitis (patients 
102, 107), rectal bleeding (patient 108), and taste alteration (patients 107, 
117).  
 
4.2.4.3 Hyperbilirubinaemia 
Asymptomatic hyperbilirubinaemia is a well-recognised side effect associated 
with capecitabine administration.  Ten events were documented amongst 
seven patients 101 (grade 1), 105 (grade 1-2), 108 (grade 2), 109 (grade 1), 
111 (grade 1), 117 (grade 1), and 119 (grade 3), but no treatment or dose 
reductions were required, as patients were asymptomatic and remained well.  
Occurrence of hyperbilirubinaemia was possibly related to dose of 
capecitabine as 4/9 patients receiving 1500mg/m2/day (in cohorts 1 and 2), 
2/4 patients receiving 1250mg/m2/day (in dose cohort 5), and 1/6 receiving 
1000mg/m2/day (in cohorts 3 and 4) had raised bilirubin levels during the 
trial.  For a number of patients this is documented as ongoing at the end of 
study, which was as a result of patients continuing capecitabine off trial after 
their 12-week trial enrolment.  Figure 4.2.4.3 presents bilirubin levels 
determined in all patients while on study. 
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Figure 4.2.4.3 Bilirubin levels in all patients 
 
 
 
 
4.2.4.4 Fatigue/constitutional symptoms 
Mild fatigue/lethargy was a common toxicity encountered on the trial.  
Although this is could be attributed to underlying malignancy in some 
patients, it was deemed related to study drug combination in 11 patients; 2 in 
dose cohort 1, 3 in cohort 2, 1 in cohort 3, 1 in cohort 4, and 3 in cohort 5.  
Patients 101, 102, 106, 108, 109, 110, 115, 116, 117 and 119 who all had 1-2 
episodes of grade 1 lethargy, and patient 114 reported an episode of grade 2 
lethargy.  No treatment was required. 
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Seven patients experienced grade 1 anorexia; 1/6 in cohort 2, 2/3 in cohort 3, 
2/3 in cohort 4, and 2/4 in cohort 5.  For 6 of these (patients 110, 111, 114, 
115, 117 and 119), this was self-limiting and resolved, whilst it was ongoing 
for 1 patient (patient 105).  Other mild (grade 1) symptoms which were 
uncommonly reported include: cold sore, oral thrush, headache, dizziness, 
dysuria, and loss of smell. 
 
4.2.4.5 Skin toxicity 
One patient (109) reported grade 1 pain in hands and feet, and grade 2 skin 
desquamation of the palms, which was thought to represent capecitabine 
induced toxicity.  Two other patients (patients 106, dose cohort 2; patient 
119, dose cohort 5) reported episodes of palmar plantar erythema.  Patient 
119 also reported grade 1 skin tenderness in the fingertips and grade 1 distal 
paresthesia of the hands and feet.  In all three patients these symptoms were 
self-limiting and resolved spontaneously.   
 
Patient 101 (dose cohort 1) had an episode of grade 2 maculopapular rash 
associated with grade 2 pruritus.  Episodes of a mild itchy, erythematous skin 
rash were encountered by patient 110, in dose cohort 3.  Patient 114 reported 
a transient grade 1 facial rash, patient 108 described episodes of dry skin, and 
patient 119 reported grade 1 rash which became pruritic.  
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4.2.4.6 Cardiotoxicity 
Patient 107 developed 5-FU cardiotoxicity (grade 3 chest pain associated with 
ST elevation) secondary to capecitabine, which resolved with treatment.  
Patient 117 reported episodes of retrosternal discomfort on exertion, which 
possibly represented pain of cardiac origin.  Although these episodes were 
fleeting, and no ECG abnormalities were ever found, a stress test suggested 
possible coronary artery pathology (performed whilst in week off 
capecitabine), but an angiogram performed later off trial was negative.  This 
patient was started on a calcium channel blocker on the basis of his stress test 
result, and did not report any further episodes of epigastric or retrosternal 
discomfort. This episode of retrosternal chest pain whilst on trial was 
therefore documented as possible cardiac related pain, possibly as a result of 
capecitabine induced coronary artery vasospam, but this was not confirmed.  
 
4.2.4.7 Thyroid toxicity 
Thyroid function was assessed at screening, end of study (at 3 months for 
those who completed the study), and then 9 and 15 months after starting the 
study.  Thyroid function test results for individual patients are presented in 
Table 25. There was no observed elevation in serum TSH in any of the patients 
to suggest hypothyroidism as a result of 131I-huA33 administration.  A few 
patients experienced a transient fall in serum TSH level, most likely 
attributable to general poor health, and not related to study drugs.  TSH levels 
are shown in Appendix 4.3. 
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4.2.4.8 Dose limiting toxicity 
Two dose limiting toxicities were documented, both of which were in patients 
in dose cohort 2.  The first was patient 105, who was a fit 60 year old man 
whose metastatic CRC had been heavily pre-treated with infusional 5-FU and 
radiotherapy, FOLFOX, and FOLFIRI.  He had progressed quickly whilst on both 
combination chemotherapy regimens.  He had a known history of rheumatoid 
arthritis for which he had been on a number of immunosuppressive agents 
including sulphasalazine and methotrexate, and had pre-existing 
lymphopenia.  Despite a good baseline performance status and initially 
tolerating his therapy infusion of 131I-huA33 well (with asymptomatic grade 3 
thrombocytopenia), he was admitted with Grade 3 febrile neutropenia in 
association with grade 4 thrombocytopenia in week 7 of the trial.  His 
recovery from this adverse event was uneventful, but restaging confirmed the 
clinical suspicion of progressive disease, and he was withdrawn (week 9).  The 
febrile neutropenia was considered a DLT and according to protocol the dose 
cohort was expanded from 3 to 6 patients. 
 
The second DLT occurred in patient 109, who had also received extensive 
prior treatment for metastatic colon carcinoma over the 2 ½ years between 
diagnosis and enrolment onto the study.  This included FOLFOX (5 cycles prior 
to liver metastectomy and 6 cycles following it), FOLFIRI, Mitomycin C with    
5-FU, and then cetuximab as part of a clinical trial.  He was the sixth patient to 
be enrolled onto dose cohort 2, but developed grade 3 diarrhoea and was 
removed from study because of this, in week 6 of the protocol.  This diarrhoea 
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was thought to be probably related to the combination of capecitabine and 
131I-huA33, hence is defined in the protocol as DLT. 
 
Due to the DLT experienced by these 2/6 patients treated in dose cohort 2 
(30mCi/m2 131I-huA33 combined with 1500mg/m2/day capecitabine), the 
protocol amendment detailed in section 4.1.14 was approved to redefine the 
capecitabine dosing for the subsequent dose cohorts. 
 
4.2.4.9 Maximum Tolerated Dose (MTD) 
Due to the observations of 2/6 DLTs experienced by patients in dose cohort 2, 
MTD of the combination was determined to be 20mCi/m2 131I-huA33 
combined with 1500mg/m2/day capecitabine. Following a protocol 
amendment, it was established that with a reduced dose of capecitabine, 
40mCi/m2 131I-huA33 could be safely combined with 1250mg/m2/day 
capecitabine. The previous dose escalation study of 131I-huA33 had 
determined MTD for 131I-huA33 alone to be 40 mCi/m2327. The current study 
was not expanded to include 131I-huA33 doses above 40mCi/m2. 
 
4.2.4.10 Serious adverse events (SAE) 
Five SAEs were documented throughout the trial; 
 Patient 105 experienced two SAE. In week 4 of study, patient 105 was 
hospitalised for management of a grade 3 exacerbation of pre-existing, 
right upper abdominal pain (related to existing liver metastases), which 
was deemed unrelated to the study treatment. In week 7, patient 105 was 
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admitted with Grade 3 febrile neutropenia in association with grade 4 
thrombocytopenia.  Following treatment with intravenous antibiotics the 
patient made a full recovery.  As described previously, this event was 
ĐŽŶƐŝĚĞƌĞĚĂ>dĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐƐƚƵĚǇƚƌĞĂƚŵĞŶƚǁĂƐĚŝƐĐŽŶƚŝŶƵĞĚ ? 
 
 WĂƚŝĞŶƚ  ? ? ? ŚĂĚ ĂŶ ^ ƌĞƉŽƌƚĞĚ ǁŚĞŶ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ƉƌŽƚŽĐŽů ƌĞůĂƚĞĚ
hospital stay was prolonged due to the development of grade 3 chest pain 
associated with ST elevation secondary to capecitabine (idiosyncratic 5FU 
cardiotoxicity) which resolved with treatment. Study treatment was 
discontinued in patient 107. 
 
 Patient 109 had two admissions with grade 3 diarrhoea, one of which was 
whilst on trial (DLT as described), and a further admission after coming off 
study, following recommencement of capecitabine chemotherapy at 75% 
of the previous dose. The second admission was prompted by further 
grade 3 diarrhoea with fever and chills on a background of grade 1 
neutropenia.  Stool cultures on this admission grew campylobacter jejunii.  
He was treated with intravenous antibiotics and fluids and discharged 
home after 5 days having made a full recovery.  Although off-study at the 
time, this episode was reported as a serious adverse event because it was 
considered a medically important event possibly related to the 
combination of capecitabine and 131I-huA33. 
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 Patient 114, a 64-year old male, was withdrawn from study due to the 
development of a concurrent secondary malignancy confirmed as Non-
Hodgkin Lymphoma.  This diagnosis followed the recent onset of 
intermittent problems with clearing his throat, losing his voice and a cough. 
A 5cm mass close to his right sternocleidomastoid muscle developed, and a 
biopsy confirmed Non-Hodgkin Lymphoma. This event was reported as an 
SAE as it was considered to be a medically important condition. It was 
considered to be unrelated to both capecitabine and 131I-huA33, and he 
was subsequently referred to the lymphoma team for further treatment. 
 
4.1.4.11 Immunogenicity 
As described in section 4.1.9, two Biosensor chips were used for HAHA 
analyses owing to the duration of the trial and the break in patient accrual 
(after the first 9 patients), which was required for a protocol amendment.  
Pre-study serum samples were run concurrently with test samples for each 
patient, but the baseline responses for the first cohort of patients, using chip 
#72, was much higher than baseline responses for the second cohort of 
patients, using chip #107.  The reason for the higher noise on the first chip 
remains unclear. 
 
HAHA positivity for samples was defined by the mean inter-patient baseline 
response + 3 × SD of pretreatment sera. This value was 330RU for the first 
cohort of patients and 14RU for the second cohort.  The difference in these 
cut-off values reflects the higher baseline for chip #72, as described. 
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No patients in the first cohort (patients 101-109) exhibited a positive HAHA 
response.  Of the second cohort, 6 patients (111, 113, 115, 117, 118 and 119) 
showed a weak intermittent positive response.  These responses were 
generally only at one or two non-consecutive time points and were only 
marginally above the threshold.  These responses were therefore not 
considered significant immune responses.  One patient, 112, showed a 
sustained, significant positive response that was considered to be a true 
immune response.  The magnitude of this response, however, was small 
(maximum 43RU, compared to baseline 10RU). Therefore a weak, 
intermittent HAHA response was observed in 6/19 patients, and a more 
robust, sustained response of low titre was observed in 1/19 patients.   
  
4.1.4.12 Long term toxicity 
Although the advanced nature disease in many patients enrolled made long-
term follow-up difficult, no toxicity in terms of thyroid function test 
abnormality, change in cardiac gated blood pool scans or respiratory function 
tests were identified in patients who were able to have these follow-up tests. 
 
4.2.5 Pharmacokinetic analysis 
Individual patient pharmacokinetic parameters T½  and T½ , V1, AUC, CL and 
Cmax for the single scout infusion of 
131I-huA33 were calculated for 18/19 
patients, excluding patient 101. Patient 101 was not included in the 
determination of individual PK parameters and mean and standard deviation 
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values due to curve fitting solution instability.  Patient 118 data gave an 
unstable curve fit solution as a result of the 60-minute measurement and so 
this data-point was removed for the modelling.  Pharmacokinetic analysis of 
scout infusion data showed consistent results across all dose levels, with: T½a 
(mean ± SD) =15.78 ± 4.68 hrs, T½b =100.24 ± 20.92 hrs; CL = 36.72 ± 8.01 
mL/hr and V1 = 3204.26 ± 605.59 mL.  The individual patient values are 
presented below in Table 4.2.5, with individual curve fits in Appendix 4.5, 
Figures 1-19. 
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Table 4.2.5 Individual patient 
131
I-huA33 pharmacokinetic data (calculated from scout dose) 
 
Patient 
Dose 
(mg/m
2
) 
T ½ alpha 
(hrs) 
Std Err 
T ½ beta 
(hrs) 
Std Err V1 (mL) Std Err 
AUC 
(hr.mg/mL) 
 
Std  Err CL (mL/hr) Std  Err 
Cmax 
(mg/mL) 
Std Err 
101* 2.87 NA NA NA NA NA NA NA NA NA NA NA NA 
102 2.41 18.93 6.56 119.76 41.21 3154.49 37.44 161.27 21.73 29.89 4.04 1.53 0.018 
103 2.78 14.71 3.0 103.48 25.18 2585.35 21.36 153.84 14.98 31.14 3.04 1.85 0.015 
104 2.64 13.84 10.68 77.27 87.48 3046.11 79.22 87.78 30.02 54.23 18.61 1.56 0.041 
105 2.39 15.28 8.25 91.32 28.33 3771.74 62.71 113.71 12.52 41.95 4.64 1.26 0.021 
106 2.38 22.66 10.51 134.17 126.24 3340.77 58.11 136.47 46.05 34.88 11.81 1.42 0.025 
107 2.76 19.58 5.84 123.25 25.88 2512.55 16.07 228.26 18.50 20.59 1.68 1.87 0.012 
108 2.47 17.90 6.06 127.81 51.35 3528.17 48.57 139.36 23.22 33.73 5.64 1.33 0.018 
109 2.61 12.72 1.74 75.27 4.07 2547.83 9.045 54.07 1.03 32.66 0.59 1.84 0.007 
110 2.29 19.36 5.78 117.38 22.45 4977.62 38.23 114.69 8.73 41.94 3.20 0.97 0.007 
111 2.82 14.69 4.44 98.26 21.29 2928.07 32.71 145.77 12.00 32.52 2.69 1.62 0.018 
112 2.75 23.46 14.37 92.90 42.74 2890.17 33.88 150.35 18.25 31.06 3.79 1.62 0.019 
113 2.64 10.66 2.48 71.56 12.04 3031.36 30.77 95.43 5.34 50.51 2.84 1.59 0.016 
114 2.31 8.00 2.50 90.99 13.47 3483.91 47.85 110.75 7.37 43.70 2.92 1.39 0.019 
115 2.61 18.50 4.91 97.06 27.34 3593.28 40.83 111.74 9.91 43.49 3.87 1.35 0.015 
116 2.33 6.97 3.04 71.06 13.89 2351.71 41.26 121.24 10.65 36.46 3.21 1.88 0.033 
117 2.44 12.25 1.93 86.63 4.81 3114.84 15.21 140.61 3.33 34.63 0.82 1.56 0.008 
118 2.27 20.38 14.17 93.82 49.05 3221.12 66.30 134.46 20.93 35.40 5.54 1.48 0.030 
119 2.37 14.12 4.50 132.27 37.42 3597.60 52.89 147.87 19.02 32.12 4.14 1.32 0.019 
Mean   SD 15.78 4.68 100.24 20.92 3204.26 605.59 130.43 36.35 36.72 8.01 1.53 0.242 
* Subject 101 data could not be accurately fitted to curve analysis, and therefore data was not included in the determination of mean results
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4.2.6 Biodistribution analysis 
The pattern of 131I-huA33 biodistribution following scout infusion was 
consistent with initial blood pool activity, with some normal colon uptake, and 
specific uptake by known sites of metastatic disease.  Tumour uptake of 131I-
huA33 was present for up to 5 weeks post therapy infusion, with clearance 
from normal colon observed over this time period.  Some thyroid uptake and 
bladder appearance due to catabolised 131I- was apparent, which is a normal 
finding following 131I- radioimmunotherapy.  Individual patient biodistribution 
imaging following scout and therapy infusions is presented in Appendix VI.  
Figure 4.2.6 shows screening FDG-PET and CT scan alongside biodistribution 
imaging for patient 108. 
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Figure 4.2.6  Baseline disease and biodistribution imaging for patient 108 
 
D0 D1 D3 D5 D14 
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4.2.6.1 Whole body clearance analysis 
Whole body clearance (T1/2 biologic) was calculated for all 19 patients 
following  131I-huA33 scout dose, and ranged from 105.42 - 357.41 hours, with 
a mean value of 219.56  62.81 hours.  Clearance for individual patients is 
shown below in Table 4.2.6.1  
 
Table 4.2.6.1. Whole body clearance for each patient  
(calculated from scout dose) 
 
Patient ID 
Injected scout dose 
(mCi) 
Biologic T1/2  
(hours) 
101 7.94 242.45 
102 8.02 357.41 
103 7.95 254.00 
104 7.83 152.31 
105 7.89 285.98 
106 7.77 260.14 
107 7.82 300.08 
108 7.82 296.36 
109 7.78 190.34 
110 8.61 235.88 
110 8.14 171.84 
112 7.96 163.77 
113 8.08 105.42 
114 8.07 176.60 
115 8.59 200.56 
116 7.58 152.45 
117 8.14 188.59 
118 7.74 210.77 
119 7.97 226.69 
Mean  SD 219.56  62.81 
 
Normal organ clearance was calculated for liver and kidney.  T1/2 biological for 
liver was 62.29  22.05 hours, and kidney was 104.89  56.22 hours. 
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4.2.6.2 Normal organ dosimetry 
The mean (  SD) calculated specific normal organ absorbed dose 
(extrapolated from scout dose imaging) for liver, spleen, kidney and lung 
according to dose cohort is shown in Table 4.2.6.2.1.  Individual patient 
administered scout and therapy absolute doses with corresponding normal 
organ absorbed doses and EDE are shown in Table 4.2.6.2.2.  Specific 
absorbed dose for normal organs is shown in Table 4.2.6.2.3. The mean 
specific absorbed dose for liver, spleen, kidney and lung were 0.12  0.03; 
0.18  0.06; 0.14  0.05; 0.09  0.03 cGy/MBq respectively.  Red marrow 
specific absorbed dose ranged from 0.041 - 0.078 cGy/MBq (1.52  W 3.06 
cGy/mCi).  
 
Table 4.2.6.2.1 
131
I-huA33 Scout Dose Mean (  SD) specific absorbed organ 
dose (cGy/MBq)  
 
Organ 
Mean (  SD) Specific absorbed organ dose (cGy/MBq) 
 per 
131
I-huA33 Therapy Dose Cohort 
20 mCi/m
2 
30 mCi/m
2 
40 mCi/m
2 
All patients 
Liver 0.10  0.01 0.13  0.03  0.12  0.02 0.12  0.03 
Spleen 0.16  0.05 0.10  0.04 0.20  0.04 0.18  0.06 
Kidney 0.17  0.05 0.12  0.01  0.13 0.05 0.14  0.05 
Lung 0.10  0.04 0.10  0.02 0.08  0.01 0.09  0.03 
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Table 4.2.6.2.2 Administered scout and therapy absolute doses with normal 
organ absorbed dose 
 
Patient 
131
I-huA33 
Therapy 
Dose 
(mCi/m
2
) 
Administered dose Absorbed dose EDE* 
Scout Therapy Total Liver Spleen Kidney Lung Total body 
MBq Gy Sv mSv/MBq 
101 20 293.6 1266.8 1539.6 1.70 1.97 3.12 2.15 1.22 0.78 
102 20 296.6 1451.3 1724.2 1.75 2.22 3.53 1.70 1.23 0.71 
103 20 294.0 1275.0 1548.1 1.36 3.44 1.85 1.07 0.99 0.63 
Mean 294.7 1331.0 1604.0 1.60 2.54 2.83 1.64 1.14 0.70 
SD 1.6 104.2 104.2 0.21 0.79 0.88 0.54 0.14 0.08 
104 30 289.9 2031.0 2320.6 4.02 4.99 1.21 1.67 1.45 0.63 
105 30 291.8 2159.3 2450.9 4.36 5.25 3.90 2.41 1.82 0.74 
106 30 287.6 2086.9 2345.1 2.11 3.49 1.71 2.87 1.47 0.62 
107 30 289.5 1853.3 2113.4 3.56 5.66 3.90 3.71 2.07 0.96 
108 30 289.5 2064.6 2382.1 2.59 4.54 3.72 2.00 1.61 0.69 
109 30 288.0 1994.3 2308.8 2.23 2.26 4.09 1.67 1.29 0.56 
110 30 318.8 2451.0 2769.8 3.16 1.96 3.80 2.46 1.60 0.58 
111 30 301.1 1990.9 2292.2 2.45 3.44 2.54 2.77 1.52 0.66 
112 30 294.4 1899.4 2166.4 3.40 1.97 2.59 2.08 1.36 0.62 
113 30 298.9 2744.3 3080.3 3.71 6.91 3.59 2.50 1.66 0.55 
114 30 298.5 3073.5 3328.9 3.54 4.96 3.57 2.42 1.83 0.54 
115 30 318.0 2830.5 3188.3 3.68 8.25 2.88 2.57 2.00 0.64 
Mean 297.1 2264.9 2562.2 3.23 4.47 3.13 2.43 1.64 0.65 
SD 10.9 407.6 419.6 0.73 1.96 0.94 0.56 0.25 0.12 
116 40 280.5 2778.4 3018.5 3.95 6.73 5.78 2.46 1.94 0.63 
117 40 301.1 2989.5 3250.1 3.62 4.64 5.33 2.18 1.90 0.58 
118 40 286.5 3359.3 3597.1 5.51 7.44 7.51 2.80 1.78 0.49 
119 40 294.9 2893.1 3150.6 4.46 7.14 2.18 3.10 2.30 0.72 
Mean 40 3005.1 3254.1 4.39 6.49 5.20 2.64 1.98 0.60 
SD 40 251.4 247.6 0.83 1.27 2.22 0.40 0.22 0.10 
Overall Mean 40 2273.3 2556.6 3.22 4.59 3.52 2.35 1.63 0.65 
SD 9.7 616.7 615.2 1.09 2.05 1.50 0.60 0.34 0.11 
 
EDE= Effective dose equivalent 
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Table 4.2.6.2.3 Specific absorbed dose for normal organs  
(As calculated from scout dose imaging) 
 
Patient 
ID 
131
I-huA33 
Therapy 
Dose 
(mCi/m
2
) 
Specific Absorbed Dose 
Liver Spleen Kidney Lung 
cGy/MBq cGy/mCi cGy/MBq cGy/mCi cGy/MBq cGy/mCi cGy/MBq cGy/mCi 
101 20 0.11 4.04 0.13 4.67 0.20 7.41 0.14 5.11 
102 20 0.10 3.70 0.13 4.70 0.20 7.48 0.10 3.60 
103 20 0.09 3.20 0.22 8.11 0.12 4.37 0.07 2.53 
104 30 0.17 6.41 0.22 7.96 0.05 1.94 0.07 2.66 
105 30 0.18 6.59 0.21 7.93 0.16 5.89 0.10 3.64 
106 30 0.09 3.30 0.15 5.44 0.07 2.67 0.12 4.48 
107 30 0.17 6.15 0.26 9.78 0.18 6.74 0.17 6.41 
108 30 0.11 4.07 0.19 7.15 0.16 5.85 0.09 3.15 
109 30 0.10 3.62 0.10 3.67 0.18 6.63 0.07 2.70 
110 30 0.11 4.22 0.07 2.63 0.14 5.07 0.09 3.29 
111 30 0.11 3.96 0.15 5.56 0.11 4.11 0.12 4.48 
112 30 0.16 5.74 0.09 3.32 0.12 4.37 0.09 3.51 
113 40 0.12 4.52 0.23 8.41 0.12 4.37 0.08 3.04 
114 40 0.11 3.89 0.15 5.44 0.11 3.93 0.07 2.66 
115 40 0.12 4.33 0.26 9.70 0.09 3.39 0.08 3.02 
116 40 0.13 4.78 0.22 8.15 0.19 7.00 0.08 2.98 
117 40 0.11 4.07 0.14 5.22 0.16 6.00 0.07 2.45 
118 40 0.15 5.59 0.20 7.56 0.21 7.63 0.08 2.84 
119 40 0.14 5.19 0.22 8.30 0.07 2.54 0.10 3.60 
Mean 0.12 4.60 0.18 6.51 0.14 5.13 0.09 3.48 
SD 0.03 1.05 0.06 2.15 0.05 1.79 0.03 1.01 
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The primary target organ for radioimmunotherapy toxicity is typically red 
marrow, which is what can be seen as the primary toxicity in this trial as 
described in section 4.2.4.1.  Red marrow specific absorbed dose ranged from 
0.041 - 0.078 cGy/MBq (1.52  W 3.06 cGy/mCi).  The mean red marrow specific 
absorbed dose extrapolated from the scout dose was found to be 0.056  
0.011 cGy/MBq (2.06  0.41cGy/mCi).  Individual patient data is presented in 
Table 4.2.6.2.4.  Absolute red marrow dose together with nadir neutrophil 
and platelet counts for each patient are shown in Table 4.2.6.2.5.  Neutrophil 
and platelet count did not seem to correlate with number of prior lines of 
chemotherapy for metastatic disease, or red marrow absorbed dose.  
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Table 4.2.6.2.4 Red marrow specific absorbed dose of 
131
I-huA33 
 
 
Patient 
Injected scout dose Red marrow specific absorbed dose 
MBq mCi cGy/MBq cGy/mCi 
101 293.63 7.94 0.078 2.89 
102 296.63 8.02 0.061 2.27 
103 294.00 7.95 0.065 2.39 
104 289.88 7.83 0.043 1.61 
105 291.75 7.89 0.052 1.91 
106 287.63 7.77 0.057 2.09 
107 289.50 7.82 0.083 3.06 
108 289.50 7.82 0.056 2.07 
109 288.00 7.78 0.060 2.22 
110 318.75 8.61 0.045 1.65 
111 301.13 8.14 0.060 2.21 
112 294.38 7.96 0.060 2.22 
113 298.88 8.08 0.041 1.52 
114 298.50 8.07 0.042 1.57 
115 318.00 8.59 0.047 1.75 
116 280.50 7.58 0.051 1.88 
117 301.13 8.14 0.053 1.97 
118 286.50 7.74 0.052 1.92 
119 294.89 7.97 0.053 1.95 
Mean  SD 295.43  9.66 7.98  0.26 0.056  0.011 2.06  0.41 
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Table 4.2.6.2.5 Absolute red marrow dose with corresponding nadir neutrophil and platelet counts 
 
Patient 
ID 
Therapy 
Dose  
Administered Dose 
(scout+therapy) 
Red Marrow Specific 
Absorbed Dose  
Extrapolated Total Red 
Marrow Absorbed Dose 
Number of lines of 
prior chemotherapy  
for metastatic disease 
Nadir Blood Count ( × 109/L) 
mCi/m
2
 mCi MBq cGy/mCi cGy Neutrophils Platelets 
101 20 41.61 1539.57 2.89 120.14 0 1.22 97 
102 20 46.60 1724.20 2.27 105.67 1 0.95 62 
103 20 41.84 1548.08 2.39 100.02 0 2.73 157 
104 30 62.72 2320.64 1.61 100.98 3 1.85 76 
105 30 66.24 2450.88 1.91 126.52 3 0.54* 15* 
106 30 63.38 2345.06 2.09 132.60 1 2.33 113 
107 30 57.12 2113.44 3.06 174.98 0 2.49* 58 
108 30 64.38 2382.06 2.07 133.27 2 0.81 46 
109 30 62.40 2308.80 2.22 138.53 4 1.74* 58* 
110 30 74.86 2769.82 1.65 123.52 1 0.7 49 
111 30 61.95 2292.15 2.21 136.91 2 1.5 74 
112 30 58.55 2166.35 2.22 130.22 3 5.3 375 
113 40 83.25 3080.25 1.52 126.54 1 2.9 139 
114 40 89.97 3328.89 1.57 141.15 1 2.7 35 
115 40 86.17 3188.29 1.75 150.80 2 1.4 38 
116 40 81.58 3018.46 1.88 153.68 1 1.4 44 
117 40 87.84 3250.08 1.97 173.04 1 1.1 48 
118 40 97.22 3597.14 1.92 187.01 0 2.8* 138* 
119 40 85.15 3150.55 1.95 166.04 2 1.7 51 
*Patient withdrawn from study early, therefore the value may not represent true nadir count 
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4.2.6.3 Tumour dosimetry 
Tumour dosimetry was calculated for 10/19 patients entered onto the trial.  
The small size of metastatic lesions prevented accurate tumour quantitation 
and dosimetry analysis in 9 patients (patients 101, 102, 103, 106, 107, 112, 
114, 116, and 118).  Tumour volume ranged from 3.07 - 41.66g.  Mean total 
tumour absorbed dose was 13.83 ± 7.61Gy (range 5.06 - 26.94Gy).  Mean 
specific absorbed dose was similar for all patients, ranging from 1.66 - 9.64 
Gy/GBq (6.15 - 35.70 cGy/mCi), with an overall mean of 5.17 ± 2.83 Gy/GBq 
(19.15 ± 10.49 cGy/mCi).  Tumour dosimetry is detailed below in Table 
4.2.6.3.1. 
 
There was no statistically significant difference in specific tumour absorbed 
dose between the 2 dose cohorts analysed.  For the 6 patients analysed who 
received 30mCi/m2 131I-huA33, the mean specific absorbed dose to tumour 
was 5.48 ±  3.03 Gy/GBq compared to the 4 patients who received 40mCi/m2, 
in which mean specific absorbed dose to tumour was 4.70 ± 2.87Gy/GBq 
(p=0.69, Table 4.2.6.3.2).  
 
Comparison of tumour dosimetry results and patient response is shown in 
Table 4.2.6.3.3.  A partial response (PR) was observed in patient 108 with a 
33.3% reduction in sum of target lesions at end of study assessment.  Patient 
108 received the MTD dose level of 30 mCi/m2 131I-huA33 combined with 
1500 mg/m2/day capecitabine.  This patient tumour dose was the second 
highest determined: 18.44 Gy.  Stable disease was observed in 10/18 
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evaluable patients at end of study.  The tumour dose could be calculated in 5 
of these patients and ranged from 5.05 - 26.94 Gy. 
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Table 4.2.6.3.1 Tumour dosimetry measurements for assessable patients on study 
 
 
Pt 
131
I-huA33 
dose level Tumour 
Mass    (g) 
131
I-huA33 Administered 
Dose 
Tumour Dose (Gy) 
Specific Absorbed 
Dose 
mCi/m
2
 Scout Therapy Scout Therapy Total Gy/GBq cGy/mCi 
104 30 31.43 289.88 2030.63 1.43 10.00 11.43 4.92 18.22 
105 30 32.04 291.75 2159.25 2.81 20.82 23.63 9.64 35.70 
108 30 10.40 289.5 2092.50 2.24 16.20 18.44 7.74 28.67 
109 30 15.36 288.00 2020.88 0.63 4.43 5.06 2.19 8.11 
110 30 10.34 318.75 2451.00 0.66 5.08 5.74 2.07 7.67 
111 30 3.07 301.13 1990.88 1.91 12.61 14.52 6.34 23.48 
113 40 16.01 298.88 2781.38 1.15 10.72 11.87 3.85 14.26 
115 40 41.66 318.00 2870.25 0.53 4.77 5.30 1.66 6.15 
117 40 14.08 301.13 2948.90 1.43 13.97 15.40 4.74 17.56 
119 40 19.58 294.00 2856.40 2.51 24.43 26.94 8.55 31.67 
Mean  13.18 299.10 2420.21 1.53  12.30  13.83 5.17 19.15 
± SD 4.01 11.22 404.80 0.81 6.80 7.61 2.83 10.49 
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Table 4.2.6.3.2 Tumour absorbed dose according to 
131
I-huA33 dose level  
(In assessable patients) 
 
Patient 
No. 
Tumour 
mass 
131 
I- huA33 
dose level 
131 
I-huA33 
Administered Dose  
(Scout + Therapy) 
Total 
absorbed 
tumour dose 
Specific tumour 
absorbed dose 
(g) (mCi/m
2
) (mCi) (MBq) (Gy) (Gy/GBq) 
104 31.43 30 62.72 2320.51 11.43 4.92 
105 32.04 30 66.24 2451.00 23.63 9.64 
108 10.40 30 64.38 2382.00 18.44 7.74 
109 15.36 30 62.40 2308.88 5.06 2.19 
110 10.34 30 74.86 2769.75 5.74 2.07 
111 3.07 30 61.95 2292.01 14.52 6.34 
Mean 65.42 2420.69 13.15 5.48 
± SD ± 4.89 ± 180.75 ± 7.26 ± 3.03 
113 16.01 40 83.25 3080.26 11.87 3.85 
115 41.66 40 86.17 3188.25 5.30 1.66 
117 14.08 40 87.84 3250 15.40 4.74 
119 19.58 40 85.15 3150.4 26.94 8.55 
Mean 85.60 3167.24 14.89 4.70 
± SD ± 1.92 ± 71.05 ± 9.08 ± 2.87 
Overall Mean  85.60  2719.31  13.83  5.17  
± SD ± 11.09 ± 410.40 ± 7.61 ± 2.83 
 
Table 4.2.6.3.3 Tumour dosimetry and response assessment 
 
Patient 
131
I-huA33 
dose level 
Tumour 
Mass    
(g) 
Overall 
Response 
Tumour Dose (Gy) 
mCi/m
2
 Scout Therapy Total 
104 30 31.43 PD 1.43 10.00 11.43 
105 30 32.04 PD 2.81 20.82 23.63 
108 30 10.40 PR 2.24 16.20 18.44 
109 30 15.36 SD 0.63 4.43 5.06 
110 30 10.34 SD 0.66 5.08 5.74 
111 30 3.07 SD 1.91 12.61 14.52 
113 40 16.01 PD 1.15 10.72 11.87 
115 40 41.66 PD 0.53 4.77 5.30 
117 40 14.08 SD 1.43 13.97 15.40 
119 40 19.58 SD 2.51 24.43 26.94 
 
PD: progressive disease; PR: partial response; SD: stable disease
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4.2.8 Efficacy assessment 
Of the 18 patients evaluable for tumour response according to RECIST, there 
was 1 PR, 10 SD, and 7 PD.  Patient 102 had a 31.6% reduction in the sum of 
his target lesions at end of study assessment, but as he developed a new 
sternal metastasis, was classified as PD overall.  Of the 10 patients who had 
SD, the percent change in the sum of target lesions was unchanged for 1 
patient; patient 103, reduced in 4 patients; patient 106 by 10.1%, patient 107 
by 12.5%, patient 111 by 23.1%, and patient 117 by 9.7%, and increased in 5 
patients; patient 109 by 3.7%, patient 110 by 10.5%, patient 114 by 8.0%, 
patient 116 by 10.4%, and patient 119 by 3.1%.  Percentage change in sum of 
target lesions is represented below in Figure 4.2.8.1, and target lesion 
assessment is detailed in Appendix 4.6. 
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Figure 4.2.8.1 Waterfall plots presenting response as the percent change in 
sum of target lesions (A) and according to RECIST (B)) 
A 
 
 
B 
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CEA levels were taken at screening at end of study assessment in week 13 
where possible.  Seven patients had a fall in their CEA level (patients 101, 106, 
108, 109, 110, 117, and 118), although this includes patient 118, who were 
not evaluable for response with CT after withdrawing at week 3.  One patient 
(107) had a stable CEA, and for 8 patients it rose (patients 102, 103, 104, 105, 
111, 112, 115, and 116).  Unfortunately a screening CEA was not available for 
patient 119.  Change in sum of target lesions, CEA levels together with tumour 
absorbed dose and CT response are summarised in Table 4.2.8.  Figures 
4.2.8.2, 4.2.8.3 and 4.2.8.4 show tumour response in patients 102, 108, and 
111 respectively. 
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Table 4.2.8 CEA levels, tumour absorbed dose, change in sum of target 
lesions, and corresponding CT response 
 
 
Patient Cohort 
Screening 
CEA 
End of Study 
CEA 
Tumour absorbed 
dose (Gy) 
% Change in sum 
 of target lesions 
CT 
Response 
101 1 2.1 1.4 N/A + 76.7 PD 
102 1 3.1 3.7 N/A - 31.6 PD 
103 1 258 544 N/A Unchanged SD 
104 2 8.8 61 11.43 + 58.9 PD 
105 2 462 1175 23.65 + 32.1 PD 
106 2 38 29 N/A - 10.1 SD 
107 2 1.6 1.6 N/A - 12.5 SD 
108 2 4.7 2.3 18.46 - 33.3 PR 
109 2 27.4 16.6 5.06 + 3.7 SD 
110 3 11.9 9.3 5.74 + 10.5 SD 
111 3 35.6 43.2 14.55 - 23.1 SD 
112 3 645 1386.3 N/A + 3.5 PD 
113 4 1005 1538.3 11.87 + 27.6 PD 
114 4 17.9 20.5 N/A + 8.0 SD 
115 4 15.2 57.4 5.30 + 7.0 PD 
116 5 243.3 408.2 N/A + 10.4 SD 
117 5 29.1 16.7 15.42 - 9.7 SD 
118 5 42.3 28.1* N/A N/A N/A 
119 5 N/A 183.5 26.96 + 3.1 SD 
* Patient not evaluable for response as withdrawn 
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Figure 4.2.8.2 Response in patient 102 
 
 
 
 
Figure 4.2.8.3 Response in patient 108 
 
 
 
  302 
Figure 4.2.8.4 Response in patient 111 
 
 
 
4.2.8.3 Survival 
Patient characteristics, prior oncological treatment with corresponding 
individual patient survival and response is shown in Table 4.2.8.3.  Median PFS 
was 5 months (range 1.0 - 48.6 months) and median OS to date is 15.2 months 
(range 3.2 - 59.4 months).  For the 11/18 evaluable patients (61%) with stable 
disease or partial response at study completion, median PFS was 6 months 
(range 7-59.4 months).   
 
Although the patient population was small and heterogeneous in terms of 
prior therapy (prior lines of chemotherapy for metastatic disease 0-4, median 
1) as well as therapy received following the trial (not formally documented), it 
was interesting to note that some patients displayed a surprisingly long PFS 
and OS.  This included patient 103, who had received no prior treatment for 
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metastatic disease when enrolled on study in 2003.  At study entry patient 
103 had retrocrural lymphadenopathy, which remained stable for 48.6 
months.  Following trial completion the patient remained on capecitabine 
until disease progression, and at time of survival analysis remained alive (59.4 
months after scout infusion) with metastatic nodal disease.  Patient 108 had 
previously received 2 lines of chemotherapy for metastatic disease, 
demonstrated a PR at end of study assessment and remained stable for 15.2 
months. 
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Table 4.2.8.3 Patient characteristics, prior oncological treatment and corresponding overall response and survival 
(OS Data Status at November 28, 2008 with Patients 103, 111, 117 and 118 follow up continuing)    
 
Pt ID Sex 
Age at Study 
Entry 
Dose 
Cohort 
Primary site 
Prior lines of 
chemotherapy  
Prior 
Surgery 
Prior XRT 
Number of 
days on 
study 
Overall 
Response 
OS 
(months) 
PFS 
(months) 
101 F 54 1 Rectum 0 Y Y 79 PD 6.2 2.6 
102 M 59 1 Colon 1 Y N 92 PD 40.1 3.0 
103 M 59 1 Colon 0 Y N 91 SD 59.4 48.6 
104 F 69 2 Colon 3 Y N 92 PD 3.2 3.0 
105 M 60 2 Rectum 3 N Y 59 PD 5.4 1.9 
106 M 66 2 Colon 1 Y N 94 SD 32.5 18.8 
107 F 66 2 Rectum 0 Y Y 50 SD 30.6 6.0 
108 M 69 2 Colon 2 Y N 95 PR 29.5 15.2 
109 M 51 2 Colon 4 Y N 43 SD 16.4 5.1 
110 M 52 3 Colon 1 Y N 92 SD 27.9 5.0 
111 F 61 3 Colon 2 Y N 92 SD 31.3 10.6 
112 F 41 3 Rectum 3 Y Y 57 PD 6.9 1.9 
113 M 58 4 Colon 1 Y N 95 PD 13.0 3.1 
114 M 64 4 Colon 1 Y N 78 SD 7.0 6.0 
115 M 59 4 Colon 2 Y N 93 PD 15.2 3.0 
116 M 66 5 Rectum 1 Y Y 94 SD 8.7 4.4 
117 M 66 5 Colon 1 Y N 94 SD 21.4 8.8 
118 M 48 5 Rectum 0 Y Y 32 N/A 8.6 1.0 
119 F 55 5 Rectum 2 Y N 94 SD 11.0 5.6 
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4.3 Summary of findings 
131I-huA33 with capecitabine is well tolerated, and the addition of 
capecitabine to 131I-huA33 does not impact on the biodistribution of 131I-
huA33, or tumour uptake.  131I-huA33 demonstrated a mean terminal half-life 
and serum clearance suited to radioimmunotherapy, allowing specific tumour 
uptake, whilst the specificity of huA33 meant normal organ uptake was 
minimal. 
 
This trial suggests that this strategy of targeted chemoradiation in metastatic 
colorectal cancer can produce anti-tumour activity whilst remaining tolerable 
for patients.   Although the number of patients enrolled was small, one PR 
was demonstrated (and some patients with SD at study completion had 
definite tumour shrinkage or mixed response on CT), which was not seen in 
the preceding trial of 131I-huA33 alone.  It is likely that the addition of 
capecitabine to 131I-huA33 contributed to this finding, and further 
investigation of this strategy is on going. 
  306 
Appendix 4 
 
Appendix 4.1 Radiolabelling procedure 
 
 
An aliquot of huA33 was radiolabelled in a vial containing Iodo beads.  After 
brief incubation, the reaction mixture was removed and the radiolabelled 
antibody purified chromatographically.  Radioactive doses were measured 
using a dose calibrator set for the 131I window.  The percentage of 
radioactivity bound to antibody was checked by ITLC-SG using 10% w/v 
trichloroacetic acid as solvent.  Antibody preparations equal to or better than 
95% isotope bound to protein were used.  Purified 131I-hu A33 was adjusted to 
5% human serum albumin and filtered through a sterile 0.22 micron filter 
before use.  All manipulations were conducted using aseptic techniques and 
within a class II biohazard hood. 
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Appendix 4.2 All adverse events with CTC grade and relatedness 
 
System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Blood and 
lymphatic system 
disorders 
Anemia 3 6 0 2 0 0 0 0 0 0 11 
Febrile neutropenia 0 0 0 0 1 0 0 0 0 0 1 
Leukopenia 4 0 6 0 5 0 0 0 0 0 15 
Lymph nodes enlarged 0 1 0 0 0 0 0 0 0 0 1 
Lymphopenia 1 0 2 0 3 0 1 0 0 0 7 
Monocytosis 0 1 0 0 0 0 0 0 0 0 1 
Neutropenia 5 0 4 0 5 0 1 0 0 0 15 
Thrombocytopenia 2 0 6 0 6 0 1 0 0 0 15 
Sub-Total 15 8 18 2 20 0 3 0 0 0 66 
Cardiac disorders 
Chest pain - cardiac 2 0 0 0 1 0 0 0 0 0 3 
Retrosternal Chest Pain 1 0 0 0 0 0 0 0 0 0 1 
SVT 0 0 0 1 0 0 0 0 0 0 1 
Tachycardia unspecified 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 3 1 0 1 1 0 0 0 0 0 6 
Endocrine 
disorders 
Hypoglycemia 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 1 0 0 0 0 0 0 0 0 1 
Eye disorders 
Soreness in eyes 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 1 0 0 0 0 0 0 0 0 1 
 
  308 
ƉƉĞŶĚŝǆ ? ? ?ŽŶƚŝŶƵĞĚ ?ůůĂĚǀĞƌƐĞĞǀĞŶƚƐǁŝƚŚdŐƌĂĚĞĂŶd relatedness 
 
System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Gastrointestinal 
disorders 
Abdominal cramp 0 2 0 0 0 0 0 0 0 0 2 
Abdominal discomfort 0 1 0 0 0 0 0 0 0 0 1 
Abdominal pain 0 0 0 0 0 1 0 0 0 0 1 
Abdominal pain localised 0 1 0 0 0 0 0 0 0 0 1 
Bloating 1 0 0 0 0 0 0 0 0 0 1 
Constipation 1 3 0 0 0 0 0 0 0 0 4 
Diarrhea 6 4 5 0 2 0 0 0 0 0 17 
Discomfort rectal 0 1 0 0 0 0 0 0 0 0 1 
Dry mouth 0 2 0 0 0 0 0 0 0 0 2 
Epigastric discomfort 0 1 0 0 0 0 0 0 0 0 1 
Flatulence 1 0 0 0 0 0 0 0 0 0 1 
Gastritis 0 1 0 0 0 0 0 0 0 0 1 
Gastroesophageal reflux 2 0 0 0 0 0 0 0 0 0 2 
Indigestion 2 0 0 0 0 0 0 0 0 0 2 
Lip dry 2 1 0 0 0 0 0 0 0 0 3 
Lip ulcer 1 0 0 0 0 0 0 0 0 0 1 
Nausea 16 2 0 0 0 0 0 0 0 0 18 
Pain epigastric  0 1 0 0 0 0 0 0 0 0 1 
Pain rectal 0 1 0 0 0 0 0 0 0 0 1 
Rectal bleeding 1 1 0 0 0 0 0 0 0 0 2 
Redness corner of 
mouth 
0 1 0 0 0 0 0 0 0 0 1 
RUQ pain 0 0 0 0 0 2 0 0 0 0 2 
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System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Gastrointestinal 
disorders 
Stomatitis 1 0 0 1 0 0 0 0 0 0 2 
Taste alteration 2 0 0 0 0 0 0 0 0 0 2 
Tender mouth 0 1 0 0 0 0 0 0 0 0 1 
Vomiting 3 2 4 0 0 0 0 0 0 0 9 
Sub-Total 39 26 9 1 2 3 0 0 0 0 80 
General disorders 
and 
administration 
site conditions 
Asthenia 0 0 0 1 0 0 0 0 0 0 1 
Chills 0 2 0 0 0 0 0 0 0 0 2 
Fever 0 1 1 1 0 0 0 0 0 0 3 
Hot flushes 0 1 0 0 0 0 0 0 0 0 1 
Hyponatremia 0 2 0 0 0 0 0 0 0 0 2 
Leg oedema 0 1 0 0 0 0 0 0 0 0 1 
Lethargy 12 5 1 2 0 0 0 0 0 0 20 
Sub-Total 12 12 2 4 0 0 0 0 0 0 30 
Hepatobiliary 
disorders 
Hyperbilirubinaemia 7 1 2 0 1 0 0 0 0 0 11 
Sub-Total 7 1 2 0 1 0 0 0 0 0 11 
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System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Metabolism and 
nutrition 
disorders 
Anorexia 7 0 0 0 0 0 0 0 0 0 7 
Hypoalbuminaemia  0 3 0 4 0 0 0 0 0 0 7 
Hypokalemia 0 0 0 0 0 1 0 0 0 0 1 
Hyponatremia 0 8 0 0 0 0 0 0 0 0 8 
Sub-Total 7 11 0 4 0 1 0 0 0 0 23 
Infections and 
infestations 
Cold sore mouth 1 0 0 0 0 0 0 0 0 0 1 
Coryza 0 1 0 0 0 0 0 0 0 0 1 
Herpes zoster 0 0 0 1 0 0 0 0 0 0 1 
Oral thrush 0 0 1 0 0 0 0 0 0 0 1 
Sub-Total 1 1 1 1 0 0 0 0 0 0 4 
Injury, poisoning 
and procedural 
complications 
Animal bite 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 1 0 0 0 0 0 0 0 0 1 
Investigations 
ALP increased 0 4 0 0 0 2 0 0 0 0 6 
ALT increased 0 0 0 1 0 0 0 0 0 0 1 
Blood creatinine 
increased 
0 1 0 0 0 0 0 0 0 0 1 
GGT increased 0 2 0 1 0 1 0 0 0 0 4 
TSH decreased 0 1 0 0 0 0 0 0 0 0 1 
Weight loss 0 0 0 3 0 0 0 0 0 0 3 
Sub-Total 0 8 0 5 0 3 0 0 0 0 16 
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System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Musculoskeletal 
and connective 
tissue disorders 
Back pain  0 0 0 1 0 0 0 0 0 0 1 
Buttock pain 0 0 0 0 0 1 0 0 0 0 1 
Chest wall pain 0 1 0 0 0 0 0 0 0 0 1 
Cramp in legs thigh 0 0 0 1 0 0 0 0 0 0 1 
Generalised muscle 
aches 
0 1 0 0 0 0 0 0 0 0 1 
Hand pain 1 0 0 0 0 0 0 0 0 0 1 
Heaviness in limbs 0 1 0 0 0 0 0 0 0 0 1 
Leg pain 0 0 0 0 0 1 0 0 0 0 1 
Musculoskeletal chest 
pain 
0 2 0 0 0 0 0 0 0 0 2 
Myopathy steroid-
induced 
0 0 0 1 0 0 0 0 0 0 1 
Pain foot 1 0 0 0 0 0 0 0 0 0 1 
Pain in ankle 0 0 0 1 0 0 0 0 0 0 1 
Shoulder pain 0 0 0 0 0 2 0 0 0 0 2 
Upper back pain 0 0 0 0 0 1 0 0 0 0 1 
Sub-Total 2 5 0 4 0 5 0 0 0 0 16 
Neoplasms 
benign, malignant 
and unspecified 
Non-Hodgkin's 
lymphoma 
0 0 0 0 0 0 0 1 0 0 1 
Sub-Total 0 0 0 0 0 0 0 1 0 0 1 
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System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Nervous system 
disorders 
Dizziness 1 2 0 0 0 0 0 0 0 0 3 
Drug-induced 
extrapyramidal side 
effects 
0 1 0 0 0 0 0 0 0 0 1 
Foot drop 0 0 0 0 0 1 0 0 0 0 1 
Headache 2 6 0 0 0 0 0 0 0 0 8 
Insomnia 0 3 0 0 0 0 0 0 0 0 3 
Lightheadedness 0 2 0 0 0 0 0 0 0 0 2 
Nerve root compression 0 0 0 0 0 1 0 0 0 0 1 
Neuropathy 0 1 0 0 0 0 0 0 0 0 1 
Numbness in feet 0 0 0 0 0 1 0 0 0 0 1 
Paresthesia distal 1 0 0 0 0 0 0 0 0 0 1 
Post herpetic neuralgia 0 0 0 1 0 0 0 0 0 0 1 
Shaking 0 2 0 0 0 0 0 0 0 0 2 
Smell loss 1 0 0 0 0 0 0 0 0 0 1 
Tremor 0 1 0 0 0 0 0 0 0 0 1 
Weakness in extremity 0 0 0 1 0 0 0 0 0 0 1 
Sub-Total 5 18 0 2 0 3 0 0 0 0 28 
Psychiatric 
disorders 
Agitation 0 1 0 0 0 0 0 0 0 0 1 
Mood altered 0 1 0 0 0 0 0 0 0 0 1 
Mood depression 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 3 0 0 0 0 0 0 0 0 3 
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System Organ 
Class (SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Renal and urinary 
disorders 
Blood urea decreased 0 2 0 0 0 0 0 0 0 0 2 
Dysuria 1 0 0 0 0 0 0 0 0 0 1 
Renal colic 0 0 0 0 0 1 0 0 0 0 1 
Sub-Total 1 2 0 0 0 1 0 0 0 0 4 
Reproductive 
system and breast 
disorders 
Pelvic pain 0 0 0 0 0 1 0 0 0 0 1 
Testicular pain 0 1 0 0 0 0 0 0 0 0 1 
Vaginal pain 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 2 0 0 0 1 0 0 0 0 3 
Respiratory, 
thoracic and 
mediastinal 
disorders 
Cough 0 2 0 0 0 1 0 0 0 0 3 
Dry cough 0 3 0 0 0 0 0 0 0 0 3 
Epistaxis 1 0 0 0 0 0 0 0 0 0 1 
Pleuritic pain 0 0 0 1 0 0 0 0 0 0 1 
Runny nose 0 1 0 0 0 0 0 0 0 0 1 
Sinus congestion 0 1 0 0 0 0 0 0 0 0 1 
Sore throat 0 2 0 0 0 0 0 0 0 0 2 
Upper respiratory tract 
infection NOS 
0 0 0 1 0 0 0 0 0 0 1 
Voice alteration 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 1 10 0 2 0 1 0 0 0 0 14 
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System Organ Class 
(SOC) 
Adverse Events  
(Lowest Level Term) 
Mild (1) Moderate (2) Severe (3) Life Threatening (4) Fatal (5) 
Total 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Related 
Not 
Related 
Skin and 
subcutaneous tissue 
disorders 
Bruising 0 1 0 0 0 0 0 0 0 0 1 
Bruising of foot 0 1 0 0 0 0 0 0 0 0 1 
Desquamation 0 0 1 0 0 0 0 0 0 0 1 
Dry skin 2 0 0 0 0 0 0 0 0 0 2 
Erythematous skin rash 2 0 0 0 0 0 0 0 0 0 2 
Facial rash 1 0 0 0 0 0 0 0 0 0 1 
Itchy skin 0 1 0 0 0 0 0 0 0 0 1 
Localized itching 0 1 0 0 0 0 0 0 0 0 1 
Maculopapular rash 0 0 1 0 0 0 0 0 0 0 1 
Palmar-plantar 
erythema 
3 0 0 0 0 0 0 0 0 0 3 
Pruritic rash 1 0 0 0 0 0 0 0 0 0 1 
Pruritis 0 0 1 0 0 0 0 0 0 0 1 
Rash NOS 1 0 0 0 0 0 0 0 0 0 1 
Skin tenderness 1 1 0 0 0 0 0 0 0 0 2 
Sweating 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 11 6 3 0 0 0 0 0 0 0 20 
Vascular disorders 
Hypertension 0 0 0 1 0 0 0 0 0 0 1 
Postural hypotension 0 1 0 0 0 0 0 0 0 0 1 
Sub-Total 0 1 0 1 0 0 0 0 0 0 2 
  Totals 104 118 35 27 24 18 3 1 0 0 330 
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 Appendix 4.3 Thyroid function tests 
 
Patient 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 
 
TSH at screening 
 
0.73 0.62 1.76 1.38 1.14 0.98 0.82 0.87 0.38 1.47 1.61 1.1 0.95 1.95 0.68 0.17 0.59 0.85 N/A 
 
TSH end of study 
 
0.61 0.46 N/A 2.1 0.27 0.94 1.64 1.08 0.05 0.06 0.93 0.37 N/A 2.6 0.81 0.23 0.35 1.29 0.23 
 
TSH at 9 months 
 
N/A 0.27 1.26 N/A N/A 3.57 1.06 1.57 0.48 2.76 2.02 N/A 1.05 N/A 0.91 N/A N/A N/A N/A 
 
TSH at 15 months 
 
N/A N/A 1.65 N/A N/A 1.74 1.22 0.97 N/A 1.11 1.27 N/A N/A N/A N/A N/A N/A N/A N/A 
N/A=not available
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Appendix 4.4 Faecal occult blood 
 
 
Patient 
Test 
number 
Pretreatment Week 7 
Chemical 
Test 
Result 
Immunology 
Test Result 
Chemical 
Test 
Result 
Immunology 
Test Result 
101 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Positive Negative Negative Negative 
102 
1 Negative N/D Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
103 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
104 
1 Positive Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
105 
1 Positive Negative Positive Negative 
2 Positive Negative Positive Negative 
3 Positive Negative Positive Negative 
106 
1 Positive Positive Positive Positive 
2 Positive Positive Positive Positive 
3 Positive Positive Positive Positive 
107 
1 Negative N/D N/D N/D 
2 Negative N/D N/D N/D 
3 Negative N/D N/D N/D 
108 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Positive Negative N/D N/D 
109 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
110 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative N/D N/D 
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Patient 
Test 
number 
Pretreatment Week 7 
Chemical 
Test Result 
Immunology 
Test Result 
Chemical 
Test 
Result 
Immunology 
Test Result 
111 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
112 
1 Negative Negative Negative Negative 
2 Negative Negative N/D Negative 
3 Negative Negative Negative Negative 
113 
1 N/D Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
114 
1 Positive Positive Negative Positive 
2 Positive Positive Positive Positive 
3 N/D N/D Positive Positive 
115 
1 N/D Positive N/D Positive 
2 Negative Negative Negative Positive 
3 Negative Positive N/D N/D 
116 
1 Negative Positive Negative Negative 
2 Negative Positive Negative Negative 
3 Negative Positive Negative Positive 
117 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
118 
1 Negative Negative N/D N/D 
2 N/D N/D N/D N/D 
3 N/D N/D N/D N/D 
119 
1 Negative Negative Negative Negative 
2 Negative Negative Negative Negative 
3 Negative Negative Negative Negative 
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Appendix 4.5 Individual patient curve fits for 
131
I-huA33 
 
 
Figure 1 patient 101 
 
 
 
 
 
Figure 2 Patient 102 
 
 
 
 
Figure 3 Patient 103 
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Figure 4 Patient 104 
 
 
 
 
Figure 5 Patient 105 
 
 
 
 
Figure 6 Patient 106 
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Figure 7 Patient 107 
 
 
 
 
 
Figure 8 Patient 108 
 
 
 
 
Figure 9 Patient 109 
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Figure 10 Patient 110 
 
 
 
 
 
Figure 11 Patient 111 
 
 
 
 
 
 
Figure 12 Patient 112 
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Figure 13 Patient 113 
 
 
 
 
Figure 14 Patient 114 
 
 
 
 
 
 
Figure 15 Patient 115 
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Figure 16 Patient 116 
 
 
 
 
 
Figure 17 Patient 117 
 
 
 
 
 
Figure 18 Patient 118 
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Figure 19 Patient 119 
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Appendix 4.6 Target lesion assessment throughout the trial with overall response 
 
Pt 
No. 
Dose    
Level 
Corrected Location of Target lesion 
Screening 
measurement (mm) 
Sum of Target 
Lesion at Baseline 
End of study 
measurement (mm) 
Sum of Target 
Lesion Wk13/EOS 
New 
lesion? 
Best 
Response 
101 1 
Left lower lobe lung lesion 15 
90 
19 
159 
  
 N  
  
PD 
Subcarinal lymph node 55 64 
Segment 2 liver lesion 10 35 
Segment 3 liver lesion 10 41 
102 1 
Pre tracheal lymph node 50 
95 
30 
65 
  
Y 
  
PD Right hilar lymph node 30 20 
Left hilar lymph node 15 15 
103 1 
Right retrocrural lymph node 33 
78 
33 
78  N SD 
Lymph node adjacent to hilum of left kidney 45 45 
104 2 
Segment 7 liver lesion 31 
90 
44 
143 
  
Y 
  
PD Medial right lobe liver lesion 29 48 
Right lobe liver lesion 30 51 
105 2 
Left lobe liver lesion 40 
109 
50 
144 
  
 N  
  
PD 
Right lobe liver lesion 40 55 
Right lower lobe lung lesion 12 15 
Precarinal lymph node 17 24 
106 2 
Segment 6 liver lesion 45 
99 
35 
89 
  
N   
  
SD 
Liver lesion (junction of right and left lobe) 15 15 
Liver lesion (junction of right and left lobe) 9 9 
Pelvic soft tissue mass 30 30 
107 2 Left upper lobe lung lesion 40 40 0 37 N  SD 
108 2 Segment 8 liver lesion 60 60 40 40 N  PR 
109 2 
Right upper lobe lung lesion 13 
82 
16 
85 
  
 N  
  
SD 
Right lower lobe lung lesion 30 30 
Left upper lobe lung lesion 21 21 
Paratracheal lymph node 18 18 
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Patient 
No. 
Dose    
Level 
Corrected Location of Target lesion 
Screening 
measurement 
(mm) 
Sum of Target 
Lesion at Baseline 
End of study 
measurement 
(mm) 
Sum of Target 
Lesion 
Wk13/EOS 
New 
lesion? 
Best 
Overall 
Response 
110 3 
Segment 7 liver lesion 37 
57 
38 
63 N SD 
Segment 8 liver lesion 20 25 
111 3 
Left infrahilar lung lesion 35 
134 
30 
103 
  
N  
  
SD 
Right lower lobe lung lesion 13 10 
Left lower lobe lung lesion 51 44 
Right adrenal mass 35 19 
112 3 
Right upper lobe lung lesion 12 
143 
15 
148 
  
  
Y 
  
  
  
PD 
Right lower lobe lung lesion (apical) 19 22 
Left upper lobe lung lesion (anterior) 10 11 
Right middle lobe lung lesion 20 28 
Segment 4 liver lesion 38 37 
Segment 3/4 liver lesion 44 35 
113 4 
Right costophrenic angle lung lesion 15 
181 
20 
231 
  
  
Y 
  
  
PD 
Segment 8 liver lesion 28 36 
Segment 7 liver lesion 54 66 
Segment 6 liver lesion 42 54 
Segment 5 liver lesion 42 55 
114 4 
Suprapubic mass 67 
112 
70 
121 
  
N  
  
SD Left lower anterior abdominal wall lesion 25 27 
Right iliac fossa mass 20 24 
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Patient 
No. 
Dose    
Level 
Corrected Location of Target lesion 
Screening 
measurement 
(mm) 
Sum of Target 
Lesion at Baseline 
End of study 
measurement 
(mm) 
Sum of Target 
Lesion 
Wk13/EOS 
New 
lesion? 
Best 
Overall 
Response 
115 4 
Right hilar lesion 29 
186 
28 
199 
  
 Y 
  
PD 
Segment 8 liver lesion 69 78 
Segment 5 liver lesion 52 56 
Portocaval lymph node 36 37 
116 5 
Left upper lobe lung lesion 16 
260 
18 
287 
  
  
 N  
  
  
SD 
Right middle lobe lung lesion 29 33 
Right lower lobe lung lesion 30 37 
Left lower lobe lung lesion (medial) 26 33 
Left upper lobe lung lesion (anteriorly) 18 20 
Right paratracheal lymph node 44 39 
Segment 5/8 liver lesion 39 50 
Left paraortic lymph node (posteriorly) 19 19 
Left paraortic lymph node (anteriorly) 18 17 
Left paraortic lymph node (at aortic bifurcation) 21 21 
117 5 
Segment 8 liver lesion 21 
103 
18 
93 
  
 N  
  
SD 
Segment 7 liver lesion 29 28 
Segment 5 liver lesion 22 17 
Segment 4A liver lesion 15 17 
Segment 6 liver lesion 16 13 
119 5 
Aortopulmonary lymph node 24 
97 
23 
100 
  
 N 
  
SD 
Right lobe liver lesion 37 40 
Superior right lobe liver lesion 23 24 
Aortocaval lymph node 13 13 
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CHAPTER 5: Discussion 
 
Optimising targeted antibodies for the treatment of 
metastatic solid tumours 
 
5.1 The future role of targeted antibodies in the treatment of solid 
tumours 
As has been described, there are currently 4 monoclonal antibodies approved in 
the US for the treatment of solid malignancies.  Despite the significant 
therapeutic promise of such targeted therapies (particularly in the adjuvant 
treatment of HER2 positive breast cancer), their impact on survival in metastatic 
solid tumours remains modest.  Many strategies to improve efficacy of such 
agents have been investigated or are being currently explored in clinical trials.  
These include combining with chemotherapy, radiotherapy or other targeted 
therapies, and improving molecular profiling of tumours to better predict 
response.  The continued discovery of new tumour associated antigenic targets 
and the subsequent development of antibodies with the ability to target these in 
a specific manner, means the potential to deliver targeted cytotoxic agents or 
radiotherapy remains a real possibility for the near future.  The 3 components to 
this thesis describe 3 alternative approaches, which were all designed to optimise 
the use of targeted antibodies for the treatment of metastatic solid tumours. 
Section 5.2 of this chapter discusses the results reported in Chapter 2, where 
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molecular markers in paired primary and metastatic CRC tissue were evaluated.  
An understanding of the relationship between these markers could be used to 
interpret their role as potential predictive biomarkers for antibodies targeting 
EGFR.  Section 5.3 discusses the results and implications of the Phase I 
biodistribution study of the Ley targeting immunoconjugate CMD-193 reported in 
Chapter 3.  Section 5.4 discusses the Phase I trial reported in Chapter 4, which 
explored the feasibility and safety of combining oral chemotherapy with 
radioimmunotherapy specific to patients with metastatic colorectal cancer in the 
form of 131I-huA33.  Each project has made an impact on the future development 
of such therapeutic strategies as will now be discussed. 
 
5.2 Optimising the use of EGFR targeting antibodies 
It is now well established that the complexity of intracellular signalling 
downstream of the EGFR is the likely principal explanation for the current limited 
survival advantage gained with anti-EGFR antibodies in the clinic.  Following the 
acceptance that EGFR expression does not predict response to EGFR targeting 
antibodies targeting EGFR, the last few years have brought significant advances in 
understanding reasons behind this, and exploring alternative potential predictors 
of response in an attempt to optimise the use of such therapeutic antibodies. 
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5.2.1 Study rationale 
The project reported in Chapter 2 aimed to answer clinically relevant questions 
relating to signalling downstream of EGFR in order to direct future trial design 
and optimise future patient selection into such trials.  One of the key questions 
identified was whether the pattern of expression, activation and mutation of key 
signalling molecules downstream of EGFR is similar in matched primary and 
metastatic tissue.  This has significant clinical implications, as currently the 
investigation of potential molecular markers of response are performed on 
archived primary tumour tissue, when in clinical practice it is usually metastatic 
disease which is being treated by monoclonal antibodies such as cetuximab.  
Clearly, if there were significant discordance between the primary and metastatic 
tissue, this would render the use of primary tissue as a surrogate for the 
assessment of biomarker expression less valuable. Whilst some evidence 
suggesting EGFR and MAPK expression in primary and secondary tumour tissue 
may not be concordant has recently been published193 194, at the time of project 
conception, little evidence could be found confirming concordance of activation 
or mutation signalling molecules downstream of EGFR in primary tumours and 
corresponding metastatic tissue.  
 
The second aim of this study was to explore inter-relationships between 
signalling molecules downstream of EGFR.  This question is of particular relevance 
for the design of future clinical trials combining EGFR antibodies with other 
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biological therapies, which target different components of the EGFR signal 
transduction cascade.  If the EGFR/RAS/RAF/MAPK pathway is activated at 
multiple levels by different (independent) mechanisms, this discovery could 
direct trials of combining EGFR antibodies with other targeted therapies in 
ƉĂƚŝĞŶƚƐ ǁŚŽƐĞ ƚƵŵŽƵƌ ?Ɛ ŵŽůĞĐƵůĂƌ ƉƌŽĨŝůĞ ŚĂƐ ďĞĞŶ ĚĞƚĞƌŵŝŶĞĚ ? ĂŶĚ ŚĞŶĐĞ
individualise treatment.  The final aim of this study was to investigate a possible 
correlation between mutations in KRAS, BRAF and PI3KCA.  The presence of a 
PI3KCA mutation in a wild-type KRAS patient could predict non-response to 
cetuximab as constitutive pathway activation could occur via the PI3K/Akt 
pathway.   
 
Whilst this project was not designed to be a comprehensive analysis of the 
complex network of intracellular pathways which translate growth promoting 
signals to the cell nucleus signals following activation of the membrane receptor, 
it focused on key activating elements thought to be of most clinical interest.  The 
results obtained aim to guide future trial design involving EGFR antibodies at our 
institution, and the use of molecular markers in response prediction and patient 
selection. 
 
5.2.2 Summary of findings 
EGFR immunohistochemical expression was positive in 5 primary tumours 
(17.2%), and 3 in metastatic tumours (10.3%).  Correlation of EGFR positivity in 
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primary and metastases did reach statistical significance (p=0.031).  
Phosphorylated EGFR expression was detected in a much higher proportion of 
tumours than membrane expression of the receptor.  Twenty-seven patients 
(87.1%) demonstrated pEGFR positivity in their primary tumour, and 19 (61.3%) 
in their metastatic disease.  pEGFR status was discordant between primary and 
metastatic disease in 10 patients (34.5%).  Primary tumours were pMAPK positive 
in 6 patients (19.4%), and metastases were positive in 5 patients (16.1%).  
Discordance between primary and metastatic tumour expression of pMAPK was 
demonstrated in 9 patients (29.0%) when paired samples were analysed.  Nine 
patients (31%) had KRAS mutations, 2 patients (6.9%) had BRAF mutations and 4 
patients (10%) had PI3KCA mutations in both primary and metastases.  There was 
complete concordance for the presence of KRAS, BRAF and PI3KCA mutations 
between primary tumours and paired metastatic tissue.   
 
No correlation was found between EGFR expression and pEGFR expression, and 
no correlation was found between EGFR expression and the presence of activated 
downstream components KRAS and BRAF mutations or pMAPK expression.  A 
statistically significant correlation between pEGFR and KRAS mutations was 
found, with 20 patients (66.7%) showing concordance between pEGFR expression 
and presence of KRAS mutation (p=0.02).  The tumours in 9 patients (30%) were 
positive for both pEGFR expression and the presence of a KRAS mutation.  No 
correlation was found between pEGFR expression and BRAF mutation or pMAPK 
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expression.  When the relationship between KRAS and BRAF mutations and 
downstream pMAPK was analysed, a statistically significant correlation between 
KRAS mutation and pMAPK expression was found, with concordance between 
KRAS mutation status and pMAPK expression in 24 patients (77.4%, p=0.01).  
Despite the overall concordance, in the 10 K-ras positive patients, 4 were also 
pMAPK positive and 6 patients were pMAPK negative. 
 
Of the 2 patients (6.5%) with BRAF mutations, both were negative for pMAPK, 
whilst pMAPK was positive in 5 cases (16.1%) where no BRAF mutation was 
detected, but 4/5 of these had a KRAS mutation, explaining this downstream 
activation.  No significant relationship was found between the presence of BRAF 
mutations and expression of pMAPK.  In one patient pMAPK expression was 
present despite an absence of KRAS, BRAF and PI3KCA mutation, indicating that 
downstream components maybe activated despite a lack of these activating 
mutations.  
 
No significant concordance was demonstrated between EGFR and pEGFR 
expression and the presence of a PI3KCA mutation (p=0.64 and p=0.58 
respectively).  When the relationship between KRAS and BRAF mutations was 
explored, they were found to be mutually exclusive, as no patient had mutation 
in both KRAS and BRAF simultaneously.  Two patients (6.5%) were negative for 
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KRAS but positive for BRAF mutations, whilst 10 patients (32.2%) were positive 
for KRAS and negative for BRAF mutations. 
 
When a relationship was explored between KRAS, BRAF and PI3KCA mutations, 
17 patients (54.8%) had no mutations.  PI3KCA mutations did not occur 
concurrently with BRAF mutations, but 2 patients (6.5%) had both a PI3KCA 
mutation and a KRAS mutation present.  Two patients who were wild type for 
KRAS and BRAF were found to have a PI3KCA mutation. 
 
5.2.3 Discussion 
The assumption that the presence of target is an accurate biomarker for the 
activity of EGFR specific targeted antibodies in CRC patients has now been proven 
to be incorrect.  With the clear evidence that immunohistochemical expression of 
EGFR in CRC does not predict efficacy of cetuximab and panitumumab, the 
discovery of accurate response predictors has been the focus of much recent 
investigation. 
5.2.3.1 Tumour characteristics 
Studies have reported a wide range of EGFR expression in CRC (30-95% of 
primary tumours 51 67 131 193-195 364-366, which may partly be accounted for by 
different IHC methods and assessment criteria.  The proportion of patients with 
EGFR positive tumours in this study was low (17.2% primaries, 10.3% metastases) 
when compared to other published studies using a similar method of IHC criteria 
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for EGFR positivity.  Scartozzi et al found that 53% of primary CRC and 46% of 
metastases were EGFR positive193 194, and Bralet et al reported positivity in 95% of 
primary tumours and 79-88% in metastases342.  One explanation for this is that 
EGFR expression may have been down regulated as a result of the high 
proportion of tumours expressing activated receptor, pEGFR.  Once EGFR is 
activated, it undergoes internalisation, resulting in a marked decrease in 
membrane-bound EGFR367, and a greater proportion of tumours expressing 
pEGFR compared to EGFR has also been reported in invasive breast cancers368.  
The level of expression of pEGFR in this study was high with 87.1% in primaries 
and 61.3% in metastases.  Few published studies could be found examining both 
'&ZĂŶĚƉ'&ZĞǆƉƌĞƐƐŝŽŶŝŶZ ?ďƵƚƵŶŶŝŶŐŚĂŵĞƚĂů ?ƐƐƚƵĚǇŽĨ ? ?ĂƌĐŚŝǀĂů
specimens from node positive CRC patients reported a contradictory result, with 
76% of cases EGFR positive but only 8% positivity for pEGFR369.  The criteria used 
for scoring was slightly different than that used in our study (deemed positive if 
>10% cells stained), suggesting a possible reason why this result is lower than 
that seen in the reported study.  Expression of pMAPK in 19.4% primary tumours 
and 16.1% of metastases was reported in Chapter 2, which is lower than that 
published in ^ĐĂƌƚŽǌǌŝĞƚĂů ?ƐƐƚƵĚǇ ?ǁŚĞƌĞƉƌŝŵĂƌǇƚƵŵŽƵƌƐĂŶĚŵĞƚĂƐƚĂƐĞƐǁĞƌĞ
positive for pMAPK in 70% of cases.  Significant heterogeneity between IHC 
methods and scoring criteria as well as differences in the fixation and storage 
conditions of the paraffin embedded tissue in different pathology laboratories, 
may have influenced the number of positives detected in different studies216.  
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These differences highlight lack of standardisation of immunohistochemical 
interpretation of such markers and the potential limitations of using archived 
paraffin embedded tissue for such an analysis. 
 
KRAS mutations were reported in 31% of patients, BRAF mutations in 6.9%, and 
PI3KCA mutations in 10%, figures which are all consistent with the published 
data130 221 230 237 241 244 248 370 371.  
 
5.2.3.2 Concordance between primary and metastatic disease 
For EGFR expression, there was concordance between primary and metastatic 
disease in the majority (86.2%), although 10.3% who had EGFR positive primaries 
had EGFR negative metastases, and 3.4% of patients with EGFR negative 
primaries has EGFR positive metastases.  Published evidence regarding 
concordance of EGFR expression in primary and metastases is contradictory.  
Italiano et al evaluated EGFR status amongst 80 paired primary/metastatic 
tumours, and found 94% of paired samples were concordant in EGFR status372.  
Scartozzi et al however, demonstrated that 36% of primary CRC expressing EGFR 
were negative in the corresponding metastatic site, and 15% of EGFR positive 
metastatic sites were negative in the corresponding primary tumour193.  Bibeau 
compared EGFR expression analysed by IHC on tissue sections and TMA in paired 
primary and metastatic CRC.  Although when tissue sections were analysed, 78% 
of paired samples showed a concordant EGFR-positive status, TMA analysis 
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revealed positivity in 65% of the primaries, 66% of the metastases, with no 
concordance between paired primary and the metastatic sites373.  The authors of 
this study concluded that EGFR expression was significantly underestimated by 
the TMA technique, with concordance differing according to whether tissue 
sections or TMAs were analysed373. 
 
Discordance between pEGFR expression in primary and metastatic tumours was 
found in 34.5% of patients.  A few small studies suggest that pEGFR positivity in 
primary tumours may have a role as a response predictor to EGFR targeted 
therapies.  Hijiya et al recently found that in lung adenocarcinoma, pEGFR 
correlates significantly with clinical responsiveness to gefitinib (P =0.0011)374, 
despite discordance in pEGFR in 50% of paired primary and metastatic NSCLC 
evaluated by Kalikaki et al375.  Little comparative evidence could be found in the 
literature describing the proportion of primary and metastatic CRC with positive 
pEGFR expression.  Amongst the 60 CRC samples examined by Bardier et al, 38% 
were positive for pEGFR, with a significant correlation between primary tumours 
and metastases (p=0.0004)365.  Personeni et al has demonstrated that pEGFR 
immunohistochemical score on primary tissue may correlate with higher disease 
control when treated with cetuximab (with or with irinotecan)218, therefore larger 
studies of pEGFR expression in primary and metastatic CRC are warranted if his 
potential role of pEGFR as response predictor is to be taken further.  
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Discordance in pMAPK expression in primary and metastatic disease (29% in this 
study) was comparable to the 25% of cases found by Scartozzi et al194, although 
the rates of positivity were higher in this study with 70% in primary tumours, and 
74% of liver metastases and  67% of lung metastases being positive (compared to 
19.4% in primary and 16.1% metastases in the reported study). 
 
The complete concordance of all 3 activating mutations in primary and metastatic 
disease confirms that these are likely to be early events in colorectal 
carcinogenesis, although this finding is not in agreement with all the published 
evidence.  Some small studies have reported complete concordance in K-ras 
mutations230 376, whilst others have found discordance in a minority of paired 
cases examined for K-ras and B-raf (8-23%)371 377 378.  Etienne-Grimaldi et al found 
38.7% of 93 CRC metastases analysed were KRAS mutant, with complete 
concordance in primary and metastatic samples230.  Suchy et al analysed 109 CRC 
specimens, and found KRAS point mutations at codon 12, position 2 in 21.1% of 
cases, with complete concordance in paired metastases376.  In the most recently 
published study, Artale et al used DNA sequencing to demonstrate a frequency of 
KRAS mutation in 27%, and B-raf mutation in 4% of the 48 CRC patients 
examined.  None of the patients carried both mutations.  Overall concordance of 
KRAS and BRAF mutational status between primary tumour and metastasis was 
reported in 92%.  Concordance was observed in 77% of 13 patients with KRAS 
mutations, whilst of the 2 patients with BRAF mutations, one patient presented 
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the same mutation in both primary tumour and metastasis, whereas the other 
patient presented the mutation in the primary alone371.  Oudejans et al also 
found discordance in KRAS mutation positivity in a minority of patients with 
paired primary and metastatic tissue they examined378.  No published evidence 
could be found examining the presence of PI3KCA mutations in primary CRC and 
corresponding metastatic tissue. 
  
5.2.3.3 Relationships between components of the EGFR/RAS/RAF/MEK/MAPK 
pathway 
dŚĞ ůĂĐŬ ŽĨ ĐŽƌƌĞůĂƚŝŽŶ ďĞƚǁĞĞŶ '&Z ? ŝƚ ?Ɛ ĂĐƚŝǀĂƚĞĚ ĨŽƌŵ Ɖ'&Z ? ĂŶĚ ƚŚĞ
presence of activated downstream components KRAS and BRAF mutations or 
pMAPK expression found in this study supports the body of evidence 
demonstrating that EGFR expression per se does not impact on downstream 
signalling, and therefore is not an accurate predictor of response to EGFR 
inhibitors such as cetuximab90 194.  A lack of correlation between EGFR expression 
and pMAPK expression was also reported by Scartozzi et al, who found that 
within the 48% of EGFR-negative colorectal primary tumours they examined, 74% 
expressed pMAPK whilst amongst the 52% EGFR-positive primaries colorectal 
cancers, 29% cases were negative for pMAPK194.  A similar discordance was seen 
between EGFR expression and pAkt expression, which was also evaluated in 
^ĐĂƌƚŽǌǌŝĞƚĂů ?Ɛ study.  
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The statistically significant correlation between pEGFR and KRAS mutations 
(66.7%, p=0.02), where 90% of the 10 patients with KRAS mutations also 
demonstrated pEGFR expression was in contrast to the lack of correlation found 
between pEGFR expression and BRAF mutation and pMAPK expression.  Of the 2 
patients with BRAF mutations however, only 1 was also positive for pEGFR.  
 
The significant overall correlation between KRAS mutation and pMAPK expression 
(concordance in 77.4%, p=0.01) was expected, as KRAS mutations are known to 
lead to activation of MAPK pathway and downstream component activation in 
the absence of ligand-dependent receptor activation236.  What was surprising 
however, was that despite this overall correlation in the whole sample, of the 10 
patients in which a KRAS mutation was present, 6 were found to be pMAPK 
negative.  Of the 2 patients with BRAF mutations, both were negative for pMAPK, 
suggesting that the presence of such mutations does not necessarily lead to 
activation on downstream MAPK in CRC.  In one patient pMAPK expression was 
present despite an absence of both KRAS and BRAF mutations, indicating that 
downstream components maybe activated via crosstalk from other pathways.  
 
Published evidence exploring the relationship between KRAS and BRAF mutations 
and downstream activation of MAPK (ERK1/2) remains controversial in a number 
of different tumour types.  Laack et al explored possible inter-relationships 
between EGFR, pMAPK, EGFR gene copy number, EGFR mutations and KRAS 
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mutations in patients with NSCLC, and found pMAPK expression status was not 
related to any of other markers analysed379.  There was also no significant 
correlation between KRAS or BRAF status and pMAPK (p-ERK1/2 expression) in 
endometrial cancers examined by Mizumoto et al suggesting that in this tumour 
type, MAPK activation may occur independently of upstream mutations in KRAS 
or BRAF380.  In ovarian cancers KRAS and BRAF mutations have been correlated 
with pMAPK (p<0.001), and as it has been shown that activation of downstream 
MEK and MAPK is critical to tumour growth and survival, such tumours may 
respond to MEK inhibition381.  In CRC, Schmitz et al found pMAPK (but not pAkt) 
correlated statistically with the presence of KRAS mutations (P=0.015), suggesting 
such mutations are likely to induce MAPK activation382.  In this study survival 
analysis of pMAPK expression correlated significantly with inferior OS.  Georgieva 
et al also found a significant correlation between MAPK activation and KRAS 
mutations, although this was only in tumours with a codon 12 mutation 
(p=0.016).  KRAS codon 13 mutations and BRAF mutations did not correlate with 
MAPK activation383. 
 
This small study has raised some interesting questions regarding the role each 
marker plays in the propagation of growth signals from the EGFR to the nucleus, 
and demonstrates that a greater understanding of the complex interactions is 
required if successful targeting of this pathway is to take place.  Whilst recent 
evidence demonstrates KRAS and BRAF mutations predict response to EGFR 
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targeting monoclonal antibodies, combinations of markers may need to be 
assessed in order to improve patient selection further.  Of particular interest 
would be the determination of pMAPK expression levels in addition to the 
presence of activating mutations, as it could be postulated that over expression 
of pMAPK in the absence of KRAS and BRAF mutations could also predict non-
response to cetuximab in wild-type tumours.  
 
The lack of correlation between EGFR and pEGFR and the presence of 
downstream PI3KCA mutations found in this study (p=0.64, p=0.58 respectively) 
provides another component to the explanation as to why EGFR and pEGFR 
expression are not good predictors of response to EGFR antibodies.  Emerging 
evidence suggests that activation of the EGFR signalling pathway as result of the 
deregulation of PI3KCA/PTEN can also contribute to the failure of cetuximab249, 
suggesting analysis of the activation of the PI3K pathway should also have a role 
in the molecular profiling of tumours in order to better predict response to EGFR 
targeting antibodies. 
 
5.2.3.4 Correlation between activating mutations 
Since the discovery that the presence of KRAS mutation can predict resistance to 
EGFR targeted antibodies, routine testing for such a mutation in patients being 
considered for treatment with cetuximab or panitumumab is now standard 
practice.  However, owing to the observation that the presence of KRAS 
  343 
mutations only accounts for 30-40% of non-responders227 229 235 384, additional 
determinants of primary resistance to EGFR-targeted therapies in colorectal 
cancers need to be discovered.  BRAF mutations in wild-type KRAS patients is one 
such recent discovery.  Whilst a number of studies have explored the effects of 
the presence of BRAF and PI3KCA mutations on response to cetuximab with 
conflicting results249 251 385, fewer have focused on the frequency of patients 
harbouring more than one activating mutation.  As was found in this study, the 
majority of published studies report that mutations in KRAS and BRAF are 
mutually exclusive in CRC130 245 386-389.  Barault et al however found 1 patient 
(0.2%) of the 586 colon adenocarcinomas evaluated had both KRAS and BRAF 
mutation390.  Less evidence could be found concerning the presence of PI3KCA 
mutations together with KRAS or BRAF mutations.  Whilst PI3KCA mutations did 
not occur concurrently with BRAF mutations in our study, 2 patients (6.5%) had 
both a PI3KCA mutation and a KRAS mutation present.  Two patients who were 
wild-type for both KRAS and BRAF were found to have a PI3KCA mutation.  This 
compares to simultaneous KRAS and PI3KCA mutations 8.2%, and a 2.2% 
incidence of concurrent BRAF and PIK3CA ŵƵƚĂƚŝŽŶƐ ŝŶ ĂƌĂƵůƚ Ğƚ Ăů ?Ɛ ƐƚƵĚǇ390.  
Other studies have found no simultaneous mutations249. 
 
Whether simultaneous mutations in KRAS and PI3KCA confer increased resistance 
to cetuximab than a single mutation remains controversial251 389.  Conflicting 
evidence also exists regarding whether PI3KCA mutations in wild-type KRAS 
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patients are associated with resistance to cetuximab.  Cappuzzo et al showed that 
PI3KCA mutations did not demonstrate a clinically relevant role as a predictor of 
resistance to cetuximab irrespective of the EGFR FISH result, and that testing for 
all 3 mutations in KRAS, BRAF and PI3KCA did not provide additional information 
over a single mutation test389.  Jhawer et al however, demonstrated maximal 
resistance to cetuximab could be predicted by the presence of simultaneous 
mutations of KRAS and PI3KCA251.  In this study, CRC cell lines with activating 
PI3KCA mutations or with loss of PTEN expression were more resistant to 
cetuximab therapy than PI3KCA wild type/PTEN expressing cell lines251.  
 
5.2.3.5 Study limitations 
This study had a number of limitations.  The small sample size illustrates the 
relative infrequency with which metastatic and primary tumour tissue is obtained 
in routine clinical practice.   
 
Many of the primary specimens were old and of poor quality, having been 
treated and stored differently amongst differing laboratories.  This made antigen 
retrieval difficult in some cases.  It is also known that different tissue fixation 
techniques from different institutions can effect how well activated proteins 
stain, and therefore may have been a potential for inconsistent results using 
immunohistochemical techniques.  The pathology report was the source of 
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primary tumour data collected, and these had been reported on by a variety of 
local pathologists. 
 
5.2.3.6 Summary 
Over the last few years a significant interest has been shown in determining 
predictors of response to antibodiĞƐ ƚĂƌŐĞƚŝŶŐ '&Z ?  ^ŝŶĐĞ ƚŚŝƐ ƉƌŽũĞĐƚ ?Ɛ
conception, a number of studies have been published looking at marker 
expression and the presence of activating mutations in the signal transduction 
pathways downstream of EGFR.  Unfortunately, the role of many of these 
markers remain controversial, owing to the differing results found in many 
studies.  Differences in tissue storage and preparation, IHC technique, and 
method of mutation analysis, maybe partly responsible for some of the 
conflicting results published in the literature.  
 
This study, although small, has confirmed that immunohistochemical markers of 
activation such as pEGFR and pMAPK are not always concordant in primary and 
metastatic disease, but that mutations in KRAS, BRAF and PI3KCA are.  It also 
confirmed that EGFR and pEGFR are not accurate predictors of 
EGFR/RAS/RAF/MAPK pathway activation, and has raised a number of questions 
which warrant further investigation.  The lack of correlation between both pEGFR 
and KRAS, BRAF and PI3KCA mutations and pMAPK suggests pathway activation 
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can occur even in the absence of receptor activation and downstream activating 
mutations.  
 
Although to date, pMAPK in primary tissue has not been shown to be an accurate 
predictor of response to EGFR antibodies, this could partly be attributable to 
heterogeneity of expression in primary and metastases.  Whilst no correlation 
was found between disease control at 12 weeks following first line, single agent 
cetuximab and IHC expression ŽĨ Ɖ'&Z ĂŶĚ ƉDW< ŝŶ 'ƌĂǀĂůŽƐ Ğƚ Ăů ?Ɛ ƌĞĐent 
study, this assessment was performed on primary tissue385, and results may have 
been different had metastatic tissue also been evaluated.  Larger studies should 
explore pMAPK expression in wild type tumours and response to cetuximab, but 
owing to the lack of correlation between paired primary and metastatic tissue, 
such studies would need to involve the evaluation of metastatic disease.  It is also 
possible that pMAPK expression may have a role in response prediction in 
combination with the assessment of activating mutations, in order to better 
select patients for combined targeted therapy. 
 
5.2.3.7 Implications for the future use of targeted antibodies in CRC 
By identifying how the EGFR/RAS/RAF/MAPK pathway is activated at different 
levels of the signal transduction cascade, the molecular basis for combined 
targeted therapies can be better understood.  Following their recent discovery 
that BRAF mutations lead to resistance to panitumumab and are evident in a 
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proportion of KRAS wild-type patients, Di Nicolantonio et al performed cell-based 
analysis which showed that BRAF-mutated CRC cells can potentially respond to 
EGFR-targeted antibodies if the BRAF inhibitor sorafenib is administered 
concomitantly with cetuximab or panitumumab130.  This is an excellent example 
of where a better understanding of the activity of multiple components of the 
EGFR/RAS/RAF/MAPK pathway can lead to the design of future studies of 
targeted therapy combinations, and studies looking at the combination of EGFR 
and sorafenib in BRAF mutation positive patients are eagerly awaited.  In those 
patients with KRAS, BRAF and PI3KCA wild-ƚǇƉĞƚƵŵŽƵƌƐƚŚĂƚĚŽŶ ?ƚ ƌĞƐƉŽŶƐĞƚo 
cetuximab/panitumumab, it would also be interesting to assess pMAPK 
expression, and whether MEK or MAPK inhibition could reverse primary 
resistance to cetuximab in this situation. 
 
Solit et al examined whether BRAF mutations predict response to MEK inhibitors 
in a number of cell lines of different cell lineage, and found that BRAF mutations 
are associated with enhanced and selective sensitivity to MEK inhibition386.  
Whilst MEK inhibition completely abrogated tumour growth in BRAF mutant 
xenografts, KRAS mutant tumours were only partially inhibited, suggesting a 
greater dependency on MEK activity and hence a potentially greater sensitivity to 
therapeutic inhibition at this level in BRAF mutant tumours386.  
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In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of 
MAPK has been shown to improve efficacy of EGFR targeted antibodies238.  
Tumour cell lines harbouring KRAS or BRAF mutations were found to be more 
sensitive to the MAPK inhibitor AZD6244, which was also found to enhance the 
antitumor activity of both docetaxel and irinotecan in human colon cancer 
xenografts391.  It has also been shown experimentally that the coexistence of an 
activating PI3KCA mutation reduces a KRAS-mutated tumour's dependence on 
downstream MEK/ERK signaling392, suggesting that in the presence of both 
mutations, combining agents that target members of the PI3K pathway with MEK 
and RAF inhibitors may lead to reversal of resistance to EGFR antibodies393.  Trials 
of such combinations are awaited.  
 
Synergistic cytotoxicity has been observed between MEK inhibitors gefitinib in 
breast cancer cell lines394 and MEK inhibitors and PI3K inhibitors in glioblastoma 
cells395.  These preclinical studies suggest that combining agents which target 
different levels of the EGFR signal transduction cascade, may show significant 
therapeutic promise.  It will be vital that careful molecular analysis is included in 
the early phase development of such combinations if patient selection is to be 
optimised.  
 
This study focused primarily on exploring the expression and mutation of 
signalling molecules downstream of EGFR in CRC primary tumours and 
  349 
metastases.  Other potential contributors to EGFR antibody resistance, possibly 
via activation of pathways downstream of Ras that have been investigated 
include, the hepatocyte growth factor receptor MET396, loss of PTEN235 249, IGFR-
1389 397 398.  Some studies have also implicated increased EGFR gene copy 
number399 400.  Finocchiaro et al assessed MET and IGF1R expression, as well as 
BRAF and PI3KCA mutations in 85 metastatic CRC patients treated with 
cetuximab-based therapy in whom EGFR and KRAS status was known396. In this 
study the rarity of MET and IGF1R gene amplification suggested these factors 
have a minimal role in primary resistance to EGFR-targeted therapy in metastatic 
CRC396. 
 
The limitations of this study in terms of access to tissue and variability in 
preparation and storage, together with the huge scope for future studies to 
evaluate additional response predictors and support early clinical development of 
combinations of targeted therapies, highlights the importance of tissue banks in 
institutions and large clinical trials.  As immunohistochemical assessment of 
response predictors can be reliant on adequate quality of tissue preservation and 
storage, as well as significant potential variability in scoring method and 
interpretation by pathologists, mutational analysis has many advantages.  DNA is 
stable in fixed tissue, results are either positive or negative, and analysis such as 
HRM can be performed on even small amounts of DNA.  This study however 
suggests further investigation is warranted looking at the evaluation 
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EGFR/RAS/RAF/MAPK activation by mutations analysis in combination with 
pMAPK expression analysis, but that ideally this IHC analysis should be performed 
on primary and metastatic tissue owing to the lack of concordance of this marker 
as has been described. 
 
5.3 Antibody-targeted chemotherapy: Immunoconjugates 
The obstacles that must be overcome to develop an efficacious immunoconjugate 
for the treatment of patients with metastatic solid tumours are numerous.  
Whilst genetic engineering has overcome immunogenicity of antibody conjugates 
and the high potency of drugs such as calicheamicin have ensured a potentially 
efficacious payload can be delivered to target cells, translating preclinical success 
into anti-tumour effects in patients remains difficult, as Chapter 3 illustrates. 
 
5.3.1 Study rationale 
As described in Chapter 1 section 1.8, the long term goal of researchers 
worldwide exploring the targeting of Ley in epithelial cancers is to utilise the 
significant potential of using antibodies to target tumour and improve the care 
(and outcome) of patients with solid tumours.  The study reported on in Chapter 
3 builds on the important work carried out first by LICR in optimising the 
therapeutic characteristics of such an anti-Ley antibody by humanisation, and 
conducting initial Phase I trials, and then by Wyeth pharmaceuticals who 
developed the immunoconjugate CMD-193.  The partnership between LICR and 
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Wyeth allowed a detailed biodistribution study in patients to be performed in 
parallel to the first in man dose escalation study performed in the US (not yet 
published).  The unexpected findings of this study had a significant impact on the 
future development of CMD-193, and confirmed that this type of Phase I 
bioimaging study should be a vital component of early clinical development of 
immunoconjugates. 
 
5.3.2 Summary of findings 
The primary objective of this study was to determine the biodistribution and 
pharmacokinetics of 111In-CMD-193.  Following infusion of 111In-CMD-193, there 
was initial blood pooling, followed by markedly increased hepatic uptake by day 2 
which persisted to day 8, and fast blood clearance.  No definite tumour targeting 
to known sites of metastatic disease was observed in any patient.  Consistent 
with these biodistribution findings, pharmacokinetic analysis determined that 
111In-CMD-193 displayed a fast clearance from blood. The final mean (± SD) 
pharmacokinetic results for 111In-CMD-193 (for all 9 patients) was: T½  = 4.76 ± 
2.15 hrs, T½  = 102.88 ± 35.67 hrs; CL = 113.22 ± 56.58 mL/hr and V1 = 4071.22 ± 
731.41 mL.  No significant differences between dose levels for these parameters 
were observed. 
 
Secondary objectives included the determination of changes in tumour 
metabolism by 18F-FDG PET following treatment with CMD-193, and to describe 
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anti-tumour responses.  Although biodistribution assessment found no evidence 
of CMD-193 targeting areas of metastatic tumour and no objective tumour 
responses were seen, analysis of tumour metabolism following CMD-193 infusion 
demonstrated some anti-tumour activity of this immunoconjugate with 1 partial 
metabolic response (PMR) on FDG-PET imaging.  Tumour response according to 
RECIST was ascertained in 8 patients, amongst whom there were 4 with stable 
disease (two patients in each dose cohort) and 4 with progressive disease on CT 
scanning.   
 
CMD-193 at doses of 1.0 mg/m2 and 2.6 mg/m2 was reasonably well tolerated, 
although 4 patients, 2 from each dose cohort, were withdrawn because of 
unacceptable toxicity, and only 1 patient completed all 6 cycles as planned.  No 
difference in toxicity was observed between patients in the 2 dose levels.  The 
main adverse events with some relationship to CMD-193, were asymptomatic 
myelosuppression and abnormal liver function.  Other related adverse events, 
including the relatively common gastrointestinal disorders, such as nausea and 
epigastric discomfort, were mild to moderate, and there were no infusion-related 
reactions, and no HAHA responses. This trial has shown that CMD-193 can be 
administered in multiple infusions (up to a maximum of 6 cycles), with 
myelosuppression and liver toxicity being the principle significant toxicities 
encountered. 
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In summary, despite evidence supporting the strategy to optimise the therapeutic 
potential of the anti-Ley antibody hu3S193 by conjugation with calicheamicin, the 
study of this immunoconjugate CMD-193 reported herein demonstrated altered 
in-vivo properties of the immunoconjugate compared to the parental antibody, 
and as a result poor tumour uptake and reduced efficacy potential was observed.  
 
There are many reasons why the promising efficacy of immunoconjugates seen in 
animal models may not be translated to patients.  These include; lack of cytotoxic 
potency, limited concentration of antigenic expression on tumour cells, inefficient 
internalisation of antibody Wantigen complexes, poor penetration of 
immunoconjugate, inefficient or premature release of the drug from the 
antibody, and immunogenicity401.  Prior studies however, suggested that the 
therapeutic potential of CMD-193 was significant, as published evidence showed 
that many of these obstacles would be overcome.  Calicheamicin is more than ten 
times more potent than doxorubicin, expression of Ley on cancer cells is in the 
region of >1 x106 molecules/cell, rapid internalisation of hu3S193 once bound to 
Ley has been demonstrated288, 111In-hu3S193 is able to penetrate solid tumours in 
xenografts and human tumours288,281, and hu3S193 is known to be non-
immunogenic in humans281. 
 
Possible explanations for the findings in this trial will now be discussed, first by 
drawing on comparisons to the parental antibody hu3S193, then by comparing to 
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other calicheamicin conjugates, particularly gemtuzumab ozogamicin.  A focus 
will be placed on the differences in biodistribution, clearance and 
pharmacokinetics, but toxicity profiles will also be discussed.  Possible directions 
for the future development of this strategy will then be discussed in section 5.3.6. 
 
5.3.3 Biodistribution and Pharmacokinetics 
A direct comparison of the biodistribution and pharmacokinetic properties of 
CMD-193 with those observed with the parental antibody hu3S193 in a prior trial 
also performed at our institution, provided a valuable chance to explore the 
possible in vivo effects on biodistribution and pharmacokinetics of antibody 
conjugation with the cytotoxic calicheamicin.   
 
5.3.3.1 Biodistribution and whole body clearance 
In the Phase I dose escalation study of 111In-hu3S193, blood pool activity which 
cleared gradually with time, and prominent specific uptake in tumour was clearly 
documented, and no consistent normal tissue/organ uptake was seen281.  
Transient stomach and bowel activity was observed post infusion in two patients 
at the highest dose level (40 mg/m2), but excellent uptake of 111In-hu3S193 was 
observed in tumour sites measuring >1.5cm (including lung, liver, nodal and bone 
disease) at all dose levels.  No increased hepatic uptake was seen in this prior 
trial281.  This is in contrast to described initial blood pooling, followed by markedly 
increased hepatic uptake by day 2 which persisted to day 8, fast blood clearance, 
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and total lack of tumour targeting to known sites of metastatic disease with CMD-
193.  Importantly, patient 103 had participated in both clinical studies, allowing 
direct comparison of biodistribution, clearance and hepatic uptake between 
CMD-193 and hu3S193 in the same patient.  Figure 5.3.3.1 illustrates the 
differences in biodistribution observed in this patient in the two trials.  Although 
this patient received 2 different doses of antibody in the two trials, 5mg/m2 of 
hu3S193 compared to 1.0mg/m2 CMD-193, the initial trial of hu3S193 
demonstrated no difference in biodistribution between dose levels of antibody, 
with no saturable compartment, and hence this comparison can be legitimately 
made. 
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Figure 5.3.3.1. Patient 103: Comparison of biodistribution in the same patient of 
111
In-CMD-193 and 
111
In-hu3S193   
 
 
  357 
For all patients (in both dose cohorts) who received 111In-CMD-193, whole 
body clearance (Effective T ½) was 47.82 ± 3.24 hr, compared to 63.75 ± 2.44 
hr in 15 patients who received 111In-hu3S193.  This difference was statistically 
significant (p<0.0001).  Whole body clearance for CMD-193 was also faster 
than that observed with other tumour targeting antibodies investigated at our 
institution14 302. 
 
Quantitative hepatic uptake and clearance for 111In-CMD-193 was compared 
to that seen with 111In-hu3S193, as show below in Figure 5.3.3.2.  This analysis 
confirmed the significant degree of hepatic uptake on gamma camera images 
observed with the calicheamicin conjugate CMD-193, but not the parental 
antibody hu3S193.  Comparison of whole body clearance and hepatic uptake 
of CMD-193 and parental antibody hu3S193 in the same patient (patient 103) 
confirmed these differences, as shown in Figures 5.3.3.3 and 5.3.3.4. The 
prolonged whole body retention of CMD-193, compared to fast blood 
clearance, is due to uptake of CMD-193 in liver (not seen with hu3S193 study). 
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Figure 5.3.3.2. Mean (± S.E.M.) hepatic uptake and clearance of 
111
In-CMD-
193 compared to 
111
In-hu3S193  
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Figure 5.3.3.3. Comparison of whole body clearance (Effective T½) in the 
same patient (103) who participated in both hu3S193 and CMD-193 trials 
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Figure 5.3.3.4. Comparison of hepatic uptake and clearance in the same 
patient (103) who participated in both hu3S193 and CMD-193 trials 
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Additional exploratory analysis using Fast Protein Liquid Chromatography 
(data not shown) confirmed retention of CMD-193 radiochemical purity and 
no evidence of instability or complex formation in vivo to explain the altered 
biodistribution and clearance.  
 
5.3.3.2 Pharmacokinetics 
The faster whole body clearance of CMD-193 compared to the parental 
antibody hu3S193 as demonstrated with biodistribution and dosimetry 
analysis, is consistent with pharmacokinetic data obtained from both trials.  
There was no statistically significant difference between trials for T½  
(p=0.358), but patients receiving CMD-193 demonstrated a significantly 
shorter mean T½  of 102.88 hours compared to 189.63 hours with hu3S193 
(p<0.001).  V1 was significantly higher for CMD-193 compared to hu3S193 
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(p=0.011), and serum clearance (CL) was significantly quicker for those infused 
with CMD-193 compared to hu3S193 (p<0.001).   
 
As discussed and summarised in Table 5.3.1, in contrast to hu3S193, CMD-193 
displayed rapid hepatic uptake, fast blood clearance and poor tumour 
targeting.  This data suggests that certain properties of the immunoconjugate 
CMD-193 unexpectedly caused it to localise to the liver in vivo.  Possible 
explanations for this altered biodistribution that will be discussed include 
factors relating to the antibody, choice of radiolabel 111In, and choice of 
cytotoxic calicheamicin. 
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Table 5.3.1 Summary of comparison of hu3S193 and CMD-193 
Parameter Hu3S193 CMD-193 
Antibody Humanized IgG1- hu3S193 Humanized IgG1 - G193 
Conjugate None 
NAc-gamma calicheamicin DMH 
acid-labile AcBut linker 
Immune effector 
function 
Potent ADCC and CDC ADCC and CDC maintained 
Binding affinity (KD) 130 nM 340 nM 
In vivo anti-tumour 
efficacy 
Tumour cell kill in preclinical 
data 
Dose-dependent regression of 
human carcinoma xenografts 
Biodistribution 
111
In-hu3S193 
111
In-CMD-193 
Mean whole body 
clearance (hrs)* 
63.75  2.44 47.82  3.24 
Pharmacokinetics 
111
In-hu3S193 
111
In-CMD-193 
T ½ a (Hr) 6.58  5.53 4.76  2.15 
T ½ b (Hr)* 189.63  62.17 102.88  35.67 
V1 (mL)* 3276.85 642.43 4071.22  731.41 
CL (mL/hr)* 22.09  9.87 113.22  56.58 
Tumour targeting 
Tumour uptake 
Excellent localisation in 
tumour in animal models and 
human patients 
1.2-6.3 g/g 
Anti-tumour efficacy in 
xenografts in animal models 
Poor tumour uptake in patients 
* Statistically significant different found between these parameters for 111In-
hu3S193 and 111In-CMD-193 
 
 
5.3.3.4 
111
In as choice of label 
Indium-111 is an optimal radiolabel for the localisation of internalised labelled 
antibody in tumours for a number of reasons.  The gamma emissions of 111In 
(171 and 247keV) are ideally suited for gamma camera imaging, it has a half-
life conducive to intact IgG imaging (2.83 days), it is known to be chemically 
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stable once internalised into cells (by forming complexes with cytoplasmic 
components)402, and can be successfully used to label antibodies with a 
bifunctional chelating agent281,403.  Endocytosed 111In-labelled-antibodies are 
delivered to lysosomes and hydrolyzed by lysosomal enzymes into metabolites 
which are retained within tumour lysosomes323 404.  
 
111In was chosen as a suitable label following a study, which examined the 
biodistribution characteristics of hu3S193 labeled with 3 different 
radioisotopes (125I, 111In, and 90Y), in a BALB/c nude mouse xenograft model of 
Ley positive breast cancer.  This study demonstrated that radiometals were 
the preferred isotope for this antigen-antibody system, with better retention 
of 111In labelled hu3S193 and its catabolites in tumour cells288.  
Autoradiography, immunohistochemistry and gamma camera imaging was 
used to determine tumour and normal tissue uptake and pharmacokinetics of 
111In-hu3S193.  The mean elimination half life of 111In-hu3S193 in this animal 
model was 69.3 hours, and at 48 hours post infusion, tumour uptake was 
~30%ID/g whilst liver uptake was <5%ID/g.  Successful tumour targeting was 
demonstrated by the distribution of radioactivity throughout regions of viable 
tumour including a degree of activity in the central necrotic area of tumours, 
and radioimmunoreactivity remained high with only 2% of free 111In detected, 
suggesting minimal leaching of 111In. 
 
The choice of chelate for conjugation with 111In radiolabel is also important as 
this can affect lipophilicity of the radiolabelled antibody, and hence the 
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proportion of radiometal accumulation in the liver405,406.  Non-specific binding 
of a radiolabelled antibody may be increased by the use of 
radionuclides/chelate systems in which the chelate is not stable enough to 
prevent loss of the radiolabel.  Leaching of 111In is not likely to be a 
contributing factor to increased hepatic uptake in this study, as this was not 
seen in the preceding trial of parental antibody which was labelled with 111In 
via the same bifunctional metal ion chelate (CHX-A  DTPA)281, and free 111In 
was not seen in the spleen or bone marrow in either trial.  Additional 
investigation on the serum of patient 102 (data not shown) confirmed that 
the abnormal hepatic uptake was not as a result of unconjugated 111In in the 
liver (free 111In could accumulate and be metabolised by hepatocytes), as 
there was no free 111In chelate or 111In in the serum to suggest this.  
 
5.3.3.5 Conjugation with NAc-gamma calicheamicin DMH 
The results of biodistribution studies and detailed serum analysis, was able to 
exclude antibody characteristics (such as low specificity or binding affinity) 
and unsuitable choice of radiolabel and chelator as possible reasons for the 
abnormal biodistribution observed in this study. An additional issue therefore 
to explore was the effects of conjugation of G193 with calicheamicin. 
 
The liver has a vital role in the uptake and metabolism of circulating 
macromolecules and immune complexes, which occurs via parenchymal cells 
(hepatocytes) or non-parenchymal cells (Kupffer cells or the sinusoidal 
endothelial cells)407.  The majority of circulating macromolecules or particles 
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adhere to hepatic cells by non-specific physiochemical forces such as 
electrostatic attraction and hydrophobic interactions, but hepatic clearance 
may also be a result of specific receptor mediated interactions, such as 
scavenger receptors, which remove acidic macromolecules408.  Size and 
charge can therefore effect the uptake of circulating macromolecules by such 
hepatic cells409, as well as effecting antibody uptake by target tumour cells.  
Nishida et al explored the effect of charge on the hepatic disposition of 
macromolecules in the rat410.  After intravenous injection, cationic 
macromolecules were rapidly eliminated from plasma because of their 
extensive hepatic uptake, while anionic and neutral macromolecules were 
slowly eliminated410.  Slinkin et al investigated the effects of different electron 
charges on F(ab')2 fragments of anti-carcinoembryonic antigen (CEA) 
monoclonal antibody (mAb)411.  Immunoreactive conjugates labeled with 111In 
were injected into nude mice bearing human colorectal carcinoma, and the 
biodistribution patterns were compared with each other and with that of an 
anti-CEA F(ab')2-DTPA control.  Highly negatively charged conjugate produced 
the lowest tumor uptake (up to 8% ID/g), which contrasted to the positively-
charged immunoconjugate, which produced the highest tumor uptake (up to 
20% ID/g)411.   
  
The pattern of biodistribution seem in the gamma camera imaging obtained 
suggests that the immunoconjugate was able to initially circulate in blood 
pool, but that hepatic uptake increased quickly, and by day two hepatic 
uptake was predominant, and this persisted to at least day 8 following 
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infusion.  This suggests that the immunoconjugate underwent some form of 
metabolic processing in the liver.  Together with the lack of free 
calicheamicin, it is therefore unlikely that calicheamicin was released 
prematurely from the antibody, or part metabolised whilst still conjugated to 
antibody. It has been argued that degree of loading of antibody with cytotoxic 
could potentially influence the targeting properties and efficacy of an 
immunoconjugate412.  The effect of calicheamicin loading on efficacy of CMD-
193 was investigated by Wyeth in their preclinical characterisation.  CMD-193 
with calicheamicin loadings of 30, 60, and 90µg of calicheamicin equivalents 
per milligram of G193 (at a fixed dose of 160 µg of conjugated calicheamicin 
per kilogram of body weight) were administered to xenografted mice every 4 
days for a total of 3 administrations141.  The anti-tumour efficacy of CMD-193 
with different calicheamicin loadings was essentially identical, suggesting that 
calicheamicin loading was unlikely to be affecting the ability of the 
immunoconjugate to target tumours, although whether this finding is 
reproducible in humans is unknown.  Other published evaluations of 
antibody Wdrug conjugates for binding to antigen-positive cells indicated that, 
in the majority of cases, the affinity of the antibody was either fully preserved 
or only slightly diminished upon conjugation of up to eight molecules of 
drug401.  In addition, there was no evidence that conjugation with 
calicheamicin increased immunogenicity (and hence clearance) of the 
conjugate, as no HAHA were detected in any patient.   
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5.3.4 Comparison with other calicheamicin immunoconjugates 
Although further exploration is clearly required in order to determine how the 
conjugation of calicheamicin may effect the biodistribution of this 
immunoconjugate, comparisons with other calicheamicin conjugates may 
provide explanations for the findings of this study.  CMD-193 is one of only a 
very few calicheamicin immunoconjugates to be investigated in solid 
malignancies, and reach clinical trials, hence comparisons will be drawn to the 
development of Mylotarg, and the only other conjugate found in the 
published literature to reach Phase II trials, CMB-401.  
 
5.3.4.1 Gemtuzumab ozogamicin 
Gemtuzumab ozogamicin (Mylotarg) is a conjugate of humanized IgG4 anti-
CD33 antibody hP67.6, covalently linked to N-acetyl gamma calicheamicin 
dimethyl hydrazide (CalichDMH) via an acid hydrolysable AcBut linker.  It 
consists of a 1:1 mixture of unconjugated hP67.6 and hP67.6 conjugated to 
 ?AL ?ŵŽůĂůŝĐŚD, ?ƉƌŽǀŝĚŝŶŐĂŶĂǀĞƌĂŐĞĚƌƵŐůŽĂĚŝŶŐƌĂƚŝŽŽĨƚǁŽƚŽƚŚƌĞĞ
drugs to one mAb.  Whilst it shares conjugation with the same cytotoxic via 
the same acid labile hydrazone linker to CMD-193, it is targeting a very 
different antigenic system in a very different disease entity.   
 
Whilst CMD-193 is known to have strong effector cell function, the parental 
antibody used in Mylotarg is IgG4, and hence is not able to induce ADCC or 
CDC.  Instead it relies on strong binding to CD33 positive cells, rapid 
internalisation and transport to lysosomes for release of its therapeutic 
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payload.  The 1:1 ratio of unconjugated:conjugated  hP67.6 is in contrast to 
the 90% of G193 which is loaded with CalichDMH in CMD-193.  This is because 
in AML patients, the unconjugated antibody is able to saturate antigen 
expressed on normal myeloid progenitors cells, whereas hu3S193 was found 
not to have a saturable compartment281.  Drug loading of antibody is similar in 
both immunoconjugates, with 5-7 moles of CalichDMH per mole of antibody 
in CMD-193, and 4-6 with Mylotarg. 
 
A Phase I dose escalation study established 9mg/m2 as the optimal 
therapeutic dose for Mylotarg, and as the half-life of hP67.6 was estimated to 
be 2-3 days, a second dose after 14 days was justified and is now standard 
practice413.  Detailed pharmacokinetic evaluation in patients with AML at first 
relapse found that the increased concentrations that were seen after the 
second dose could be explained by saturation of CD33 binding sites and a 
decrease in clearance by CD33 positive blast cells as a result of the reduced 
tumour burden following the first dose414 415.  After administration of the first 
9 mg/m2 dose of gemtuzumab ozogamicin, the pharmacokinetic parameters 
(mean ± SD) of hP67.6 were as follows: peak plasma concentration, 2.86 ± 
1.35 mg/L; AUC, 123 ± 105 ŵŐ ?Ś ?> ? t1/2, 72.4 ± 42.0 hours; and clearance, 
265 ± 229 mL/h414.  The values for volume of distribution suggest that 
gemtuzumab ozogamicin does not extensively distribute beyond the plasma 
compartment (and hence fits a single compartmental model).  The very 
different natures of the target antigenic system makes it difficult to make 
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meaningful comparisons of pharmacokinetic parameters between Mylotarg 
and CMD-193.  
 
Unlike CMD-193, whose pharmacokinetic properties were significantly 
different from the parental antibody, the short half-life and rapid clearance of 
Mylotarg, can be explained by its target antigen CD33, rather than 
conjugation with calicheamicin. The constant production and turnover of 
leukemia cells in vivo where new antigen sites capable of binding therapeutic 
antibodies are continually being produced, explains the short half life of CD33 
antibodies416. The estimated volume of distribution documented by Dowell et 
al414 was consistent with those estimated from published biodistribution 
studies of other radiolabelled anti-CD33 antibodies, which reported specific 
bone marrow uptake and distribution of the antibody only in organs with a 
large blood pool, such as spleen and liver416.  No published biodistribution 
studies of Mylotarg could be found to confirm this.  The influence of antigenic 
burden on pharmacokinetic parameters was also demonstrated by Dowell et 
al.  The mean last observable t1/2 for hP67.6 was 72.4 hours after the first dose 
and 93.7 hours after the second dose.  As they concluded, peripheral blast 
counts decreased after the first dose of Mylotarg, and so the clearance due to 
internalisation by blasts is decreased, explaining the increase in plasma 
concentrations of hP67.6, and longer serum half-life with second dose414.  As 
was seen with CMD-193, plasma concentrations of unconjugated 
calicheamicin were low and could only be measured for a relatively short time 
following the end of drug infusion.  The concentration profiles of 
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calicheamicin also followed the same time course as hP67.6, demonstrating 
drug linker stability and accurate delivery of calicheamicin to CD33 positive 
cells414.  
 
Although Mylotarg appears to share a number of pharmacokinetic features 
with CMD-193, such as short half-life and rapid clearance, the very different 
nature of antigenic target means the explanations for these characteristics 
when administered to patients is actually very different.   
 
5.3.4.2 CMB-401 
CMB-401 (hCTM01-calicheamicin) is an immunoconjugate which combines an 
N-acetyl/analogue of calicheamicin with a polymorphic epithelial mucin (PEM) 
targeting humanised antibody hCTM01 (with 2-3 moles calicheamicin per 
molecule of antibody) using an amide-based linkage.  The tumour associated 
antigen PEM (MUC-1 gene product) is expressed on apical surface of secretory 
epithelia and is overexpressed in many epithelial cancers.  After pre-clinical 
evidence demonstrated significant growth inhibition of human breast cancer 
xenografts in vitro, an initial biodistribution study of 111In-labeled hCTM01 in 
patients with ovarian cancer demonstrated a significantly higher uptake in 
tumour deposits compared to normal tissues417.  However all patients showed 
immune complex formation, which were present by the end of the infusion 
and attributed to interaction with circulating antigen.  Liver activity was also 
notably high.  Hepatic uptake in this biodistribution study of labelled antibody 
was thought to be partly due to expression of PEM in normal bile duct cells, 
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and most likely the result of degree of circulating antigen and uptake by the 
liver of the resulting immune complexes417.   
 
A subsequent dose escalation Phase I study of the calicheamicin 
immunoconjugate CMB-401 in patients with epithelial ovarian cancer, 
included a pre-dose of unconjugated antibody which aimed to minimise 
uptake in normal tissues and complex formation with circulating antigen145.  
Toxicity included haematological toxicity (mild neutropenia, 3 patients with 
grade 3-4 thrombocytopenia, and frequent effects on haemoglobin).  Mild 
liver toxicity was documented, with transient rises in serum transaminases 
being commonly observed.  MTD was defined by malaise, haematological 
toxicity and gastro-intestinal haemorrhage (seen in 6% or patients)145.  Once 
this trial had established tolerability and MTD, Chan et al performed a Phase II 
trial in 21 patients with recurrent ovarian cancer, where a pre-dose of 
unconjugated antibody (35mg/m2) was followed by 16mg/m2 of CMB-401146.  
No complete or partial responses were observed, although 4 patients had a 
>50% decrease in baseline CA125 levels.  Surprisingly, considering the 
reported liver toxicity and gastrointestinal haemorrhage in the preceding 
Phase I trial, these adverse events were not reported in this trial146.  
Treatment related AEs included anaemia, thrombocytopenia, nausea, 
asthenia, anorexia, diarrhoea and headache.  Lack of efficacy (and hence 
further development) was attributed to probably instability of the amide 
linker used in CMB-401, although free calicheamicin and measurement of 
serum complex formation was not mentioned.  Published evidence of 
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biodistribution and pharmacokinetic assessment of CMB-401 in patients could 
not be found, and hence it is not possible to draw comparisons with CMD-193 
above the common toxicity profile relating to calicheamicin.  As with CMD-
193, the haematological and gastrointestinal (and hepatic) toxicity is 
attributable to calicheamicin, and possibly some targeting of normal epithelial 
tissues expressing target antigen.  The level of circulating PEM antigen 
together with an unstable amide linker are likely to be the reasons behind the 
failure of this agent, but it is difficult to draw conclusions without evidence 
regarding circulating immune complexes with the loading dose, amount of 
free calicheamicin, and biodistribution imaging. 
 
5.3.5 Adverse event profile 
As described, although CMD-193 at doses of 1.0 mg/m2 and 2.6 mg/m2 was 
reasonably well tolerated, only 1 patient completed all 6 cycles as planned.  
The main adverse events with some relationship to CMD-193 were abnormal 
liver function and asymptomatic myelosuppression. 
 
5.3.5.1 Hepatotoxicity 
The liver toxicity seen in some patients following administration of CMD-193 
may be explained by rapid hepatic uptake and metabolism of calicheamicin.  
Several enzyme systems in human liver microsomes, hepatocytes, and cytosol 
are involved in the activation/metabolism of the NAc-gamma calicheamicin 
DMH that it encounters.  Metabolic pathways in microsomes are 
hydroxylation and demethylation, whilst the formation of NAc-epsilon 
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calicheamicin and its derivatives are thought to be the major pathways in 
cytosol.  Both human liver microsomal and cytosolic metabolites have been 
found in human hepatocytes, suggesting that NAc-gamma calicheamicin DMH 
can be transported into human hepatocytes. Liver toxicity induced by NAc-
gamma calicheamicin DMH or its metabolites is the likely explanation for the 
liver toxicity seen with CMD-193.  Whilst liver toxicity was documented with 
CMD-401, in this case it was attributed to expression of target antigen in liver 
bile duct cells, rather than to uptake of calicheamicin metabolites by 
hepatocytes146.  Interestingly the only DLT seen in the prior study of the 
parental antibody hu3S193 was also hepatic toxicity, an asymptomatic grade 3 
rise in alkaline phosphatase.  Transient elevation of ALT and AST were also 
documented as possibly related to study drug in this patient.  The patient in 
whom the DLT was reported was noted to have extensive liver metastases 
and baseline grade 2 ALP elevation at study entry281, so this adverse event 
could have been related to underlying disease rather than hu3S193.   
 
Hepatic toxicity is also a feature of gemtuzumab ozogamicin therapy.  Whilst 
in this study rapid hepatic uptake of CMD-193 could expose hepatocytes to 
calicheamicin metabolites, such rapid hepatic uptake and clearance has not 
been demonstrated with Mylotarg following administration in patients with 
AML (although biodistribution assessment in humans has not been reported).  
With Mylotarg, hepatotoxicity can be explained partly by sinusoidal 
obstruction syndrome, the mechanism of which probably involves targeting of 
CD33+ cells in the sinusoids of the liver, activation of stellate cells, damage to 
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sinusoidal endothelial cells, sinusoidal vasoconstriction, and ischaemic 
hepatocyte necrosis418.  This clinical syndrome of veno-occlusive disease is 
commonest in patients who have previously undergone hematopoietic stem 
cell transplantation and is characterised by portal hypertension, jaundice, and 
elevated serum AST level419. 
 
5.3.5.2 Haematological toxicity 
Myelosuppression following CMD-193 can be explained by the 
myelosuppressive effects of small amounts of free calicheamicin. Despite the 
amount of free calicheamicin being below the limit of quantification in our 
study, the high potency of even small amounts of free calicheamicin may have 
caused the myelosuppression encountered, coupled with the fact that Ley is 
weakly expressed on granulocytes20 269.  The rapid recovery of blood counts 
(particularly following the significant fall in platelet count seen in some 
patients) supports the argument that small amounts of circulating free 
calicheamicin principally affected circulating platelets rather than the bone 
marrow, as recovery was seen within days.  CMB-401 led to grade 3-4 
anaemia in 21%, granulocytopenia in 9% and thrombocytopenia in 9% of 
patients suggesting this is a likely effect of calicheamicin conjugation146.  
Mylotarg leads to profound but usually self limiting myelosuppression in the 
majority of patients who receive it, but this is due to expression of CD33 on 
normal myeloid progenitor cells420. 
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Mild gastrointestinal upset including nausea, anorexia, epigastric pain was 
observed with CMD-193, which is most likely due to calicheamicin effects.  
Malaise and emesis were commonly experienced in ovarian cancer patients 
infused with CMB-401, suggesting that these symptoms could also be 
attributable to calciheamicin146.  
 
5.3.5 Tumour response  
Although biodistribution assessment of 111In-CMD-193 confirmed poor 
tumour targeting, and no objective responses on CT, one partial metabolic 
response was documented on FDG PET.  This may have been as a result of 
passive targeting, which is where the enhanced permeability and retention 
effect of tumours (because of leaky fenestrated endothelium of its blood 
vessels) allows circulating macromolecules (such as CMD-193) to be taken into 
tumours421.  Alternatively, the low level of targeting achieved by CMD-193 
specifically to Ley expressed on tumour cells was sufficient to result in a partial 
metabolic response, highlighting the potency of calicheamicin conjugates in 
inducing tumour cell kill.  Optimisation of targeting of calicheamicin to 
tumours has obvious potential for therapy of metastatic solid tumours, and 
justifies ongoing development of new immunoconjugates. 
 
5.3.6 Future directions for optimising Le
y
 targeting immunoconjuates  
Whilst the strategy of conjugating calicheamicin with tumour targeting 
antibodies has been successfully validated in haematological malignancies, 
significant barriers to further clinical development of CMD-193 were 
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identified by this Phase I biodistribution study in patients with Ley expressing 
solid tumours.  Despite the strong preclinical evidence that CMD-193 retained 
similar effector cell function and binding affinity with Ley, and was able to 
target xenograft tumours in mice and induce dose-dependent regression, this 
was not the case in patients with metastatic solid tumours in our study.  
Ongoing research into the optimal methods to conjugate calicheamicin to 
antibodies, and the development of improved pre-clinical models, is aimed at 
understanding the precise role of immunoconjugate physicochemical 
properties on in-vivo human tumour targeting and catabolism.  Our study also 
highlights the vital role of bioimaging studies in the early clinical development 
of immunoconjugates in cancer patients.  
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5.4 Optimising radioimmunotherapy: Targeted chemoradiation 
It remains an unanswered question whether radioimmunotherapy will have 
an impact in the treatment of solid malignancies.  As described in section 
1.6.6, trials using a variety of tumour targeting antibodies conjugated with 
radioisotopes in solid malignancies including prostate, renal, lung, ovarian and 
colorectal cancers have been performed, so far with limited success.  The 
exception has been the emerging promise of radioimmunotherapy in lung 
cancer169.  The discovery of the A33 antigen and the characterisation of the 
huA33 antibody, and subsequently 131I-huA33, has presented an ideal 
opportunity to develop this treatment modality for patients with metastatic 
colorectal cancer.  Chapter 4 described a trial performed combining 131I-
huA33 and capecitabine, the results of which will now be discussed and 
compared with the published data.  
 
5.4.1 Study rationale  
The clinical characterisation of huA33 demonstrated that this antibody has a 
suitable elimination half-life and is able to specifically localise at high levels to 
metastatic colorectal cancer cells.  131I-huA33 has also shown prolonged intra-
tumoural retention of antibody and therapeutic payload, whilst elimination 
from normal bowel is consistent with the physiological turnover of normal 
colonocytes, avoiding significant bowel toxicity.  As previously described in 
section 1.9.5 the rationale for concurrent capecitabine was to radiosensitise 
and provide synergistic anti-tumour effects, but owing to the potential bowel 
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and haematological toxicity with both 131I-huA33 and capecitabine, the safety 
of this combination needed careful assessment. The trial reported in Chapter 
4 was designed to determine the safety and tolerability of capecitabine 
administered in combination with 131I-huA33 in patients with metastatic 
ĐŽůŽƌĞĐƚĂů ĐĂŶĐĞƌ ? ǁŚŝůƐƚ ĂůƐŽ ĞǀĂůƵĂƚŝŶŐ ƚŚŝƐ ĂŶƚŝďŽĚǇ ?Ɛ ƉŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐ ?
biodistribution and immunogenicity, and tumour response. 
 
5.4.2 Summary of findings 
Nineteen eligible patients were enrolled and received a scout and therapy 
dose of 131I-huA33 1 week later.  The most frequently observed toxicity 
included myelosuppression, gastrointestinal symptoms, hyperbilirubinaemia, 
fatigue, and minor skin toxicity.  Thrombocytopenia was common, with 
asymptomatic grade 1-3 thrombocytopenia in 13/19 patients, and an episode 
of grade 4 thrombocytopenia in one patient.  Asymptomatic grade 1-3 
neutropenia was seen in 12/19 patients treated whilst Grade 4 neutropenia 
was observed in one patient who also developed febrile neutropenia (the first 
of 2 dose limiting toxicities). Myelosuppression did not appear to be directly 
related to red marrow absorbed dose or dose level of 131I-huA33.  Mild 
gastrointestinal symptoms were common, particularly nausea, vomiting and 
diarrhoea, most likely as a result of the addition of capecitabine.  Grade 3 
diarrhoea was the second dose limiting toxicity documented.  Asymptomatic 
hyperbilirubinaemia, a well-recognised side effect associated with 
capecitabine, occurred in 7 patients.  
 
  378 
Normal organ absorbed doses for kidney, liver, spleen and lungs were far 
below levels required to cause organ toxicity, and were therefore not clinically 
significant.  131I-huA33 demonstrated a mean terminal half-life and serum 
clearance suited to radioimmunotherapy (T½  =100.24 ± 20.92 hrs; CL = 36.72 
± 8.01 mL/hr), allowing specific and prolonged tumour uptake, whilst 
specificity of huA33 meant normal organ uptake was minimal.  
Immunogenicity was minimal with 37% of patients demonstrating a low level 
HAHA titre.  Of the 18 patients evaluable for tumour response, there was 1 
PR, 10 SD, and 7 PD.  Together with a median PFS of 5 months and OS of 15.2 
months (to date) in patients with often extensive metastatic disease, response 
assessment suggests a degree of efficacy in terms of disease stabilisation 
despite only 1 objective partial response.   
    
5.4.3 Comparison with prior 
131
I-huA33 trial 
Comparison to the prior LICR sponsored dose escalation trial of 131I-huA33 
(20-50mCi/m2) in 15 metastatic CRC patients327, provided the opportunity to 
assess the additional toxicity of combination with chemotherapy, confirm the 
in vivo properties of 131I-huA33 (pharmacokinetics and biodistribution), and 
determine whether the addition of capecitabine improves anti-tumour 
efficacy. 
 
5.4.3.1 Adverse events profile 
The type and grade of drug related adverse events observed were similar 
between the preceding 131I-huA33 (protocol LUD98-015) LICR sponsored 
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Phase I dose escalation trial327, and the current study (protocol LUD2002-017).  
Myelosuppression was a common finding in both studies.  Whilst the rate of 
thrombocytopenia and febrile neutropenia was similar in both trials, 
incidence of neutropenia, leukopenia (and lymphopenia) was slightly higher 
when 131I-huA33 was combined with capecitabine.  Thrombocytopenia was 
reported in 80% (131I-huA33 at doses of 20-50mCi/m2) compared to 79% (131I-
huA33 (20-40mCi/m2) + capecitabine).  Neutropenia was seen in 53% who 
received 131I-huA33 compared to 79% when administered with concurrent 
capecitabine. Febrile neutropenia was reported in 7% compared to 5%, and 
leukopenia was seen in 53% compared to 79% in the current study.  Anaemia 
was not a common finding thought to be attributable to study drug, with only 
1 patient (5%) on the current study being documented.  These differences are 
minor and unlikely to be clinically significant. 
 
Although a number of patients in 131I-huA33 alone LUD98-015 trial reported 
gastrointestinal adverse events of nausea, indigestion, diarrhoea, and 
constipation, none of these were considered by the investigators to be related 
to study drug.  Predictably, a number of gastrointestinal symptoms considered 
related to the investigational drug combination were experienced in this trial 
with the addition of capecitabine, the commonest being diarrhoea in 32% of 
patients, nausea (74%), and vomiting (21%). This impacted on the dose of 
capecitabine that was possible to deliver in conjunction with 131I-huA33. 
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The incidence of HAHA, 37 % in the current study, was similar to the incidence 
of HAHA in the prior study (27%). In the prior trial, one patient developed a 
 ‘ ‘ƐĞƌƵŵƐŝĐŬŶĞƐƐ ? ? Wlike clinical syndrome in association with Biacore evidence 
of HAHA formation. Symptoms of myalgias, chills, and fatigue were prominent 
and commenced 1 week following the 131I-huA33 therapy dose.  The Biacore 
measured titres of HAHA were low in the current study and no serum sickness 
was observed. The rate of positive HAHA response was lower than that 
observed when huA33 was previously combined with BOF-Strep 
chemotherapy422, where 7/12 (58%) patients developed HAHA with repeated 
exposure (as huA33 was administered weekly).  This most likely reflects the 
impact of continued exposure to huA33 on the development of HAHA in this 
patient group. 
 
The incidence of study related rashes was similar in both trials, with 27% 
reported with 131I-huA33327 and 26% of patients in the current trial.  Pruritis 
was more common in patients on the first trial327, being reported by 47% 
compared to 11% of patients enrolled to the current study.  Cardiac toxicity 
observed in this study was attributable to capecitabine, not 131I-huA33. 
 
In summary, toxicity in the current study was similar to prior trials of 131I-
huA33, and the addition of capecitabine to 131I-huA33 was found to be 
tolerable in this patient population. 
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5.4.3.2 Biodistribution and dosimetry 
Biodistribution assessment in both 131I-huA33 trials enabled direct comparison 
of tumour dosimetry and tumour targeting capability.  The methodology used 
in this trial, where dosimetry from scout dose is used to predict post therapy 
doses to tumour and normal organs, is a well validated approach423.  The 
pattern of biodistribution in the current study was similar to the previous 
huA33 biopsy based protocol (LUD95-01)302 and 131I-huA33 trial (LUD98-
015)327, in which biodistribution following scout infusion was consistent with 
initial blood pool activity, often with some normal colon uptake, and specific 
uptake by known sites of metastatic disease. Virtually identical tumour uptake 
and biodistribution was seen in both scout and post therapy image datasets in 
all patients. 
 
Tumour dosimetry 
Tumour absorbed dose calculated by dosimetry showed a mean specific 
absorbed dose (all patients) of 5.17  2.83Gy/GBq (p=0.25) in the current trial, 
compared to 6.49  2.47 Gy/GBq in the prior trial of 131I-huA33 alone. This 
was not statistically different (Table 5.4.3.2.1). Uptake in tumour was also 
seen for over one month post therapy infusion, highlighting the prolonged 
retention in tumour of huA33. 
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Table 5.4.3.2.1 Dosimetry parameter comparison between 
131
I-huA33 Trials 
 
Dosimetry Parameter 
131
I-huA33 
131
I-huA33 + 
capecitabine  
T test 
p value 
Mean specific absorbed tumour 
dose (all patients) Gy/GBq 
6.49 +/- 2.47 
(N=13) 
5.17 +/- 2.83 
(N=10) 
0.25 
Total tumour dose at 30mCi/m2 
dose level (Gy) 
17.49 +/- 11.68 
(N=2) 
(Range 12.04-20.67)  
13.12 +/- 7.24 (N=6) 
(Range 5.10-23.60)  
0.47 
Total tumour dose at 40mCi/m2 
dose level (Gy) 
19.26 +/- 11.68 
(N=3) 
(Range 12.04 - 32.73)  
14.88 +/- 9.04 (N=4) 
(Range 5.3 - 26.9)  
0.60 
 
Trials investigating other strategies have reported similar dosimetry data424-
427.  Despite consistent tumour dosimetry with the prior trial, in this trial a 
partial response was observed when concurrent capecitabine was added, 
together with long lasting stable disease in a number of patients, suggesting 
potential synergy and improved efficacy which warrants further investigation. 
 
Whole body clearance and normal organ dosimetry 
Mean whole body clearance of 131I-huA33 was comparable between trials.  In 
the current study it was found to be 219.56  62.81 hours, which compared to 
227.52  46.15 hours in the prior study of 131I-huA33 (p=0.68)327.  Slight 
differences in normal organ clearance between studies was observed. The T1/2 
biological for liver was 62.29  22.05 hours in the current study compared to 
79.74  16.06 hours in 15 patients on the prior trial (p=0.02). Kidney clearance 
was 104.89  56.22 hours in the current study compared to 105.43  31.84 
hours in the previous trial (p=0.24). These minor differences were most likely 
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due to improved methodology in region of interest and attenuation correction 
analysis in the current study, resulting in more accurate data.  Importantly, 
whole body clearance and red marrow dose, which had similar methodology 
between trials, and are the most clinically relevant results, showed no 
difference between studies.    
 
In conclusion, the extrapolated normal organ and whole body doses following 
therapy infusions were all well below the range at which toxicity is expected 
from radioimmunotherapy, and biodistribution analysis confirmed expected 
in vivo biodistribution with specific uptake by known sites of metastatic 
disease, and prolonged retention in tumour following therapy. 
 
5.4.3.3 Pharmacokinetics  
When compared to the previous 131I-huA33 radioimmunotherapy trial LUD98-
015327, some differences were observed between T½  and T½  values: the 
earlier study T½ = 22.96  12.53 hours (p=0.031 when compared to current 
trial), T½ = 135.20  46.91 hours (p=0.008) (Table 5.4.3.3).  Importantly 
however, the clearance of 131I-huA33 which is less strongly influenced by 
inter-patient variability, was highly comparable between studies, with CL = 
36.72 ± 8.01 mL/hr in the current study and CL= 35.21  10.02 ml/hr in the 
preceding study (p=0.632).  In the initial Phase I trial of 131I-huA33, protocol 
LUD95-010, the mean T½  was 12.74 ± 4.03 hrs, and T½  was 86.92 ± 22.12 
hrs.  No statistically significant difference was found between these 
parameters when compared to the current trial (p=0.077 and 0.106 
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respectively). V1, which is a measure of central compartment distribution, 
was comparable between all 3 trials.   
 
The small differences in T½  and T½  between trials may be due to patient 
numbers, as the lack of difference in Cl and V1 indicates no clinically relevant 
differences between studies. Greater inter-patient variability was observed in 
the PK parameters determined in the earlier LUD98-015 protocol327, with T½  
range of 9.46 - 62.34 hours, and T½  range 64.4 - 229.6 hours, compared to 
the current study where T½  range = 6.97 - 23.46 hours and T½  range = 71.06 
- 134.17 hours (Table 5.4.3.3). These results together with small patient 
numbers may have contributed to these apparent differences in mean T½  
and T½  between trials.  
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Table 5.4.3.3 Comparison of PK parameters between two 
131
I-huA33 trial 
 
 
*Chong et al327 
 
5.4.3.4 Tumour response 
Of the 18 patients evaluable for tumour response according to RECIST, there 
was 1 PR, 10 SD, and 7 PD in this current study.  As described in section 4.2.8, 
despite only 1 objective PR, other patients had definitive reductions in the size 
of target lesions despite overall response being SD pr PD.  Tumour response 
did suggest that the combination of 131I-huA33 with capecitabine was more 
efficacious when compared to 131I-huA33 alone in which SD was seen in 4/15, 
and PD in 11/15 patients327.  Phase II trials are required to confirm the efficacy 
of this combination. 
 
Although the patient population was small and heterogeneous in terms of 
prior therapy (prior lines of chemotherapy for metastatic disease was 0-4, 
median 1) and therapy received following the trial (not formally documented), 
Parameter 
LUD 98-015* (N=15) LUD 2002-017 (N=18) T test 
P value 
Mean SD Mean SD 
T ½ alpha (hr) 22.96 12.53 15.78 4.68 0.031 
T ½ beta (hr) 135.20 46.91 100.24 20.91 0.008 
Clearance (ml/hr) 35.21 10.02 36.72 8.01 0.632 
Serum compartment 
volume (V1) 
3.48 0.64 3.20 0.61 0.214 
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it was interesting to note that some patients displayed a surprisingly long PFS 
and OS.  The careful patient selection required to assess suitability for such a 
Phase I trial, and the fact survival data was collected retrospectively should be 
noted when interpreting this survival data.  Patients were often selected on 
the basis of their stable clinical state, and slowly progressive disease 
(particularly those which had not received prior chemotherapy for metastatic 
disease).  This is likely to have influenced the unexpectedly long duration of 
survival in a few patients.  Whilst this Phase I trial was not designed to 
evaluate survival, it was of interest to perform a descriptive, retrospective 
assessment, particularly for those patients who demonstrated stable disease 
at the end of the study.  Despite all these factors, a median PFS of 5 months 
and OS of 15.2 months in this group of patients to date, suggests a degree of 
efficacy in terms of disease stabilisation despite only 1 objective partial 
response. 
 
5.4.3.5 Conclusions 
The results of this trial suggest that a strategy of targeted chemoradiation in 
metastatic colorectal cancer can produce anti-tumour activity whilst 
remaining tolerable for patients.  An increase in observed leukopenia 
following therapy was expected with the addition of capecitabine, but 
importantly this did not translate into an increased incidence of neutropenic 
sepsis.  Gastrointestinal toxicity was greater when 131I-huA33 was combined 
with capecitabine, but these toxicities were generally tolerable and self-
limiting.  Whilst some minor differences between trials in elimination half-life 
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and normal organ dosimetry were seen, these were attributable to inter-
patient variability and differences in methodology.  Parameters such as whole 
body clearance, and serum clearance were consistent across trials, as was the 
most clinically relevant normal organ dose, red marrow.  Although the 
number of patients enrolled was small, one PR was demonstrated (and some 
patients with SD at study completion had definite tumour shrinkage or mixed 
response on CT), which was not seen in the preceding trial of 131I-huA33 
alone.  It is likely that the addition of capecitabine to 131I-huA33 contributed 
to this finding, and further investigation of this strategy is on going. 
  
5.4.4 Comparison with other radioimmunotherapy strategies: Bexaar  
131I-tositumomab (Bexaar), the radio-iodinated anti-CD20 antibody FDA 
approved for the treatment of relapsed B cell NHL in 2003, is the most 
obvious agent with which to compare and contrast to 131I-huA33.  
Tositumomab is a murine IgG2 monoclonal antibody (previously called B1) 
directed against the human B-lymphocyte-restricted differentiation antigen 
CD20, which is a transmembrane protein expressed on pre-B lymphocytes, 
mature B lymphocytes and >90% of B-cell non-Hodgkin's lymphomas (NHL)428 
429.  It does not bind T cells, granulocytes, haematopoietic stem cells, or any 
normal non-haematopoietic tissues428 429.  In contrast to many other tumour-
associated antigens, CD20 does not shed from the cell surface or internalise 
following antibody binding. This lack of internalisation of CD20 directed 
radiolabelled antibodies as beneficial by avoidance of possible dehalogenation 
of 131I-labelled antibody and subsequent release of free iodine from the 
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cell430.  This is in contrast to 131I-huA33, which is known to internalise with 
retention of radioisotope in tumour for up to 6 weeks, although the 
mechanism for this is not yet fully understood, and is not via an 
endosomal/lysosomal trafficking pathway. 
 
Despite being a murine IgG2, Bexaar has been shown to induce cytotoxicity by 
CDC and ADCC431, and lead to the induction of apoptosis431, as well as by 
delivery of its ionizing radiation therapeutic payload.  HuA33 is able to direct 
cell-mediated immune lysis of human colon cancer cells in vitro319, and anti-
tumour activity was observed following administration of unlabelled huA33, 
although multiple infusions administered in this protocol lead to HAHA (and 
related toxicity) in the majority of patients319.  Quantitative measurements of 
A33 monoclonal antibody binding to cell surface A33 antigen on colon cancer 
cell lines predicted the immune-mediated lytic capability of huA33318. 
 
5.4.4.1 Pharmacokinetics and biodistribution 
In early studies, pre-treatment with unlabelled tositumomab, consistently 
prolonged blood and whole-body clearance of labelled antibody was observed 
compared with the administration of trace-labelled antibody without pre-
treatment.  The observed antibody dose-dependent pharmacokinetics of 
slower clearance and a longer terminal half-life following larger pre-doses of 
unlabelled anti-B1 antibody, confirmed the presence of a saturable 
compartment.  Pre-treatment with unlabelled antibody therefore allowed 
improved in vivo biodistribution and pharmacokinetics by partial or complete 
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pre-saturation of nonspecific binding sites, or collections of CD20 positive cells 
such as the spleen429, and superior tumour targeting432.  This is in contrast to 
huA33, in which pharmacokinetic analysis showed no saturable normal tissue 
compartment, and no loading dose requirement for optimal tumour targeting. 
 
Bexaar consists of both tositumomab and 131I-tositumomab, and is 
administered in two doses: the dosimetric dose, and the therapy dose 7-14 
days later.   The dosimetric step is required to individualise total body dose.  
Without this, significant inter patient variability in antibody clearance, tumour 
burden, bone marrow or splenic involvement, and variable cross reactivity 
with normal B cells, can lead to unpredictable doses of radiation to tumour 
and most importantly red marrow.  After the whole body radiation dose 
estimate is calculated following the dosimetric step, the therapy-administered 
activity can be calculated to deliver a maximum of 75cGy whole body dose, 
limiting potential haematologic toxicity433.  Patient-specific dosing, based on 
total body clearance, provided a consistent radiation dose despite variable 
pharmacokinetics, by allowing each patient's administered activity to be 
adjusted for individual patient variables.  Biodistribution trials of 131I-huA33 
however, have shown that biodistribution patterns of 131I-huA33 are similar 
amongst patients.  Whilst with this radioimmunotherapy schedule a scout 
dose is used 1 week prior to therapy dose, this is purely to demonstrate 
predicted biodistribution pattern and tumour uptake, and exclude an 
abnormal uptake prior to administering the therapy dose.  Dosimetric 
calculations based on these biodistribution images were not required prior to 
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therapy infusion. 
As with 131I-huA33, blood pharmacokinetics of Bexaar follows a two-
compartment model, but AML patients with high tumour burden, 
splenomegaly, or bone marrow involvement were noted to have more rapid 
clearance, shorter half-life, and larger volume of distribution for Bexaar, 
emphasising the importance of patient-specific dosing of the therapeutic dose 
for this agent.  Initial investigation of the parental antibody B1 found that the 
median elimination half-life (T1/2 ) was 66.4 hours and ranged from 26.3 to 
196.7 hours429.  No significant alteration was found when the antibody was 
conjugated with therapeutic doses of 131I, but half-life was found to be 
affected by tumour burden.  In 53 patients with different degrees of disease 
burden, overall mean body clearance (t½) was 68.9 hours compared to 50 
hours in patients with splenomegaly434.  In another study of 43 patients with 
B-cell lymphoma in relapse, the mean serum retention half-times of 185-370 
MBq (5-10 mCi) of 131I-B1 antibody were 35.5 ± 16.8, 48.2 ± 17, and 48.1 ± 
23.3 h after doses of 0.5, 2.5 and 10 mg/kg respectively435.  This compares to 
the T1/2  of 
131I-huA33 (administered with capecitabine) in the current trial, 
where a T1/2  of 100.24  20.92 hours (range 71.06 - 134.17 hours) was 
determined.  No statistically significant differences between scout and 
therapy doses of 131I-huA33 have been observed.  The shorter elimination 
half-life of tositumomab can partly be explained by the fact it is a murine 
antibody, whereas huA33 is a humanised IgG1.   
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Tumour uptake of 131I-tosituzumab averaged 9x10-3 ± 3x10-3 %ID/g in patients 
with favorable biodistribution435.  Using a hybrid-SPECT method for calculating 
dose to tumour, Koral et found the dose values ranged from a minimum of 
1.25 Gy to a maximum of 25.4 Gy with 131I-tositumomab436.  The results of the 
current trial with 131I-huA33 show higher tumour dose, with a mean total 
tumour absorbed dose of 13.83 ± 7.61Gy (range 5.06 - 26.94Gy), and mean 
specific absorbed dose of 5.17 ± 2.83 Gy/GBq (19.15 ± 10.49 cGy/mCi).  The 
small scale of this Phase I trial means direct comparisons of response rates 
should be made with caution, but the lower response rate seen with 131I-
huA33 despite concurrent capecitabine, is a reflection of a number of factors 
which make radioimmunotherapy more challenging in solid malignancies.  
These include less radiosensitive tumours, metastatic disease that is less 
accessible to circulating antibodies, and bulky and often necrotic tumours 
making antibody penetration more difficult.  Despite these obstacles, the 
current study clearly shows it is possible to deliver potentially therapeutic 
doses of radiation to metastatic colorectal cancer utilising the huA33 
antibody, and that responses can be achieved when combined with 
capecitabine. 
 
5.4.4.2 Normal organ dosimetry and toxicity 
On the basis of the sequential whole body imaging and the MIRDOSE 3 
program, the median absorbed doses of 131I-B1 to the most clinically 
important target organ, red marrow, was 0.65 mGy/MBq.  This compares to 
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that found with 131I-huA33 of 0.56  0.11 mGy/MBq.  Specific absorbed dose 
to kidney, liver, lung and spleen for 131I-B1 and 131I-huA33 were also 
comparable437.  Mean specific absorbed doses with Bexaar were 
0.152cGy/MBq for liver, 0.174cGy/MBq for lung423 compared to 0.117  0.029 
and 0.081  0.019 for liver and lung respectively with 131I-huA33.  In addition, 
for both agents, doses to normal organs were below normal tissue tolerated 
doses.  With a Bexaar total body dose of 75cGy, biodistribution trials found no 
significant radiation-induced toxicity to organs other than toxicity to bone 
marrow.  As with 131I-huA33 and other radioimmunotherapeutics, dose-
limiting toxicity for patients receiving Bexaar is haematological, with transient 
myelosuppression being widespread.  Of the patients receiving a 75cGy total 
ďŽĚǇĚŽƐĞŝŶ<ĂŵŝŶƐŬŝĞƚĂů ?ƐƐƚƵĚǇ ?'ƌĂĚĞ ?-4 thrombocytopenia was seen in 
40%, Grade 3-4 neutropenia in 55% and grade 3-4 anaemia in 10%438.  This 
compares to 36.8% Grade 3-4 thrombocytopenia, 31.6% grade 3-4 
neutropenia and no grade 3-4 anaemia with 131I-huA33 combined with 
capecitabine.  High dose 131I-tositumomab therapy with stem cell support has 
also shown high response rates and long term durable responses182.  
 
Although 131I-tositumomab shares characteristics with 131I-huA33 such as 
similar dose to normal organs and toxicity profile, it targets a very different 
circulating antigen, on NHL cells, which are very sensitive to radiation and 
easily accessible.  Despite shorter elimination half life, and similar tumour 
absorbed doses, greater sensitivity to radiation and accessibility to target 
antigen has led to partial or complete response rates of up to 75% in B cell 
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NHL have been observed when administered as monotherapy in Phase I/II 
trials158 161 439.  
 
5.4.5 Comparison with other radioimmunotherapeutic strategies in solid 
tumours 
As described, it is clear that when comparisons are made to 
radioimmunotherapy in haematological malignancies, the very different 
target antigen-antibody systems means conclusions must be drawn with 
caution.  The results of the administration of 131I-huA33 with capecitabine in 
this Phase I trial should therefore also be compared to radioimmunotherapy 
strategies with 131I in other solid malignancies, as they provide a more 
clinically relevant benchmark for comparison.     
  
5.4.5.1 
131
I-cG250 in Renal cancer 
Two sequential high-dose treatments of radioimmunotherapy with 131I-cG250, 
an antibody targeting carbonic anhydrase IX antigen, were administered to 29 
patients with metastatic renal cell carcinoma440.  Following initial dosimetric 
analysis, the first therapy dose of 2220 MBq/m2 131I-cG250 was given 1 week 
later.  If no grade 4 haematologic toxicity was observed, a second low dose 
was given 3 months later (1110 or 1665 MBq/m2).  As with other 
radioimmunotherapy studies, no correlation was found between 
haematologic toxicity and radiation-absorbed doses, and there were large 
variations in tumour-absorbed doses.  Mean radiation absorbed doses in men 
to metastases after the first infusion was 7.74  9.89 cGy/mCi (2.09  2.67 
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mGy/MBq), which is slightly less than that seen in the current 131I-huA33 
study (Table 5.4.5.1), despite a faster mean T½  of 58.0  9.4 hours in those 
with no evidence of HACA.  Immunogenicity was higher with this chimeric 
antibody, with 8/29 patients developing HACA, although this was partly 
attributable to more than one infusion being administered to the majority of 
patients.  The authors concluded that future radioimmunotherapy studies 
with radiolabelled cG250 should be aimed at small-volume disease or 
adjuvant treatment. 
 
5.4.5.2 
131
I-hMN-14 in CEA expressing cancers  
Using CEA specific antibodies conjugated with radiation to target colorectal 
cancer is an approach that has been explored by a number of investigators.  
Behr et al enrolled 69 patients with CEA expressing tumours (which included 
31 colorectal, 9 lung, 7 breast cancers and a variety of other tumour types) to 
receive a diagnostic study (0.3-2.6 mg of protein; 6.8-28.8 mCi 131I-labelled IgG 
or fragments), followed within 4 weeks by a high-dose therapy injection of 
anti-CEA antibody NP-4 or MN-14 (4.0-27.5 mg of antibody; 29.8-238.9 
mCi)441.  Profound differences were found in the clearance of the antibody 
between different types of cancer. In colorectal cancer patients, serum 
T1/2=17.6  12.6 hours compared to 44.2  23.7 hours in all other cancers, and 
whole body T1/2= 53.2  30.1 versus 114.6  59.7 hours (P <0.001). 
Consequently, significantly lower red marrow (2.1  1.0 cGy/mCi versus 4.3  
1.6 cGy/mCi) was seen in colorectal cancer patients as compared with other 
tumour types (P < 0.001).  The authors suggested that different CEA-
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expressing cancer types may produce heterogeneous CEA molecules, hence 
variability in clearance due to varying clearance rates of different circulating 
CEA sub-species.  A later Phase I/II trial enrolled 57 patients with CEA-
expressing tumours with a similar schedule of 131I-labeled murine anti-CEA 
IgG1 antibody, NP-4442.  A diagnostic study (1-3 mg of IgG and 8-30 mCi of 131I) 
was followed by the therapeutic dose (4-23 mg and 44-268 mCi), based on the 
radiation dose to the red marrow.  Again, blood T1/2 was significantly lower in 
colorectal cancer when compared to all other tumour types (21.4  11.1 hr 
versus 35.8  13.2 hr, p < 0.01), as was whole-body T1/2.  Myelotoxicity was 
dose-limiting, tumour absorbed doses were inversely related to the tumour 
mass and ranged between 2 and 218 cGy/mCi. Modest anti-tumor effects 
were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed 
responses and 7 with stabilisation of previously rapidly progressing disease).  
 
The CEA targeting radioimmunotherapeutic 131I-hMN-14 IgG was administered 
to metastatic gastrointestinal and colorectal cancer patients443.  Seventeen of 
21 enrolled patients received both the diagnostic and therapy infusions.  The 
primary dose-limiting toxicity was comparable to 131I-huA33, being 
haematological toxicity at 40 mCi/m2, and mean red marrow dose and mean 
tumour radiation dose were 2.2  2.4 cGy/mCi, and 24.2  22.6 cGy/mCi 
respectively (compared to 2.06  0.41 and 19.15  10.49 cGy/mCi respectively 
for 131I-huA33 in the current trial).  Despite good tumour targeting and 
acceptable toxicity profile, no objective responses were seen.  More recently 
this same agent, now named 131I-labetuzumab, showed a promising potential 
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survival advantage in a small trial when given adjuvantly following R0 
resection of CRC liver metastasis at a dose of 40-60 mCi/m2180 444.  This 
suggests this agent maybe more suitable to the treatment of minimal residual 
disease rather than bulky advanced tumours, but larger studies are required 
to assess efficacy further.  No published evidence could be found exploring 
the strategy of combining 131I-labetuzumab with chemotherapy, but it is likely 
this will be a future step to improve efficacy. 
 
5.4.5.3 
177
Lu-J591 in prostate cancer 
Prostate cancer provides an ideal setting for which to develop 
radioimmunotherapy as a therapeutic strategy owing to it radiosensitivity, 
and disease natural history.  Small metastatic deposits in bone and lymph 
nodes provide a potentially accessible target for a circulating antibody 
conjugated to a radioisotope.  A suitable target antigen prostate specific 
membrane antigen (PSMA) is present with high levels of expression, which led 
to the development of a specific PSMA targeting antibody J591, which 
internalises once bound, and demonstrated excellent tumour targeting157 174 
445. 
 
ĂŶĚĞƌ Ğƚ Ăů ?Ɛ ĚĞǀĞůŽƉŵĞŶƚ ŽĨ177Lu-J591 has taken radioimmunotherapy in 
prostate cancer into Phase II trials.  Phase I evidence demonstrated 177Lu-J591 
is able to target prostate cancer metastases with sensitivity and specificity, 
was well-tolerated and non-immunogenic, with a single-dose MTD of 70 
mCi/m2, and suggested anti-tumour activity157.  Repeated dosing was also 
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investigated in a proportion of patients, although this lead to more 
cumulative myelotoxicity, and hence was poorly tolerated at doses 65% of the 
MTD.  No clear relationship between a history of prior chemotherapy or 
radiotherapy and the degree of toxicity was found in this study.  Radiation 
dosimetry calculations found similar normal organ dosimetry to that found 
with 131I-huA33.  With 177Lu-J591 at MTD of 70 mCi/m2, radiation dose to liver 
was 7.7  2.23 cGy/mCi, an acceptable dose to normal liver, slightly higher 
than that seen with 131I-huA33 (4.33  1.04 cGy/mCi), most likely due to 
antigen expression in normal liver.  Radiation doses to kidney (5.20  1.29 
cGy/mCi) and spleen (7.28  3.41 cGy/mCi) were also well within acceptable 
limits, and consistent with those seen with 131I-huA33.  Although no patients 
in this trial had an objective measurable disease response (PR or CR), four 
patients had PSA declines of 50%, and 16 patients had PSA stabilisation, 
suggesting that 177Lu-J591 may have biologic activity.  The Phase II study is 
ongoing, but preliminary results suggest a single dose 177Lu-J591 demonstrates 
anti-tumour activity in patients with progressive metastatic prostate cancer 
with reversible myelosuppression150.  Preclinical data in human prostate 
cancer xenografts combining RIT with taxanes have demonstrated therapeutic 
synergy without excess toxicity446.  This suggests that as has been 
demonstrated with the addition of capecitabine to 131I-huA33, concurrent 
chemotherapy to PSMA targeting radioimmunotherapy maybe the next step 
for future development of this treatment modality in prostate cancer. 
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5.3.5.4 Summary 
The results of the current trial compare well with other trials of 
radioimmunotherapy in solid tumours in terms of radiation absorbed dose to 
tumour and normal tissues, as summarised below in table 5.3.5.4.   
 
Table  5.3.5.4  
131
I-huA33 characteristics compared to similar strategies in 
other solid tumours 
 
Publication Current study Brouwers
440
 Bander
157
 
Antibody 
131
I-huA33 
131
I-cG250 
177
Lu-J591 
Malignancy CRC Renal cancer
+
 Prostate cancer 
Dose to tumour (cGy/mCi) 19.15  10.49 7.74  9.89 Not reported 
Dose to kidney (cGy/mCi) 4.78  1.82 3.74  1.11 5.20  1.29 
Dose to liver  (cGy/mCi) 4.33  1.04 2.37  0.15 7.77  2.23 
Dose to lung (cGy/mCi) 3.00  0.70 2.15  0.33 2.79  0.80 
Dose to spleen (cGy/mCi) 6.19  2.19 3.63  1.48 7.28  3.41 
Dose to red marrow (cGy/mCi) 2.06  0.41 1.44  0.22 1.17  0.37 
T ½  (hours) 100.24  20.92 58.0  9.4 44  16 
Clearance (mL/hr) 36.76  8.01 Not reported 88  47 
 
 
Compared to many other antibodies used in radioimmunotherapy trials, 
huA33 has favourable characteristics of prolonged tumour retention (up to 4-
6 weeks, not seen with other antibodies), and optimal serum clearance 
properties.  The potential of radiosensitisation with capecitabine, which is 
particularly well suited as an active chemotherapy drug in colorectal cancer, 
makes this combined approach highly attractive.  In our trial, the addition of 
capecitabine did improve efficacy as one PR, some mixed responses and 
apparent disease stabilisation was observed in many patients.  This will, of 
course, need to be further explored in Phase II trials. 
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5.4.6 Future direction for optimising radioimmunotherapy with huA33 
Attempting to improve the radiation dose absorbed by tumours should be a 
high priority in building on the current progress, and taking this promising 
clinical development strategy further.  Although the tolerability and anti-
tumour activity of the combination of 131I-huA33 and capecitabine warrant 
further study, improvements in radiation responsiveness in CRC may be 
achieved through a number of strategies.   Combining targeted 
chemoradiation with biological agents such as EGFR inhibitors may also be a 
promising line of future development. 
 
5.4.6.1 Improvements in radiation dose delivery: 
177
Lu-huA33 
As described in section 1.6.6.1, radioisotope path length, energy of emission, 
stability of conjugate, likely size of lesions to target, as well as internalising 
properties of the antibody should be considered when determining the choice 
of isotope for radioimmunotherapy147.  Because patients with metastatic solid 
tumours often have a significant disease burden (as apposed to 
micrometastatic disease), beta emitters (such as 131I, 177Lu, 90Y) are more 
suited to radioimmunotherapy in this scenario147.  Although 131I has been the 
most extensively studied for use as a radioimmunotherapeutic, it may not be 
the optimal choice.  Brouwers et al used animal models to confirm that the 
residualising radionuclide 177Lu can provide improved therapeutic efficacy 
compared to 131I, 90Y and 186Re when conjugated with the chimeric antibody 
G250447.  Absorbed tumour dose was 807Gy for 177Lu-cG250, 76Gy for 131I-
cG250, and 95Gy for 90Y-cG250 in this model.  
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Recent preclinical work on 177Lu-huA33 performed by LICR (unpublished) is 
consistent with these findings.  The tissue distribution of 177Lu-huA33 (using 
chelate CHX- ?-DTPA) in BALB/c nude mice bearing LIM215 xenografts was 
shown to demonstrate excellent tumour localisation and retention, and 
minimal uptake in normal tissues.  High uptake (to a maximum of 122 
%ID/gm) and prolonged retention in tumour confirmed the suspected 
improved biodistribution properties of 177Lu when conjugated with huA33, as 
was also seen with 177Lu-cG250447.  Using this data, together with that derived 
from experiments using other residualising antibodies, mathematical 
modelling was used to demonstrate that 177Lu-huA33 can provide a ~180% 
increase in tumour self mean absorbed dose compared to 131I-huA33.  This 
translates to a tumour: red marrow dose advantage of 2.6:1 for 177Lu-huA33 
compared to 131I-huA33.  This dosimetry modelling suggests a significant 
increase in mean absorbed dose to tumour using 177Lu whilst maintaining a 
low red marrow dose (and hence not increasing myelotoxicity).  
 
5.3.6.2 Targeted chemoradiation with epidermal growth factor inhibition 
Section 1.6.2.2 described how the addition of EGFR antibodies to external 
beam radiotherapy can lead to cell cycle arrest and enhance tumour cell 
death74 89, with radiotherapy and concurrent cetuximab now having an 
established role in the treatment of squamous cell carcinoma (SCC) of the 
head and neck.  The concept of combining radioimmunotherapy with EGFR 
inhibition has shown potential therapeutic efficacy in animal models, with 
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significant enhancement of efficacy of 90Y-CHX-A''-DTPA-hu3S193 (humanised 
anti-Lewis Y antibody conjugated with 90Y) with concurrent EGFR inhibition184.  
The mechanism of this enhanced efficacy is proposed to be due to anti-EGFR 
antibody inhibition of DNA-protein kinase mediated DNA break repair75.  This 
combination of radioimmunotherapy and EGFR inhibition has yet to be 
investigated in Phase I CRC trials. 
 
Combining cetuximab with targeted chemoradiation using 177Lu-huA33 and 
capecitabine for the treatment of metastatic CRC has therapeutic promise.  It 
is predicted that the radiation dose absorbed by tumour will be improved 
with the use of 177Lu-huA33, and radiosensitivity of disease (and potentially 
activity) will be improved by the addition of capecitabine and cetuximab.  
Whilst it has been established that radioimmunotherapy can be combined 
with capecitabine, and the non-overlapping toxicity of cetuximab supports 
this novel combined approach, it is not yet known whether further addition of 
EGFR inhibition is tolerable.  A two-stage protocol looking at dose escalation 
of 177Lu-huA33 with concurrent capecitabine and the addition of cetuximab is 
currently in development to take this concept of delivering 
radioimmunotherapy in metastatic CRC further. 
 
5.4 Overall thesis conclusions 
As this thesis has described, many strategies have been employed in attempts 
to optimise therapeutic antibodies for the treatment of cancer.  The reported 
projects have described 3 differing approaches, which aimed to make an 
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impact on the ongoing development of such targeted treatment in metastatic 
solid tumours. 
 
In the search for improved predictors of response to anti-EGFR antibodies, 
expression of markers of EGFR pathway activation such as pEGFR and pMAPK 
were found to be discordant between primary and metastatic CRC.  Although 
this may have been partly due to limitations in IHC, they are unlikely to be 
useful biomarkers for response unless metastatic tissue is also analysed.  
Confirmation that mutations in KRAS, BRAF and PI3KCA are concordant in 
primary and metastatic tissue supports the evidence to suggest these are 
early events in CRC tumourigenesis, and the analysis of archived primary 
tissue alone for mutation screening.  PI3KCA mutations, shown to be present 
in patients with both wild-type and mutant KRAS, provide both an additional 
method for resistance in wild type tumours and a mechanism for high 
resistance in those with mutant primary tumours.  These results suggest 
screening patients for all 3 mutations should be encouraged for future trials of 
anti-EGFR antibodies. 
 
The results of the CMD-193 biodistribution study had an immediate and 
significant impact on the future development of this immunoconjugate, and 
has highlighted the importance of such studies in the early development such 
novel therapies.  The conjugation of the Ley targeting antibody with a 
calicheamicin derivative was shown to unfavourably effect the in vivo 
properties of the immunoconjugate, leading to fast clearance via the liver and 
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poor tumour localisation.  As a result of this trial, this agent is now unlikely to 
be developed further in its current form. 
 
Finally, it has been demonstrated that targeted chemoradiation in the form of 
131I-huA33 combined with capecitabine can be administered safely and 
effectively to patients with metastatic CRC.  Whilst biodistribution, 
pharmacokinetic and tumour targeting properties remained favourable in 
such patients, 1 objective response and a number of disease stabilisations 
were documented suggesting anti-tumour activity.  This strategy will be taken 
further as a direct result of these findings, with a similar trial replacing the 
radioisotope 131I with 177Lu in a further attempt to improve radiation dose to 
tumour whilst maintaining tolerability, before the subsequent addition of an 
EGFR antibody in the Phase I setting. 
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